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Abstract
The primary aim of this work was to identify novel mutations in genes that cause mitochondrial 
disorders. Due to the clinical and genetic heterogeneity among these patients, a variety of 
analytical approaches were used.
In patients from pedigrees which exhibited maternal inheritance or in whom cybrid cell studies 
indicated a mitochondrial mutation, mitochondrial DNA (mtDNA) was sequenced. A novel 
mutation in a subunit of complex I (ND3) was identified in a patient with cardiomyopathy. The 
functional relationship between mutant load and complex I activity, lactate/pyruvate ratios and 
oxygen consumption was investigated. However, the pathogenic status of this mutation 
remains uncertain.
Where a mtDNA mutation had been excluded or other factors such as consanguinity suggested 
involvement of a nuclear gene, results from respiratory chain (RC) enzyme assays were used to 
prioritise candidate genes for sequence analysis. A homozygous G555E mutation was 
discovered in the flavoprotein subunit of succinate dehydrogenase in a patient with late-onset 
Leigh syndrome and complex II deficiency. Another patient has previously been described with 
the same mutation but presented with a substantially more severe lethal infantile form of the 
disease. Fibroblast cultures derived from both patients were used to compare the activities and 
stability of RC enzymes in order to explain this phenotypic variability.
In consanguineous pedigrees where analysis of candidate genes had proved unsuccessful, 
homozygosity mapping was used to search for novel nuclear genes involved with mitochondrial 
disorders. A novel gene for complex I deficiency was mapped to 5 genetic regions in an Israeli 
family using the new 10K SNP chip from Affymetrix. Analysis of eight candidate genes 
(including NDUFV2 and AFG3L2) was negative. In another highly consanguineous Israeli 
pedigree with mtDNA depletion, microsatellite analysis was used to narrow a candidate region 
on chromosome 13 down to 20Mb. A complex rearrangement was found in this region in a 
gene called SUCLA2. This gene codes for a citric acid cycle protein, which is thought to affect 
mitochondrial nucleotide pools via an interaction with nucleoside diphosphate kinase.
Mutations in the gene for mitochondrial DNA polymerase gamma were found in 13/17 paediatric 
patients in the majority of whom Southern blots had indicated depletion of mtDNA, and also in a 
three-generation pedigree with premature external ophthalmoplegia associated with early 
menopause.
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Abbreviations used
ACRS amplification-created restriction site
APS ammonium persulphate
ATP adenosine 5’-triphosphate
A 26o absorbance at 260nm
BN Blue Native
bp base pairs
BSA bovine serum albumin
CFTR cystic fibrosis transmembrane conductance regulator
CGH comparative genome hybridisation
cM centi-Morgans
COX cytochrome c oxidase
CRS Cambridge Reference Sequence
CS citrate synthase
CSF cerebrospinal fluid
CT computed tomography
Da daltons
ddH20  double-distilled water
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
dNTP deoxynucleotide triphosphate
DTNB 5,5' dithio-bis 2-nitrobenzoic acid
ECG echocardiogram
EDTA ethylene diamine tetra acetic acid, dipotassium salt
EEG electroencephalography
EC Enzyme Commission
FAD flavin adenine dinucleotide
FCS fetal calf serum
FH fumarate hydratase
FSH follicle stimulating hormone
g gram / 9.8 newtons per kilogram (gravitational)
GDAS GeneChip DNA analysis software
h hours
k 103
kb 103 base pairs
I litre
LH luteinizing hormone
LHON Leber’s hereditary optic neuropathy
LS Leigh syndrome
Mb 106 base pairs
MELAS mitochondrial encephalopathy, lactic acidosis and stroke-like episodes
mg milligram
min minutes
mM millimolar
MNGIE mitochondrial neurogastrointestinal encephalomyopathy
mtDNA mitochondrial DNA
MRI magnetic resonance imaging
MTS mitochondrial targeting sequence
mRNA messenger RNA
NAD nicotinamide adenine dinucleotide
nM nanomolar
OXPHOS oxidative phosphorylation
PBS phosphate-buffered saline
PCR polymerase chain reaction
PEO premature external ophthalmoplegia
pmol 10'12 moles
POF premature ovarian failure
POLG mitochondrial DNA polymerase gamma
PVDF polyvinylidene fluoride
qPCR quantitative PCR
RC respiratory chain
RFLP restriction fragment length polymorphism
RNA ribonucleic acid
ROS reactive oxygen species
rpm revolutions per minute
rRNA ribosomal RNA
P° rhoO cells, cells lacking mtDNA
s seconds
SDH succinate dehydrogenase
SUCLA2 p-chain of the ADP-forming succinyl-CoA ligase
TEMED N,N,N',N'-tetramethylethylenediamine
TIM translocase of the inner membrane
TOM translocase of the outer membrane
tRNA transfer RNA
pg microgram
pM micromolar
pi microlitre
UPD uniparental disomy
UTR untranslated region
UV ultra violet
V volts
WT wild-type
°C degrees centigrade
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1.1. Overview of the mitochondrion
1.1.1. Mitochondrial structure and basic function
Mitochondria are double membrane bound organelles that are present in almost all eukaryotic 
cells. Their main function is to convert energy from chemical fuels, to a more usable form 
(ATP). These organelles are usually thought of as cylindrical in shape, somewhat similar to 
bacteria, with a diameter of 0.5-1.0pm. The most noticeable feature, as observed using 
electron microscopy, is their highly convoluted inner membrane (see Figure 1.1). This is the site 
of many important enzymatic reactions, mostly concerned with energy metabolism. Studies 
have also shown that mitochondria are dynamic and can change shape, divide and even fuse 
with one another (Hales, 2004). This dynamic capability is important to cellular function, 
especially in peripheral nerves where mutations in mitofusin 2 (a mitochondrial fusion protein) 
have recently been shown to cause Charcot-Marie-Tooth neuropathy type 2A (Zuchner et al.,
2004).
Outer membrane
Inner membrane
Inter membrane 
space
Matrix
Cristae
Figure 1.1: Electron micrograph and schematic diagram of a single
mitochondrion (adapted from www.a3243g.com/image_mitochondria.asp).
Rough
endoplasmic
reticulum
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1.1.2. Evolution of eukaryotic cells
Eukaryotic cells are thought to have arisen over a billion years ago upon endocytosis of a free- 
living a-proteobacterium by a primitive eukaryotic cell. Since this initial uptake, these proto­
mitochondria have lost most of their genome and have become dependent on numerous 
nuclear gene products that have to be transported into the mitochondria. A symbiotic 
relationship has thus developed, as the eukaryotic cell also relies on the mitochondria for most 
of its energy production.
The transfer of genetic material from organelle DNA to the nucleus has occurred on numerous 
occasions over the history of eukaryotic evolution. This mechanism has recently been shown to 
be the cause of a sporadic case of Palister-Hall syndrome in which the GLI3 gene was 
disrupted by a de novo 72bp insertion of mitochondrial DNA sequence (Turner et al., 2003). 
Other evidence for this transfer from mitochondria are the numerous pseudo-mitochondrial 
genes spread all over the nuclear genome (Tourmen et al., 2002) as well as many functional 
nuclear genes for mitochondrial proteins that are closely related to a-proteobacterial genes.
The 1,112kb genome of Rickettsia prowazekii, an obligate intracellular parasite that was the 
causative agent of the typhus epidemic, has been sequenced. Phylogenetic analysis indicates 
that it is more closely related to mitochondria than any other microbe (Andersson et al., 1998). 
Another interesting genome with regards to eukaryotic evolution belongs to the freshwater 
protozoon Reclinomonas Americana mitochondria. At 69kb, it is the largest mitochondrial 
genome known, and codes for 97 genes. It is thought to resemble the ancestral proto- 
mitochondrial genome more than any other mitochondrial genome sequenced to date (Lang et 
al., 1997). The study of both of these genomes has provided important clues about the 
evolution of mitochondria and eukaryotic cells.
1.1.3. Mitochondrial genetics
Human mitochondria contain their own small circular genome. These 16,569 base pairs are 
maternally inherited and were first sequenced in 1981 (Anderson et al., 1981), thus becoming 
one of the first genomes to be sequenced in its entirety (see Figure 1.2). This work was done 
two years before PCR was devised, and so involved the laborious process of extracting 
mitochondrial DNA (mtDNA) from human placenta, digesting this DNA and then two cloning 
steps before the Sanger chain termination reactions could be run. The resulting sequence is 
commonly referred to as the Cambridge Reference Sequence (CRS). This sequence was 
updated in 1999 to account for sequencing errors, polymorphisms and HeLa cell contamination 
of the original sample (Andrews et al., 1999a). Nowadays, with automated capillary sequencing 
and other new technologies, the mitochondrial genome can easily be sequenced in a couple of 
days.
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The structure of 
DNA is described - 
Crick and Watson 
(1953)
50 years progress 
in genetics Publication of draft Human Genome - 
(2001)
Genetic code 
deciphered - 
Nirenberg (1966)
H. influenzae 
sequenced - (1995)
PCR developed - 
Karry Mullis (1983)
C. efegans 
sequenced
-(1998)
First Recombinant 
DNA - Berg (1972)
DNA “Fingerprinting" 
invented - Jeffreys 
(1984)
DNA polymerase Human mitochondrial Yeast genome
isolated - Komberg genome sequenced - sequenced -
(1958) Anderson (1981) (1996)
Figure 1.2: Key events in the progress of genetics over the last 50 years.
The human mitochondrial genome encodes 22 transfer RNAs and two ribosomal RNAs (12S 
and 16S), which along with numerous nuclear-encoded factors, are needed to synthesize the 13 
proteins that are also encoded by mtDNA. The 13 proteins are all structural subunits of the 
oxidative phosphorylation system. Seven genes encode complex I subunits, another encodes 
cytochrome b  (a component of complex III), three are for complex IV subunits and two encode 
complex V subunits (see Figure 1.3).
A different genetic code is used by the mitochondrion to translate these 13 proteins: unlike the 
nuclear genetic code, UGA translates to a tryptophan instead of termination, AUA codes for 
methionine instead of isoleucine (however AUG is still always the start codon) and AGA / AGG 
are terminators instead of coding for arginine (see Table 1.1).
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Figure 1.3: The 16.6kb circular mitochondrial genome contains 37 genes.
Complex I subunits are shown in orange, complex III in yellow, complex IV in blue, 
complex V in green, the two rRNA genes in white and the tRNAs as black circles. 
Also shown are the two origins of replication for the light and heavy strands (Ol and 
Oh respectively), seven of the most common disease causing point mutations and 
the D-loop. The majority of mtDNA deletions fall within the major arc between Ol 
and Oh as indicated. The common deletion is also shown. Adapted from Smeitink 
etal (2001).
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Table 1.1: The human mitochondrial genetic code.
Phe
F
uuu
uuc
Thr
T
ACU
ACC
ACA
ACG
Asp
D
GAU
GAC
Leu (1) UUA Ala GCU Glu GAA
L (UUA/G) UUG A GCC
GCA
GCG
E GAG
Leu (2) CUU Tyr UAU Cys UGU
L (CUN) cue
CUA
CUG
Y UAC C UGC
lie
1
AUU
AUC
Ter UAA
UAG
Trp
W
UGA
UGG
Met AUA His CAU Arg CGU
M AUG* H CAC R CGC
CGA
CGG
Val GUU Gin CAA Ser (2) AGU
V GUC
GUA
GUG
Q CAG S (AGU/C) AGC
Ser
S (UCN)
(1) UCU
UCC
UCA
UCG
Asn
N
AAU
AAC
Ter AGA
AGG
Pro ecu Lys AAA Gly GGU
P CCC
CCA
CCG
K AAG G GGC
GGA
GGG
Changes from the universal code highlighted in red.
There are thought to be about 2-10 copies of mtDNA per mitochondria and approximately 103 to
104 per cell, with the exception of gametes which contain approximately 102 in sperm and over
105 in oocytes (Steuerwald et al., 2000). Although present at such high copy number, mtDNA 
typically constitutes only about 1-5% of total cellular DNA because it is such a small molecule in 
relation to nuclear DNA.
Whether or not mtDNA can recombine has been an area of debate. Although recombination 
occurs in yeast mtDNA, data from humans has until recently remained controversial. An 
elegant study using muscle tissue which had two different populations of mtDNA has recently 
shown that recombination does occur albeit at a low rate (Kraytsberg et al., 2004). The authors 
used primers specific to each mitochondrial haplotype to amplify recombined mtDNA molecules. 
This method was originally developed to search for recombination hotspots in sperm (Jeffreys 
and Neumann, 2002). Another recent study examined allelic combinations in multiple 
individuals with two different heteroplasmic mtDNA mutations. Higher rates of recombination 
were observed (as shown by the presence of all four allelic combinations, or “tetraplasmy”) 
when the two mutations were more distant, than when the mutations were adjacent (Zsurka et 
al., 2005).
In the nucleus, positively-charged histones are used to package DNA into dense chromatin. 
This does not occur in the mitochondrion. The open structure of mtDNA, the relatively limited
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proof-reading mechanisms and the high levels of reactive oxygen species within the 
mitochondrial matrix are all partly responsible for the sequence showing a much faster 
evolutionary rate (about 2.2-2.9% per million years) than is observed in the nucleus (Torroni et 
al., 1994). For this reason, together with the fact that it is maternally inherited and undergoes 
limited levels of recombination, mtDNA has been used extensively for phylogenetic analysis of 
ancient human migrations (see Figure 1.4). The data suggest that all human mtDNA can be 
traced back to a single woman living in Africa (Cann et al., 1987). This woman has been 
popularized as “African Eve”. mtDNA has similarly been used to track more recent maternal 
ancestry and this process has even been commercialized (see www.oxfordancestors.com/your- 
maternal.html).
Figure 1.4: Human migrations as determined by mtDNA sequence (from 
www.mitomap.org, reproduced with permission). Letters indicate mtDNA 
haplogroups and numbers indicate years from present day.
The human mitochondrial genome exhibits a high degree of economy. Mitochondrial genes 
contain no introns and some termination codons have to be made up by the mRNA polyA tails. 
The two mitochondrial genes for ATP synthase subunits overlap by 46 nucleotides, and 7bp of 
the NADH dehydrogenase subunit 4 are shared by NADH dehydrogenase subunit 4L. The only 
significant non-coding region is called the displacement loop (or D-loop), which is situated 
between the phenylalanine (F) and proline (P) tRNA genes. It can form a triplex that is 
important in the initiation of DNA replication and is 1121 bp long (positions 16024-576). This 
economy of sequence is in stark contrast to the nuclear genome with its long intergenic regions 
(for example, the heterochromatin on the Y chromosome) and the many genes that contain 
numerous introns (for example DMD, a gene with 78 introns, mutations in which cause 
Duchenne Muscular Dystrophy).
The overall GC content of the human mitochondrial genome is 44.4%, which is slightly higher 
than the 41% observed for the rest of the human genome (Lander et al., 2001). However, there 
is an asymmetric distribution of nucleotides between the two strands. Centrifugation with a 
caesium chloride density gradient can be used to separate the strands of mtDNA into the heavy
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stand (GT = 62.2%, containing 28 genes) and the light strand (GT = 37.8%, containing 9 
genes). For this reason, H and L have become the accepted nomenclature for denoting which 
strand is being referred to.
1.1.4. Oxidative Phosphorylation
Oxidative phosphorylation (OXPHOS) is carried out by five multimeric enzyme complexes (see 
Table 1.2), which are embedded in the inner mitochondrial membrane and convert 
electrochemical energy into ATP. Complexes l-IV, which are also called the respiratory chain 
(RC), pass electrons from NADH or succinate to ubiquinone (coenzyme Q10) and then onto 
cytochrome c. The final electron acceptor is molecular oxygen (see Figure 1.6). The energy 
that results from differences in standard electron potentials of RC reactions (see Table 1.3) is 
harnessed by the simultaneous pumping of protons into the intermembrane space. The 
resulting proton gradient of about 150mV that is set up across the inner mitochondrial 
membrane is then used by complex V (ATP synthase), which couples the flow of protons back 
across the membrane to the production of ATP from ADP and inorganic phosphate. ATP is 
transported out of the mitochondrion by adenine nucleotide translocator, a homodimeric gated 
pore in the inner mitochondrial membrane, to the cytosol, where it can be used by the cell as a 
source of energy. The hypothesis that a chemiosmotic mechanism could couple respiration to 
the production of ATP was initially proposed over 40 years ago by Peter Mitchell (Mitchell, 
1961).
Intermembrane space
Succinate
ADP+Pi ATPFumarate Matrix
Figure 1.5: The oxidative phosphorylation system consists of five multimeric protein complexes 
that are situated in the inner mitochondrial membrane. Electrons get passed on from NADH 
and succinate via coenzyme Q10 (Q10) and cytochrome c (CytC). This passage of electrons is 
linked to the pumping of protons across the membrane. The resulting electrochemical gradient 
is utilised by complex V to produce ATP.
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Table 1.2: Summary of the five oxidative phosphorylation complexes. The genetic 
origins of the subunits are shown.
Complex Name Total subunits mtDNA Nuclear
1 NADH-CoQ oxidoreductase 46 7 39
II Succinate-CoQ oxidoreductase 4 0 4
III CoQ-cytochrome c oxidoreductase 11 1 10
IV Cytochrome c oxidase 13 3 10
V ATP synthase 16 2 14
Total 90 13 77
Table 1.3: Standard electron potentials of some respiratory 
chain reactions.
Oxidant Reductant n E0 (v)
NAD+ NADH + H+ 2 -0.32
Fumarate Succinate 2 0.03
Ubiquinone (oxidised) Ubiquinone (reduced) 2 0.10
Cytochrome b (+3) Cytochrome b (+2) 1 0.07
Cytochrome c (+3) Cytochrome c (+2) 1 0.22
1/2 0 2 + 2H+ H20 2 0.82
n is the number of electrons transferred, E0 is the standard oxidation-reduction 
potential at pH 7.0 and 25°C, oxidant + e- = reductant. Adapted from (Stryer,
1995).
1.1.5. Other mitochondrial functions
Not all of the genes necessary to make a mitochondrion are involved with synthesis of ATP. 
The citric acid cycle and many other important metabolic reactions such as fatty acid 13- 
oxidation, oxidation of pyruvate and the metabolism of amino acids and steroids all occur in the 
mitochondrial matrix. Mitochondria also contain the rate-limiting enzymes for heme synthesis 
(5-aminolevulinic acid synthetase) and pyridimine biosynthesis (dihydroorotate dehydrogenase). 
The release of mitochondrial cytochrome c has also been linked to the onset of apoptosis and 
has become an exciting new field of research (recently reviewed in Jiang and Wang, 2004). 
Apoptosis inducing factor (AIF) is a 57kDa flavoprotein which is normally found in the 
mitochondrial inter membrane space. Studies have shown that AIF also gets released upon 
opening of the mitochondrial permeability transition pore, and translocates to the nucleus where 
it mediates chromatin condensation and DNA fragmentation, resulting in apoptosis. An 
absence of AIF has been shown to compromise composition and function of complex I in vitro, 
and in a mouse model (Vahsen et al., 2004).
Recent studies have shown that dominantly acting mutations in the citric acid cycle enzymes 
fumarate hydratase (FH) and succinate dehydrogenase (SDH, subunits B, C and D) can cause
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skin leiomyomata or paraganglioma (Tomlinson et al., 2002; Baysal et al., 2000; Niemann and 
Muller, 2000; Astuti et al., 2001). This poses the question of why complete loss of enzymatic 
function of FH or SDH leads to neurodegeneration (e.g. Leigh syndrome), yet a similarly 
complete loss of enzymatic function due to a germline heterozygous mutation followed by 
somatic loss of the wild-type allele results in cancer. A plausible explanation was that these 
proteins have a secondary tumour suppressing role, in addition to their well-characterized citric 
acid cycle catalytic activities.
Mutations in FH and in SDH subunits block the citric acid cycle which results in the 
accumulation of succinate and fumarate. This in turn appears to stabilize hypoxia-inducible 
factor 1 alpha (HIF1a), the central signalling molecule in the hypoxia pathway (Pollard et al.,
2005). Increased HIF1a upregulates expression of downstream target molecules such as 
vascular endothelial growth factor and ultimately promotes angiogenesis. Pseudohypoxic-drive 
is also the basic mechanism of tumorigenesis in von Hippel-Lindau syndrome and tumours from 
these patients also exhibit high density of vessels throughout as well as increased HIF1a levels. 
The VHL protein is part of the E3-ubiquitin ligase complex which degrades hydroxylated HIF1a.
1.1.6. Mitochondrial proteins
Over the last few years, a lot of different proteomic tools have been utilised in order to define a 
reference mitochondrial proteome. At present, over 1000 proteins are considered to be 
involved in the normal physiologically functioning mitochondrion. In addition to the use of 
standard 2D-PAGE followed by identification by mass spectrometry, and other techniques 
involving peptide mass fingerprinting (Lescuyer et al., 2003), other functional approaches have 
included looking at mutant or RNAi induced growth phenotypes in model organisms such as 
yeast and C. elegans (Steinmetz et al., 2002; Kamath et al., 2003).
Most mitochondrial proteins that are encoded by nuclear genes are known to use a short N- 
terminal positively charged mitochondrial targeting sequence (MTS). Once transportation has 
taken place, these 20-30 amino acid sequences are cleaved from the mature protein. 
Algorithms such as MITOP (Claros and Vincens, 1996), Predotar (http://genoplante- 
info.infobiogen.fr/predotar/), and TargetP (www.cbs.dtu.dk/services/TargetP) have been written 
to try to predict whether the N-terminal sequence will target a protein to the mitochondria. 
However, these are very unreliable at present, producing many false negatives, as can be seen 
by the examples in Table 1.4 where false negatives include BCS1L, thymidine phosphorylase 
and the ADP/ATP translocase 1.
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Table 1.4: MITOPII scores for known mitochondrial proteins.
Gene Protein Ensembl protein 
reference
Probability o f export to 
mitochondria
SURF1 Surfeit locus protein 1 ENSP00000277404 0.9971
COX 15 Cytochrome c oxidase assembly 
protein COX15 homolog
ENSP00000016171 0.9755
NDUFV1 NADH-ubiquinone oxidoreductase 
51kDa subunit
ENSP00000301482 0.9653
SC01 SC01 ENSP00000255390 0.9649
PE01 Twinkle ENSP00000309595 0.9565
DGUOK Deoxyguanosine kinase ENSP00000306964 0.9558
ATP5B ATP synthase beta chain ENSP00000262030 0.9543
SDHD Succinate dehydrogenase subunit D ENSP00000280356 0.9322
SC02 SC02 ENSP00000252785 0.9054
MTIF2 Translation initiation factor IF-2 ENSP00000263629 0.9013
POLG DNA polymerase gamma subunit 1 ENSP00000268124 0.8941
COX8 Cytochrome c oxidase polypeptide 
VIII
ENSP00000301901 0.8861
UQCRC2 Ubiquinol-cytochrome-c reductase 
complex core protein 2
ENSP00000268379 0.8094
COX4 COX4 ENSP00000253457 0.6244
COX5A Cytochrome c oxidase polypeptide 
Va
ENSP00000311266 0.5718
COX10 Protoheme IX famesyltransferase ENSP00000261643 0.3922
ANT1 ADP/ATP transiocase 1 ENSP00000281456 0.2422
HK2 Hexokinase type II ENSP00000290573 0.0520
BCS1L Mitochondrial chaperone BCS1 ENSP00000248430 0.0232
TP Thymidine phosphorylase ENSP00000252029 0.0035
Version 1.0a4 of MITOPII was used for this analysis. Mitochondrial localization was predicted by a score over 0.5. 
False negatives are indicated by shading.
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1.2. Mitochondrial disorders
1.2.1. Prevalence
A review of the epidemiological literature indicates that the prevalence of mitochondrial 
disorders is at least 1 in 8,500 (Chinnery and Turnbull, 2001). This makes them, as a group, 
one of the most common types of genetic disorder. This estimate includes both childhood and 
adult cases (up to the age of retirement) as well as individuals at risk of developing a 
mitochondrial disease due to having a pathogenic mutation.
1.2.2. Phenotypes
One of the most common mitochondrial disorders is the genetically heterogeneous Leigh 
syndrome (LS). LS, which is also known as infantile subacute necrotizing 
encephalomyelopathy and first described over 50 years ago (Leigh, 1951), is a progressive 
disease with the first symptoms (including optic atrophy, ataxia and dystonia) usually appearing 
before two years of age. Magnetic resonance imaging scans show characteristic necrotic 
lesions in subcortical brain regions. Other conditions typically caused by RC defects include 
mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), myoclonus 
epilepsy with ragged red fibres (MERRF), Pearson syndrome, Leber’s Hereditary Optic 
Neuropathy (LHON), Alpers syndrome and mitochondrial neurogastrointestinal 
encephalomyopathy (MNGIE).
With most mitochondrial diseases, the muscles (cardiac and skeletal), the central nervous 
system and other tissues with high energy requirements are usually the main ones affected and 
so these diseases are often termed mitochondrial encephalomyopathies.
1.2.3. Mutations in mtDNA
1.2.3.1. Evidence for mitochondrial location
Point mutations in mtDNA only account for approximately 20% of OXPHOS defects (Smeitink et 
al., 2001). However at the last count, there were 118 different disease-causing mitochondrial 
point mutations described (Servidei, 2004). Except for one isolated case in which paternal 
inheritance was described (Schwartz and Vissing, 2002), mtDNA is inherited maternally and so 
this type of inheritance pattern in a disease pedigree is highly suggestive of a mitochondrial 
mutation.
The production of transmitochondrial cybrids can be used to confirm that the mutation is 
mitochondrial (see Figure 1.6). mtDNA is derived from enucleated patient cell lines. These 
cells are then fused with wild-type cells that have lost all their mtDNA (termed p°). If the
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enzyme deficiency is not rescued by the wild-type nuclei, then the mutation must be 
mitochondrial. Conversely, if the defect is corrected, then the mutation must be nuclear.
enuc lea ted  ce ll line  (no  
n u c le a r D NA) p ro d u ce d  
from  p a tie n t fib rob lasts  
w ith R C  de fic iency
p  ce ll
d o n o r nuc leus  
(no m tD N A )
T ransm itochondria l 
cyb rid  p ro d u ce d  -  
a ssay  resp ira to ry  cha in
Figure 1.6: Production of transmitochondrial
cybrids. PEG, polyethyleneglycol.
Histology is another commonly used method for confirming mtDNA disease. Modified Gomori 
trichrome staining often shows ragged-red muscle fibres due to excessive subsarcolemmal 
proliferation of mitochondria (see Figure 1.7). Ragged-red fibres can result from an 
accumulation of mtDNA defects due to antiretroviral treatment (see section 1.2.5.1), the aging 
process (Muller-Hocker, 1990), or a defective nuclear-encoded mtDNA maintenance system 
(see section 1.2.4.3), so do not necessarily imply that a mtDNA mutation is the primary cause of 
disease.
Figure 1.7: Modified Gomori trichrome
staining. Ragged-red fibres (arrow) suggest 
the presence of a mtDNA defect. Reproduced 
with permission from Shamima Rahman.
Finding a normal complex II activity when the other OXPHOS enzymes are reduced suggests 
defective synthesis of mtDNA-encoded proteins, because complex II is the only complex coded 
by nuclear genome alone (Hargreaves et al., 2002). This pattern can result from mitochondrial
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tRNA and rRNA mutations, and large-scale mtDNA rearrangements. However, various nuclear- 
encoded factors are also involved in the translation of mtDNA transcripts, so although it is the 
mtDNA encoded subunits affected, the inheritance is not exclusively mitochondrial. Other 
nuclear factors are similarly involved with the maintenance of mtDNA (see section 1.2.4.3).
1.2.3.2. tRNA and rRNA mutations
Although the 22 tRNA genes make up only about 10% of mtDNA sequence, they account for a 
disproportionate amount (-75%) of the known mitochondrial mutations (Smeitink et al., 2001). 
The most common of these are 3243A>G in tRNALeu which, in most cases, causes MELAS 
(Goto et al., 1990; Kobayashi et al., 1990), and 8344A>G in tRNALys which causes MERRF 
(Shoffner et al., 1990). The locations of these two mutations and five other of the most common 
disease causing point mutations are shown in Figure 1.3. Pathogenic mutations in the two 
rRNA genes are much less common.
1.2.3.3. Mutations in structural subunits
Numerous disease-causing mutations have been found in all 13 mitochondrial genes encoding 
OXPHOS subunits. CO I and CYTB are particularly prone to mutation with 28 and 19 different 
mutations described on the mitomap database (www.mitomap.org), respectively. In most 
cases, mutations in a single subunit can cause a range of different phenotypes depending on 
which amino acid residue is affected, the level of heteroplasmy and tissue distribution of the 
mutation, and the presence of secondary modifying mutations. For example, whilst it is known 
that mutations in ND5 can cause LS and LHON, more recent studies have shown that ND5 may 
also be a hotspot for MELAS mutations (Liolitsa et al., 2003) and is implicated in the 
tumorigeneis of thyroid cancer (Abu-Amero et al., 2005).
1.2.3.4. mtDNA deletions
The majority of all deletions in mitochondrial DNA tend to fall within the major arc of the 
mitochondrial genome (see Table 1.5 and Figure 1.3), situated in between the origin of light 
strand replication (5721-5798bp) and the origin of heavy strand replication (110-441 bp). 
Identical deletions have been reported in Kearns-Sayre Syndrome (KSS), Pearson syndrome, 
and chronic progressive external ophthalmoplegia (CPEO). However, the tissue distribution of 
the mutant mtDNA is different. In Pearson syndrome, high levels of mutant mtDNA are present 
in all tissues, particularly in the blood. In KSS, deletions are more localized to muscle and the 
central nervous system. In CPEO, it is thought that the mutant load is further localized to the 
skeletal and ocular muscles.
A common deletion seen in KSS is 4977bp long (see Table 1.5 and Figure 1.3). This knocks 
out C03, ND3, ND4L, ND4 and ATP6 as well as half of the ATP8 and ND5 genes. The 
mitochondrial tRNAs for glycine, argenine, histidine, serine and leucine(CUN) are also in this
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region. As repeats are often found to flank deletion breakpoints (see Table 1.5), it has been 
hypothesised that the deletion mechanism is based upon illegitimate homologous recombination 
(Schon et al., 1989). These single mtDNA rearrangements usually arise sporadically, because 
large mtDNA deletions tend to be eliminated from the female germ line and so are not inherited.
Multiple mtDNA deletions can be seen in some patients with progressive external 
ophthalmoplegia (PEO). These mtDNA rearrangements arise due to impaired maintenance of 
mtDNA resulting from nuclear mutations. The nuclear genes involved in mtDNA maintenance 
are described in section 1.2.4.3.
Table 1.5: The four most common mitochondrial deletions.
Junction Deletion size (bp) Genes deleted Flanking
repeats
Repeat location n
8469:13447 4977 MTND5-MTA TP8 D, 13/13 8470-8482/13447-13459 200
8271:8281 9 MTNC3 NR NR 700
7841:13905 6063 MTC02-MTND5 D, 6/8 7842-7849/13905-13912 108
8648:16085 7436 MTA TP6-MTTP D, 12/12 8637-8648/16073-16084 >70
D = direct repeat, NR = no repeats reported, the fraction indicates the identity of the two 
flanking repeats, n = number of subjects in which the deletion was detected. Data from 
Mitomap (www.mitomap.org).
1.2.4. Mutations in nuclear genes
1.2.4.1. Structural genes
In addition to the 13 mtDNA encoded proteins, 77 proteins which are translated on cytoplasmic 
ribosomes are targeted to the mitochondria for inclusion into the 5 large enzyme complexes that 
make up the OXPHOS system. Mutations in many of these genes have been found to be the 
cause of RC disorders. For example, the flavoprotein (Fp) subunit gene of SDH has been 
implicated in complex II deficiency in patients with RC disorders. This was the first nuclear gene 
mutation discovered to cause a human RC disorder (Bourgeron et al., 1995). Many other 
nuclear structural genes are now also known to be candidates for these disorders. For 
example, mutations in 9 of the 39 nuclear-encoded structural subunits of complex I {NDUFS1, 
NDUFS2, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFV1, NDUFS6, and NDUFV2) have all 
been associated with complex I deficiency. These mutations are associated with a variety of 
autosomal recessive, severe, early onset, clinical phenotypes including LS, cardiomyopathy, 
and encephalomyopathy. UQCRB is the first of the 10 nuclear complex III subunits in which 
pathogenic mutations have been discovered (Haut et al., 2003), whereas no mutations have yet 
been found in nuclear subunits of complex IV or V (see Table 1.6 ).
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Table 1.6: Selection of nuclear genes associated with OXPHOS disorders, grouped by type.
Gene Affected
complex
Location Identification method Reference
Nuclear structural genes
NDUFS4 (AQDQ) I 5q11 Candidate gene analysis van den Heuvel et 
al., 1998
NDUFS7 (PSST) 1 19p13 Candidate gene analysis Triepels et al., 1999
NDUFS8 (TYKY) 1 11q13 Candidate gene analysis Loeffen etal., 1998
NDUFV2 1 18p11 Candidate gene analysis Benit et al., 2003
NDUFS6 1 5p15.33 Candidate gene, Homozygosity 
mapping, MMCT and 
transcriptome analysis
Kirby et al., 2004
SDHA II 5p15 Candidate gene analysis Bourgeron et al., 
1995
UQCRB III 8q22 Candidate gene analysis Haut et al., 2003
Assembly factors
B17.2L 1 5q Bioinformatics Ogilvie et al., 2005
BCS1L III 2q33 Candidate gene analysis de Lonlay et al., 
2001; Visapaa et 
al., 2002
SURF1 IV 9q34.2 MMCT Tiranti et al., 1998; 
Zhu et al., 1998
COX10 IV 17p12-11.2 Homozygosity mapping Valnot et al., 2000a
COX15 IV 10q24.2 Functional complementation Antonicka et al., 
2002
SC01 IV 17p12-13 Linkage Valnot et al., 2000b
SC02 IV 22q13 Candidate gene Papadopoulou et 
al., 1999
ATP12 V 17p11 Candidate gene De Meirieir et al., 
2004
mtDNA maintenance and mRNA processing
TP (thymidine 
phosphorylase)
1, III, IV, V 22q13.32-qter Linkage analysis Hirano et al., 1998; 
Nishino et al., 1999; 
Nishino et al., 2000
ANT1 (ADP/ATP 
transiocase 1)
1, III, IV, V 4q34 Linkage analysis Kaukonen et al., 
1999; Kaukonen et 
al., 2000
Twinkle (helicase) 1, III, IV, V 10q24 Linkage analysis Li et al., 1999; 
Spelbrink et al., 
2001
POLG (catalytic subunit 
of DNA polymerase 
gamma)
1, III, IV, V 15q25 Linkage analysis Van Goethem et al., 
2001; Naviaux and 
Nguyen, 2004
DGUOK
(deoxyguanosine
kinase)
1, III, IV, V 2p13 Homozygosity mapping Mandel et al., 2001
TK2 (thymidine kinase) 1, III, IV, V 16q22 Candidate gene analysis Saada etal., 2001
SLC25A19
(mitochondrial
deoxynucleotide carrier)
1, III, IV, V 17q25.3 Linkage + haplotype analysis Rosenberg et al., 
2002
LRPPRC IV 2p21 Linkage disequilibrium and 
“integrative genomics"
Lee et al., 2001; 
Mootha et al., 2003
Mitochondrial translation defects
MPRS16 (mitochondrial 
ribosomal protein 16)
1, III, IV, V 10q22.2 Candidate gene Miller et al., 2004
PUS1 (pseudouridine 
synthase 1)
1, III, IV, V 12q24.33 Homozygosity mapping Casas et al., 2004; 
Bykhovskaya et al., 
2004; Zeharia et al., 
2005
EFG1 (mitochondrial 
elongation factor G1)
1, III, IV, V 3q25.32 MMCT and deletion mapping Coenen et al., 2004
Other nuclear genes still to be found
Putative ATP synthase 
gene
V nuclear p  fusions Housteketal., 1999
Gene for a “novel 
syndrome affecting 
multiple mitochondrial 
functions”
Multiple 2p14-2p16.1 MMCT & homozygosity mapping Seyda et al., 2001
MMCT, microcell-mediated chromosome-transfer.
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1.2.4.2. Assembly genes
As might be expected with such large enzyme complexes, many proteins although not being 
structural subunits themselves, are involved with the assembly process. Mutations in genes 
encoding these assembly factors can also cause RC deficiency (see Table 1.6). As yet, the 
majority of assembly genes associated with human diseases have been for complex IV. Many 
of these human genes were discovered through their homology to yeast genes which, when 
mutated, also cause RC and growth defects (Petruzzella et al., 1998).
For example mutations in SC02, which encodes a protein involved in copper trafficking to 
complex IV, results in infantile cardioencephalomyopathy (Papadopoulou et al., 1999). Copper- 
histidine supplementation in SC02-deficient myoblasts has been shown to rescue COX activity 
in vitro and more recently to resolve severe hypertrophic cardiomyopathy in a patient with SC02 
mutations (Freisinger et al., 2004).
Mutations in COX10, which encodes heme A:farnesyltransferase and catalyzes the first step in 
the conversion of protoheme to the heme A prosthetic groups of cytochrome c oxidase, can also 
cause COX deficiency (Valnot et al., 2000). Other assembly factors that have been found to be 
mutated in OXPHOS disorders include SURF1 (Zhu et al., 1998; Tiranti et al., 1998), a relatively 
common cause of LS (see Table 1.7); BCS1L which has been implicated in complex III 
disorders (de Lonlay et al., 2001; Visapaa et al., 2002); and most recently ATP12, a complex V 
assembly factor (De Meirleir et al., 2004).
1.2.4.3. Genes involved with maintenance of mtDNA
There appears to be no de novo synthesis of deoxynucleotides in the mitochondria. The 
nucleotides required for replication of DNA either need to be imported from the cytosol by the 
mitochondrial deoxynucleotide carrier, or are recycled using the salvage pathway. The 
production of cytosolic nucleotides is closely regulated with the cell cycle, so in cells that have 
stopped dividing, the mitochondria must rely solely on the salvage pathway.
Deoxyguanosine kinase (dGK) and thymidine kinase 2 (TK2) are an important part of this 
mitochondrial deoxynucleoside salvage pathway. These proteins are responsible for the initial 
rate-limiting phosphorylation step. dGK phosphorylates deoxyguanosine and deoxyadenosine, 
whilst TK2 phosphorylates deoxythymidine, deoxycytidine and deoxyuridine. Mutations in either 
of these genes can result in recessive mtDNA depletion syndrome (Mandel et al., 2001; Saada 
et al., 2001). Another enzyme, thymidine phosphorylase (TP) is involved with the degradation 
of thymidine to thymine. Mutations in the gene encoding this enzyme cause increased cellular 
levels of thymidine, an overload to the mitochondrial thymidine salvage pathway and result in 
mtDNA instability and MNGIE (Nishino et al., 1999). Mutations in the skeletal muscle isoform of 
the ADP/ATP translocase (ANT1J cause multiple mtDNA deletions and PEO, but with dominant 
inheritance (Kaukonen et al., 2000). These studies demonstrate that balanced pools of each
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nucleotide are required for effective mtDNA maintenance. A diagram summarizing 
mitochondrial nucleotide metabolism and the salvage pathway is presented as Figure 8.2 in the 
final chapter of this thesis.
Instability of mitochondrial DNA can also result from defective proteins that are directly involved 
with the process of mtDNA replication. Mutations in the gene encoding the catalytic subunit of 
mitochondrial DNA polymerase gamma (POLG) can cause multiple deletions in mtDNA in 
patients with dominantly inherited PEO (Van Goethem et al., 2001). Mutations in Twinkle 
(C10ORF2), which encodes a protein with structural similarity to the phage T7 gene 4 
primase/helicase, also cause autosomal dominant PEO and multiple mtDNA deletions 
(Spelbrink et al., 2001).
Recently, POLG mutations have been associated with mtDNA depletion and Alpers syndrome, 
without the characteristic deletions seen previously (Naviaux and Nguyen, 2004). The reason 
why some POLG mutations cause dominantly inherited multiple mtDNA rearrangements whilst 
others cause recessive mtDNA depletion syndrome remains unclear.
1.2.4.4. Genes involved in mRNA processing
An ancestral mutation in the LRPPRC gene, which encodes a mRNA-binding protein likely to be
involved in mtDNA transcript processing, is the cause of French-Canadian LS (Mootha et al.,
2003).
1.2.4.5. Mitochondrial translation defects
Mitochondrial elongation factor G1 (Coenen et al., 2004), mitochondrial ribosomal protein 16 
(Miller et al., 2004) and pseudouridine synthase 1 (Bykhovskaya et al., 2004; Zeharia et al., 
2005) are all nuclear-encoded factors involved with translation of mitochondrial transcripts and 
have been linked to mitochondrial disorders in humans.
1.2.5. Other causes of damage to mtDNA and mitochondrial defects
1.2.5.1. Retroviral treatment
Various anti-retroviral therapies have been developed to treat AIDS, and in recent years this 
has greatly improved the prognosis. In combination with elective caesarean section, anti­
retrovirals can also significantly decrease vertical transmission rates of HIV to about 1% 
(Mandelbrot et al., 1998). Zidovudine, a nucleoside analogue also known as azidothymidine or 
AZT, was the first of these drugs to be approved in 1987. An absence of the 3’-hydroxyl group 
present in thymidine (see Figure 1.8 ), means that the compound is more lipophilic and can more 
easily cross membranes and the blood-brain barrier. The other effect of this missing hydroxyl 
group is that if the active phosphorylated form of AZT is incorporated into DNA, other
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nucleotides cannot be attached to it. Thus DNA synthesis is terminated. AZT inhibits the viral 
reverse transcriptase 100 times more effectively than the nuclear DNA polymerases. However 
as the mitochondrial DNA polymerase gamma is related to viral reverse transcriptases, AZT is 
also thought to inhibit mitochondrial DNA synthesis. A recent study on HIV patients undergoing 
active anti-retroviral therapy who had severe side effects, found significant mitochondrial 
damage; lactate accumulation, mitochondrial morphologic alterations in muscle, and 
biochemical defects in muscle and liver. Southern blot and PCR-based analyses found multiple 
deletions of the muscle mtDNA and reduction of the mtDNA copy number in the majority of 
patients (Vittecoq et al., 2002).
AZT Thymidine
OH
Figure 1.8: Chemical structure of azidothymidine (AZT) 
in comparison to thymidine. The difference between the
two molecules is highlighted in red.
1.2.5.2. Age
mtDNA deletions have been found to accumulate with age. In a study of subjects ranging from
3 to 91 years old, long-range PCR of the whole mitochondrial genome in the young controls (3
to 23 years old) yielded only one band (16.6kb) while amplification from older controls revealed 
one or more additional smaller bands. The amplification from the 91-year-old control showed a 
pattern similar to patients with multiple mtDNA deletions (Tengan and Moraes, 1996).
1.2.5.3. Radiation
Radiation might also be a cause of mtDNA deletions. A recent study showed an increase of 
both relative mtDNA content and number of mtDNA deletions in papillary thyroid carcinoma cells 
from patients possibly exposed to radioactive fallout from Chernobyl than in control tumours 
(Rogounovitch et al., 2002).
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1.2.6. Problems faced when studying mitochondrial disorders
There remains a high proportion of cases where, despite sequencing all known candidate genes 
(both nuclear and mitochondrial) and looking at possible environmental causes, the cause of the 
mitochondrial disorder remains unknown.
Various factors make the study of mitochondrial disorders more challenging than might 
otherwise be expected. Firstly, wild-type and mutant mtDNA can coexist in the same cell. This 
phenomenon is termed heteroplasmy. Random segregation of mtDNA when a cell divides 
means that the daughter cells can have very different levels of heteroplasmy (see Figure 1.9). 
This, together with the different selective pressure against the mutation in different tissues, 
means that from cell to cell (see Figure 1.7) and from tissue to tissue, mutant load can be vastly 
different. To be sure of a complete picture, more sensitive techniques such as pyrosequencing 
(White et al., 2005) or denaturing high performance liquid chromatography (van Den Bosch et 
al., 2000; Meierhofer et al., 2005) should be considered, to complement standard mtDNA 
sequencing. Both these methods can detect mutations reliably at levels down to 1% 
heteroplasmy. One should also aim to analyse DNA from as many tissues as is practical to get 
a complete picture of mutant load in the patient and increase the chances of finding the 
mutation. Mutant load can even be determined in single muscle fibres using a modified PCR- 
RFLP (Taylor et al., 2001a; Zsurka et al., 2005) and quantitative PCR methods (He et al., 2002).
MUTANT MITOCHONDRIA
WILD TYPE MITOCHONDRIA NUCLEUS
SEGREGATIONRANDOM
80% 100%
% Mutant Mitochondrial DNA
Figure 1.9: Random segregation of mitochondria in daughter cells.
Depending on its level of heteroplasmy in different tissues, the same mtDNA mutation can 
cause a range of conditions (for example, the deletions described in section 1.2.3.4). 
Conversely, mutations in different genes can cause the same disease. This genetic 
heterogeneity is perhaps best exemplified by LS which can be caused by mutations in complex 
IV assembly genes, complex I genes, complex II genes, pyruvate dehydrogenase genes,
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ATPase 6  and mitochondrial tRNA mutations (see Table 1.7). Unless complementation 
analysis has been undertaken, this genetic heterogeneity makes it risky to combine pedigrees 
for mapping studies or to group patients into cohorts for association studies.
Table 1.7: Causes of Leigh or Leigh-like syndrome. Adapted from (Dahl, 1998),
frequencies originally from (Rahman et al., 1996).
Defect Frequency (%) Affected genes
mtDNA mutation 18 MTATP6, MT-tRNALys and mtDNA 
deletions
Pyruvate dehydrogenase 10 PDHA1
Complex I 19 NDUFS8
COX deficiency 14 SURF1
Complex II + other 39 SDHA
Finally, because of the severity of these disorders, large pedigrees are uncommon and so 
conventional linkage analysis is not always possible. Therefore, one has to rely on either 
homozygosity mapping in consanguineous families, or other alternative methods to find nuclear 
genes associated with these disorders (see Table 1.6 ). If a specific biochemical phenotype can 
be assayed, then microcell-mediated chromosome-transfer (MMCT) can be used on 
immortalised patient cell lines. In MMCT, microcells are created which harbour a single human 
chromosome tagged with a selectable marker. These are fused with the patient’s fibroblasts 
and if the biochemical defect is corrected, then the gene in question must reside on that human 
chromosome. This technique has proved successful in the identification of mutations in the 
SURF1 gene as a common cause of LS (Zhu et al., 1998) and of SUMF1 as a cause of multiple 
sulfatase deficiency (Cosma et al., 2003), a lysosomal storage disorder. The technique has 
also been used to map a novel syndrome affecting multiple mitochondrial functions to the short 
arm of chromosome 2 (Seyda et al., 2001).
A combined or “integrative genomics” approach has also been used successfully in a couple of 
instances to select candidate genes for mutational analysis (Mootha et al., 2003; Tiranti et al.,
2004). In both cases this approach was used when a large number of known or predicted 
genes (30 and -130 respectively) lay within the critical interval defined by linkage analysis. The 
lack of any obvious candidates led both authors to use neighbourhood analysis of expression 
microarray data to determine which of these genes are co-regulated with known mitochondrial 
genes. The approach used by Mootha e t a l also combined tandem mass spectrometer data to 
further narrow down the number of genes before mutational analysis.
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1.2.7. Potential gene therapy
Unfortunately with many of these mitochondrial diseases, life expectancy is low and the therapy 
options at present are very limited. One approach has been to use concentric exercise training 
in patients to induce muscle hypertrophy and stimulate muscle satellite cells (which typically 
have a lower mutational load) to fuse with myofibres. This was initially shown to increase wild- 
type mtDNA in muscle and was termed “Gene Shifting” (Taivassalo et al., 1999). However, a 
follow up study with a larger group of 1 0  patients indicated that although the physiological and 
biochemical defects were improved after a 14 week period of exercise, the ratio of mutant to 
wild-type genomes did not decrease (Taivassalo et al., 2001). A previous and very similar 
approach used bupivacaine hydrochloride instead of exercise to induce muscle necrosis and 
regeneration (Clark et al., 1997). However a further study in which this chemical was injected 
into the levator eye muscle of patients with ptosis was not successful (Andrews et al., 1999b).
Another approach has been to recode mutated mitochondrial genes using the “universal” code 
and add an artificial MTS for allotropic expression. This has been successfully accomplished in 
vitro for MTATP6 (Manfredi et al., 2002) and A/D4 (Guy et al., 2002) but this has not yet been 
repeated in vivo. tRNAs have also been targeted from the cytosol into the mitochondria. In 
fibroblasts from a patient with MERRF caused by the A8433G tRNA(Lys) mutation, an imported 
tRNA was functionally active and partially rescued several mitochondrial functions, showing how 
the RNA import pathway may also potentially be used to treat patients with mtDNA disease 
(Kolesnikova et al., 2004).
Restriction endonucleases which can digest mutant mtDNA (but leave wild-type DNA 
unscathed) have also been targeted to the mitochondrion. A recent in vivo study has 
successfully targeted ApaLI to mouse tissues and observed a significant shift in heteroplasmy in 
muscle and brain (Bayona-Bafaluy et al., 2005). This approach can only work for patients 
harboring certain heteroplasmic pathogenic mutations which create a restriction site that is not 
otherwise present in human mtDNA.
In summary, there are numerous exciting methods being developed for the treatment of 
mitochondrial disorders. However, translating this research to the successful treatment of 
human disease is still a long way off.
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1.3. Aims of this thesis
The broad aims of this study were to discover novel mutations and genes that can result in 
mitochondrial dysfunction and ultimately lead to human disease. Functional studies on any 
mutations found might lead to a better biochemical understanding of mitochondrial and RC 
function. This work may also lead to improved and earlier diagnosis, the availability of prenatal 
testing and counselling of parents with affected children, and may in the future lead to better 
treatment strategies and management of clinical symptoms.
Due to the clinical and genetic heterogeneity amongst patients with mitochondrial disease, it 
was intended to use three main analytical approaches. Firstly, in patients from pedigrees 
suggestive of maternal inheritance or in whom cybrid cell studies indicated a mitochondrial 
mutation, mtDNA would be sequenced. Any mutations found would then be assessed for 
heteroplasmic load in different tissues, and functional studies of any novel change would be 
carried out to prove pathogenicity. In cases where mtDNA mutations were excluded, alternative 
nuclear candidate genes could then be considered. These experiments are described in 
Chapter 3.
Secondly, where biochemical or Southern blot data suggested a good nuclear candidate gene, 
this would be sequenced. Thus in Chapter 4 the aim was to sequence the four genes that 
encode SDH subunits in order to find the underlying molecular cause of disease in a patient 
with a rare complex II deficiency. In Chapters 6  and 7, the goal was to sequence the gene 
encoding the mitochondrial DNA polymerase in a long-standing cohort of patients, and thus 
explain Southern blot data which had previously indicated quantitative or qualitative mtDNA 
defects.
Finally, in patients where all good candidates had previously been excluded, the intention was 
to use homozygosity mapping in order to map novel disease genes. In Chapter 5, two Israeli 
pedigrees are described, one with complex I deficiency, and the other demonstrating mtDNA 
depletion. Consanguinity in both families provided the opportunity to map regions of the 
genome that were shared identical-by-descent in affected patients and that were not shared by 
unaffected siblings. Thus the aim was to first identify and confirm a genetic candidate region, 
and then to decipher the pathogenic mutation involved. In another patient with multiple 
mitochondrial enzyme defects, it was intended to look for homozygosity at a specific genetic 
locus on chromosome 2  which had previously been linked to multiple mitochondrial defects. 
Homozygosity mapping was also to be used to uncover the molecular cause of disease in three 
Cypriot families, in whom a single ancestral mutation was hypothesized.
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Chapter 2: Materials and methods
General materials and methods that are common to multiple chapters are described in detail 
here. Methods which are used only in specific chapters have been incorporated into those 
respective chapters. All results given in patient details sections are from clinical service 
laboratories, unless otherwise stated.
2.1. DNA methods
2.1.1. DNA extractions
DNA extractions were carried out from whole blood, cultured fibroblasts, cybrid cells and muscle 
biopsy samples using the Nucleon BACC Genomic DNA extraction kit (Amersham), according 
to the manufacturer’s protocol. Prior to DNA extraction, muscle samples were cut into small 
pieces using a sterile scalpel and placed into a 1.5ml eppendorf containing 600pl of DNA 
extraction buffer (0.1 M EDTA, 10mM Tris, pH 8.0), 40pl of 10% sodium dodecyl sulphate (SDS) 
and 100pl proteinase K (20mg/ml, Ambion) and incubated for 4h at 56°C.
2.1.2. DNA quantification
DNA was quantified by measuring absorbance of a 1/40 dilution of the sample at 260nm (10D = 
50pg/ml of double-stranded DNA) on the Eppendorf BioPhotometer. DNA purity was 
determined by measuring the A26onm/A28onm ratio. A ratio of 1.8-2.0 indicated suitable purity for 
the DNA to be used in further experiments. A ratio of less than 1.8  indicated contamination with 
protein or phenol (which could interfere with PCR) and meant that quantification of DNA would 
not be accurate.
2.1.3. Polymerase chain reaction
DNA fragments were amplified using the polymerase chain reaction, usually abbreviated as 
PCR (Mullis et al., 1986; Saiki et al., 1988). The standard PCR mix consisted of 1.5mM Mg2+, 
1mM dNTPs (0.25mM of each, Bioline), 200nM of each primer and 0.025U/fil of DNA 
Polymerase (Bioline). Reaction volumes were made up to 20pl with double-distilled water 
(ddH20). For all PCRs, ~100ng of template DNA was used. The standard cycling conditions 
consisted of an initial denaturation step at 95°C for 5min, followed by 35 cycles of denaturation 
at 95°C for 30s, annealing at 55°C for 30s and extension at 72°C for 30s. The final extension 
step at 72°C was for 1 0 min. Unless otherwise stated, PCR products and RFLP fragments were 
separated on a 1.5% agarose gel that contained 0.25pg/ml of ethidium bromide and then 
visualised under UV illumination. 500ng of a 100bp ladder (Invitrogen) was used as a size 
standard.
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In PCRs where optimisation was necessary, varying the annealing temperature (50-65°C) was 
sufficient in most cases. In some reactions, the Mg2+ concentration was also increased to 
2.5mM. On rare occasions, the addition of 5% dimethyl sulfoxide (DMSO) was necessary to 
disrupt base-pairing and thus facilitate strand separation for efficient amplification of GC rich 
fragments.
To monitor for any possible contamination, a negative control tube containing 1jil of ddH20  
instead of template DNA was included for each reaction.
2.1.4. Sequencing
Primers and unincorporated dNTPs were removed prior to sequencing reactions. Unless 
otherwise stated, this was done using the EXOSAP method. (The exonuclease I (Exol) 
catalyzes the removal of nucleotides from single-stranded DNA in the 3’ to 5’ direction, and thus 
digested the remaining PCR primers, whilst shrimp alkaline phosphatase (SAP) was used to 
dephosphorylate unincorporated dNTPs.) 15pl of PCR product and 1.5pl of the 10x SAP 
reaction buffer were incubated with 0.75U of SAP (USB) and 7.5U of Exol (NEB) at 37°C for 
25min followed by denaturation of the enzymes at 80°C for 15min.
Di-deoxy sequencing reactions were carried out using the BigDye Terminator (version 3.1) cycle 
sequencing kit from Applied Biosystems, according to manufacturer’s instructions. 4jal of the 
EXOSAP reaction product was added to 2pl of the RR mix, 3fo.l of the 5x reaction buffer, 
3.3pmol of either the forward or reverse primer, and ddH20  to make up the reaction volume to 
20pl. Cycling consisted of a 1min initial denaturation at 96°C, followed by 35 cycles of 
denaturation at 96°C for 30s, annealing at 50°C for 15s and extension/chain termination at 60°C 
for 4min.
To purify the sequencing reactions, 96 well filter plates (Millipore) were filled with Sephadex G- 
50 (cross-linked dextran gel, Sigma). The Sephadex was then rehydrated with 350pl of ddH20  
in each well and left for at least an hour at 4°C. The plate was spun at 91 Og for 5min to remove 
the excess water and to flatten the Sephadex. The sequencing samples were dropped onto the 
top of the Sephadex, the filter plate was then placed on top of a clean 96 well plate and then 
spun again at 91 Og for 5min.
Purified sequencing reactions were denatured at 95°C for 2min, placed immediately onto ice 
and then run on the automated MegaBACE™ capillary sequencer (Amersham) for 100min at 
9000V. Sample injection was at 3000V for 60s.
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2.1.5. Microsatellite analysis
Microsatellite markers flanking the locus in question were selected from the Research Genetics 
Human Screening Set 8 , the ABI PRISM™ Linkage Mapping Set (ABI) or from the Ensembl 
Human Genome Browser. After PCR amplification, the labelled DNA fragments were diluted 
1/10 to 1/18 with ddH20 , depending on strength of PCR product and then run together with the 
ET550-R size standard (final concentration 1/20, Amersham Biosciences) at 10,000V for 75min 
on the MegaBACE™, according to manufacturer’s instructions. Samples were denatured at 
95°C for 2min and placed on ice before loading. Sample injection was at 3000V for 45s. The 
data were analysed using Genetic Profiler software (Amersham).
For experiments on Patient 13’s DNA, microsatellites were run on the ABI377. 1pl of Genescan 
500 TAMRA size standard, 3pl of formamide and 1pl of blue loading dye (25mM EDTA, pH 8.0 
and 50mg/ml blue dextran) was mixed per PCR reaction to be analysed. Then 3pl of this 
loading mix was mixed with 1pl of the diluted PCR reaction. This was denatured at 95°C for 
5min and placed on ice before loading 2pl on a 4% acrylamide gel. After manual tracking of 
lanes and matching to the TAMRA size standard, the Genescan software was used to size the 
microsatellites.
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2.2. Spectrophotometric enzyme assays
2.2.1. General points about these enzyme assays
• The solvent used in the preparation of all reagents was fresh, distilled H20, unless 
otherwise stated.
• All skeletal muscle homogenates and fibroblasts were stored at < -70°C. Prior to assay, 
sample homogenate or cell suspension was thawed and refrozen in liquid nitrogen
twice, and then thawed and diluted in the appropriate assay buffer. The freeze-thaw
cycles were to break the cell membrane.
• Enzyme activity may be lost by poor sample handling, e.g. delay in freezing biopsy.
• Samples were mixed in cuvettes by covering the top of the cuvette with parafilm film
and inverting four times.
• The dilution factor was usually 1/5 for muscle samples. However, fibroblasts have 
lower RC activities and so were not diluted.
• Enzyme activities were expressed as a ratio to citrate synthase to normalise for 
mitochondrial enrichment.
• These protocols were based upon the standard operating procedures used by the 
Neurometabolic Unit, National Hospital, London.
2.2.2. Complex I
Oxidation of NADH is catalyzed by mitochondrial complex I [EC 1.6.5.3.]. Electrons are 
transferred from NADH to ubiquinone (coenzyme QO, which is reduced to ubiquinol. Activity 
was measured as the rotenone-sensitive decrease in NADH at 340nm (see Figure 2.1). BSA 
was also added as a carrier protein, to help solubilise ubiquinone. The method below has been 
modified from that described (Ragan et al., 1988).
340nm
rotenone
NADH
ubiquinone ubiquinol
Figure 2.1: Schematic diagram of the complex I assay.
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Reagents:
1 ) 25mM potassium phosphate, 1 0 mM MgCI2, pH 7.2
2) 100mM KCN
3) 50mg/ml BSA (fatty acid free)
4) 5mM ubiquinone (CoQO
5) 1mM rotenone, 4mg/10ml ethanol
6 ) 5mM NADH (made up fresh)
Method:
Assay was carried out at 30°C on a Kontron Unikon 940 spectrophotometer. This was set up as 
follows: auto rate assay; X 340nm; auto rate; reading 30 x 0.5min1; cell changer mode 6 S/6 R; 
auto zero on; calculation off. Samples were set up as follows:
Sample (pi) Reference (pi)
Phosphate buffer 800 800
BSA 50 50
NADH 30 30
KCN 1 0 1 0
Homogenate 2 0 2 0
H20 80 90
Total 1 0 0 0 1 0 0 0
Cuvettes were mixed gently and placed in spectrophotometer (references at back), left for 2 min 
to reach 30°C. 10pl ubiquinone was added to the front cuvettes, which were then mixed. 
Regular spectrophotometric measurements at 340nm were commenced. After 5min, 20p.l 
rotenone was added and cuvettes were mixed. It took 2-3min for the rotenone to take effect, 
after which measurement was continued for a further 5min.
Calculation:
AAi = absorbance/min prior to rotenone addition 
AA2 = absorbance/min after rotenone addition 
AA = AAf - AA2
Using Beer-Lambert Law: AA = e x c x I
e = extinction coefficient, I = path length (1 cm), c = concentration
AA = c £340™ of NADH = 6.81 x 103 M'1cm'1
8
= mole/min/l.
-  1000
= mole/min/ml.
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x 50 (dilution factor of sample (20pl) in 1000[il) 
x 5 (dilution factor of sample prior to assay)
= mole/min/ml. (best expressed as nmole/min/ml)
2.2.3. Complex II
Complex II (succinate dehydrogenase) was assayed essentially as described (Birch-Machin, 
1993): Complex II [EC 1.3.5.1] transfers electrons from succinate to ubiquinone, which is 
reduced to ubiquinol. Ubiquinol subsequently reduces 2,6-dichlorophenolindophenol (DCPIP). 
Complex II activity was thus measured by the succinate-dependent 2-thenoyltriflouroacetone 
(TTFA) sensitive reduction of DCPIP at 600nm (see Figure 2.2).
600nm
DCPIP (ox) DCPIP (red)
ubiquinone ubiquinol ubiquinone
succinate turn a rate
FA
Figure 2.2: Schematic diagram of the complex II assay.
Reagents:
1) 100mM potassium phosphate, pH 7.4
2) 2.5mM EDTA
3) 3mM DCPIP (made up fresh)
4) 100mM KCN (a complex IV inhibitor)
5) 0.5M succinate
6) 100mM TTFA, 22mg/ml ethanol
7) 5mM ubiquinone (C0 Q1)
8) 1mM rotenone
Method:
Assay was carried out at 30°C on a Kontron Unikon 940 spectrophotometer. This was set up as 
follows: auto rate assay; X 600nm; auto rate; reading 30 x 0.5min'1; cell changer mode 6S/6R; 
auto zero on; calculation off. Samples were set up as follows:
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Sample (pi) Reference (pi)
Phosphate buffer 500 500
EDTA 40 40
KCN 10 10
DCPIP 40 40
Homogenate 20 20
Rotenone 10 10
Succinate 40 40
TTFA 10
H20 320 330
Total volume: 1000 1000
Cuvettes were mixed gently, placed in the spectrophotometer (references at the back) and left 
for 10min to minimise succinate dependent non-linear reaction. 10pl ubiquinone was added to 
the front cuvettes. These were mixed. Measurement of absorbance at 600nm was initially for 
6-7min. After this time, 10pl TTFA was added to the front cuvettes. These were mixed and 
measurements continued for a further 7min.
Calculation:
AA-i = absorbance/min prior to TTFA addition, AA2 = absorbance/m in after TTFA addition 
AA = AA-i - AA2
Using Beer-Lambert Law: AA = e x c x I 
6 = extinction coefficient, I = path length (1cm), c = concentration
AA = c £6oonm of oxidised DCPIP = 19.1 x 103M'1 cm'1
8
= mole/mi n/l 
-  1000
= mole/min/ml
x 50 (dilution factor of sample (20pl) in 1000pl) 
x 5 (dilution factor of sample prior to assay)
= mole/min/ml. (best expressed as nmole/min/ml)
Temperature sensitivity of complex II was assessed by repeating the assay at 26°C and 41 °C 
(in addition to the standard 30°C) in a similar fashion to recent studies on acyl-CoA 
dehydrogenase mutations (O'Reilly et al., 2004).
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2.2.4. Complex ll+lll
Complex II [EC 1.3.99.1] catalyses the oxidation of succinate (C4H60 4) to form fumarate. 
Electrons are transferred through complex II to ubiquinone, which is reduced to ubiquinol. 
Ubiquinol is then used to reduce cytochrome c, a reaction which is catalysed by complex III [EC
1.10.2.2.]. Complex ll+lll activity was measured by the succinate-dependent, antimycin A 
sensitive reduction of cytochrome c at 550nm (see Figure 2.3). The potassium cyanide (KCN) 
inhibits the oxidation of reduced cytochrome c by complex IV. This method is based on one 
described previously (King, 1967).
550nm
cytc (ox) cytc (red)
ubiquinone ubiquinol ubiquinone
antimycin A
succinate fumarate
Figure 2.3: Schematic diagram of the complex ll+lll assay.
Reagents:
1) 166mM potassium phosphate, pH 7.4
2) 15mM EDTA
3) 0.8mM cytochrome c
4) 100mM KCN
5) 0.5M succinate (disodium salt)
6) 1mM antimycin A, 2mg/2ml ethanol
Method:
Assay was carried out at 30°C on a Kontron Unikon 940 spectrophotometer. This was set up as 
follows: auto rate assay; X 550nm; auto rate; reading 30 x 0.5min'1; cell changer mode 6S/6R; 
auto zero on; calculation off. Samples were set up as follows:
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Sample (pi) Reference (pi)
Phosphate buffer 600 600
EDTA 20 20
KCN 10 10
Cytochrome c 125 125
Homogenate 20 20
H20 185 225
Total 1000 1000
Cuvettes were mixed gently, placed in spectrophotometer (references at back) and left for 2min. 
40pl of succinate was added to the front cuvettes. Cuvettes were mixed and absorbance at 
550nm measured for 6-7min. After this time, 10pl of antimycin A was added to front cuvettes, 
which were mixed. Measurements continued for a further 5min.
Calculation:
AA, = absorbance/min prior to antimycin A addition 
AA2 = absorbance/min after antimycin A addition
AA = AAi - AA2
Using Beer-Lambert Law: AA = 8 x c x I 
8 = extinction coefficient, I = path length (1cm), c = concentration
AA = c &550nm of reduced cytochrome c = 19.2 x 103 M'1 cm'1
8
= mole/min/l.
-s- 1 0 0 0
= mole/min/ml.
x 50 (dilution factor of sample (20pl) in 1000pl) 
x 5 (dilution factor of sample prior to assay)
= mole/min/ml. (best expressed as nmole/min/ml)
2.2.5. Complex IV
This assay measures the oxidation of reduced cytochrome c at 550nm (see Figure 5.4) by 
cytochrome c oxidase [EC 1.9.3.1.]. Activity is highly dependent on the concentration of 
cytochrome c. Consequently, activity is expressed as first order rate constant. This method is 
based on one described previously (Wharton and Tzagoloff, 1967).
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550nm
cytc  (red) cy tc  (ox)
0 2 + 2H+ 2H20
Figure 2.4: Schematic diagram of the complex IV assay.
Reagents:
1) 100mM potassium phosphate buffer, pH 7.0
2) 10OmM ferricyanide (k+)
3) 10mg/ml cytochrome c  (oxidised), (made up fresh)
4) Reduced cytochrome c: A few crystals of ascorbic acid (Na+) were added to oxidized 
cytochrome c  in water (10mg/ml). This was mixed and left for a few minutes until the solution 
changed from a deep red into a brighter pink colour. Ascorbic acid (Na+) was removed from 
reduced cytochrome c by using a small PD10 gel filtration column (Amersham). The column was 
first rinsed with 50ml 1:10 dilution of the assay buffer prior to use. Reduced cytochrome c was 
added to the column in a maximum volume of 2.5ml. The column was then eluted with a further 
50ml of 1:10 buffer and reduced cytochrome c was collected. It was important that only the 
purest reduced cytochrome c was collected as any ascorbic acid might affect the oxidation of 
the reduced cytochrome c during the assay. Therefore only the darkest band of eluent was 
collected from the column.
Method:
Assay was carried out at 30°C on a Kontron Unikon 940 spectrophotometer. This was set up as 
follows: time drive assay; 550nm; cell changer mode 6S/6R; auto zero off; calculation off; data 
displayed as curve.
To determine the concentration of the reduced cytochrome c, 950^1 of water and 50^1 of 
reduced cytochrome c were dispensed into two cuvettes and mixed. One cuvette was placed in 
the front cell, the other in the back cell, and spectrophometer was set to autozero. 10pl of 
ferricyanide was added to the back cuvette, and then mixed. The absorbance was noted, and 
Beer-Lambert’s law was used to calculate concentration of reduced cytochrome c.
Using Beer-Lambert Law: a = 8 x c x I
8 = extinction coefficient, I = path length (1cm), a = absorbance, c = concentration
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a_= c Essonm of reduced cytochrome c = 19.2 x 103 M'1 cm'1
e
= mole/l (M) 
x 20 (dilution factor)
= M (best expressed as pM)
Samples were set up as follows in assay:
Sample (pi) Reference (pi)
Buffer 100 100
Cytochrome c (reduced) X X
Water 880-X 890-X
Total 1000 1000
X = volume of stock reduced cytochrome c to give final concentration of 50pM
Cuvette contents were mixed and placed into the spectrophotometer, sample cuvette in front 
and reference in back rack. Autozero was pressed. 10pl of ferricyanide was added to the 
reference. This was mixed. Absorbance measurements at 550nm were commenced. 20pl of 
homogenate was added to the front cuvette. This was mixed. Measurements were continued 
for 5-6min. Absorbance data was displayed in a table. The first maximum positive absorbance 
value after the addition of the homogenate was recorded. Further absorbances were noted at 
1 min intervals.
Example of calculation: (from an authentic sample)
Real time Reaction time Absorbance k/min
0.9667 0* 1.0441
1.9667 1 0.9076 In 11.04411 -h 1 = k 
[0.9076]
2.9667 2 0.7915 In [1.0441U  2 =k- 
[0.7915]
3.9667 3 0.6932 In M.04411 t 3 = k- 
[0.6932]
* zero reaction time was at point of maximal absorbance after sample addition, In = natural log 
The mean value of k^ k2 and k3 was calculated = k (mean rate constant) 
k was multiplied by dilution factors:
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x 50 (dilution of sample, 20pl in 1000pl) 
x 5 (dilution of sample prior to assay)
= rate constant per minute = k/min/ml
2.2.6. Citrate synthase
The condensation of oxaloacetate and acetyl-CoA to form citrate and free Coenzyme A is 
catalysed by citrate synthase [EC 4.1.3.7.]. The activity of this enzyme was measured at 
412nm by the reaction of free CoA with DTNB (see Figure 2.5). This assay is based on one 
previously described (Shephard and Garland, 1969).
412nm
DTNB DTNB-CoA
acetyl-CoA 
oxaloacetate
CoA
citrate
Figure 2.5: Schematic diagram of the citrate synthase assay.
Reagents:
1) 100mM Tris/0.1% v/v Triton, pH 8.0
2) 10mM acetyl-CoA
3) 20mM oxaloacetate (made up fresh)
4) 20mM DTNB (5,5' dithio-bis 2-nitrobenzoic acid), a few crystals of KHC03 were added to 
help dissolve (made up fresh)
Method:
Assay was carried out at 30°C on a Kontron Unikon 940 spectrophotometer. This was set up as 
follows: auto rate assay; X 412nm; reading 30 x 0.5min'1; cell changer mode 6S/6R; auto zero 
on; calculation off. Samples were set up as follows:
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Sample (pi) Reference (pi)
Tris buffer
Homogenate
Acetyl-CoA
DTNB
Total
950
20
1000
10
10
960
20
10
10
1000
Cuvettes were mixed gently and placed in spectrophotometer (references at back). 10pl of 
oxaloacetate was added to the sample (front) cuvettes. Cuvettes were mixed and absorbance 
measurements at 412nm were commenced.
Calculation:
A = absorbance/min
A = c &4i2nm of DTNB = 13.6 x 103 M'1 cm'1
= mole/min/l 
-5-1000
= mole/min/ml
x 50 (dilution of sample, 20pl in 1000pl) 
x 5 (dilution of sample prior to assay)
= mole/min/ml (best expressed as nmole/min/ml)
8
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2.2.7. Control ranges
Control ranges are expressed as a ratio to citrate synthase activity (see Table 2.1). Muscle 
ranges were set up from 30 disease control samples and have been described previously 
(Rahman et al., 2001a). Reference intervals in the case of the fibroblasts were originally set up 
from 12 disease control samples. Every so often, 30 or more results are plotted out to check 
there is a normal distribution and that the samples that are suspected of being deficient should 
be distributed outside the lower limit of normal. These control ranges were determined by the 
Neurometabolic Unit, National Hospital, London, UK.
Table 2.1: Respiratory chain reference ranges for muscle and fibroblasts.
Complex Muscle Fibroblasts
Complex I 0 .104-0 .268 0.379 -  0.923
Complex ll+lll 0.040 -  0.204 0.070 -  0.243
Complex II 0.052 -  0.258 0.095 -  0.205
Complex IV 0 .014-0 .034 0.007 -  0.036
Expressed as a ratio to citrate synthase.
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2.3. Cell culture methods
2.3.1. Culture medium and other reagents
DMEM culture medium
500ml DMEM (containing 110mg/l sodium pyruvate and 4.5g/l glucose, Gibco)
2.5ml penicillin/streptomycin (10U/pl penicillin G sodium, 10pg/pl streptomycin sulphate, in 
0.85% saline, Gibco)
50ml fetal calf serum (FCS, PAA Laboratories)
Some respiratory chain defects can inhibit the production of the uridine necessary for nucleic 
acid synthesis (discussed in a recent review by Chretien and Rustin, 2003). Therefore if a 
patient was suspected of a RC defect, exogenous uridine (Sigma) was added to a final 
concentration of 50mg/l.
10% DMSO medium for cryopreservation of cells 
4.5ml DMEM culture medium 
0.5ml DMSO (Sigma)
4% Trypsin
100ml Versine (1:5000, Gibco)
4ml Trypsin (1:250, Gibco)
All reagents were sterilised using a 0.22pm Millex filter (Millipore) and then heated to 37°C 
before use. Tissue culture hoods were cleaned and sprayed with 70% ethanol before use. 
Flasks and gloves were also sprayed with ethanol before moving cells from incubator to hood or 
vice versa.
2.3.2. Incubation of cells
Cells were grown in 25cm2 flasks with 10ml of culture medium and incubated at 37°C with C 02 
levels set at 5%.
2.3.3. Splitting cells
To split cells, 1 in 5 (or 2.32 generations), 5 new sterile cell culture flasks were labelled with 
patient initials, date and passage number. The old medium was aspirated off and cells were 
washed with 10ml of PBS. 2ml of fresh 4% trypsin was added to the flask and incubated with 
the cells at 37°C for 2-3 minutes. Meanwhile, 8ml of new medium was added to the labelled 
flasks. After trypsinisation, the old flask was tapped to ensure all cells were dislodged. 8ml of 
new DMEM medium (containing FCS) was added to neutralise the trypsin, making a total of
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10ml. This was mixed and then 2ml was dispensed into each of the five new flasks. The new 
flasks were tilted in each direction to ensure an equal distribution of cells.
2.3.4. Cryopreservation
Cells were washed in PBS and then trypsinised as above. After neutralisation of the trypsin, 
cells were pelleted by centrifugation at 1500rpm for 5min (at 4°C), and then resuspended in 
0.5ml of 10% DMSO culture medium. This cell suspension was dispensed into a 
cryopreservation vial and cooled to -80°C in Mr. Frosty freezing container (Nalgene) that 
ensured a slow cooling rate of ~1°C per minute. The vial was then transferred to a liquid 
nitrogen storage facility.
2.3.5. Thawing frozen cells
Cryogenic storage vials were removed from liquid nitrogen storage and left for a few moments 
at room temperature to equilibrate. The cells were then rapidly thawed at 37°C and then 
dispensed into a 25cm2 flask. The cell culture medium was then added slowly, drop by drop at 
first, until 9.5ml had been added. The flask was tilted in each direction to ensure an equal 
distribution of cells. The flask was incubated for 4 hours to allow the cells to attach to the 
bottom surface of the flask. The medium was then changed for new cell culture medium to get 
rid of the DMSO.
2.3.6. Harvesting cells for enzyme assays and DNA extraction
At least 2 confluent flasks were used and all steps were carried out on ice wherever possible. 
The old medium was aspirated and cells were washed with PBS and trypsinised as described 
above. After neutralisation, the two flasks-worth of cells were pooled and then spun at 1500rpm 
for 5min. The supernatant was removed, cells were washed with 5ml PBS and then spun 
again. The cell pellet was resuspended in 100fil of PBS and then snap frozen in dry ice or liquid 
nitrogen and finally transferred to -80°C freezer where they were stored until the RC enzyme 
assays were to be carried out.
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2.4. Immunoblotting protocols
2.4.1. Isolation of mitochondria by differential centrifugation
Twenty confluent 25cm2 flasks were harvested by trypsinisation. Cell pellets were washed in 
5ml of PBS supplemented with protease inhibitors (1mM phenylmethylsulfonyl fluoride (PMSF),
1 pg/ml of leupeptrn and 1 pg/ml of pepstatin A, all Sigma). Cell pellets were frozen and stored at 
-80°C.
Cell pellets were thawed and put on ice. From this point onwards all procedures (including 
centrifugations) were carried out on ice or at 4°C. The cells were resuspended in 1 ml ice-cold 
homogenisation buffer (10mM Tris HCI pH 7.4, 1mM sodium EDTA, 250mM sucrose, 1mM 
PMSF, 1 pg/ml of pepstatin A, 1 pg/ml of leupeptin; protease inhibitors were added to the ice-cold 
buffer shortly before use). Cells were pelleted by centrifugation at 4000g for 5min. The 
supernatant was discarded and the cell pellet was resuspended in 2ml ice-cold homogenisation 
buffer and transferred to an ice-cold, 2ml glass tissue homogeniser. Cells were homogenised 
(>20 strokes) and transferred to a centrifuge tube. Nuclei, cell debris and unbroken cells were 
pelleted by centrifugation at 1500g for 10min. The supernatant was transferred to a new tube 
and kept on ice. The pellet was resuspended in 2ml ice-cold homogenisation buffer and 
transferred back to the tissue homogeniser. The pellet was homogenized as before and 
transferred to a centrifuge tube. Nuclei and cell debris were pelleted by centrifugation at 1500g 
for 10min. The two supernatants were combined and centrifuged once again at 1500g for 
10min. The supernatant was transferred to a clear centrifuge tube and mitochondria were 
pelleted by centrifugation at 11,500g for 12min. The supernatant was discarded and the pellet 
of mitochondria was resuspended in 100pl homogenisation buffer. The resuspended 
mitochondria were stored at -80°C.
Spectrophotometric measurements of citrate synthase activity (see section 2.2.6) were 
performed to determine the relative concentrations of mitochondrial protein in each sample.
2.4.2. Western blotting
An 8.75% separating gel mix and a 3% stacking gel mix were made up using the reagents listed 
below. The gel mixes were filtered at 0.2pm prior to the addition of APS and TEMED. Once the 
APS and TEMED had been added, the separating gel was poured into 0.75mm plates (BIORAD 
mini PROTEAN II system) and overlaid with ddH20 . After this had set, the water was removed, 
APS and TEMED were added to the 3% stacking gel mix and this was poured over the 
separating gel. The comb was placed into position. The gel was left to set for at least 45min.
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3.75M Tris 
0.5M Tris
8.75% Separating gel 3% Stacking gel
920)uil
500|il
40% acrylamide 2.2ml
46|il
3.25g
4.4ml
450pl
25|il
1.80g
3.25ml
20% SDS 
Urea
ddH20
Filter at 0.2/jm
10% APS 44|j.l
6(il
25|j.l
3(ilTEMED
Meanwhile, the samples were prepared by combining equal amounts of mitochondrial protein 
preparations with a similar volume of 2x Dissociation Buffer (2x DB: 100mM Tris-HCI pH 6.5, 
24% (v/v) glycerol, 8% (w/v) SDS, 4% (v/v) (3-mercaptoethanol, 0.02% (w/v) bromophenol 
blue). Additional volumes of 1x DB were added to the samples (including blanks) to ensure 
each lane contained an equal volume of DB. Samples were incubated at 37°C for 30mins and 
then spun for 1min at 13k rpm on a bench top centrifuge. The supernatant was transferred to a 
new tube prior to loading
Wells were rinsed and the samples were loaded. Gels were run at 100V for 15min and then 
200V for 1 h, or until blue dye had almost run off the gel.
PVDF membranes (Millipore) were wetted with methanol, then equilibrated in Towbin’s Buffer 
(TB, 25mM tris-base, 192mM glycine, 20% methanol). The transfer sandwich was setup, with 
the black plastic side down. The sponge pad was the first layer, followed by Whatmann 3MM 
paper, then the gel (stacking gel had been discarded). The wet PVDF membrane was placed 
on top of this ensuring no air bubbles appeared. Then there was another layer of Whatmann 
3MM paper and another sponge pad. This was all done whilst submerged in TB. The transfer 
unit was assembled with the black side of the sandwich nearest the black electrode. An ice 
pack and a small magnetic stirrer were also placed in the tank. The tank was then filled with 
TB, the stirrer turned on, and the unit was and run at 100V for 75min. The membranes were 
labelled and then left overnight to air dry.
Once dried, the membranes were labelled, cut in two (if necessary), wetted briefly in methanol 
and then equilibrated in PBS until membranes sank, before being blocked for 1h in 10% (w:v) 
milk powder. 20ml sterilin tubes were also coated in 10% milk powder. The blots were placed 
into these sterilin tubes with the protein side facing in. Blots were then washed 3 times for 
10min in 3ml PBS/Tween (1x PBS, 0.3% Tween 20) on roller mixer. Primary antibodies were 
added (see below for concentrations used) and blots were incubated on the roller mixer for 2h. 
Blots were washed 3 times in PBS/Tween as before. 3ml of the secondary antibody (1/4,000
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PBS/Tween dilution of Goat anti-mouse, BIORAD) was then added. Incubation was for 1h. 
Blots were washed 3 times in PBS/Tween as before and for an additional 10min in 1xPBS.
Antibody Dilution factor (in PBS/Tween)
SDHA 1/7,500
SDHB 1/200
VDAC 1/7,500
MTC02 1/7,500
Manufacturer
Molecular Probes 
Molecular Probes 
Calbiochem 
Molecular Probes
MTC02, COX polypeptide II; VDAC, voltage-dependent anion-selective channel
Western Lighting Chemiluminescence Reagent Plus (Perkin Elmer) was used with 
chemiluminescence photographic film for detection of protein. The Enhanced Luminol Reagent 
and the Oxidizing Reagent were mixed in equal quantities. The blot was placed into this active 
reagent for 1 min. Exposure times of 15s-8min were used.
2.4.3. Blue Native gel electrophoresis
For immunoblot analysis of one-dimensional native gels, mitochondrial fractions were resolved 
on blue native 8-18% polyacrylamide gels as devised by Schagger (Schagger, 1995; Williams et 
al., 2004). Enzymatic activity staining for succinate dehydrogenase and for cytochrome c 
oxidase was essentially carried out as described (Van Coster et al., 2001).
18% and 8% separating gel mixes and a 4% stacking gel mix were made up using acrylamide- 
bis (48% acrylamide, 1.5% bis), 3x gel buffer (1.5M 6-aminocaproic acid, 150mM bistris) and 
other reagents listed below. The gel mixes were filtered at 0.2pm prior to the addition of APS 
and TEMED. Once the APS and TEMED had been added to the high and low percentage 
separating gel mixes, 7ml of each were pipetted into the wells of the gradient gel pouring 
equipment. A pump was used at constant speed to pour the gels into four 0.75mm plates 
(BIORAD mini PROTEAN II system). The gradient gels were overlaid with butanol. After these 
gels had set, the butanol was removed, APS and TEMED were added to the 4% stacking gel 
mix and this was poured over the separating gels. Combs were placed into position. The gels 
were sealed with clingfilm and then left overnight, or for up to a week at 4°C.
Acrylamide-bis (AB) 
3x gel buffer (3X) 
ddH20  
Glycerol
10% APS 
TEMED
High (18%)
3.63ml 
3.3ml 
1.32ml 
1.98g
35pl
3.5pl
Low (8%)
1.98ml
3.96ml
5.86ml
Filter at 0.2pm 
70pl 
7pl
4% Stacking gel
0.5ml
2ml
3.5ml
50pl
5pl
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All mitochondrial protein preparations were diluted to the same concentration (down to the 
concentration of the most dilute sample, as determined by citrate synthase activity), in a total 
volume of 30pl, using 250mM sucrose buffer. 30(il of 1.5x protein solubilising solution (1.5M 6- 
aminocaproic acid, 75mM bistris, 1mM PMSF, 1|ig/ml of pepstatin A, 1ng/ml of leupeptin) and 
7.5pl of 20% (w/v) laurylmaltoside was added. This mix was left on ice for 15min, spun on a 
benchtop centrifuge at 13,000rpm for 20min at 4°C and then the supernatant was placed into a 
new tube. 7.5pl of loading buffer (1M 6 aminocaproic acid, 5% Serva blue G) was added to 
make a total of 75pl. 10pl of this mix was loaded onto the gels to be used for immunoblotting. 
Enzymatic activity staining is much less sensitive, so for these gels, as much sample as 
possible was loaded (20-25pl).
Blue Native gels were run at 100V for 20min, then at 8mA (or 4mA for 1 gel) using Anode buffer 
(50mM bistris, pH 7.0) and Cathode buffer A (50mM tricine, 15mM bistris, 0.02% Serva blue G, 
pH 7.0). The current was switched off once the blue dye had reached the bottom of the gel. If 
the gel was to be used for enzyme activity staining, Cathode buffer A was replaced with 
Cathode buffer B (50mM tricine, 15mM bistris, 0.002% Serva blue G, pH 7.0) halfway through 
the run.
Immunoblotting was carried out as described in section 2.4.2, except for 2 additional washes on 
the membrane in methanol before blocking, to remove excess Serva blue G. In Chapter 6 the 
POLG antibodies used were, a 1/400 dilution of POLG Ab3 N-terminal antibodies and 1/400 
dilution of POLG Ab4 cocktail (both NeoMarkers, Lab Vision corporation).
For enzyme activity staining, the gel strips were first destained for a few minutes in anode buffer 
and rinsed briefly in ddH20 . Then the succinate dehydrogenase stain (4.5mM EDTA, 10mM 
KCN, 0.2mM phenazine methosulphate, 84mM sodium succinate, 10mM Nitro Blue tetrazolium 
chloride, 1.5mM phosphate buffer pH 7.4) or the cytochrome c oxidase stain (50mM NaPj buffer 
pH 7.4, 0.5mg/ml diaminobenzidine, 1 mg/ml cytochrome c, 2^g/ml catalase) were added and 
the gel strips incubated overnight at 37°C. Gel strips were soaked in ddH20  to stop the 
reactions.
2.4.4. 2D gel electrophoresis
Blue-Native gel slices were soaked in 3ml of reducing buffer (RB, 1% (v:v) (3-mercaptoethanol, 
1% (w:v) SDS) for 15min in a sealed tube in a fume hood. Waste RB was discarded into a 
suitable container before disposal. The gel slices were then soaked in 3ml of equilibrating 
buffer (EB, 50mM tris, 1% (w:v) SDS) for 2 x 10min. Glass plates were assembled as described 
in the BioRad protocol, sandwiching the gel slice in the region of the plates where the stacking 
gel is poured. A few mm were left between the top of the gel slice and the top of the plates so 
that the gel slice could be completely sealed in stacking gel. The orientation of the gel slice was 
noted. Once the 8.75% separating gel had been filtered, the APS and TEMED were added and
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the gel was poured. Enough space was left between the top of the separating gel and the gel 
slice for a stacking gel. The separating gel was overlayed with 10OpI of water-saturated butanol 
and left to set. The butanol was removed from the top of the separating gel; the stacking gel 
was filtered, APS and TEMED were added, and then it was poured, ensuring the gel slice was 
covered. The stacking gel was overlayed with butanol. Once the stacking gel had set, it was 
left a further 30min before running. Gels were run at 100V until the front from the gel slice was 
well into the stacking gel. The voltage was increased to 200V (run at constant-voltage) until the 
front reached the bottom of the gel. The gels were blotted and probed as directed in the 
previous section.
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2.5. Online resources
Affymetrix Netaffx www.affymetrix.com/analysis/netaffx
Chromas sequence analysis freeware www.technelysium.com.au/chromas.html
Compilation of mammalian MT-tRNAs http://mamit-trna.u-strasbg.fr/
EBI ClustalW protein alignment www.ebi.ac.uk/clustalw
Ensembl database www.ensembl.org/Homo_sapiens/textview
Human Mitochondrial Genome databasewww.genpat.uu.se/mtDB
MitoAnalyzer www.cstl.nist.gov/biotech/strbase/mitoanalyzer.html
Mitomap database www.mitomap.org
MitoP2 http://ihg.gsf.de/mitop2/start.jsp
NCBI Blast 2 Sequences www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi
NCBI database www.ncbi.nlm.nih.gov
POLG mutation database http://dir-apps.niehs.nih.gov/polg
Primer3 primer design http://frodo.wi.mit.edu
Prospectr candidate gene prioritisation www.genetics.med.ed.ac.uk/prospectr
RCSB Protein Data Bank www.rcsb.org/pdb
SNP consortium database http://snp.cshl.org/
Swiss-Pdb-Viewer www.expasy.org/spdbv
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Chapter 3: Sequencing of mitochondrial DNA
3.1. Introduction
Mutations in the 16.6kb mitochondrial genome are responsible for approximately 20% of 
OXPHOS defects (Smeitink et al., 2001). The most common mitochondrial mutations (e.g. 
3243A>G, 3260G>A, 8344A>G and 8993T>G) can be screened using simple restriction digest 
assays and these are usually the first tests to be carried out in dedicated clinical diagnostic 
laboratories. However, with the advent of current high-throughput sequencing, denaturing high 
performance liquid chromatography and microarray resequencing technologies, the whole 
molecule can now be analysed in just a day or two. Therefore, it is usually sensible to exclude 
the possibility of a mitochondrial mutation before starting the time-consuming process of looking 
for nuclear genes involved. This is especially important when there is other evidence that the 
mutations might be mitochondrial.
In this chapter, three patients are described; the first from a pedigree suggestive of maternal 
inheritance, the second expressing an isolated complex III defect which it is known can be 
caused by mitochondrial cytochrome b (cytb) mutations, and the third in which cybrid studies 
have previously demonstrated that a mitochondrial mutation is involved.
In all three cases, deviations from the Cambridge Reference Sequence were found which were 
absent from the MitoMap database of known polymorphisms. However, before these mutations 
could be considered pathogenic, other evidence such as presence of heteroplasmy, 
evolutionary conservation of the amino acid and functional data were needed.
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3.2. Patient details
3.2.1. Patient 1
Patient 1 (P1) was of Zambian descent and presented with infantile retinal dystrophy. The fact 
that her older maternal half-sister also had this same disease (see Figure 3.1), meant that a 
recessive mode of inheritance was improbable. Examination of the mother’s eyes was normal, 
suggesting that this was unlikely to be a dominant disorder. A strong possibility was thus a 
maternally inherited mitochondrial mutation. The mother was hypothesised to have a low 
mutant load that was below the threshold needed to cause the disease, with an increased 
mutant load in her germ cells and subsequent progeny.
□ H — O n — □
1 7 y ^ ^
P1
Figure 3.1: Pedigree of P1. Shaded
symbol indicates infantile retinal dystrophy.
3.2.2. Patient 2
Patient 2 (P2) had congenital lactic acidosis, hyperammonaemia and a bilateral hearing 
impairment. Enzyme activity results suggested that these symptoms might be secondary to a 
respiratory chain defect and further investigation of complex II and III activities separately 
indicated that complex III was impaired (see Table 3.1).
Table 3.1: Respiratory chain enzyme assays from P2’s muscle biopsy.
Complex P2 muscle Paediatric reference range for muscle
Complex l/CS 0.101* 0.104-0.268
Complex
ll+lll/CS
No detectable 
activity
0.040-0.204
Complex IV/CS 0.015 0.014-0.034
Complex I l/CS 0.138 0.052-0.258
Complex 11 l/CS 0.002* 0.008-0.028
These assays were performed by the Neurometabolic Unit, National Hospital, 
London, UK. Asterisks indicate where the ratios lie outside the control range.
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3.2.3. Patient 3
Patient 3 (P3) was born by normal delivery to healthy unrelated parents. On day 3 of life, an 
echocardiogram indicated severe cardiomyopathy. She was jaundiced, with severe liver 
disease and a lactic acidosis. Deficiency of complex I and IV of the respiratory chain (see Table 
3.2) was also diagnosed in fibroblasts. A previous sibling had died on day two of life with similar 
symptoms.
Further investigation showed that she did not have any of the common mtDNA mutations 
(3243A>G, 3260G>A, 4269A>G, 8344A>G and 8993T>G) which have all been associated with 
cardiomyopathy. Sequencing of the three mtDNA COX subunits and tRNA genes in muscle 
DNA had not revealed any mutations (Rahman, 2002). However, transmitochondrial cybrid cell 
studies (see Figure 1.6 in Introduction) had previously implicated a mitochondrial origin of the 
disease as wild-type nuclei did not rescue the complex IV deficiency (Louise Turner and Mark 
Cooper, unpublished data).
Table 3.2: Respiratory chain enzyme assays from P3’s cultured fibroblasts.
Complex P3 fibroblast Paediatric reference range
Complex l/CS 0.050* 0.177+-0.070
Complex 11+11 l/CS 0.273 0.232+-0.090
Complex IV/CS 0.009* 0.020+-0.003
Data from Mark Cooper, University Department of Clinical 
Neurosciences, Royal Free and University College Medical School, 
London. Asterisks indicate where the ratios lie outside the control range.
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3.3. Methods
3.3.1. mtDNA sequence analysis
The mitochondrial genome was amplified using 45 overlapping PCR reactions, with a mean 
length of 482bp and overall coverage of 131% (see Table 3.3). The standard PCR conditions 
described in Chapter 2 were used, except 50pl reaction volumes were used. Also, as 
mitochondrial DNA is already multicopy, only 30 cycles were necessary. The standard 
sequencing protocol is given in Chapter 2.
3.3.2. Interpretation of mtDNA sequence
Sequencing electropherograms were analysed using the freely available CHROMAS software 
(version 1.45, www.technelysium.com.au/chromas.html). ABD files were edited manually where 
the base calling software had made obvious mistakes, and the H strand sequences were 
reverse-complemented. The sequences were then compared to the revised CRS (Andrews et 
al., 1999a) using the NCBI online Blast 2 Sequences tool (Tatusova and Madden, 1999). Any 
changes from the reference sequence were noted. The sequences were also scanned by eye 
for minor peaks that may indicate a heteroplasmic mutation.
To determine whether the observed sequence changes have previously been described (either 
as neutral polymorphisms or as known mutations), they were compared firstly to those listed in 
the Mitomap and then in the Human Mitochondrial Genome databases (www.mitomap.org, 
www.genpat.uu.se/mtDB). If the change was novel, then the amino acid change was 
determined by hand and then confirmed using the online MitoAnalyzer tool (Lee and Levin, 
2000). In some cases, sequence alignment was carried out using the CLUSTALW tool on the 
EBI website (www.ebi.ac.uk/clustalw) using amino-acid sequences obtained from the NCBI 
protein database (www.ncbi.nlm.nih.gov).
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Table 3.3: mtDNA sequencing primers.
PCR F Primer Sequence (5’-3’) R Primer Sequence (5’-3’) Size
(bp)
371
Genes Contained
1 L336 AACACATCTCTGCCAAACCC H706 GGATGCTTGCATGTGTAATC F (577-647), 12S 
(648-1601)
2 L660 CCTAGCCTTTCTATTAGCTC H1040 ATGTTAAAGCCACTTTCGTA 381 12S
3 L901 GGT CACACGATTAACCCAAG H1430 TGCTAAATCCACCTTCGACC 530 12S
4 L1412 GTCGAAGGTGGATTTAGCAG H2022 CAACCAGCTATCACCAGGCT 611 12S.V (1602-1670), 
16S (1671-3229)
5 L1917 AGCTACCTAAGAACAGCTAA H2541 GGTGCCTCTAATACTGGTGA 625 16S
6 L2466 AAAAGGAACTCGGCAAATCT H3023 GCGGCTGCACCATCGGGATG 558 16S
7 L2925 TACCCTAGGGATAACAGCGC H3287 GAACCTCTGACTGTAAAGTT 363 16S, L(UUR) (3230- 
3304)
8 L3056 CCTACGTGATCTGAGTTCAG H3406 GTAGTTGTATATAGCCTAGA 351 16S, L(UUR)
9 L3285 TT CAATT CCT CTT CTTAACA H3745 CTAGGGTGACTTCATATGAG 461 L(UUR), ND1 (3307- 
4262)
10 L3704 TGCGAGCAGTAGCCCAAACA H4325 TAAGGGGGTTTAAGCTCCTA 622 ND1, I (4263-4331)
11 L4215 ATATGTCTCCATACCCATTA H4643 CTTGATGGCAGCTTCTGTGG 429 ND1,1, Q (4329- 
4400), M (4402-4469), 
ND2 (4470-5511)
12 L4393 CCATCCTAAAGTAAGGTCAG H4899 GGTATATGATTGAGATGGGG 507 Q, M, ND2
13 L4854 CTTCTTCTCACATGACAAAA H5470 GTGGTAAGGGCGATGAGTGT 617 ND2
14 L5464 TTACCACGCTACTCCTACCT H5988 GGACTCCAGCTCATGCGCCG 525 ND2, W (5512-5576), 
A (5587-5655), N 
(5657-5729), C (5761- 
5826), Y (5826-5891), 
COXI (5904-7445)
15 L5866 CCAATGCTTCACTCAGCCAT H6485 TAGGACTGCTGTGATTAGGA 620 Y, COXI
16 L6426 GCCATAACCCAATACCAAAC H6968 GCCAGTCAGGCCACCTACGG 543 COXI
17 L6799 TAGACACACGAGCATATTTC H7196 GAGAAAGT GTT GT GGGAAG A 398 COXI
18 L7115 CCTAGACCAAACCTACGCCA H7650 GTGATAAGCTCTTCTATGAT 536 COXI, S (7445-7516), 
D (7518-7585)
COXII (7586-8269)
19 L7588 GGCACATGCAGCGCAAGTAG H7992 AGGAGTCGCAGGTCGCCTGG 405 COXI I
20 L7865 TCCCTTACCATCAAATCAAT H8445 TTTAGTT GGGT GAT GAGGAA 581 COXII, K (8295-8364), 
ATPase 8 (8366- 
8572)
21 L8196 ACAGTTTCATGCCCATCGTC H8726 GTTCGTCCTTTAGTGTTGTG 531 COXII, K, ATPase 8, 
ATPase 6 (8527- 
9207)
22 L8646 CCG ACTAAT CACC ACCC AAC H9244 GGTTTTACTAT ATGATAGGC 599 ATPase 6, COXIII 
(9207-9990)
23 L9151 AT CCAAG CCTACGTTTT C AC H9744 CTGAGGCTTGTAGGAGGGTA 594 ATPase 6, COXIII
24 L9638 CACCTGAGCTCACCATAGTC H10107 GTAGTAAGGCTAGGAG GGTG 470 COXIII, G (9991- 
10058)
25 L9983 AGGGT CTTACT CTTTTAGTA H10452 CATAATTTAAT GAGT CG AAA 470 COXIII, G, ND3 
(10059-10404), R 
(10405-10469)
26 L10362 CT GGCCTAT GAGT G ACTACA H10724 ATAT GT GTT GG AG ATT GAGA 363 ND3, R, ND4L 
(10470-10766)
27 L10651 TTGCCATACTAGTCTTTGCC H11158 GATGATAGCCAAGGTGG GGA 508 ND4L, ND4 (10760- 
12137)
28 L11091 CAGCCACAG AACTAAT CATA H11449 TACTATTGACCCAGCGATGG 359 ND4
29 L11374 AAAG ATACCT CTTTACGG AC H11854 AGCGAGGCTTGCTAGAAGTC 481 ND4
30 L11758 CTACGAACGCACTCACAGTC H12191 GTAAGCCT CTGTTGT CAG AT 434 ND4, H (12138- 
12206)
31 L12069 TGTTCATACACCTATCCCCC H12395 AGGATGGGGGGAATTAGGGA 327 ND4, H, S(AGY) 
(12207-12265) 
L(CUN) (12266- 
12336)
ND5 (12337-14148)
32 L12309 AATTTTGGTGCAACTCCAAA H12876 GATATCGCCGATACGGTTGT 568 L(CUN), ND5
33 L12829 AACACAGCAGCCATTCAAGC H13389 GTTAAGGTTGTGGATGATGG 561 ND5
34 L13301 CACACCTAGCATTCCTGCAC H13841 AGGGCT GTTAG AAGT CCTAG 541 ND5
35 L13702 CGCCTGGCAGCCGGAAGCCT H14217 GTAGTAGTTACTGGTTGAAC 516 ND5, ND6 (14149- 
14673)
36 L13926 TAGCATCACACACCGCACAA H14446 GGAGTATCCTGAGGCATG GG 521 ND5, ND6
37 L14300 ATTCAGCTTCCTACACTATT H14883 GTGATTTGGAGGATCAGGCA 584 ND6, E (14674- 
14742), Cyt b (14747- 
15887)
38 L14595 AAATAGGAGAAGGCTTAGAA H15038 TGTGTAGGAAGAGGCAGATA 444 ND6, E, Cyt b
39 L14983 CCGCTACCTTCACGCCAATG H15343 GAATAGGAGGTGGAGTGTTG 361 Cyt b
40 L15221 GACCTAGTTCAATGAATCTG H15649 TAGGATGAGGATGGATAGTA 429 Cyt b
41 L15553 GCCCGAATGATATTTCCTAT H15996 GCTTTGGGTGCTAATGGTGG 444 Cyt b, T (15888- 
15953), P (15955- 
16023)
42 L15788 ACCATCATTGGACAAGTAGC H16084 CGGTTGTTGATGGGTGAGTC 297 Cyt b, T, P
43 L15875 CTCAAATGGGCCTGTCCTTG H16345 TGTAATGTGCTATGTACGGT 471 Cyt b, T, P
44 L16240 AACTGCAACT CCAAAGCCAC H33 GTGAGTGGTTAATAGGGTGA 363 D-loop (16024-576)
45 L16527 CCTAAATAGCCCACACGTTC H390 TCTGGTTAGGCTGGTGTTAG 433 D-loop
tRNA genes are indicated by the one-letter amino-acid code. Locations of genes are shown on first presentation.
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3.3.3. Sequence analysis of BCS1L
BCS1L was amplified from genomic DNA and sequenced using standard conditions as 
described in the methods chapter. The primers, listed below, are identical to those described 
previously (de Lonlay et al., 2001), except for 5F, 5R and 6R which were designed with Primer3 
(http://frodo.wi.mit.edu). Data were analysed by eye using CHROMAS software, and the 
sequence was compared to the BCS1L sequence as listed on the Ensembl database 
(ENSG00000074582) using the NCBI online Blast 2 Sequences tool (Tatusova and Madden, 
1999).
exon 1F: 5'-TGT AAG GTT TGG TGT TTC CCT TT-3' 385bp
exon 1R: 5'-TTT CTA CTC TCA CAG CCC TCC-3'
exon 2F: 5'-TGG GTT TGA CCC ATT CAC TC-31 281 bp
exon 2R: 5'-GGC CTG CTT ATT CCA ACT TC-3'
exon 3F: 5‘-TGG AAG AAT CAG CCA TGG TGA-3' 325bp
exon 3R: 5'-TGG CTG GAG ACC AAC CTG T-3'
exon 4F: 5'-TTT CCG TAC CAA GGT TAT CAG-3' 234bp
exon 4R: 5'-TTC CAA CCC TAT CAG CCT AG-31
exon 5F: 5'-AGG CGG TGA GGA GAG TAG C-3' 299bp
exon 5R: 5'-TCC CCT GTT CCA CAG TTA CC-3'
exon 6F: 5'-TTT ATG CTG GGC TAT GAC TAC T-3' 241 bp
exon 6R: 5'-CTG TTC CTC CCA AGG CAC TA-3'
exon 7F: 5'-TGG GTG CTA GTG TGA CCT GC-31 351 bp
exon 7R: 5'-TTT AGT GTG GCA GAT GTT TAT T-3'
3.3.4. Mitochondrial RFLP digests
3.3.4.1. PCR-RFLP for tRNA variants in P1
The 525bp wild-type amplicon #14 (see Table 3.3) was digested into 311 bp and 214bp 
fragments. The recognition site {ACCJGC(N)J) was disrupted by the 5774T>A mutation (site of 
mutation indicated in bold). The lack of a second cut site meant that BspW did not cut with a 
high efficiency (Gormley et al., 2002), therefore BfuA\ (a BspMI isoschizomer) was used 
instead. The PCR product also had to be cleaned up with microcon YM-100 columns (Amicon, 
carried out according to manufacturer’s instructions) to improve digestion efficiency. Digestions 
were carried out with 1.5pl of purified PCR product, 1pl of 10x NEB buffer III, and 5U of BfuA\ 
(NEB) in a total reaction volume of 10pl. Digestion reactions were carried out overnight at 50°C 
and fragments resolved on a 1.5% agarose gel.
The 297bp amplicon #42 (see Table 3.3) was digested into 150bp and 147bp fragments by 
Xmn\, (recognition site: GAANN/NNTTC) only in the presence of the 15942T>C mutation.
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Digestions were carried out with 4pl of PCR product, 1pl of 10x NEB buffer II, 100pg/ml of BSA
and 20U of Xmn\ (NEB) in a total reaction volume of 10jil. Digestion reactions were carried out
overnight at 37°C and fragments resolved on a 1.8% agarose gel.
3.3.4.2. PCR-RFLP for cytochrome b change in P2
The wild-type 429bp amplicon #40 (see Table 3.3) was digested into 209bp, 186bp and 34bp 
fragments by BsaH1 (GR/CGYC). 15431G>A abolishes one of the recognition sites resulting in 
395bp and 34bp fragments. Digestions were carried out with 4pl of PCR product, 1pl of 10x 
NEB buffer IV, 100pg/ml of BSA and 10U of BsaH1 (NEB) in a total reaction volume of 10pl. 
Digestion reactions were carried out for 4h at 37°C and fragments resolved on a 1.5% agarose 
gel.
3.3.4.3. PCR-RFLP for A549 specific D-loop polymorphism
The A549 epithelial cell line that had previously been used to create the cybrid cell lines 
contains a mtDNA polymorphism in which there are 4 CA repeats rather than the standard 5 at 
position 514 in the D-loop. Mismatch primers were used to create an Alu\ site (AG/CT) upon 
amplification of A549 mtDNA that was not present with the wild-type.
L371 (“A549F”): 5’-CTA ACA CCA GCC TAA CCA GA-3’
H535 (“A549R”): 5’-GGT TAG CAG CGG TGT GTG AG-3’ (underlined A was a mismatch)
PCRs were carried out with the above primers, using standard conditions. Digestion reactions 
were carried out in 15pl volumes with 5pl of PCR product, 1.5pl of NEB buffer II and 10U of Alu\ 
(NEB). Reactions were left at 37°C overnight. The 165bp and 143bp fragments were resolved 
on a 4% gel (3% low melting point agarose and 1% normal agarose).
3.3.4.4. Quantification of 10306A>G in P3
A 213bp fragment containing the polymorphic site was amplified using L10259 and H10472 as 
primers (see below). This PCR was optimised by reducing the annealing temperature from the 
standard 55°C to 53°C, and increasing Mg2+ concentration from 1.5mM to 2.5mM.
L10259: 5’-GAA ATT GCC CTC CTT TTA CC-3’
H10472: 5’-CAT TTG GTA AAT ATG ATT ATC-3’
To obtain an approximation of the level of 10306A>G, 5pl of the PCR product was digested with 
1.5p.l of NEB buffer IV and 5U of Bfal in a 15pl reaction volume. Reactions were carried out at 
37°C overnight and then samples were run on a 4% gel (3% low melting point agarose and 1% 
normal agarose). Wild-type molecules are cleaved into 122bp and 91 bp fragments whereas the
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presence of 10306A>G creates a second restriction site (C/TAG) and the fragments produced 
are 122bp, 47bp and 44bp (see Figure 3.2).
Wild Type
FAM g a a a ttg c c c  t c c t t t t a c c  cctaccatga gccctacaaa caactaacct gccactaata
gttatgtcat ccctcttatt aatcatcatc c/ (91bp)
tagccctaag tctggcctat gagtgactac aaaaaggatt agactgaacc gaattggtat
atagtttaaa caaaacgaat gatttcgact cattaaatta t g a t ,  a t e a t  a t r t a c c a a a
t g  HEX (1 2 2 b p )
10306A>G
FAM gaaattgccc tccttttacc cctaccatga gccctacaaa caac/ (44bp)
tagcctgcca ctaatagtta tgtcatccct cttattaatc atcatcc/ (47bp)
tagccctaag tctggcctat gagtgactac aaaaaggatt agactgaacc gaattggtat
atagtttaaa caaaacgaat gatttcgact cattaaatta t g a t a a t c a t  a t t t a c c a a a
t g  HEX ( 122bp )
B W T A10306G Uncut
r—  213bp/213bp
122bp
91bp
4 4 bp
Figure 3.2: The PCR-RFLP method used to detect and quantify 10306A>G. 
Blue denotes forward primer labelled with FAM, orange denotes reverse 
primer labelled with HEX, and green denotes Bfa\ recognition sequence. A. 
Sequence of expected digestion products. B. Schematic diagram showing 
expected sizes of products on a gel. WT, wild-type.
For accurate quantification of mutant load, the PCR-RFLP was carried out as described above, 
but with the addition of 5’ fluorescently labelled primers (L10259-FAM and H 10472-HEX) at the 
beginning of the last (30th) cycle. These products were digested with Bfal as before and run on 
the ABI377 (as described for the microsatellite analysis in Chapter 5) but using a 6% acrylamide 
gel instead of the usual 4% as the fragments were so small. To compensate for this change 
and to make sure the 213bp fragment ran off the gel, the run-time was increased to 3h. Once 
the run had finished, lanes were tracked and analysed using Genescan and the areas under 
each peak were used to calculate the ratio of 91 bp to 122bp fragments, and from this the 
percentage of 10306A>G present in each sample.
3.3.5. Isolation of mitochondria for complex I assay
Two 85cm2 flasks of fibroblasts derived from P3 were grown up and harvested by trypsinisation. 
The cells were washed 3 times with PBS and then suspended in 1ml of ice cold fibroblast 
homogenisation buffer (250mM sucrose, 2mM HEPES, 0.1 mM EGTA, pH7.4). From this point 
onwards, all steps were performed on ice or at 4°C.
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The cell suspension was homogenized in a 1 ml Wheaton glass homogeniser (20 strokes) and 
then centrifuged at 600g (2.4k rpm) for 10min. The supernatant was set aside on ice whilst the 
pellet was resuspended, rehomogenised and centrifuged at 600g as before. The two 
supernatants, were pooled and spun at 11,000g (12.5k rpm) for 10min. This pellet was 
resuspended in 1ml hypotonic buffer (25mM potassium phosphate, 5mM magnesium chloride, 
pH 7.2), and spun at 11,000g (12.5k rpm) for 5min. The supernatant from the hypotonic wash 
was discarded and the mitochondria were resuspended in 280pl hypotonic buffer. The sample 
was frozen at -80°C until Complex I assay was carried out (as described in Chapter 2).
3.3.6. Lactate / Pyruvate measurements
3.3.6.1. Sample preparation
PBS buffer was pre-heated to 37°C for 1h. Two confluent flasks of cells were used for each 
cybrid clone. The culture medium was drained from the flask. Cells were washed with 7ml of 
PBS and overlaid with 3ml of PBS. The cells were then incubated at 37°C for 1h to deplete 
glycogen reserves. The PBS was then replaced with 1.5ml PBS containing 1 mM glucose. After 
1h, 100pl of 1.6M perchloric acid was added to deproteinize the sample. Cells were scraped 
from the dish and together with the acidified buffer the sample was spun at 4°C and 1000rpm 
(~200g) for 5min. After centrifugation, the supernatant was snap frozen in liquid nitrogen, and 
then stored at -80°C for the lactate / pyruvate assays, and the cell pellet was overlaid with 100pl 
ddH20 , frozen in liquid nitrogen and then stored at -20°C, to later be assayed for protein 
content. This method has been adapted from that used on fibroblasts by Brian Robinson 
(Robinson et al., 1990; Robinson et al., 1986).
3.3.6.2. Lactate /  Pyruvate measurements
Lactate measurements were carried out using an enzymatic method utilising lactate 
dehydrogenase (LDH). The oxidation of lactate is linked to the reduction of the co-factor NAD, 
to NADH. The associated increase in fluorescence emission of light at 450nm, caused by 
NADH when excited by light at 340nm can be directly correlated with the lactate concentration. 
The analytical range was 0.075 - 6.0mM. Lactate and pyruvate measurements were carried out 
along with routine blood and cerebrospinal fluid samples by Helen Aitkenhead and colleagues in 
Chemical Pathology, Great Ormond Street Hospital.
3.3.6.3. BCA protein assay
Standards were set up ranging from Opg to 50pg of BSA in a total volume of 50pl. The 100fil 
test samples underwent 3 freeze-thaw cycles to break the cell membranes, then 2.5^1 was 
diluted with ddH20  also in a total of 50pl. These were made in replicate. 1ml of Bicinchoninic 
acid (Pierce) was added to each tube. Reaction mixes were incubated at 37°C for 10min before
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the addition of 20pl of CuS04. The tubes were vortexed and incubated at 37°C for a further 
35min. Reaction mixes were then transferred to plastic cuvettes and absorbance was 
measured at 562nm. Protein concentrations were calculated by comparison to the standard 
curve.
3.3.7. Oxygen consumption measurements
To measure respiration rates in living cells, one confluent 25cm2 flask of the cybrid cells was 
harvested by trypsinisation. The cells were washed and then resuspended with 80^1 of PBS 
(Sigma, 150mM NaCI, 150mM phosphate buffer, pH 7.2). The preparation was kept on ice until 
measurements were taken.
The Clark-type oxygen electrode was calibrated with air-saturated respiration buffer (10mM 
phosphate buffer, pH 7.4), assuming 444ng atoms 0 2 / ml at 30°C. A few grains of sodium 
dithionite were added to get the zero oxygen calibration point. Intermediate levels of oxygen 
were calculated assuming linearity.
50pl of the cell suspension were added to 190\i\ of respiration buffer. The following reagents 
were then added in turn, at appropriate time points to measure the complex I and complex II 
rates (see Figure 3.3):
• 2.5pl glutamate (1M, pH 8.0) and 1.5pl malate (1M, pH 8.0)
• 1 pi ADP (25mM) to induce state 3 respiration
• 5pl digitonin (2.5pg/pl) to permeabilise the plasma membrane
• 4pl rotenone (1 mM) to inhibit complex I
• 2pl succinate (1M) to restart respiration through complex II
Data were obtained using a MacLab system with chart-recording software. After each sample, 
the electrode and chamber were washed with ethanol to remove traces of rotenone and then 7- 
8 times with water and then dried with tissue-paper. The respiration rates were calculated from 
the gradient of the traces. Protein concentration was assayed using the Lowry assay (Lowry et 
al, 1951).
75
Chapter 3: Sequencing of mitochondrial DNA
Rotenone
1
A  / 1
/
Succinate
Digitonin
1
I
Glutamate, ▼
Malate +
ADP
1t
Figure 3.3; Example of a typical oxygen consumption trace 
for the cybrid cells (NS11) as measured by the oxygen 
electrode. Arrows indicate where the various reagents have 
been added. Time is on the X axis (1cm / min) and % oxygen 
is on the Y axis.
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3.4. Results
For all three patients, there were a large number of nucleotides which deviated from the CRS 
(see Table 3.4). The majority of these could be excluded on account of their presence in the 
mitomap database of known neutral mtDNA polymorphisms.
Table 3.4: Summary of mtDNA sequencing results.
Polymorphism Gene Control P1 P2 NS9 NS10
73A>G* D-loop + + N/A N/A N/A
150C>T* D-loop - + N/A N/A N/A
152T>C* D-loop - + N/A N/A N/A
189A>G* D-loop - + N/A N/A N/A
195T>C* D-loop + + N/A N/A N/A
200A>G* D-loop - + N/A N/A N/A
207G>A* D-loop - + N/A N/A N/A
215A>G* D-loop + - N/A N/A N/A
263A>G* D-loop + + N/A N/A N/A
303insC* D-loop - + N/A N/A N/A
311insC* D-loop - + N/A N/A N/A
489T >C* D-loop - - N/A + +
(750A>G*) 12S rRNA + + N/A + +
(1438A>G*) 12S rRNA + + N/A N/A +
1811A>G* 16S rRNA + - N/A - -
2352T>C* 16S rRNA - + N/A - -
2706A>G* 16S rRNA + + N/A + +
4216T>Ci ND1 (Y304H) - - N/A + +
(4769A>G*) ND2 (syn) + + N/A + +
5147G>A* ND2 (syn) + - N/A - -
5774T>A tRNA cys - + N/A - -
6221 T>A* COX1 (syn) - + N/A N/A N/A
6587C>T* COX1 (syn) - + N/A N/A N/A
7028C>T* COX1 (syn) + + N/A N/A N/A
8386C>T ATP8 (syn) - - N/A + +
8634T>C ATP6 (syn) - + N/A - -
8701 A>G* ATP6 (T59A) - + N/A - -
(8860A>G*) ATP6 (T112A) + + N/A + +
9254A>G COX3 (syn) - + N/A N/A N/A
9540T>C* COX3 (syn) - + N/A N/A N/A
10306A>G ND3 (N83S) - - N/A + -
10398A>G* ND3 (T114A) - + N/A + +
10499A>G* ND4L (syn) - - N/A + +
10819A>G* ND4 (syn) - + N/A - -
10873T>C* ND4 (syn) - + N/A - -
10915T>C* ND4 (syn) + - N/A - -
11002A>G* ND4 (syn) - - N/A + +
11024C>T ND4 (syn) - + N/A - -
11251A>G* ND4 (syn) - - N/A + +
11377G>A* ND4 (syn) - - N/A + +
11467A>G* ND4 (syn) + - N/A - -
11719G>A* ND4 (syn) + + N/A + +
12308A>G* tRNA leu (2) + - N/A - -
12372G>A* ND5 (syn) + - N/A - -
12570A>G ND5 (syn) - - N/A + +
12612A>G* ND5 (syn) - - N/A + +
12705C>T ND5 (syn) - + N/A - -
13105A>G* ND5 (I257V) - - N/A + +
13470A>G ND5 (syn) + - N/A - -
13509OT ND5 (syn) + - N/A - -
13708G>AB ND5 (A458T) - - N/A + +
14152A>G* ND6 (syn) - + N/A - -
14212T>C* ND6 (syn) - + N/A - -
14569G>A* ND6 (syn) - + N/A - -
(14766C>T*) Cyt b (T7I) + + + + +
14783T>C* Cyt b (syn) - - + - -
15043G>A* Cyt b (syn) - - + - -
15257G>Aa Cyt b (D171N) - - - + +
15262T>C Cyt b (syn) + - - - -
(table continued on following page)
77
Chapter 3: Sequencing of mitochondrial DNA
(continued)
15301G>A* Cyt b (syn) - + + - -
(15326A>G*) Cytb (T194A) + + N/A + +
15431 G>A Cyt b (A229T) - - + - -
15452C>A* Cyt b (L236I) - - - + +
15565T>C Cyt b (syn) + - - - -
15670T>C Cyt b (syn) - + - - -
15679A>G Cyt b (syn) - - - + +
15940T>C tRNA thr + - N/A - -
15942T>C tRNAthr - + N/A - -
16051A>G* D-loop + - N/A N/A N/A
16172T>C* D-loop + - N/A N/A N/A
16206A>C * D-loop + - N/A N/A N/A
16215A>G* D-loop + - N/A N/A N/A
16230A>G* D-loop + N/A N/A N/A N/A
16304T>C* D-loop + - N/A N/A N/A
16311T>C* D-loop + - N/A N/A N/A
16327C>T* D-loop - + N/A N/A N/A
+, contains nucleotide change; sequence identical to CRS; N/A, not 
available; *, listed in Mitomap as a polymorphism; a, in mitomap as a 
mutation associated with LHON but thought to be secondary; syn, 
synonymous. The single difference detected between NS9 and NS10 
(cybrids cell lines derived from P3) is highlighted. Other mutations of 
interest are shown in bold. Some of the polymorphisms listed above are 
in parenthesis as they have now been shown to be due to rare 
polymorphisms in the CRS: 750A>G, 1438A>G, 4769A>G, 8860A>G, 
14766C>T and 15326A>G.
3.4.1. P1
Complete sequencing of blood mtDNA for this patient showed two changes of possible interest, 
both in tRNA genes: 5774T>A was in the tRNA gene for cysteine and 15942T>C was in the 
tRNA gene for threonine. (See Figure 3.4 and Table 3.4 for complete sequence data.) 
However, various lines of evidence indicated that they were both rare non-pathogenic 
polymorphisms. Firstly, the sequence electropherogram suggested that both changes were 
homoplasmic, whereas most pathogenic mutations (other than those for LHON) tend to be 
heteroplasm ic. Also, the 15942T>C change has been found in 6/2104 normal controls 
(www.genpat.uu.se/mtDB). In addition, an online comparison of tRNA sequences across a wide 
range of species indicated that both these positions were not conserved (see http://mamit- 
trna.u-strasbg.fr/Sequences.html; T5774 corresponds to the last base of the T-loop N this is 
shown as an A, as the tRNA for cysteine is one of the 9 genes coded on the light-strand, whilst 
T15942 corresponds to position 62 of the T-stem).
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C C O B  C A G C A T T G A A 6 C T C
P1
WT
Figure 3.4: Electropherograms showing A. 5774T>A and 
B. 15942T>C mutations. Arrows indicate mutated base.
WT, wild-type.
Although initially the blood samples from the patient’s unaffected mother and affected maternal 
half-sister were not available, these samples were later obtained and subsequently analysed. 
The sequence data indicated that the mother and half-sister also both harboured 5774T>A and 
15942T>C. PCR-RFLP showed that both 5774T>A and 15942T>C were homoplasmic in this 
family (see Figure 3.5).
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525bp
311bp
214bp
297bp  
147/150bp
Figure 3.5: PCR-RFLP analysis using BfuA \ and X m n\ suggests 
that P1’s two tRNA sequence changes are homoplasmic in all 
three members of this family. A. Digestion of amplicon #14 with 
B fuA \ results in an uncut fragment of 525bp in the presence of 
5774T>A. B. Digestion of amplicon #42 with X m n I results in two 
fragments of 147/150bp in the presence of 15942T>C. UC, uncut;
S, older sibling; WT, wild-type.
3.4.2. P2
Patient P2 had an isolated complex III deficiency. Therefore cytb was sequenced in muscle 
DNA, as it is the only complex III subunit encoded by mtDNA, and is a known cause of complex 
III deficiency in human disease (Dumoulin et al., 1996; Andreu et al., 1999). There was just one 
change of possible interest that was absent from the mitomap database of neutral 
polymorphisms: 15431G>A (see Figure 3.6 and Table 3.4), which predicted an alanine to 
threonine substitution at amino acid residue 229 (A229T).
o
100bp WT
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H e  Lys Asp Thr Leu Gly Leu
P2
lie Lys Asp Ala Leu Gly Leu
A T  C A A A G A C G C C C  T C G  G C  T T A
WT
Figure 3.6: Electropherogram showing 15431G>A transition 
as indicated by the arrow. Amino-acid translation shown 
above. WT, wild-type.
429bp^
395bpA-
209bp ►
186bpA-
Figure 3.7: PCR-RFLP analysis of 15431G>A using BsaH 1
shows that the cytb change was homoplasmic. The 15431G>A 
mutation disrupts a cut site in amplicon #40 such that the 209bp 
and 186bp fragments seen for the wild-type sample runs as a 
single 395bp fragment. UC, uncut; WT, wild-type; C, cut.
15431G>A appeared to be homoplasmic in the sequence electropherogram (see Figure 3.6) 
and upon PCR-RFLP analysis (see Figure 3.7). It is in a region that is not well conserved (see 
Figure 3.8). In addition, alanine to threonine is a fairly conservative amino-acid substitution as 
both are small residues. Despite not being in mitomap, the change has been found in 12/2104
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controls in a larger online database of mtDNA sequence variations found in normal controls 
(www.genpat.uu.se/mtDB).
Homo
Pan troglodytes
Pan paniscus
Gorilla
Papio
Equus
Sus
Bos
Ovis
Canis
Rattus
Mus
Xenopus
Drosophila
Caenorhabditis
GSNNPLGITSHSDKITFHPYYTIKD 
GSNNPLGITSHSDKITFHPYYTIKD 
GSNNPLGITSHSDKITFHPYYTTKD 
GSNNPLGIPSHSDKITFHPYYTIKD 
GSNNPCGISSDPDKITFHPYYTTKD 
GSNNPSGIPSDMDKIPFHPYYTIKD 
GSNNPTGISSDMDKIPFHPYYTIKD 
GSNNPTGISSDVDKIPFHPYYTIKD 
GSNN PTGIPSDTDKIPFHPYYTIKD 
GSNNPSGITSDSDKIPFHPYYTIKD 
GSNNPTGLNSDADKIPFHPYYTIKD 
GSNNPTGLNSDADKIPFHPYYTIKD 
GSTNPTGLNSDPDKVPFHPYFSYKD 
GSNNPIGLNSNIDKIPFHPYFTFKD 
GSTSSLYCHGDYDKVCFSPEYLGKD
LGLLLFLLSLMTLTLFSPDLLGDPD 254 
LGLFLFLLILMTLTLFSPGLLGDPD 254 
LGLFLFLLALMVLTLFSPDLLGDPD 254 
LGLFLFLLTLMTLTLFSPDLLGDPD 254 
LGVAPLLLALMTLTLFSPDLLNDPD 254 
LGLLLLILLLLTLVLFSPDLLGDPD 254 
LGALFMMLILLILVLFSPDLLGDPD 254 
LGALLLILALMLLVLFAPDLLGDPD 254 
LGAILLILILMLLVLFTPDLLGDPD 254 
LGALLLLLILMSLVLFSPDLLGDPD 254 
LGVFMLLLFLMTLVLFFPDLLGDPD 254 
LGILIMFLILMTLVLFFPDMLGDPD 254 
LGFLIMLTALTLLAMFSPNLLGDPD 255 
VGFIVMIFILISLVLISPNLLGDPD 255 
YN-IVIWLLFIVLSLIYPFNLGDAE 250
*  *  * * » ★ * . * *  • • * • • * * * •
Figure 3.8: Alignment of cytb using CLUSTALW multiple sequence alignment software
(www.ebi.ac.uk/clustalw). Position 229 (boxed) is not well conserved. Small amino acids
shown in red, acidic residues in blue, basic residues in magenta, hydroxyl, amine & basic
residues in green.
All this evidence led to the conclusion that the only change in cytb, 15431G>A, does not appear 
to be pathogenic. Therefore it was concluded that a mutation in a nuclear gene must be the 
cause of this patient’s disease. BCS1L, a gene  encoding a complex III assembly factor that 
was identified due to homology to its yeast counterpart (Petruzzella et al., 1998) and previously 
shown to cause tubulopathy, encephalopathy, liver failure and GRACILE (growth retardation, 
aminoaciduria, cholestasis, iron overload, lactacidosis, and early death) syndrome in humans 
(de Lonlay et al., 2001; Visapaa et al., 2002) was sequenced. All seven exons of BCS1L  were 
found to be normal.
3.4.3. P3
3.4.3.1. C hecking  fo r  m tD N A  con tam ina tion  o f  cyb rids
Transmitochondrial cybrid studies had previously been carried out on a cell line from a patient 
presenting with cardiomyopathy and complex I and IV deficiency. A wild-type nucleus from 
A549 epithelial cells (lung carcinoma) had not corrected the COX activity and so the mutation 
was assumed to be mitochondrial.
A PCR-RFLP method used for detection of an A549 specific D-loop polymorphism confirmed 
that none of the 12 cybrid cell lines (NS6-NS29) were contaminated with A549 mtDNA (see 
Figure 3.9).
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< 165bp 
M 143bp
Figure 3.9: The A549 specific polymorphism PCR-RFLP using Alu\
showed that none of the P3 cybrid clones (NS6-29) were contaminated 
with mtDNA from A549 cells. UC, uncut; +, positive control DNA from 
A549 cells; wild-type.
3A.3.2. Sequence data and analysis of 10306A>G
The three mitochondrial COX genes and the tRNA genes had already been sequenced in 
muscle DNA from P3 (Rahman, 2002). No mutations had been found and very little of the 
muscle DNA sample was remaining. Therefore the remainder of the mitochondrial genome was 
sequenced in cybrid clone NS9, chosen on account of its low COX activity (COX/CS = 0.009) 
and presumed high mutant load. A nucleotide change (10306A>G) was found in ND3 (see 
Figure 3.10A). This results in an asparagine to serine substitution at amino acid position 83 
(N83S), which appears to be moderately conserved across a selection of mammals and other 
organisms (see Figure 3.11). The change was not present in an online database of 2104 
control mitochondrial sequences (www.genpat.uu.se/mtDB). Sequencing also showed 
polymorphisms at 4216, 13708 and 15257 which indicate that this patient is from the European 
mitochondrial haplogroup J (Herrnstadt et al., 2002) (see Table 3.4 for full mtDNA sequence 
results and Figure 1.4 in the Introduction).
Another cybrid clone (NS10) was selected for sequencing because of its high residual complex 
IV activity (COX/CS = 0.025), and presumed low mutant load. 10306A>G was only found at low 
levels: this was the only difference found between the two cell lines (see Figure 3.10B and 
highlighted in Table 3.4).
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Ala Lau Gin Thr Thr Sar Lau Pro Leu Mat Val
N S 1 0 - F
NS10 - R
Figure 3.10: Sequence electropherograms showing 10306A>G
(marked with arrow) in both the forward and reverse directions, and 
amino-acid translation. A. in DNA from cybrid cell line NS9. B. 
10306A>G is only at low levels in NS10.
Homo
Gorilla
Pan troglodytes
Pan paniscus
Rattus
Mus
Papio
Equus
Bos
Ovis
Sus
Canis
Xenopus
Drosophila
Caenorhabditis
FLVAITFLLFDLEIAL-LLPLPWALQTT 
FLVAITFLLFDLEIAL-LLPLPWALQTT 
FLVAITFLLFDLEIAL-LLPLPWALQTA 
FLVAITFLLFDLEIAL-LLPLPWALQTA 
FLVAITFLLFDLEIAL-LLPLPWAIQTT 
FLVAITFLLFDLEIAL-LLPLPWAIQTI 
FLVAITFLLFDLEIAL-LLSLPWALQTA 
FLVAIT FLLFDLEIAL-LLS LPWALQTA 
FLVAITFLLFDLEIAL-LLPLPWASQTA 
FLVAITFLLFDLEIAL-LLPLPWASQTT 
FLVAITFLLFDLEIAL-LLPLPWASQTN 
FLVAITFLLFDLEIAL-LLPLPWASQTN 
FLIAILFLLFDLEIAL-LLPFPWAAQLN 
FLITIIFLIFDVEIAL-ILPMIIIMKYS 
SVLVFSTYYLNSELNFNYYYFVLLIFVG
LPLMVMSSLLLIIILALSLAYEWLQKGLDWT 114 
LPLMVMSSLLLIIILTLSLAYEWLQKGLDWT 114 
LPLMVTSSLLLITILALSLAYEWLQKGLDWT 114 
LPLMVMSSLLLITILALSLAYEWLQKGLDWA 114 
TTTMMATAFILVTILALGLSYEWTQKGLEWT 114 
TSTMMIMAFILVTILSLGLAYEWTQKGLEWT 113 
LPTMIKTSIMFITILALSLAYEWTQKGLDWT 114 
LPTMIKTSIMFITILALSLAYEWTQKGLDWT 114 
LNTMLTMALFLIILLAVSLAYEWTQKGLEWT 114 
LNTMLTMALLLIFLLAVS LAYEWTQKGLEWT 114 
LKTMLTMAL FLLILLAAS LAYEWTQKGLEWA 114 
LTTMLIMALLLISLLAASLAYEWTEKGLEWT 114 
PSIVILWAALILTLLTLGLIYEWLQGGLEWA 113 
IMIWTITSIIFILILLIGLYHEWNQGMLNWS 116 
MFSLNFSNSIFTMLLSWDLLGISS FFLVXFY 119
Figure 3.11: Alignment of ND3 using CLUSTALW multiple sequence alignment software 
(www.ebi.ac.uk/clustalw). Position 10306 (boxed) shows moderate sequence conservation, 
indicated by a single dot.
The problem with the standard PCR-RFLP method is that any heterohybrid molecules that are 
formed in the last cycle of the PCR reaction would not be digested. Therefore any attempt to 
quantify the percentage of molecules containing the restriction site (i.e. the 10306A>G allele) 
would be an underestimate. In order to accurately determine the degree of heteroplasmy of
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10306A>G in the 12 transmitochondrial cybrid cell lines as well as in blood, fibroblast and 
muscle DNA from the patient, an assay was designed using last-cycle fluorescent PCR-RFLP 
(see section 3.3.4 4).
The ratio of the areas under the peaks at 91 bp (the FAM signal) and 122bp (the HEX signal) 
was calculated for the positive control. Even though there would have been equal numbers of 
either fragment present, the ratio was 1.35 indicating that the FAM signal is inherently stronger 
than the HEX signal (see Figure 3.12).
BOO 1600 2400 3200 4000 4000 5600 6400
3 8  03*C • *ve /  
3 0  03-C ♦vo /
□ B  3Y  03-C - ♦vo I
JCT
4 B (H * 0  NSiO : 
4 R 04*0 NSIO /
4 Y 04*0 * NSIO f
Wild-type control
NS10
600 1600 2400 3200 4000 4000 5000
1600
900
0
1206
60C
0
1 B -01 -A  • NS9 
tR  01*A NS9 /
□ H  » V O fA  • NSO /
H H  2B  02*8 - JS /
a s  2R* 02*0 JS /
□ B  8 Y 02*0 JS /
NS9
Blood from mother
BOO 1600 2400 3200 4000 4B00 5600 6400
240C.
I20C 1
II 116 11 "Control uncut (A) /  11 A ; i  "Control uncui (A) / 11 Y 11 •Control uncui (A) /
12 D 12-nepM  Mood . 
12 0  i2*n«po» Bkxxt
□ H  t2 Y 12-HepMi Blood i
Control uncut
P3’s blood
Figure 3.12: Examples of electropherograms used for quantification of 10306A>G.
FAM / HEX ratios were also calculated for the cybrid cell lines and for blood, fibroblast and 
muscle DNA samples. In these samples, a proportion of the 91 bp fragments would have been 
amplified using mutant mtDNA as a template. These would contain 10306A>G and therefore 
would be further digested into 47 and 44bp fragments. As expected, in these samples the ratios 
were less than for the positive control sample, in which the 91 bp fragment was not cut. 
Therefore using the 1.35 ratio as a normalisation factor, the percentage of 10306A>G contained 
in each sample could be estimated (see Table 3.5).
These results showed that the 10306A>G mutant load in blood, fibroblast and muscle DNA 
samples from P3 was 70%, 71% and 49% respectively. The mutant load in transmitochondrial 
cybrid clones varied a great deal, from 0% in NS15 to 90% in NS13. These results seemed to 
agree with standard PCR-RFLP results (see Figure 3.13). The reproducibility was also
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monitored by quantification of 10306A>G in blood, fibroblast, and muscle DNA on three 
separate occasions. Although there was some deviation, the method appears to be 
reproducible (see Figure 3.14).
Table 3.5: Results from fluorescent PCR-RFLP method for 10306A>G quantification.
HEX signal FAM signal
Clone Size Volume Size Volume Ratio % WT % 10306A>G
NS6 122.30 17970 93.71 20441 1.14 84.2% 15.8%
NS7 122.33 24219 93.90 4515 0.19 13.8% 86.2%
NS8 122.28 12819 93.81 8512 0.66 49.2% 50.8%
NS10 122.29 19775 93.76 26431 1.34 98.9% 1.1%
NS11 122.29 19844 93.96 8634 0.44 32.2% 67.8%
NSW 122.24 21410 93.95 4817 0.22 16.7% 83.3%
NS13 121.48 14462 93.32 1912 0.13 9.8% 90.2%
NS15 121.82 16351 93.48 22124 1.35 100.0% 0.0%
NS25 122.20 11581 93.92 13349 1.15 85.3% 14.7%
NS27 122.23 11339 94.03 9480 0.84 61.9% 38.1%
NS29 121.84 17991 93.77 11324 0.63 46.6% 53.4%
P3 blood 122.21 22673 94.15 9307 0.41 30.4% 69.6%
P3 fibroblasts 122.21 25512 94.15 9951 0.39 28.9% 71.1%
P3 muscle 122.15 21916 94.14 15148 0.69 51.2% 48.8%
Wild-type 122.22 14878 94.06 20099 1.35 100.0% 0.0%
uncut 215.43 46073 214.04 69128 1.50 n/a n/a
N.B. The quantification for NS9 did not work and so the results from 
the preliminary run were used (91%).
l44/47bp
l44/47bp
Figure 3.13: Agarose gels used to estimate 10306A>G mutant 
load using PCR-RFLP. UC, uncut; +ve, positive control DNA; 
NS6-29 are cybrid clones containing mtDNA from P3; B, Blood; F, 
Fibroblasts; M, Muscle.
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a P3 blood 
0 P3 fibroblasts 
D P3 muscle
Figure 3.14: Reproducibility of 10306A>G
quantification. Results from two preliminary runs (PR1 
and PR2) shown in comparison to final results (FR).
3.4 3.3. Correlation of 10306A>G with enzyme function
Because the percentage of 10306A>G in the cybrid cell lines was found to vary so considerably, 
an attempt was made to use these cybrid cell lines to provide functional evidence of 
pathogenicity. The percentage mutant load was compared to the enzyme activities of these 
cybrid cell lines (see Table 3.6). However, unlike previous studies which have shown an 
inverse correlation of mutant load with complex I activity (McFarland et al., 2004a), in this case 
there was no correlation with complex I activity (see Figure 3.15) or with complex IV activity 
(Figure 3.16). The complex IV results were unexpectedly low and so were repeated -  the 
results quoted are averages of two replicates.
90.0%
80.0%
70.0%
600%
50.0%
40.0%
30.0%
10.0%
0.0%
Table 3.6: Percentage 10306A>G vs enzyme assay results.
Clone % 10306A>G average COX Complex 1
Original COX 
results*
NS6 16% n/a n/a 0.016
NS7 86% 0.0027 0.095 0.016
NS8 51% 0.0028 0.007 0.019
NS9 91% 0.0025 n/a 0.009
NS10 1% n/a n/a 0.025
NS11 68% 0.0027 0.028 0.018
NS12 83% 0.0014 n/a 0.014
NS13 90% 0.0024 0.074 0.025
NS15 0% 0.0021 0.058 0.021
NS25 15% 0.0026 0.072 0.02
NS27 38% 0.0027 0.029 0.017
NS29 53% 0.0021 0.007 0.02
NSF n/a 0.0056 n/a n/a
Boxed are the first two results obtained which initially hinted at a link between 
10306A>G and COX activity. * results obtained by Mark Cooper and 
colleagues at the Royal Free Medical School.
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Correlation between 10306 and Complex I?
0.10 
0 .08  
0 .0 6  
0 .04  
0.02 
0.00
0%  20%  40%  60%  80%  100%
% 10306A>G
Figure 3.15: Complex I activity vs percentage
10306A>G. Complex I activity is expressed as a ratio to 
citrate synthase.
Correlation between 10306 and COX?
0 .0 0 6  
0 .0 0 5  
0 .0 0 4  
0 .0 0 3  
0.002 
0.001 
0.000
0 %  2 0 %  4 0 %  6 0 %  8 0 %  1 0 0 %
% 10 3 0 6A > G
Figure 3.16: COX activity vs percentage 10306A>G 
(present data). Complex IV activity is expressed as a 
ratio to citrate synthase.
The cybrids had previously been assayed for COX activity by Mark Cooper’s group at the Royal 
Free. Plotting these results against mutant load hinted at a slight downward trend. The two 
cybrid clones which were sequenced had already suggested a correlation (NS9 with 91% 
mutant load and a COX/CS ratio of 0.009; NS10 with 1% mutant load and a COX/CS ratio of 
0.025). However, the NS13 clone in particular, with 90% mutant load and yet a high COX/CS 
activity (0.025) greatly reduced the significance of the overall correlation (see Figure 3.17).
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Correlation between 10306 and COX?
0.030
NS13
0.025 ►
0.020
0.015
R = 0.1973
0.010
NS9
0.005
0% 20% 40% 60% 80% 100%
% 10306A>G
Figure 3.17: COX activity vs percentage 10306A>G.
(Results from Mark Cooper). Complex IV activity is 
expressed as a ratio to citrate synthase.
Although not initially available, a blood sample from the P3’s unaffected mother was later 
acquired and analysed by fluorescent PCR-RFLP. This indicated that about 40% of mtDNA 
was mutant for 10306A>G, in comparison to the 70% found in blood from P3.
3 .4 .3  4. R esu lts  from  Lacta te  /  P yru  vate m easu rem en ts
The normal physiological ratio of lactate to pyruvate is below 20. In comparison, lactate /
pyruvate ratios measured in PBS that was incubated with cybrid cells for 1h were slightly higher, 
ranging from 23.14 to 30.28 (see Table 3.7). Cybrids with the highest and lowest mutant loads 
had been chosen to maximise the chances of observing a functional effect. However, plotting 
the 10306A>G mutant load against these lactate / pyruvate ratios did not reveal a correlation 
(see blue data points in Figure 3.18). There was also no correlation between mutant load and
the lactate/mg protein results (see pink data points in Figure 3.18).
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Table 3.7: Lactate / Pyruvate results from cybrid cell lines.
mg protein Lactate Pyruvate
Sample (ave of 2 runs) (mM) (mM) L /P L /P  ave L / mg protein
N S 1 3 A 0 .8 6 3 .9 4 0 .1 6 1 2 4 .4 7 2 6 .4 6 4 .5 6
N S 1 3 B 0 .7 7 3 .8 7 0 .1 3 6 2 8 .4 6 5 .0 4
N S 1 5 A 0 .8 2 2 .8 1 0 .1 1 4 2 4 .6 5 2 5 .1 7 3 .4 1
N S 1 5 B 0 .4 8 3 .9 3 0 .1 5 3 2 5 .6 9 8 .2 1
N S 2 5 A 0 .6 5 4 .9 7 0 .2 0 9 2 3 .7 8 2 7 .0 3 7 .6 4
N S 2 5 B 0 .4 5 5 .4 5 0 .1 8 0 3 0 .2 8 1 2 .0 9
N S 1 2 A 0 .2 9 3 .6 8 0 .1 5 9 2 3 .1 4 2 6 .2 9 1 2 .5 8
N S 1 2 B 0 .5 3 4 .1 2 0 .1 4 0 2 9 .4 3 7 .71
L / mg protein 
ave
4 .8 0
5 .8 1  
9 .8 7  
1 0 .1 5
♦  L / P
I  L /  protein (m M /m g)
0 20 40 60 80 100
%A10306G
Figure 3.18: Lactate / Pyruvate vs percentage 10306A>G.
3.4.3.5. O xygen e lectrode  expe rim en ta l data
The complex I linked rate of respiration varied from 5.83 to 14.06 ng atoms 0 2 / min / mg (see 
Table 3.8). The cell line with the highest mutant load (NS9) also had the lowest respiration rate. 
However, in general, the respiration rate did not appear to correlate with mutant load (see blue 
data points in Figure 3.19). Due to the slow growing of these very old cybrid cells, and some 
contamination issues, it was not possible to perform replicates on all of the cybrid cell lines.
25
20
15
10
5
♦  ♦
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Table 3.8: Oxygen electrode results from cybrid cell lines.
%10306A>G ng atoms O/min/mg Average Slice / Glu + Mai Ratio
NS7a 86 14.06 11.55 0.75
NS7b 86 9.04 0.93
NS8a 51 8.33 11.02 1.28
NS8b 51 13.70 0.69
NS9 91 5.83 5.83 N/A
NS11a 68 9.14 10.55 1.10
NSUb 68 11.96 0.75
NS12a 83 10.28 9.67 1.18
NS12b 83 9.05 1.12
NS13 90 11.10 11.10 0.88
NS15. 0 9.85 9.85 0.95
NS29 53 11.81 11.81 0.89
Total
All cybrid cell lines were assayed in duplicate except for NS9, NS13, NS15 and NS29.
Ave
0.84
0.99
N/A
0.93
1.15
0.88
0.95
0.89
0.95
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Instead of normalising to protein concentration, it is possible to normalise to complex II induced 
respiration. The complex II / complex I ratio is usually about 1.18 in muscle (personal 
communication, lain Hargreaves). The results obtained here were close to this figure although 
there was some deviation (0.69 to 1.28). Again, this variation did not appear to correlate with 
mutant load (pink data points in Figure 3.19).
The addition of glutamate, malate and ADP did not increase the initial respiratory rate (see 
Figure 3.3 for a typical trace). This suggests that the cells already had sufficient substrate and 
that ADP levels in the cells were high enough for maximal state 3 respiration.
12
10
Oxygen electrode results
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Figure 3.19: Respiration rates of cybrid cell lines against mutant load.
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3.5. Discussion
3.5.1. P1
Two half-sisters from Zambia are described who both presented with infantile retinal dystrophy. 
The pedigree was consistent with mitochondrial inheritance as these sisters shared the same 
mother, but had different fathers. Two mitochondrial tRNA sequence variants were detected 
which appeared homoplasmic upon PCR-RFLP analysis. However, the fact that the mother 
was asymptomatic and yet carried the same homoplasmic tRNA changes as her two daughters, 
was evidence against these changes being pathogenic. By itself this would not completely 
exclude pathogenicity as homoplasmic mutations have been described before that appear to 
have reduced penetrance (McFarland et al., 2002). Other evidence against pathogenicity is that 
both changes were not conserved through evolution and that 15942T>C was found in 6 normal 
control mtDNA sequences in an online database. Ideally, to be entirely sure that the 5774T>A 
is not pathogenic, Zambian controls should be screened to determine whether this is a common 
polymorphism in this ethnic group. Although the Human Mitochondrial Genome database 
(www.genpat.uu.se/mtDB) does contain some African sequences, none of these are Zambian 
and access to such a panel of controls was not possible.
Maternal inheritance is not the only possible explanation for the inheritance pattern shown in 
P1’s pedigree (Figure 3.1). The disease could also be caused by a dominant mutation with 
reduced penetrance, or by gonadal mosaicism. Another explanation for the present failure to 
find a pathogenic mtDNA mutation is that because DNA was sequenced from blood, the mutant 
load may have been too low to be detectable (see General discussion below).
Although the 22 tRNA genes make up only about 10% of mtDNA sequence, they are thought to 
account for as many as 75% of known mitochondrial mutations. It is not known whether this 
pattern is genuine, or simply due to an ascertainment bias, as many of the first mtDNA point 
mutations to be described were in tRNA genes (Goto et al., 1990; Kobayashi et al., 1990; 
Shoffner et al., 1990). Functional studies of the two tRNA mutations described here could 
provide further evidence for or against pathogenicity. For example, steady state levels of tRNA 
can be determined in tissues derived from the patient (McFarland et al., 2002). In vitro 
experiments have also been performed on tRNA mutations which assay CCA addition (Tomari 
et al., 2003), aminoacylation charging (Kelley et al., 2000; Wittenhagen et al., 2003), 
dimerization (Wittenhagen and Kelley, 2002) and stability of anticodon stem (Wittenhagen et al., 
2003).
3.5.2. P2
Cytochrome b is the only complex III subunit encoded by the mitochondrial genome and has 
previously been associated with complex III deficiency in individuals with progressive exercise
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intolerance (Dumoulin et al., 1996; Andreu et al., 1999). It was therefore an obvious candidate 
gene in a patient with an isolated complex III deficiency. Cytb sequence analysis identified a 
single homoplasmic variant which has been excluded as the cause of disease on account of its 
presence in 12 normal control mtDNA sequences, the corresponding amino-acid’s lack of 
phylogenetic conservation, the conservative nature of the amino-acid substitution as well as the 
fact that the mutation was homoplasmic. A cytb mutation was also constructed in yeast which 
was equivalent to human A229T by Dr. Brigitte Meunier (Wolfson Institute for Biomedical 
Research, University College London). The mutant strain grew well on respiratory medium and 
it was clear that the mutation had no dramatic, if any effect on the mitochondrial cytochrome bc^  
complex activity, as judged by the respiratory growth. Membrane was also prepared from the 
yeast and the quinol cytochrome c reductase activity was monitored. There was no effect; the 
activity was normal. Therefore it is likely that A229T is also without effect in human cells.
The exclusion of cytb led to the conclusion that a defective nuclear gene underlies the complex 
III deficiency in P2. The nuclear-encoded assembly factor BCS1L has also been excluded as 
the cause of the isolated complex III deficiency in P2. Recent studies have shown that 
mutations in UQCRB can impair complex III function in human disease (Haut et al., 2003) and 
so should be sequenced in P2.
3.5.3. P3
Transmitochondrial cybrid studies had previously been carried out on a cell line from a patient 
presenting with cardiomyopathy and a complex I and IV deficiency. A wild-type A549 nucleus 
had not corrected the COX activity and therefore the mutation was assumed to be of 
mitochondrial origin. A 10306A>G mutation was detected in cybrid clone NS9, chosen for 
sequence analysis on account of its low COX activity and presumed high mutant load. This 
transition mutation predicted an asparagine to serine substitution at a moderately well 
conserved position in ND3 and was not present in an online database of over 2000 normal 
control mtDNA sequences.
A last-cycle fluorescence PCR-RFLP was designed to accurately determine the 10306A>G 
mutant load. The level of heteroplasmy in blood, fibroblast and muscle DNA samples from P3 
was 70%, 71% and 49% respectively. The mutant load in a blood sample from the unaffected 
mother was 40%. A second cybrid cell line was sequenced on account of its high residual COX 
activity. The 10306A>G mutation was not present (mutant load was later determined by 
fluorescence PCR-RFLP to be 1%) and this was the only sequence change found between 
these two cybrid cell lines.
Because the percentage of 10306A>G in NS9, NS10 and the other 10 cell lines was found to 
vary considerably in the present work, an attempt was made to use these cybrids to provide 
functional evidence of pathogenicity. However, complex I and IV activities, lactate / pyruvate 
measurements and oxygen electrode experiments all failed to correlate with mutant load as
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expected and thus did not provide convincing functional evidence of pathogenicity for the 
10306A>G mutation. There were a number of possible explanations for this. Firstly, it may be 
that due to the slow growth rates and susceptibility to contamination of these old cybrid cells, 
insufficient replicates were run to minimise the experimental noise. Secondly, the mutant loads 
could have deviated in the time between being measured and the functional assay being 
performed (especially the oxygen electrode experiments, which were carried out last). Previous 
studies have demonstrated that mutant load can shift in cybrids cell lines, and that in some 
cases the nuclear genetic background can influence whether an increase or decrease is 
observed (Dunbar et al., 1995). However, in these experiments, uridine and pyruvate 
supplements were added to the culture medium in an attempt to minimise any negative 
selection of respiratory deficient cells. Thirdly, it may be that the wrong functional assays were 
chosen and ATP synthesis would have been a better marker to measure the effect of this 
mutation. A final explanation is that 10306A>G is simply a polymorphism that is heteroplasmic 
because it is relatively new and has not yet had time to progress to fixation.
Other ND3 mutations (T10158C and T10191C) have been described which cause disease 
(Taylor et al., 2001b; Lebon et al., 2003; Crimi et al., 2004; McFarland et al., 2004a). The 
sequence conservation of these affected amino-acid residues is no more conserved than for 
10306A>G (see Figure 3.20). However, these both involved the substitution of a serine by a 
proline residue which is likely to induce a bend in the amino acid chain and thus affect protein 
folding.
T10158C — S34P (Crimi T10191C -» S45P (Taylor
2004, McFarland 2004a) 2001b, McFarland 2004a)
Homo LLLMIITFWLPQLN-GYMEK S TPYECGFDPM S PARVPFSMKF 55
Rattus FILISIAFWLPQMN-LYSEK A NPYECGFDPT s SARLPFSMKF 55
Mus LTLILVAFWLPQMN-LY SE- A NPYECGFDPT s SARLPFSMKF 54
Papio ALLTIIMFWLPQLN-SYAEK A NPYECGFDPL N PARIPFSMKF 55
Equus ALLTIIMFWLPQLN-SYAEK A NPYECGFDPL N PARIPFSMKF 55
Gorilla LLLMIITFWLPQLN-SYMEK T NPYECGFDPV S PARIPFSMKF 55
Pan troglodytes LLLMIITFWLPQLN-SYMEK S TPYECGFDPM s PARVPFSMKF 55
Pan paniscus LLLMIITFWLPQLN-SYMEK s NPYECGFDPM s PARVPFSMKF 55
Bos TLLVIIAFWLPQLN-VY SEK T SPYECGFDPM 3 SARLPFSMKF 55
Ovis TLLVTIAFWLPQLN-VY SEK T SPYECGFDPM G SARLPFSMKF 55
Sus SLLVLIAFWLPQLN-AYSEK T SPYECGFDPM G SARLPFSMKF 55
canis S L LVLIAFWLPQLN-1Y TDK T SPYECGFDPM G SARLPFSMKF 55
Xenopus TILAILSFWLPQMT-PDMEK L SPYECGFDPL G SMRLPFSMRF 54
Drosophila TIVMFLASILSKKALIDREK S SPFECGFDPK S SSRLPFSLRF 57
Caenorhabditis S VWLMPTFKLGIFF LEWDFL S LKFNFYFNSI L FSFILFLVTF 59
* — ■ • t ■ i . t ; *
Figure 3.20: Sequence conservation of other ND3 mutations. Aligned 
using CLUSTALW multiple sequence alignment software 
(www.ebi.ac.uk/clustalw).
The structure of complex I has not yet been determined and therefore the function of ND3 is not 
certain. However the most recent ND3 mutation report indicates that this subunit may have an
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important role in the assembly of the enzyme. Western blotting demonstrated that the T10191C 
mutation results in a decrease of the 20kDa subunit (likely to be ND6) and of NDUFA9 
(Leshinsky-Silver et al., 2005). Another study on mtDNA haplotypes has shown that ND3 could 
be an important factor in Parkinson’s disease susceptibility among white individuals (van der 
Walt et al., 2003).
In conclusion, a heteroplasmic mutation in ND3 has been detected in a patient with severe 
cardiomyopathy and a combined complex I and complex IV defect. Due to the mtDNA 
bottleneck during oogenesis, neutral polymorphisms are very quickly eliminated from the 
mtDNA genome and so heteroplasmy is often suggestive of pathogenicity. In addition, the 
mutation was not present in a database of over 2000 control mtDNA sequences, is situated at a 
moderately conserved region of the protein sequence and is present at reduced levels in the 
unaffected mother. However, the functional studies carried out as described here had not been 
fully validated on cybrid cell lines and the results presented are not convincing. The age of the 
cybrids cell lines (over 10 years) may also have influenced these data. Finally, the finding that 
the mutant load was lower in muscle than in blood is also peculiar (see discussion below). 
Unfortunately as this is a historical case, it is not possible to obtain further blood or muscle 
samples from this patient to confirm this unusual pattern. In addition, DNA from cardiac muscle 
(the most severely affected tissue) was not available for testing. Therefore the pathogenic 
status of A10306G remains questionable.
3.5.4. General discussion about mtDNA sequencing
Even with mtDNA sequencing runs where the quality of the data is high, base-calling software 
will miss heteroplasmic polymorphisms unless the mutant load is approaching 50%. This 
default threshold can be reduced by adjusting the base-calling settings, but this would increase 
analysis time. Although electropherograms were also scanned by eye, it is estimated that 
heteroplasmic peaks corresponding to mutant loads of -20% or less could have been missed, 
especially in electropherograms where there is some background noise.
White blood cells often have a reduced mtDNA mutation load when compared to other tissues 
from the same patient. A previous study has shown that the 3243A>G mutation load in blood 
decreases over time in blood cells from MELAS patients (Rahman et al., 2001). The post­
mitotic tissues (e.g. neurons, cardiac and skeletal muscles), which usually contain the highest 
levels of mutated mtDNA, are unfortunately also the least accessible. Therefore, sequencing 
mtDNA extracted from blood (as was done for P1) further increased the likelihood that any 
mutation would have been missed. For another patient (P3), the DNA from muscle was limited 
so cybrids with a low complex IV activity were used as a source of DNA as they were assumed 
to have a high mutant load.
The possibility of using epithelial cells spun down from a 50ml urine sample was briefly 
investigated in a patient with the common 3243A>G MELAS mutation. This showed increased
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mutant load in comparison to blood. However, in a second patient the 50ml urine sample did 
not yield enough cells for DNA extraction. Another non-invasive method would be to try using 
buccal mucosal cells, as some researchers have found that the mutation load often exceeds 
that in blood (Chinnery et al., 1999). Hairs are not so good as they tend to have variable levels 
of heteroplasmic mutations (Tully et al., 2004).
There is now a wealth of sequence data available as a result of high-throughput sequencing 
technologies. An online database containing over 2000 normal control mtDNA sequences 
(www.genpat.uu.se/mtDB) has greatly helped analysis of most mtDNA sequence variants by 
removing the need to screen controls. The exception is when the patient is from a rare ethnic 
background. P1 was from Zambia and unfortunately, none of the 2104 control mtDNA 
sequences from the Human Mitochondrial Genome database were from this precise ethnic 
group. As the greatest amount of human genetic variation is found in Africa, the 5774T>A 
change could well be a common Zambian polymorphism.
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Chapter 4: Phenotypic variability caused by a SDHA mutation
4.1. Introduction
Complex II of the mitochondrial oxidative phosphorylation system (OXPHOS) has four subunits 
and catalyses the reduction of ubiquinone (CoQ10) by succinate. It is unique amongst the five 
OXPHOS enzyme complexes, as all subunits are encoded by nuclear DNA. The SDHA subunit 
of complex II contains the prosthetic group FAD and (along with SDHB) protrudes into the 
mitochondrial matrix. The catalytic site for oxidation of succinate is situated within this subunit. 
Mutations in the SDHA gene encoding this flavoprotein subunit (SDHA) of complex II have 
previously been reported in patients with Leigh syndrome (Bourgeron et al., 1995; Goto Y et al., 
1998; Parfait et al., 2000; Van Coster et al., 2003) and late onset optic atrophy, ataxia and 
myopathy (Birch-Machin et al., 2000). The iron-sulfur subunit (SDHB) and membrane-spanning 
subunits (SDHC and SDHD) together form the catalytic site where ubiquinone is reduced. 
Mutations in these subunits are associated with hereditary phaeochromocytoma and 
paragangliomas (Astuti et al., 2001; Niemann and Muller, 2000; Baysal et al., 2000). These 
published mutations are summarized in Tables 4.1 and 4.2.
Table 4.1: Summary of mutations in SDHA.
Reference Mutation Pisorder
Level of 
parental 
consanguinity
Ethnicity Gender MRI Age of onset / 
death
Bourgeron et 
al., 1995
1660C>T R554W Leigh
syndrome
First cousins Tunisian Female 
(2 sisters)
Leukodystrophy 
& necrosis of 
substantia nigra 
and basal 
ganglia
Died aged 19 
months
Parfait et al., 
2000
1 A>C 
1571C>T
M1L
A524V
Leigh
syndrome
Unrelated N/A Female Necrotic lesions 
in basal ganglia
Age of onset of 
9 months
Birch-Machin 
et al., 2000; 
Taylor et al., 
1996
1351C>T R451C Optic 
atrophy, 
ataxia and 
myopathy
Unrelated N/A Female 
(2 sisters)
Atrophy in 
cerebellum and 
brainstem
Symptoms not 
until 5th decade. 
Progressive. 
Dominant
P5 (Van 
Coster et al., 
2003)
1664G>A G555E Leigh
syndrome
?
First cousins Of Middle 
Eastern origin
Female Died before 
signs of LS 
could develop
Died aged S'A 
months
All mutations are numbered from the initiation codon.
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Table 4.2: Mutations described in other succinate dehydrogenase subunits.
Reference Mutation Disorder Inheritance
SDHB
Astuti et al., 2001 402C>T
724C>G
725delC
394T>C
R91X
P198R
T runcating 
L88S
Familial pheochromocytoma 
and paraganglioma
Sporadic
pheochromocytoma
Sporadic and familial
SDHC
Niemann and Muller, 
2000
3G>A Destroys start 
codon
Autosomal dominant 
paraganglioma, type 3
Familial
SDHD
Baysal et al., 2000 Q36X, R38X, P81L, D92Y, 
H102L
Hereditary paraganglioma Familial
This chapter describes a 9-year-old boy with relatively mild Leigh syndrome (LS) and complex II 
deficiency caused by a homozygous mutation in the SDHA gene. This mutation has previously 
been reported to cause a lethal-infantile presentation of the disease (Van Coster et al., 2003). 
Such marked phenotypic heterogeneity, although typical of heteroplasmic mutations in the 
mitochondrial genome, is more unusual for nuclear mutations.
In order to try to explain this phenotypic difference, the activities and stability of mitochondrial 
respiratory chain enzymes were compared in cultured fibroblasts derived from both patients. 
Other reasons for the phenotypic variability are also considered.
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4.2. Patient details
4.2.1. Patient 4
Patient 4 (P4) was born to healthy first-cousin Palestinian parents (see Figure 4.1) and had 
normal early developmental milestones. He walked at 16 months but at 22 months his walking 
deteriorated and he had frequent falls. Examination revealed myopathic facies with mild ptosis, 
mild hypotonia and generalised weakness. He deteriorated rapidly over the next month and 
could no longer walk or sit. Repeat examination demonstrated increased weakness, particularly 
affecting proximal muscles. By 25 months he was able to walk a few steps in a crouched 
position but he had developed generalised hypertonia, with increased deep tendon reflexes and 
bilateral extensor plantar responses.
Fasting blood lactate was raised on 2 occasions (3.7 and 5.0mM, normal range <2mM) but 
fasting blood and cerebrospinal fluid (CSF) lactates were both normal on two further occasions. 
Brain MRI demonstrated abnormal signal in the pons, periaqueductal region and medial thalami, 
with no evidence of white matter involvement. Repeat MRI demonstrated extensive 
symmetrical hyperintensity in the dorso-medial thalami, base of pons, lower medulla and upper 
cervical spinal cord. Visual Evoked Potential (VEP), electroretinogram (ERG), 
electroencephalogram (EEG), nerve conduction studies and white cell enzyme assays were all 
normal. Histology of biopsied skeletal muscle did not show any abnormalities including 
succinate dehydrogenase (SDH) stain. A screen for mitochondrial DNA rearrangements (using 
long range PCR and Southern blot) and the common point mutations at nucleotide positions 
3243, 8344 and 8993 was negative.
The patient’s clinical condition improved gradually from 4 years. At 6.5 years he had mild 
spasticity in all 4 limbs, with weakness and wasting of shoulder muscles. Further MRI revealed 
some improvement in the thalamic, midbrain and pontine changes, but no change in the cervical 
cord lesions. Blood lactate was again normal, as were fatty acid oxidation flux and activities of 
pyruvate carboxylase and the pyruvate dehydrogenase complex in cultured skin fibroblasts. 
Repeat muscle biopsy showed mild fibre size variation only.
18t cousins
Figure 4.1: Pedigree of Patient 4.
101
Chapter 4: Phenotypic variability of mitochondrial disease caused bv a nuclear mutation
Over the last 3 years the patient’s clinical course has been relatively stable, although his motor 
function is variable. On some days he is able to walk 200 metres, but on other days needs to 
use a wheelchair. At the age of 9.5 years he does not have any apparent cognitive impairment 
and is able to attend a mainstream school. He is thin, speaks with a quiet voice and has 
nystagmus, myopathic facies and spastic paraparesis with generalised muscle weakness and 
wasting.
4.2.2. Patient 5
The clinical details of patient 5 (P5) have previously been published (Van Coster et al., 2003). 
In brief, he is reported to have had severe hypotonia, hepatosplenomegaly, cardiomegaly, and 
respiratory difficulties and died aged 51/2 months. Complex II deficiency was measured in both 
muscle and fibroblasts.
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4.3. Methods
4.3.1. Determination of RC enzyme activities and CoQ10 concentration
The standard mitochondrial respiratory chain enzyme assays are described in Chapter 2. 
Complex II and III are normally measured together. However, if a low result is obtained, the two 
enzymes can also be measured separately. The isolated complex II assay is also described in 
Chapter 2. Activity is also dependent on the concentration of coenzyme Q10.
The complex III assay was carried out as described (Krahenbuhl et al., 1994). Muscle CoQ10 
was measured using high-performance liquid chromatography (Boitier et al., 1998). These two 
assays were carried out by other researchers in the Neurometabolic Unit at the National 
Hospital (London, UK).
4.3.2. Sequence analysis
Messenger RNA was extracted from fresh blood of P4 using the PAXgene Blood RNA kit 
(Qiagen) and cDNA was synthesised using the Omniscript Reverse Transcriptase kit (Qiagen) 
according to manufacturer’s instructions. Oligo-dT and random nonamers were used to prime 
first strand synthesis. Sequence analysis was performed on P4 and a wild-type control using 
six overlapping primer pairs reported previously (Bourgeron et al., 1995), with an additional 
primer 5RN replacing 5R because of a discrepancy between the original published sequence 
and that currently found on the Ensembl database -  underlined T was originally a C (Morris et 
al., 1994). All primers are listed below. Standard PCR conditions were used except for 
annealing temperatures which are given below.
PCR reactions were treated with EXOSAP and sequenced as described in Chapter 2. The 
sequences were assembled into a contig using Sequencher™ 4.2 (Gene Codes). The resulting 
sequence was analysed by eye and then compared to the SDHA sequence from Ensembl 
(ENST00000264932) using the NCBI online Blast 2 Sequences tool (Tatusova and Madden, 
1999).
Exons Name Primer sequence Conditions, size
1-4 SDHA1F 5'-GAC TGC GCG GCG GCA ACA GCA-3’ 62°C, 421bp
SDHA1R 5'-GCC AGT CGG AGC CCT TCA CGG-3’
4-6 SDHA2F 5'-AGG AGG ACA ACT GGA GGT GGC-3’ 60 °C, 400bp
SDHA2R 5'-CTT ATG CGA TGG ATG GAC CCG-3’
6-8 SDHA3F 5'-GTG TCA TCG CAC TGT GCA TAG-3’ 58 °C, 340bp
SDHA3R 5’-ACC GAG ACA CCA CAT CTC TAG-3’
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8-10 SDHA 4F 5’-GTT TAT GGA GCG ATA CGC CCC-3’ 58 ° C, 423bp
SDHA 4R 5'-GCC CGA CCA AAG ACA ACC AGG-3’
10-13 SDHA5F 5'-GTA CAT GGT GCC AAC CGC CTC-3’ 58°C, 422bp
SDHA 5RN 5'-TTC C G I GCC TCT GCT CCG TAG-3’
13-15 SDHA6F 5'-GAA CCT GAT GCT GTG TGC GCT-3’ 58°C, 411 bp
SDHA 6R 5'-TCA ATG TAC TCC TTC TTC CCC-3’
N.B. The PCR product from Exon 2 produced a non-specific band. Therefore the correctly 
sized product had to be cut from the gel and purified with QIAquick Gel Extraction Kit (according 
to manufacturers protocols) prior to sequencing.
4.3.3. RFLP analysis
4.3.3.1. RFLP analysis of G555E (1664G>A) in cDNA
The 1664G>A mutation in exon 13 was confirmed in cDNA upon digestion of the 422bp 
amplicon #5 with BsaJI as described previously (Van Coster et al., 2003). The wild-type allele 
results in fragments of 306, 62, 35 and 19bp, whilst the G555E allele abolishes a restriction site 
(C/CNNGG, site of mutation shown in bold), resulting in fragments of 341, 62 and 19bp. 
Digestions were carried out with 6pl of PCR product, 3pl of 10x NEB buffer II, 5U of enzyme 
(NEB) in a total reaction volume of 30pl. Incubation was carried out for 2h at 60°C, after which 
the enzyme was inactivated for 20min at 80°C.
4.3.3.2. RFLP analysis of G555E (1664G>A) in gDNA
An amplification-created restriction site approach was used to screen control genomic DNA in 
which a new forward primer (5’-GAT GGA ACT TTT TGT GTC CCC GG-3’, site of mismatch 
underlined) was used in combination with 5RN. Upon amplification (using 58°C as the 
annealing temperature), a single Smal site (CCC/GGG) is created in the 117bp wild-type PCR 
product, which is abolished by the mutation. The 96bp and 117bp fragments were resolved on 
a 4% agarose gel. Digestions were carried out with 6pl of PCR product, 3pl of 10x NEB buffer 
IV, 40U of enzyme (NEB) in a total reaction volume of 30pl. Incubation was carried out for 5h at 
25°C, after which the enzyme was inactivated for 20min at 65°C.
4.3.4. Analysis of microsatellites and SNPs
Microsatellite markers flanking the SDHA locus on chromosome 5 were identified from the 
Research Genetics Human Screening Set 8, the ABI PRISM™ Linkage Mapping Set (ABI) or 
else identified using the Ensembl Human Genome Browser (www.ensembl.org/Homo_sapiens). 
The primer sequences and fluorescent dyes used are listed below. After PCR amplification, the
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labelled DNA fragments were diluted, run on the MegaBACE™ and data analysed as described 
in Chapter 2.
D5S2488F 5’-HEX-CAT TGT TTC TGC TTA TTG TTG G-3’
D5S2488R 5’-CCT TTT GTG AGC CAG ACA TT-3’
D5S2509F 5’-FAM-CTC TGG GCC AGA AGC CTT-3’
D5S2509R 5’-CAC AAG GTG GAT ATT GCG TG-3’
D5S1981F 5’-FAM-CCT GTA CCA ATC CAT GC-3’
D5S1981R 5’-GAG CCA TGT GAG TGT CC-3’
D5S2849F 5’-HEX-CCT GGA AGA ACC AAT GCT TA-3’
D5S2849R 5’-TTG AGC CCA GAA AGT TTG AG-3’
D5S406F 5’-TET-CCT GCC AAT ACT TCA AGA AA-3’
D5S406R 5’-GGG ATG CTA ACT GCT GAC TA-3’
D5S2505F 5’-TET-TGT TGG AAG ACT TCT CAG CC-3’
D5S2505R 5’-CAC ACA TGC TGT GTC TCT CA-3’
ResGen 227-245bp
Ensembl 102-103bp
Ensembl 224-268bp
ResGen 194-214bp
ABI 160-186bp
ResGen 257-297bp
SNPs flanking the SDHA gene locus were identified using the SNP consortium database 
(http://snp.cshl.org/) and were genotyped in P4 and P5 by sequencing genomic DNA with 
primers rs2115273F (5’-AGA CCG AAG GGC CTG AAC-3’) and rs2115273R (5’-GGT GCA 
AAC AGT GCT AGA AGC-3’) that had been designed using Primer3 (http://frodo.wi.mit.edu). 
PCR reactions used standard conditions described in Chapter 2, except for the annealing 
temperature which was 63.5°C. The resulting 365bp fragment was sequenced as described in 
Chapter 2.
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4.4. Results
4.4.1. Enzyme assay results from muscle biopsies
Spectrophotometric assay of respiratory chain enzymes indicated a combined defect of 
complexes II and III in P4’s first muscle biopsy, but the small biopsy size precluded further 
investigations. This combined defect of complexes ll+lll was confirmed in the second muscle 
biopsy 41/2 years later. Further investigation demonstrated normal muscle CoQ10 concentration 
and complex III activity, but reduced complex II activity (see Table 4.3). The spectrophotometric 
complex II assay (a measure of the reaction kinetics rather than an end point assay) is more 
sensitive than histological SDH staining, which was normal in P4’s muscle.
Table 4.3: Respiratory chain enzyme activities and CoQ10 concentration in muscle.
P4
Reference range2y 1 
month
6y 9 
months
Complex I 0.118 0.185 0.104-0.268 (n = 30)
Complex ll+lll 0.016* 0.023* 0.040-0.204 (n = 30)
Complex IV 0.014 0.023 0.014-0.034 (n = 30)
Complex II ND 0.025* 0.052-0.258 (n = 30)
Complex III ND 0.017 0.008-0.028 (n = 30)
CoQ10 (pmol/mg) ND 291 140-580 (n = 14)
Activities are expressed as a ratio to citrate synthase to normalise for mitochondrial 
enrichment (Heales et al., 1996). Asterisks indicate where the values lie outside 
the control range. ND, not determined.
4.4.2. SDHA sequence analysis
Sequence analysis of SDHA was performed first because this is the only subunit in which 
mutations have been associated with LS and complex II deficiency. The only two sequence 
changes found were; a homozygous 1664G>A transition at the start of exon 13 in cDNA from 
P4 (see Figure 4.2A), and a heterozygous SNP (rs1126417 synonymous for Proline 297) in the 
wild-type control. The 1664G>A mutation predicted the substitution of a well-conserved glycine 
at position 555 (see Figure 4.2B) with a glutamic acid residue (G555E). A recently described 
structure of porcine complex II (Sun et al., 2005) indicated that the corresponding glycine 
residue is situated in a polypeptide loop between the SDHA and SDHB subunits (see Figure 
4.3). The G555E mutation was confirmed in P4 using BsaJI digestion of the RT-PCR fragment 
(see Figure 4.4). G555E has been reported once previously, in a patient (P5) with a fatal- 
infantile mitochondrial RC disease (Van Coster et al., 2003).
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Figure 4.2: Analysis of SDHA by sequencing and phylogenetic
conservation. A. cDNA sequence from patient P4 and control (WT) 
showing the 1664G>A mutation. B. Alignment of SDHA proteins from 
different species using the ClustalW tool (www.ebi.ac.uk/clustalw). The 
residues that correspond to G555 are boxed. The most highly conserved 
amino acids are indicated by an asterisk.
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Gly613^ v 
Asp22^/“
Figure 4.3: Structure of porcine succinate dehydrogenase at 2.40A
resolution (PDB entry 1ZOY). Viewed with DeepView / Swiss-PdbViewer 
(www.expasy.org/spdbv) with SDHA in orange shading, SDHB in blue, 
SDHC in green and SDHD in red. Ubiquinone, heme, FAD and other 
prosthetic groups are shown in black. The positions of glycine 513 in SDHA 
and aspartate 22 in SDHB are indicated, and are equivalent to glycine 555 in 
human SDHA (see Figure 4.2B), and aspartate 50 in human SDHB (see 
Figure 4.9), respectively.
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600bp>
500bp*
400bp^
300bp^
ladder uncut
4422bp 
•4341 bp 
■4306bp
Figure 4.4: Confirmation of G555E using PCR-RFLP in
cDNA. Upon digestion with BsaJl, the 422bp PCR fragment is 
cut, resulting in a 306bp in the wild-type and a 341 bp fragment 
in the presence of G555E.
Fibroblasts were obtained from P5 as a gift from Rudy Van Coster, and from which DNA was 
extracted. A genomic PCR-RFLP confirmed the mutation in both patients (P4 and P5) and 
showed that P4’s parents were heterozygous for this mutation (see Figure 4.5), whereas 60 
control individuals (44 Caucasian and 16 African Americans) were all wild type. (Although P4 
and P5 are homozygous for the mutation, there was still a weak band at 96bp thought to 
indicate non-specific amplification of a pseudogene that does not contain G555E. Even though 
this low level non-specific amplification meant that it was difficult to differentiate between G555E 
heterozygotes and homozygotes, the difference between heterozygotes and wild-type was 
much clearer. Therefore, as long as heterozygous controls were included in each batch, this 
method was considered satisfactory to screen for G555E.) Including the individuals screened 
previously (Van Coster et al., 2003), a total of 186 control chromosomes have now been shown 
to be negative for G555E.
117bp^
96bp^
Figure 4.5: Detection of G555E in genomic DNA. Upon digestion 
with Smal, the wild-type 117bp PCR fragment is cut, resulting in 96 
and 21 bp fragments. The G555E mutation abolishes the recognition 
site. M is mother of P4, F is father of P4, WT is wild type.
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Results from 3 telomeric SNPs (rs2864963, rs3756715 and rs3756718) and a microsatellite 
(D2S2488) close to the SDHA locus were consistent with an ancestral disease haplotype that 
extended at least 124kb and is shared by P4 and P5 (see Table 4.4). Alleles at more distant 
centromeric microsatellites (D5S1981, D5S2849, D5S406 and D5S2505) were not shared. The 
closest microsatellite to the gene (D5S2509) was not informative.
Table 4.4: SNP and microsatellite results around the SDHA locus.
C h r 5  S N P s/ 
m arke rs
P4 P4-M other P 4-Father P5 P o s itio n
(bp)
Het
D5S2488 240,240 237,240 237,240 240,240 180,431-
180,657
0.75
rs3756718 A/A A/G A/G A/A 270,830 0.47
rs2864963 t n T/C T/C TfT 270,988 N/A
rs3756715 A/A A/G A/A A/A 271,036 N/A
G555E +/+ +/- +/- +/+ 304,453 N/A
D5S2509 102,102 102,102 102,102 102,102 395,710-
395812
N/A
D5S1981 261,261 261,267 261,261 261,263 1,207,429- 
1,207,692
N/A
D5S2849 201,205 205,209 201,201 205,209 3,449,559 0.75
D5S406 178,182 168,178 168,182 168,178 5,047,184-
5,047,361
0.79
D5S2505 294,294 294,294 294,298 289,289 5,870,113-
5,870,397
0.80
The patient described here is labelled P4, the patient described by Van Coster et al 
is P5. DNA from parents of P5 was not obtained. Heterozygosity scores are also 
shown, if available. Shared ancestral haplotype shown in bold. N/A, not available.
4.4.3. Comparative enzyme assay results from cultured fibroblasts
Deficiency of complex II that had been observed in muscle was confirmed in fibroblasts derived 
from P4. The RC activities were almost identical to results obtained from fibroblasts derived 
from P5 (see Table 4.5).
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Table 4.5: Mitochondrial RC enzyme activities in cultured fibroblasts.
P4 P51 Reference range
Complex II 0.040* 0.048* 0.095-0.205 (n = 12)
Complex ll+lll 0.032* 0.029* 0.070-0.243 (n = 12)
Complex IV 0.010 0.010 0.007-0.036 (n = 12)
Activities are expressed as a ratio to citrate synthase to normalise for 
mitochondrial enrichment (Heales et al., 1996). Asterisks indicate 
where the values lie outside the control range. The patient described 
here is labelled P4, the patient described by Van Coster et al is P5.
1Skin biopsy obtained immediately post-mortem.
4.4.4. Immunoblots and activity staining
In order to confirm the results obtained by Van Coster et al, which suggest that G555E can 
disrupt the stability of the holo-enzyme, immunoblotting and activity staining experiments were 
carried out on mitochondrial preparations of fibroblasts derived from both patients. Denaturing 
SDS-PAGE immunoblots showed that the SDHA subunit was moderately decreased in P4 and 
P5 (reduced to -75% of control levels), whereas the SDHB subunit was more severely affected 
(-25-50%, see Figure 4.6A). Blue Native PAGE immunoblots indicated that the fully assembled 
SDH enzyme was also severely depleted in P4 and P5 (-25%, see Figure 4.6B), and this was 
confirmed with catalytic activity staining (see Figure 4.6C).
111
Chapter 4: Phenotypic variability of mitochondrial disease caused bv a nuclear mutation
Control
P4 P5 100% 75% 50% 25% 12.5%
SDHA-6 8  kDa
SDHB-2 9  kDa
VDAC -  30 kDa s p » « p #  life
Control
P4 P5 100% 75% 50% 25% 12.5%
•4SDHA-SDHB subcomplex
MTC02 -  26 kDa
B
Complex 11-130 kDa 
SDHA antibody
Complex 11-130 kDa 
SDHB antibody
Complex IV -  200 kDa 
MTC02 antibody
C
Activity stains
Figure 4.6: Proteomic analysis of complex II subunits using SDS and BN 
PAGE. A. SDS-PAGE immunoblots showing SDHA and SDHB subunits of 
complex II in mitochondrial protein isolated from cultured fibroblasts by 
differential centrifugation. Percentages represent a dilution series of protein 
from control fibroblasts. P4, P5 and C-100% were normalised with respect to 
MTC02 and VDAC. B. Immunoblots of Blue Native gels showing the fully 
assembled 130-kDa complex II and 200-kDa complex IV. C. Catalytic activity 
staining of complex II and IV. The patient reported here is P4, the patient 
described by Van Coster et al is P5.
•^holo-complex II
•4SDHA-SDHB subcomple> 
•*SDHA
Complex II 
P5 P5 C-100%
Complex IV 
P4 P5 C-100%
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4.4.5. Temperature sensitivity of complex II
The complex II spectrophotometric assay was repeated at 26°C and 41 °C to assess the 
temperature sensitivity of the mutation. Both patients had a greater deficit in complex II activity 
at 41 °C in relation to controls than at 26°C (see Table 4.6). Complex II appeared to be slightly 
more temperature sensitive in P4 than in P5 although more replicates would be needed to 
confirm this.
Table 4.6: Mitochondrial complex II enzyme activities at 26°C and 41 °C.
Fibroblast assays P4 P5 Control
Complex II at 26°C 0.029 0.015 0.123
0.021 0.023 0.129
19.8% 15.1%
Complex II at 41 °C 0.003 0.011 0.075
(0.000) (0.006) (0.071)
2.1% 11.6%
Expressed as a ratio to citrate synthase and as average percentage of the 
control. The second mitochondrial preparation was assayed again after an 
additional freeze-thaw cycle; these results are shown in parenthesis.
An extra freeze-thaw cycle also decreased complex II activity in the two patient samples more 
than it did in the control sample, providing further evidence that the G555E containing enzyme 
is less stable than the wild type enzyme, although again no replicates were done.
4.4.6. 2D gel results
Mitochondrial proteins were resolved by 2D native-denaturing gels and probed for SDHA (see 
Figure 4.7). The presence of two spots indicated that the enzyme was not fully denatured 
before running the second dimension. The higher spot is likely to be the SDHA-SDHB 
subcomplex. There is slightly more of this subcomplex with the control than with P4 suggesting 
that the interaction SDHA-SDHB is weaker when the G555E mutation is present.
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A C P4 Denatured B 2D -  C C 2 D - P 4
Native Native
SDS
^SDHA-SDHB subcomplex 
<«SDHA
SDS
Figure 4.7: BN and 2D gels run in order to interpret sub-assembled complex II bands. A, 
Repeating the SDHA immunoblot of the Blue Native gel with denatured protein run along side. 
B and C, SDHA immunoblots of 2 dimensional gels. Arrows indicate direction of Blue Native 
gel and of denaturing SDS-PAGE separation, B with protein from control and C with protein 
from P4.
4.4.7. Repeat Blue Native gel with new mitochondrial preparations
Repeating the Blue Native gel immunoblotting experiment with new mitochondrial protein 
preparations again showed a small difference in the relative amounts of SDHA-SDHB 
subcomplex in P4 and P5 (see Figure 4.8).
P4 P5 C
Complex 11-130 kDa 
SDHA antibody
<  holo-complex II
<  SDHA-SDHB subcomplex
<  SDHA
Figure 4.8: SDHA immunoblot of BN gel with new preparations of mitochondrial protein.
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4.5. Discussion
The present study describes a patient (P4) with LS and isolated deficiency of complex II (see 
Table 4.3). Complex II defects are rare and this is the first case identified at this centre out of 
more than 1000 biopsies assayed, of which the majority were paediatric (personal 
communication, lain Hargreaves). This boy is also the first paediatric complex II patient from 
the UK. The only other report of the G555E mutation is in a patient (P5) with a lethal-infantile 
presentation (Van Coster et al., 2003). P5 was also of Middle Eastern origin (personal 
communication, Rudy Van Coster), suggesting the possibility of an ancestral mutation, and data 
from the closest 4 polymorphic loci supported this hypothesis (see Table 4.4). Although 
situated at the first position of exon 13, normal-sized cDNA amplification products indicate that 
the mutation does not affect splicing.
The reduced level of holo-complex II, as determined by Blue Native PAGE and subsequent 
immunoblotting and enzyme activity staining has been quantified, and suggests that the 
mutation acts through reduced stability of the enzyme complex by increasing negative charge in 
an important polypeptide loop. This hypothesis is supported by the observation that the first 
mutation described in SDHA (R554W) substituted tryptophan for arginine at the preceding 
amino acid, also increasing the net negative charge of this loop (Bourgeron et al., 1995).
The structure for human complex II is still not fully resolved, but the porcine counterpart has 
recently become available at 2.40A resolution; PDB entry 1ZOY (Sun et al., 2005). Due to a 
different numbering system, G513 is analogous to G555 and is positioned in a polypeptide loop 
between the SDHA and SDHB subunits (see Figure 4.3). It was previously suggested that 
G555E disrupts hydrogen bonding, leading to complex II instability (Van Coster et al., 2003). A 
model based on the new structure suggests rather that instability is caused by the repulsion of a 
similarly charged aspartate residue that is in close proximity. The aspartate 22 in porcine SDHB 
corresponds to aspartate 50 in the human version of this protein, and phylogenetic analysis 
indicates that this negative charge has been conserved through evolution (see Figure 4.9).
Homo sapiens 
Sus scrofa
TAPRIKKFAIYRWDP D KAGDKPHMQTYEVDL 65 
TAPRIKKFAIYRWDP D KTGDKPHMQTYEIDL 37 
TAPRIKKFAIYRWDP D KTGDKPHMQTYEIDL 65 
AAPRIKKFAIYRWDP D KTGDKPRMQTYEVDL 67 
AAPRIKTFAIYRWDP D KAGDKPRMQTYKVDL 67 
ATSRIKKFSIYRWDP D KPGDKPRMQTYEVDL 67 
HTPRLKTFKVYRWNP D EPSAKPHLQSYQVDL 59 
— NRIKTFEIYRFNP E APGAKPTVQKFDVDL 79
Canis familiaris 
Mus muscuius 
Rattus norvegicus
Gallus gallus 
S. cerevisiae 
C. elegans
Figure 4.9: Alignment of SDHB proteins from different species using the 
ClustalW tool (www.ebi.ac.uk/clustalw). The residues that correspond to 
porcine Asp22 are boxed.
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Although the mutation is in the SDHA subunit, the levels of SDHB appear more severely 
depleted than those of the SDHA subunit (see Figure 4.6A). Closer inspection of immunoblots 
from previous studies describing the R554W and the G555E mutations in SDHA reveals a 
similar pattern (Birch-Machin et al., 1996; Van Coster et al., 2003). It is therefore postulated 
that as individual proteins, SDHB is intrinsically less stable than SDHA.
Unlike heteroplasmic mtDNA mutations which can present in different tissues depending on 
mutant load, identical mutations in nuclear genes tend to have a similar clinical outcome. There 
are exceptions to this generalisation Nsome nuclear mutations do not show 100% penetrance. 
Homoplasmic mitochondrial LHON mutations are also not always fully penetrant; a recent study 
has indicated that an X-chromosome haplotype vastly increases the risk of developing the 
disease in carriers of homoplasmic G11778A and T14484C mutations (Hudson et al., 2005). 
However, the majority of nuclear genes involved with oxidative phosphorylation do tend to follow 
this rule (for example identical SURF1 mutations always cause early onset LS). The two pairs 
of sisters in whom SDHA mutations have been described (see Table 4.1) also had a very similar 
outcome (Bourgeois et al., 1992; Taylor et al., 1996).
P4 is alive aged 9 years, has a mild, predominantly neurological presentation and is able to 
attend a mainstream school, whereas P5 had severe hypotonia, hepatosplenomegaly, 
cardiomegaly, and respiratory difficulties and died aged 5Vfe months (Van Coster et al., 2003). 
The possible aetiology of this phenotypic variability of the SDHA G555E mutation was 
investigated. In view of the parental consanguinity, the possibility of a second mutation further 
disrupting complex II was considered. (It could not be mutation near the SDHA locus, for 
example a functional SDHA promoter polymorphism, because of the ancestral nature of the 
mutation.) The difference in clinical phenotypes could not be attributed to differences in 
complex II or complex IV activity (see Table 4.5). The thermal stability of the enzyme appeared 
to be decreased in both patients, but also could not explain the more severe presentation in P5 
(see Table 4.6) as if anything, fibroblasts from P5 seemed to have more residual activity.
Immunoblot analysis demonstrated that the size of the band corresponding to the partially 
assembled complex II differs slightly (see immunoblot with SDHA antibody in Figure 4.6B): in P4 
this band co-migrated with denatured SDHA, whereas in P5 and the control cell line, this band 
was slightly higher, corresponding to the SDHA-SDHB subcomplex (see Figure 4.7A). In order 
to further support this interpretation, SDHA was resolved on a 2 dimensional native-denaturing 
gel (see Figure 4.7B and C). However, the presence of two spots for both P4 and control 
samples after separation in the second denaturing dimension indicated that the proteins had not 
been completely denatured. The fact that there was more residual SDHA-SDHB subcomplex in 
the control than in P4 is further evidence that the G555E mutation disrupts this normally strong 
interaction.
This difference observed in the partially assembled complex II (see Figure 4.6B and 4.7A) was 
replicated in further experiments with independent mitochondrial preparations (see Figure 4.8),
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suggesting it is not due to protein degradation or some other artefact, although its functional 
significance remains unclear. Future work will include sequencing SDHB in P4 to see if there 
are any polymorphisms which might be influencing its interaction with SDHA.
Other explanations for the phenotypic variability include environmental factors (for example 
hypoglycaemia and in utero or post-natal metabolic stress). Intercurrent infections are also 
known to be a possible precipitant of neurodegenerative episodes in patients with mitochondrial 
disease (Edmonds et al., 2002). Variations in other mitochondrial RC enzymes (although no 
differences were seen in COX, see Table 4.5, Figure 4.6B and 4.4C), or polymorphisms in the 
recently proposed but as yet unmapped second isoform of this gene (Tomitsuka et al., 2003) 
are other possible modulatory factors that require further investigation. Another alternative is 
that the mutation could be sexually dimorphic, having a more severe phenotype in females: to 
our knowledge, this is the first SDHA mutation to be described in a male patient (see Table 4.1). 
Supporting this hypothesis is the fact that a boy with isolated complex II deficiency detected 
using magnetic resonance spectroscopy had a relatively mild presentation of disease in 
comparison to the two sisters described, although their complex II enzyme assay results were 
very similar (Brockmann et al., 2002). (The underlying molecular cause of disease in these 
three patients is not yet published but is likely to be defective SDHA.) Unfortunately, the rarity 
of SDHA mutations means it is currently impossible to try and correlate phenotype with 
genotype and environmental factors on a large scale.
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Chapter 5: Homozygosity mapping of mitochondrial disorders
5. 1. Introduction
5.1.1. Homozygosity -  a definition
Homozygosity is defined as having two copies of the same allele at a particular site on a 
chromosome. In an outbred population, homozygosity at any particular polymorphic locus 
occurs by chance, according to Hardy-Weinberg equilibrium (allele frequencies are p and q, 
p+q=1, genotype frequencies are p2, 2pq, q2, see Figure 5.1). Homozygous loci are thus 
scattered randomly throughout the genome. However, DNA of children produced from 
consanguineous marriages will usually contain multiple extended regions of homozygosity in 
which numerous consecutive polymorphic loci (SNPs, microsatellites, minisatellites etc.) will all 
be homozygous. This occurs because two copies of the same haplotype from a single 
ancestral chromosome have been inherited through two distinct routes down the family tree 
(see Figure 5.2). In this case the homozygosity is not by chance and the loci can be described 
as being “Identical by Descent’ rather than just “Identical by State”. The more closely related 
the parents, the greater the proportion of the child’s genome that is likely to be homozygous 
(see Table 5.1) and the greater the chance that one of these regions contains a rare recessive 
disease-causing mutation.
1
A A aa
0.8
Aa 2pq
0.6
0.4
0.2
0 V 1 "*1------- 1-------1------- 1------- 1------- 1------- 1------- 1 9
p = 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
q = 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0
Figure 5.1: Hardy-Weinberg principle for two alleles. 
The x axis shows the allele frequencies p (for allele a) 
and q (for allele A) and the y axis shows the genotype 
frequencies. The three possible genotypes are 
represented by the different plots (adapted from 
http://en.wikipedia.org/).
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s r i
Figure 5.2: A hypothetical consanguineous first-cousin pedigree 
showing inheritance of an ancestral mutation (horizontal black 
line) from the great grandmother. In the affected child this 
recessive mutation will be flanked by the homozygous ancestral 
haplotype (red).
Table 5.1: Coefficient of inbreeding for different degrees of consanguinity.
Parental relationship Coefficient of inbreeding*
Parent-Child 1/4
Siblings 1/4
Aunt/Uncle, Niece/Nephew 1/8
Half-siblings 1/8
1st cousins 1/16
1st cousins once removed 1/32
2na cousins 1/64
* Fraction of genome likely to be homozygous-by-descent in offspring or 
equivalently, the chance that any particular locus will be homozygous-by- 
descent.
5.1.2. Homozygosity mapping
Analysis of homozygosity-by-descent can be used to map disease genes in consanguineous 
families. It is an especially important technique for the study of mitochondrial disorders for two 
reasons. Firstly, due to their severity and early-onset, the large multigenerational pedigrees that 
are necessary for a traditional linkage analysis approach are uncommon. Secondly, the fact 
that many mitochondrial disorders are genetically heterogeneous (e.g. Leigh syndrome, see 
Table 1.7 in Introduction) means that it is risky to combine linkage results from multiple smaller 
pedigrees. Homozygosity mapping was first described by Eric Lander in 1987:
On
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“An efficient strategy for mapping human genes that cause recessive traits has 
been devised that uses mapped restriction fragment length polymorphisms 
(RFLPs) and the DNA of affected children from consanguineous marriages.
The method involves detection of the disease locus by virtue of the fact that the 
adjacent region will preferentially be homozygous by descent in such inbred 
children.” (Lander and Botstein, 1987)
The modern approach utilizes microsatellite markers instead of RFLPs, when searching for the 
homozygous candidate regions. Panels of 300-400 markers are commonly used which are 
spaced at ~5Mb intervals.
5.1.3. Mapping using the SNP microarrays
SNP-calling microarrays can also be used for determination of homozygous regions in the 
genome. Recently Affymetrix has diversified from their expression arrays and introduced a 
microarray (the “GeneChip Mapping 10K array”) that can genotype over 10,000 SNPs in parallel 
in one single hybridisation. This development makes homozygosity scans much quicker, and 
the vastly increased automation decreases the chance of any user errors. Although the mean 
heterozygosity of individual SNPs is only about half that of microsatellites, the fact that over 
10,000 can be analysed in one experiment, rather than -400 microsatellites means that much 
smaller regions of homozygosity can be detected (see Figure 5.3). A comparative study 
showed candidate regions for bipolar disorder reached statistical significance with the new 
technique where they had not with the less dense set of microsatellites (Middleton et al., 2004). 
Even though this technology is relatively new, it has already been used to help map a gene for 
neonatal diabetes (Sellick et al., 2003). As well as homozygosity mapping, the assays have 
other uses, for example they have been used to analyze genomewide loss of heterozygosity in 
prostate cancer cells in order to help identify new oncogenic factors (Lieberfarb et al., 2003).
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Figure 5.3: Comparison of GeneChip SNPs to a 400 microsatellite panel. Locations of the 10K 
GeneChip SNPs are shown in red, microsatellites are in blue. (From www.affymetrix.com, 
reproduced with permission.)
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5.2. Pedigrees for homozygosity mapping studies
5.2.1. Israeli family with complex I deficiency (P6)
Patient 6 was the 6th child born to first cousin Sepharadic Jewish parents (see Figure 5.4). At 2 
months he was referred to neurologists because he seemed neither to focus nor to follow 
moving objects. He was then noted to have severe muscle hypotonia. Since then, he has been 
slow to reach developmental milestones and has severe microcephaly. At 4 years of age, he 
cannot roll over, sit or feed himself. He is blind, and mumbles only, but his hearing is not 
impaired.
The activity of complex I in muscle was only 7% compared to controls, whereas fibroblast 
mitochondria were normal. COX activity was also normal. His two sisters and three brothers 
are all healthy. Sequencing of known candidate genes for complex I deficiency (NDUFS2, 3, 4, 
6, 7, 8 and NDUFV1) did not reveal any mutations. Analysis of microsatellites showed 1425 
and 1426 to be identical twins.
1410 1411
1423 1424 1427 1425 1426 Patient 6
Figure 5.4: The Israeli complex I pedigree.
Because the parents are first cousins, regions of homozygosity in each of their children should 
total, on average, 1/16 of the genome. Analysis of P6 alone would result in too large a region of 
homozygosity to proceed directly to candidate gene analysis. However, the siblings in this 
family are unaffected and so cannot be homozygous for the disease haplotype. This should 
allow the exclusion of some of the patient’s homozygous regions to identify a smaller candidate 
region than would be otherwise possible.
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5.2.2. Cypriot mtDNA depletion patients (P7-P10)
The clinical details of all 4 Cypriot mtDNA depletion patients have previously been published 
(Morris et al., 1998; Hargreaves et al.t 2002).
Patient 7 was the first child of healthy unrelated Cypriot parents (see Figure 5.5). She was 
delivered at term by Caesarean section, and birth weight was 3.1kg. She was noted to be 
hypotonic at birth and initially had feeding difficulties, but these gradually improved over the first 
3 months of life. At 4.5 months she presented acutely with fever, anorexia, lethargy and 
hypotonia, and rapidly developed liver failure. On examination the liver was enlarged 3cm 
below the costal margin and she had bilateral cataracts. She was irritable and had marked 
truncal hypotonia with increased peripheral tone. Investigations confirmed poor liver function, 
with hypoproteinaemia, increased transaminases and prolonged blood clotting times. She had 
recurrent hypoglycaemia after relatively short periods of fasting, and elevated blood (3.7- 
7.7mM) and CSF lactate concentrations. She also had evidence of moderate pancreatic 
insufficiency and renal tubular dysfunction. Brain MRI, electroencephalography and 
echocardiography were normal. There was initial improvement in her liver failure and 
hypoglycaemia following the introduction of regular high-energy feeds. However, she 
deteriorated after an intercurrent infection at the age of 8 months and died at 9 months. RC 
complexes I and IV were reduced (see Table 5.2) and there was 10.4% residual mtDNA in 
skeletal muscle as determined by Southern blotting (Hargreaves et al., 2002). Depletion was 
also observed in fibroblast and myoblast cultures derived from this patient. Patient 8 was the 
younger sister of P7 and presented with very similar clinical features.
5.2.2.1. Patients 7 and 8
Figure 5.5: Cypriot mtDNA depletion pedigrees.
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Table 5.2: Respiratory chain enzyme assay results from Cypriot patients.
Complex P7 P9 P10 Paediatric reference 
range for muscle
Complex I 0.091* 0.058* 0.021* 0.104-0.268
Complex II N/A 0.109 0.187 0.052 - 0.258
Complex ll+lll 0.084 0.014* 0.010* 0.040 - 0.204
Complex III N/A 0.005* 0.005* 0.008 - 0.028
Complex IV 0.011* 0.004* 0.011* 0.014-0.034
All activities shown as a ratio to citrate synthase. Asterisks indicate where the
ratios lie outside the control range. N/A, not available.
5.2.2.2. Patient 9
This girl was the second child of unrelated Cypriot parents, her older sister being healthy (see 
Figure 5.5). She was born at term, with a birth weight of 2.6kg (<10th centile). From the age of 
2 weeks, she had recurrent episodes of vomiting, failed to thrive and became increasingly 
hypotonic. She appeared to see initially but by 3 months she had roving eye movements with 
bilateral dense cataracts. At 4 months she had a hypoglycaemic seizure (blood glucose 
undetectable with appropriate insulin, cortisol and growth hormone concentrations). Following 
this, she was noted to be jaundiced, (total bilirubin 142mM, conjugated bilirubin 65mM), with 
raised transaminases (ALT 102 IU/l; AST 202 IU/I) and coagulopathy (PT 24s, control 14s; 
APTT 70s, control 38s). The liver was enlarged with a homogeneous, echobright texture. 
Cranial ultrasound examination was normal. The blood lactate concentration ranged from 4.3 to 
8.6mM with a lactate:pyruvate ratio of 59. Muscle biopsy at 4.5 months revealed excess red 
granularity in the trichrome stain (but no true ragged red fibres), excess lipid droplets and 
patchy absence of COX staining. The patient deteriorated rapidly, developed ascites and died 
at 5 months with Klebsiella septicaemia. RC complexes I, III and IV were all reduced (see 
Table 5.2) and a Southern blot demonstrated 0.3% residual mtDNA in skeletal muscle 
(Hargreaves et al., 2002). Depletion was also observed in fibroblast and myoblast cultures. 
After P9, the mother had six subsequent miscarriages. The mother was from a consanguineous 
family.
5.2.2.3. Patient 10
Patient 10 was the first child of healthy, unrelated Cypriot parents (see Figure 5.5) and was born 
at term after a normal pregnancy. Birth weight was 4.2kg and there were no immediate 
neonatal problems. However she fed poorly from birth and was admitted for investigation of 
failure to thrive at 5 months. At this time hypotonia and delayed motor milestones were noted, 
and two weeks later myoclonic seizures commenced. At 8 months she developed respiratory 
failure after a prolonged seizure and required artificial ventilation. Investigations revealed 
elevated lactates in plasma (4.7-5.8mM) and CSF (3.1 mM), and evidence of renal tubular
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dysfunction with raised urinary N-acetylglucosaminidase/creatinine ratio (4400, reference range 
1.9-42.6) and retinol binding protein/creatinine ratio (740, reference range 3.5-27.3) ratios. 
Muscle biopsy showed severe myopathic features. RC complexes I, III and IV were all reduced 
(see Table 5.2) and Southern blot demonstrated 10.0% residual mtDNA in skeletal muscle 
(Hargreaves et al., 2002). Depletion was also observed in fibroblast but not in myoblast 
cultures derived from this patient.
5.2.2.4. Summary of patients and previous molecular findings
These four children (Patients 7-10, see Figure 5.5) all had a hepatocerebral presentation of 
disease which was associated with mtDNA depletion. Deoxyguanosine kinase (DGUOK) was 
an obvious candidate, but this gene had already been sequenced, with no mutations found. 
Sequencing of the mitochondrial thymidine kinase gene (TK2), which is also known to be 
involved with mtDNA depletion, was not performed as these patients did not have the 
predominantly myopathic phenotype usually associated with mutations in this gene. POLG was 
not sequenced initially because at that time POLG mutations were thought to exclusively cause 
deletions in mtDNA -  the link to mtDNA depletion and Alper’s syndrome had not yet been 
described (Naviaux and Nguyen, 2004).
To find the disease gene, it was therefore hypothesised that since these three mtDNA depletion 
families have such a strikingly similar condition (including cataracts in the first two families) and 
they are from a small, isolated population (July 2005 estimate: 780,133, www.cia.gov), they are 
likely to be homozygous for an identical ancestral mutation, flanked by a region of common 
homozygosity which should be detectable with a sufficiently dense set of markers.
5.2.2.5. Prediction of the power of this technique
To predict whether the 10K GeneChip method would be sufficiently powerful to detect the small 
regions of homozygosity that might arise, another isolated population in which disease genes 
have been found on account of flanking regions of homozygosity was considered:
“The community of Charlevoix was started in 1675, with 599 founders of 
French descent arriving, in the course of seven generations, from Quebec City.
There has been little migration into the SLSJ region since 1870, and the 
community has grown from 18,000 in 1852 to 320,000 in 2000. Because of the 
founder effect in a young population, large blocks of ancestral DNA have been 
shown to flank the disease mutations in this population. Specifically, recent 
studies have demonstrated that ancestral haplotypes spanning 8-1 OcM are 
common to 40%-60% of affected chromosomes (4-6cM being common to 
nearly 80%) of populations with rare diseases from this region.” (Lee et al.,
2001)
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The 8cM quoted above equates on average to a physical distance of about 7.4Mb, or in terms 
of the 10K GeneChip about 35 SNPs, which should be just above the threshold for detection. 
Therefore, assuming that the Cypriot patients were similar to the French-Canadian population, 
in that they have had a common ancestor since 1675, a very crude estimate would be that there 
is about a 50% chance of detecting the resulting region of homozygosity flanking the disease 
gene. Of course, this estimate also relies on the validity of the above assumption of a single 
ancestral mutation.
If the hypothetical regions of homozygosity that are shared between all three families are too 
small to be detected, results from the two affected siblings (Patients 7 and 8) can also be 
analysed independently, before going on to investigate the other families. According to the last 
clinical report, P10 had not yet developed cataracts, suggesting the possibility of a different 
aetiology in this patient. Therefore, because of the cost of the microarrays, this sample was 
kept back for analysis at a later date.
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5.2.3. The Arab-lsraeli mtDNA depletion pedigree (P11 and P12)
Patients 11 and 12 in this highly inbred Arab-lsraeli family presented with encephalomyopathy 
and mtDNA depletion with an inheritance pattern characteristic of an autosomal recessive 
mutation (see Figure 5.6). The patients were anaemic and the plasma lactate levels were 
elevated. They also had generalized muscle hypotonia and mild ptosis. The high degree of 
consanguinity in both branches of this family and the fact that there were multiple affected 
children made it an excellent opportunity for homozygosity mapping with a higher chance of 
success than for the families described above.
1st cousins Double 1st cousins1st cousins
m •  oDZ
Patient 12Patient 11
Figure 5.6: The Arab-lsraeli mtDNA depletion pedigree.
Degree of consanguinity is indicated. DZ, dizygotic twins.
5.2.4. Patient with a syndrome affecting multiple mitochondrial functions (P13)
Patient 13 (see Figure 5.7) was born to consanguineous parents (said to be “distantly related”, 
although precise relationship could not be ascertained) and first presented with persistent 
vomiting in the neonatal period. After 3 months, developmental regression was observed. At 8 
months, CSF lactate was 3.5mM (normal range <2mM) and pyruvate dehydrogenase was 
deficient in cultured skin fibroblasts. After 10 months, myoclonic jerks and recurrent generalised 
seizures were reported.
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Patient
Figure 5.7: Pedigree of Patient 13.
At age 18 months, a muscle biopsy was performed to assay activity of the respiratory chain 
enzyme complexes. Low activities of Cl, Cll+lll and cytochrome c oxidase were observed (see 
Table 5.3). Cytochrome c oxidase activity was also measured from patient fibroblasts and 
again, a low result of 25nmol/mg (normal range 30-90nmol/mg/min, data from Garry Brown, 
Genetics Unit, Department of Biochemistry, University of Oxford, UK) was obtained.
Analysis of amino acids from blood plasma indicated raised levels of alanine (612nM, compared 
to normal levels of below 480^M), but branched chain amino acids (such as valine, leucine and 
isoleucine) were within the normal range. In urine, levels of alanine, taurine and isoleucine 
were increased whereas leucine and valine were normal. There was also a slight increase of 
Krebs cycle intermediates as well as a mild dicarboxylic aciduria.
These symptoms resembled those of four patients described by Seyda et al in which 2p14-16 
was implicated. The four patients in that report also exhibited pyruvate dehydrogenase 
deficiency, an amino acid imbalance including raised alanine, raised lactate levels, and reduced 
activities of more than one mitochondrial respiratory chain enzyme complex (Seyda et al., 
2001). The fact that the parents of P13 were consanguineous meant that analysis of 
microsatellite markers found in this area (2p14-16) would determine whether a homozygous 
mutation in the same gene was involved.
Table 5.3: Respiratory chain enzyme assay results from P13’s muscle biopsy.
Complex P13’s
muscle
Paediatric reference range for muscle
Complex I 0.068* 0 .104-0 .268
Complex ll+lll 0.010* 0.040 -  0.204
Complex IV 0.010* 0.014-0 .034
All activities shown as a ratio to citrate synthase. Asterisks indicate where
the ratios lie outside the control range.
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5.3. Methods
5.3.1. Affymetrix 10k GeneChip (version 1.0)
5.3.1.1. Preparation and labelling ofDNA
The concentration of genomic DNA was adjusted to 50ng/jal using reduced EDTA TE buffer 
(0.1 mM EDTA, 10mM Tris HCI, pH 8.0). 250ng of genomic DNA was then digested for 2h at 
37°C with 2|xg BSA (NEB) and 10U of Xba\ (NEB, cuts at T/CTAGA sites) in a 20pl reaction 
volume. Special Xba adaptors (supplied with kit) were ligated to the ends of the resulting 
fragments during a 2h incubation at 16°C. This was carried out in a reaction volume of 25pl, 
using a final adaptor concentration of 0.25pM and 500U of T4 DNA ligase (NEB). After both 
these incubations, the enzymes were denatured by heating to 70°C for 20min.
The Xba adaptors enabled genome amplification using a single universal PCR primer. First of 
all, the ligated DNA fragments were diluted to a volume of 100pl, 10f.il of which was used as 
template for each subsequent PCR reaction. For each sample, six 100pl PCR reactions were 
set up with final concentrations of 250pM of each dNTP, 2.5mM of MgCI2 and 0.75pM of Xba 
primer (5’-ATT ATG AGC ACG ACA GAC GCC TGA TCT-3') together with 10U of AmpliTaq 
Gold (Applied Biosystems). Thermal cycling was carried out on the DNA Engine tetrad (MJ 
Research) and consisted of 3 min at 95°C, followed by 35 cycles of 95°C for 20s, 59°C for 15s 
and 72°C for 15s. Final extension was for 7 min at 72°C after which reactions were held at 4°C. 
The “Heated Lid” and “Calculated Temperature” features were used.
The 200-1 OOObp PCR products were then purified using 6 QIAquick spin columns for each 
sample. Elution was performed sequentially using 55pl of elution buffer for every three 
columns. The resulting 110pl of DNA was then concentrated by evaporation at 50°C with the lid 
open until the volume was reduced to around 50pl.
DNA was quantified as described in Chapter 2 to ensure that approximately 20pg in 45pl 
volume was used for the next step. Purified DNA was fragmented using 0.24U of DNase I in a 
total reaction volume of 55pl. Incubation at 37°C for 30min was followed by denaturation at 
95°C for 15min. 1.5% Agarose gels were run after PCR and fragmentation steps to ensure that 
they had worked (see Figure 5.8).
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Figure 5.8: PCR product before and after DNase I fragmentation.
P, 4pl of reference DNA PCR product. F1, 6(il of reference DNA 
fragmentation reaction. F2, 8pl of reference DNA fragmentation 
reaction.
The DNA, mostly less than 200bp by this stage, was labelled using GeneChip DNA Labelling 
Reagent at a final concentration of 0.143mM and 102U of Terminal Deoxynucleotide 
Transferase in a reaction volume of 70pl. Incubation at 37°C for 2h was followed by 
denaturation at 95°C for 15min and then a 4°C hold step. Tubes were briefly spun prior to 
hybridisation.
5.3.1.2. H yb rid isa tion  a n d  scann ing  o f  a ssa ys
12pil of MES stock (1.22M MES, 0.89M [Na+], Sigma), 13pl DMSO (Sigma), 13pl of 50x 
Denhardt’s Solution (Sigma), 3pl of 0.5M EDTA (Ambion), 3pl of 10mg/ml Herring Sperm DNA 
(Promega), 2pl of Oligonucleotide Control Reagent, 3pl of 1 mg/ml Human Cot-1 (Invitrogen), 
1pl of 3% Tween-20 (Pierce) and 140|il of 5M TMACL (Sigma) were added to the 70fil of 
labelled DNA. This hybridisation mix was denatured at 95°C for 10min and then cooled on 
crushed ice for 10 seconds. Tubes were spun briefly and then placed at 48°C for 2min. 200(il 
of the denatured hybridisation cocktail was injected into the 10K probe array and hybridised at 
48°C for 16-18h at 60rpm. (This is 3°C higher than for the expression arrays, which do not 
need to discriminate between SNPs.)
After 16h, the hybridisation cocktail was removed and replaced with 250^1 of Non-Stringent 
Wash Buffer. 500pl aliquots of staining reagents were prepared with final concentrations of 
0.01% Tween-20, 1x Denhardts and 6x SSPE (BioWhittaker Molecular Applications) with either 
10|ag/ml of Streptavidin, 5pg/ml of biotinylated antibody or 10pg/ml Streptavidin Phycoerythrin. 
Various washing and staining steps were then carried out using the GeneChip Operating
130
Chapter 5: Homozvaositv mapping of mitochondrial disorders
System software (GCOS) as specified by the DNAARRY_WS2_450 protocol using these 
reagents and the specialised FS-450 fluidics station.
Any excess fluid was cleaned from around the septa, which were then sealed using Tough 
Spots (USA Scientific). The arrays were then scanned with a pixel value of 3pm and 
wavelength of 570nm on the GeneArray® 2500 scanner, using the GCOS software.
All steps of the protocol are summarized in Figure 5.9A.
N.B. This protocol is identical to that of the manufacturer except for the number of PCR 
reactions per sample which were increased from 4 to 6, and the resulting need to concentrate 
samples by evaporation. These minor modifications to the protocol were made in order to 
increase the yield of DNA.
5.3.1.3. Data analysis
The GeneChip DNA analysis software (GDAS) from Affymetrix was used to analyse the data. 
DAT image files were inspected for hyper intensities, scratches and other artefacts. The 
alignment of the grid was checked by examining the alternating pattern of intensities at the 
border and the checkerboard pattern in each corner of the image that is produced by the B2 
oligonucleotide (part of the Oligonucleotide Control Reagent, see Figure 5.9B). A batch 
analysis was then run on all the average cell intensity data (CEL) files which produced a results 
report (see Table 5.5 in Results section).
The SNP annotations were updated using either the 2nd April release (complex I samples) or the 
11th August 2004 release (mtDNA depletion samples) from NetAffx Analysis Centre 
(www.affymetrix.com/analysis/netaffx). The default thresholds were used: 0.80 for the call 
zones and 0.07 for male / female calls. Increasing the call zones boundaries would have 
increased call rates at the expense of accuracy, so was not changed.
SNP data was exported into a Microsoft Excel spreadsheet, where it was sorted by 
chromosome and then by chromosome position. Homozygous calls were scored as 1 whilst 
heterozygous calls were scored 0. Moving averages were then calculated for 31 consecutive 
SNPs all along the genome and plotted against chromosome position (see Figure 5.11 and 5.13 
in Results section). This made it easy to scan through looking for regions of significant 
homozygosity (over 30 consecutive homozygous SNP calls). Some NoCalls within or close by 
these homozygous regions were edited by eye from the GDAS plots.
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Figure 5.9: The 10K GeneChip protocol summarized step by 
step. A. Manufacturer’s protocol for use of the 10k GeneChip 
shown schematically B. Alignment of grid with scanned image 
from Patient 6 hybridisation. A larger version of this image is 
presented in Appendix I. Adapted from Kennedy et al., 2003.
5.3.1.4. Significance of homozygous regions
To estimate the number of consecutive homozygous SNPs needed for significance in an 
individual, the situation was modelled in Excel using the random number generator function to 
independently get 70% chance of homozygosity at each of 10,000 consecutive imaginary SNPs 
(see Equations 1-4). This simulation was run 1,000 times and the mean longest homozygous 
region obtained was 23.5 SNPs long (range 17-39). The chances of obtaining a region of more 
than 30 consecutive homozygous SNPs was <5% (40/1,000) and so this figure was used as the 
cut-off value for significance. Stretches of homozygosity of greater than 29 SNPs were found in 
>5% (56/1,000) of runs. The results for a 100K GeneChip were also modelled (See Figure
5.10).
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Formula Cell
Equation 1: Generates random number between 0 and 1 =RAND() A2
Equation 2: 70% chance of being AA or BB =IF(A2<0.7,1,0) B2
Equation 3: Counter =IF(B2=0,0,C1+1) C2
Equation 4: GeneChip simulation result =MAX(C2:C10,001) C10,002
N.B. Equations 1-3 were copied down from row 2 to row 10,0001. Cell C1 was set to zero.
40% T
10K
100K
Longest run of homozygosity
Figure 5.10: Data from the Microsoft Excel GeneChip simulation 
showing the approximate chances of obtaining a homozygous run of 
a certain number of SNPs for the 10K and 100K GeneChips.
However, the method described above assumes completely random distribution of average 
SNP homozygosity, which is likely to be false. Therefore the results from the Affymetrix control 
DNA, which had been run in training were also analysed. This DNA was not from a 
consanguineous family and so any homozygous regions will have arisen purely by chance. 
Other than the X chromosome (which was hemizygous as the control DNA is from a male), the 
longest stretch of homozygosity in this sample was a run of 33 SNPs on chromosome 6, 
followed by a run of 18 on chromosome 21.
Woods et al used a different method to suggest 45 SNPs (and at least 3cM) as a cut-off for 
single affected offspring from a consanguineous marriage. However in the present study, it was 
decided to use the 30 SNP threshold value obtained from the Excel model, as it would be less 
likely that any smaller regions of homozygosity are missed. Although time consuming, any false 
positive regions could always be eliminated later on by analysing microsatellites. If multiple 
affected siblings are analyzed, then the shared region of homozygosity does not have to be so 
large for significance (see Table 5.4). Woods et al have various “ExcludeAR” spreadsheets 
available for download at http://leedsdna.info/science/Autozygosity/spreadsheets.htm which can 
automatically highlight these regions (Woods et al., 2004).
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Table 5.4: Significance thresholds for homozygosity using different numbers of patients.
Number of affected 
individuals
Number of shared 
homozygous SNPs
If siblings Genetic Distance
1 >45 N/A >3cM
2 >11 >22 >3cM
3 >6 >15 >2cM
4 >3 >11 >1cM
From Woods et al, 200*1. Significance levels used for calculations are <0.001.
5.3.2. Analysis of homozygosity using microsatellites
Microsatellites were chosen to confirm GeneChip results, to flank the chromosome 13 region of 
interest and to look for homozygosity around 2p14-16. Microsatellites were selected from the 
Research Genetics Human Screening Set 8 (ResGen), the ABI PRISM™ Linkage Mapping Set 
(ABI) or else identified using the Ensembl Human Genome Browser 
(www.ensembl.org/Homo_sapiens). PCR reactions were carried out using 5’ fluorescently 
labelled forward primers (see primer pairs listed below). Methods for microsatellite analysis are 
given in Chapter 2.
Microsatellites for the complex I pedigree:
D3S2403F 5’-HEX-ACA GAT TGA GAC CAT GTG TCA-3’
D3S2403R 5-CAC ACT CAA AAT ACA TGA AGG C-3’
D6S1266F 5-FAM-TCC ACT AGC TCC ACC TTC AG-3’
D6S1266R 5’-GGC TCT GCA TTT ACC ATG TT-3’
D9S2169F 5’-FAM-TTC CCA AAA GTT GCC ATC TA-3’
D9S2169R 5-AGC CCA AAA TGT TAT GCA AG-3’
D11S934F 5’-FAM-GCT GTC CCT GAC AAC TAC ATG C-3’
D11S934R 5’-FAM-TTC CAT CAG AAC TGG GAA TGA G-3’
D11S1320F 5’-FAM-AAC ATT ACT AAA AGG TTA AAT GAG C-3’
D11S1320R 5’-ATT AAG GCA CCA AAT GGG-3’
D18S843F 5’-FAM-GTC CTC ATC TGT AAA ACG GG-3’
D18S843R 5-CCA CTA ACT AGT TTG TGA CTTTGG-3’
D18S542F 5’-TET-TTT CCA GTG GAA ACC AAA CT-3’
D18S542R 5-TCC AGC AAC AAC AAG AGA CA-3’
ResGen 248-292bp 
ResGen ~119bp 
ResGen 283-295bp 
ABI 299-327bp
ABI 256-272bp
ResGen 179-191 bp 
ResGen 178-198bp
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Microsatellites for the Cypriot pedigrees:
D2S2964F 5’-HEX-GGG AGT GGG GTA AAA AAA AA-3’ 
D2S2964R 5’-CCT CTA ACC CCC AGA AAT GT-3’
D2S1790F 5’-FAM-ACA TGT CGA TCT CAG CGT TC-3’
D2S1790R 5’-GAG TTT TAT TGG CCA AAG CA-3’
D2S2333F 5’-TET-AGA AAC CAT GCC CTT G-3’
D2S2333R 5’-TGC AGT CAC CTG TGT AGA A-3’
D16S411F 5’-FAM-TCA TCT CCA AAG GAG TTT CT-3’
D16S411R 5’-GTG CAT GTG TTC GTA TCA AC-3’
Microsatellites for the Arab-lsraeli mtDNA depletion pedigree:
D13S155F 5’-FAM-ACA GCC AGC ACA TTT ATT GA-3’
D13S155R 5’-GGT ATA TTC TCA GAG CCT GGA T-3’
D13S1319F 5’-TET-ACA TGG NAC TTA TTC CCG TT-3’
D13S1319R 5’-CGT GAG AGA TGA TTG ACT TCA TAG-3’
D13S801F 5’-FAM-CCA TCA CCT TCT TTG ACT GG-3’
D13S801R 5’-GTG AAA GTA AAG CAG AAA GAT GC-3’
D13S1320F 5’-TET-GAA AAA CAG GTA ATG CCA-3’
D13S1320R 5’-TGA AGT AAC TCT GAA CAC TCA A-3’
D13S1289F 5’-FAM-GTT TCT CCA GAA CAG AAC CAA TAA G-3’
D13S1289R 5’-TAA CCA TGT AAG CCA GTC CC-3’
D13S1268F 5’-TET-TGG GCA ACA GAG CAA GAC-3’
D13S1268R 5’-TGT AAA CAA GTA AGA ATC CCA AAG G-3’
D13S1296F 5’-FAM-TGC AGA AAT GTG AGC C-3’
D13S1296R 5’-TCC ACC TAG AGC AAC TAC C-3’
D13S787F 5’-FAM-ATC AGG ATT CCA GGA GGA AA-3’
D13S787R 5’-ACC TGG GAG TCG GAG CTC-3’
D13S325F 5’-FAM-TCC TTT AAG TGT CTA GAG AGG AGG-3’
D13S325R 5’-TCT CTC TCA GAA GTT TGG AAG C-3’
D13S788F 5’-TET-GAT TGA GGT AGG GTC CCA AG-3’
D13S788R 5’-GCT CCA TAA TTG TGT GAG CC-3’
D13S800F 5’-HEX-AGG GAT CTT CAG AGA AAC AGG-3’
D13S800R 5’-TGA CAC TAT CAG CTC TCT GGC-3’
N.B. Annealing temperature for D13S787 was increased to 59°C.
Ensembl 216-264bp 
ResGen 284-328bp 
Ensembl 214-260bp 
ABI 215-235bp
Ensembl 204-218bp 
Ensembl 168-195bp 
Ensembl 170-194bp 
Ensembl 224-268bp 
Ensembl 102-122bp 
Ensembl 108-150bp 
Ensembl 206-228 
ResGen 261-277bp* 
ResGen 210-246bp* 
ResGen 242-272bp 
ResGen 295-319bp
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Microsatellites for Patient 13:
D2S1772F 5’-FAM-TTC TAA GTA AAG AGT CTT CTT TGG G-3’
D2S1772R 5’-TAA TTC AAA TCT TTC CTG TCA GG-3’
A346YB5F 5’-TET-TTG CCC ACC ATT CTA AGA CC-3’
A346YB5R 5’-TGG CTC AAG CAT CAA ACA C-3’
D2S147F 5’-FAM-TGC ACA CAA GTC CTG G-3’
D2S147R 5’-GAA TGG TGG TTG CCA G-3’
D2S337F 5’-HEX-GTC TGC ATT CCC ACG A-3’
D2S337R 5’-TGC TCC TGG CTT ATT TCA-3’
A053XF9F 5’-TET-CAA ATA TGT ACT GGA CTG GCT C-3’
A053XF9R 5’-CAG AAT TGC TCA TAG GAT AGA ACC-3’
D2S1337F 5’-HEX-TTC TGA GAC CAG GTT ATA AAA GC-3’
D2S1337R 5’-ATA CAG AAG TAG GGG TAA ACA TAG G-3’
D2S2739F 5’-HEX-CTG GTG TTT AGA ATA TCT GTC TAG G-3’
D2S2739R 5’-ATC TGT TAT TCA CTT TAA CTG AGG C-3’
N.B. All chromosome 2 microsatellites were amplified using annealing 
* expected size did not agree with that obtained experimentally.
Ensembl 154-202bp 
Ensembl ~117bp 
Ensembl 126-144bp 
Ensembl 233-255bp 
Ensembl ~154bp 
ResGen 194-206bp* 
ResGen 281-329bp 
temperatures of 56°C
5.3.3. Sequencing of candidate genes
DNA sequencing was carried out using standard procedures (see Chapter 2). The following 
primers were designed using primer 3 for use on genomic DNA:
NDUFV2:
1F 5’-CTC GCT CCC TCC CGT CAG-3’ 61 ° C+5% DMSO 328bp
1R 5’-GGA GAC ACG GAG AGC AAG AG-3'
2F 5’-TTC CAT TGT TGT AAA TTA TGA ATC CT-3’ 54 °C 266bp
2R 5’-TGG ATT TAC CCC AAT TTC CA-3’
3+4F 5’-CAT TCA CAC TTG AGA GAA TTT GG-3’ 54 °C 385bp
3+4R 5’-GAA CTA AGG CAA AAA TGA ATC C-3
5F 5’-AAT TAA AGC TCC ATT ACT AAC ACT G-3’ 54 °C 289bp
5R 5’-CCA AAT CTA GAG AGA CAA TTC TAC TT-3’
6F 5’-ATA ACC TGG TCC TTA GAG TGT TT-3’ 54 °C 230bp
6R 5’-TGT TTT AAA TAT GAC ATC ATA CAA CTT-3’
7F 5’-CAG ATT TCA GCC GTA GAA AGT-3’ 57 °C 337bp
7R 5’-GAA AGA TTA ATT TAG GTG AGC CAC T-3’
8F 5’-GGG CTC TTG TGA GGT AAC CA-3’ 65 °C 359bp
8R 5’-TGC TAC GGT TAG CAT GAG GA-3’
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VHL
1AF 5-GAA ATA CAG TAA CGA GTT GGC CTA GC-3’ 276bp
1AR 5’-ACC TCG GCC TCG TCC CAG T-3*
1BF 5’-CCC GGG TGG TCT GGA TCG-3’ 492bp
1BR 5’-ACC CTG GAT GTG TCC TGC CTA AG-3'
2F 5’-CGG TGT GGC TCT TTA ACA ACC-3’ 224bp
2R 5-CAA GTG GTC TAT CCT GTA CTT-3'
3F 5’-TTC CTT GTA CTG AGA CCC TAG T-3’ 281 bp
3R 5-TAC CAT CAA AAG CTG AGA TGA AAC AGT GTA AGT-3'
N.B. Annealing temperature of exon 1 was increased to 60°C.
Because of the limited availability of cDNA from P6, the sequencing of the genes listed below 
was done in collaboration with Orly Elpeleg. Primers were designed and cDNA was amplified in 
Israel, whilst sequencing reactions, MegaBace runs, and sequence analysis was carried out at 
ICH. Sequencing of AFG3L2 was carried out entirely by Orly Elpeleg, which is why the primer 
sequences used are not presented here.
OGG1
OGG1 variant 1a Gl:21396494 
1F (“OGG1 1”) 5 -GAG GCC TGG TTC TGG GTA G-3’
1R (“OGG1 2”) 5’-GGC ACT GGC ACT CAC GTA AC-3’
2F (“OGG1 3”) 5-CCA GCT TGA TGA TGT CAC CT-3’
2R (“OGG1 4”) 5-GGA TGG GGA GAG AGA AGT GG-3’
Specific for OGG 1 variant 2a Gl:8670533 
2R (“OGG8”) 5’-GCC ATT TCT CAG GTT GGA CT-3’
KIAA0020
1F (“KIAA0020 1 ”) 5-TGG AAG TTA AAG GGA AAA AGC A-3’
1R (“KIAA0020 2”) 5’-GTA CTC CAC GAT GGC TGA TG-3’
2F (“KIAA0020 3") 5'-GGA AGC ATC AGC CAT CGT-3’
2R (“KIAA0020 4”) 5-GAT TCT AGG AGC TCC CGT CTG-3’
3F (“KIAA7”) 5-CCC CAG AGA TCC TGC ACA TA-3’
3R (“KIAA0020 6”) 5'-GGG AAA CAG AAC AGA GAA CAG AA-3’
LSM3
1F (“LSM3-1") 5-AAA GGG CGC AGG GTTT-3’ 466bp
1R (“LSM3-2”) 5-TTT CAG GAG TGG AAG AAT CC-3’
770bp
709bp
642bp
689bp
623bp
928bp
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CAMK1
1F (“CAMK1-5”) 5-GAA GGC CCC AGG TGG AAG-3’
1R (“CAMK1-6”) 5-CCT ATG GAC CAG CAA TCC AC-3' 
2F (“CAMK1-3”) 5-TTG CTG GTC CAT AGG TGT C-3’ 
2R (“CAMK1-4”) 5'-AGA AAC TCC CGG TTC AGG-3’
RCL1
1F (“RCL1-1”) 5-ACG AGT CCC GCG TCT GTC-3’
1R (“RCL1-2”) 5-CAG AAT CCA CAA TCC GGT TC-3’ 
2F (“RCL1-3”) 5-GTC ACC TCA GAT GGC GAA C-3’
2R (“RCL1-4”) 5-GAC TTG GTC CCA TTG GTG TC-3’
599bp
599bp
700bp
597bp
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5.4. GeneChip Results
A CD containing all the raw data obtained from the 10K GeneChip is enclosed in the back of 
this thesis.
5.4.1. Overall performance of GeneChip
The call rate was good (>94%) for all samples except for Patient 8 (see Table 5.5). This could 
have been because the DNA was of inferior quality, or due to the fact that this sample had been 
frozen at N20°C after the ligation step for approximately two months. Contamination is another 
possibility. Studies have shown that contamination with another sample by up to 20% can 
decrease average call rates down to 87% but with no effect on signal detection or concordance 
rates (Matsuzaki et al., 2004b).
Table 5.5: Results report from GDAS.
Sample Gender SNP Call Signal Detection AA Call AB Call BB Call
CDCL M 97.24% 99.36% 34.39% 31.46% 34.15%
1423 F 94.53% 98.30% 34.77% 29.85% 35.38%
1424 ► Israeli M 96.37% 99.49% 35.24% 29.33% 35.43%
1425 M 97.05% 99.34% 34.41% 30.87% 34.73%
1427 , M 98.63% 99.88% 34.68% 30.92% 34.41%
P7 F 96.60% 99.45% 33.61% 33.63% 32.76%
P8 > Cypriot F 89.27% 98.75% 34.71% 30.93% 34.36%
P9 . F 94.54% 98.45% 33.39% 34.51% 32.10%
Control A M 95.19% 98.64% 33.29% 33.52% 33.19%
Control B M 98.68% 99.79% 32.84% 34.22% 32.94%
Average N/A 95.81% 99.15% 34.13% 31.92% 33.95%
The average SNP heterozygosity for the samples from the Israeli family (30.49%) was lower 
than for the Cypriot samples (33.02%), which in turn was lower than for the control DNA 
(33.87%). This is consistent with the fact that the Israeli family were known to be 
consanguineous whilst the Cypriot families were not (although they were from an isolated 
population).
Concordance between the two runs of identical control DNA was 99.95%, showing that the 
method is highly accurate. This accuracy is because these microarrays include an in-built set of 
replicates: not just two oligos (one for each allele as one might expect), but 40 discriminatory 
oligos are spotted onto the array for each SNP. In addition, results are automatically rejected 
by GDAS if results do not lie within the 0.80 call zones. This method is also much less
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susceptible to manual pipetting and spectral-overlap related errors that may arise occasionally 
for microsatellites.
5.4.2. Other considerations: SNP annotations
With the initial SNP annotations, results indicated one heterozygous call (rs0718948) in the 
middle of a long tract of homozygosity in Patient 6’s sister 1424 (see Figure 5.11 A). This was 
considered to be an unlikely scenario. However, this SNP moved from 58.4Mb to 126.3Mb 
once the annotations had been updated using the 2nd April release (see Figure 5.11B). SNP 
annotations are updated by Affymetrix every quarter.
This is indicative of the fact that although the draft human sequence has been available since 
2001, there are still many gaps in the sequence and thus online SNP databases are still 
somewhat dynamic. Caution should be taken when interpreting results, especially where there 
is a single unexpected SNP call.
♦ P6
■ 1424
1423
1267
20000000 4X00000 00000000 80000000
chromosome poation
20000000 40000000 60000000 80000000
chromosome position
Figure 5.11: Average homozygosity on Chromosome 10 highlighting annotation error. 
A. With old annotations from December 2003. B. Annotations from 2.4.04. Arrow 
indicates initial location of rs0718948. Average homozygosity is calculated for each 
SNP and the nearest 15 SNPs on either side. Homozygosity is scored as 1, 
heterozygosity as 0. Thus when the moving window average hits 1, there are over 30 
consecutive homozygous SNPs. Results for 1427 are missing as this analysis was done 
prior to running this sample.
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5.4.3. Results from Israeli complex I family
5.4.3.1. GeneChip results
There were 11 regions of homozygosity (>30 consecutive homozygous SNPs) identified in the 
GeneChip results from Patient 6. These regions totalled 180Mb, which is about 1/16 of the 
genome and thus was consistent with the parents being first cousins (see Table 5.6 and Table 
5.1).
After subtraction of regions that were also homozygous for the same ancestral haplotype in the 
unaffected siblings (see Figure 5.13), there were 5 candidate regions that totalled 50Mb which 
looked promising (see Table 5.7). Microsatellites from these regions were used to confirm 
homozygosity in the patient and heterozygosity in the unaffected siblings (see Figure 5.12 and 
Figure 5.13), and thus back-up the SNP data.
Table 5.6: Regions of homozygosity in Patient 6.
Chr Position (Mb) Size (Mb)
2 71.33-107.21 35.88
3 5.53-14.88 9.35
3 74.15-95.39 21.24
4 178.05-183.23 5.18
6 0 - 23.63 23.63
9 0.24 - 7.56 7.32
9 7.56- 13.57 6.01
11 125.62-end (134.93) 9.31
14 69.12-89.50 20.38
18 5.90-25.19 19.29
18 54.17-76.90 22.73
Total 180.32 Mb (-1/16 of genome)
Table 5.7: Complex I candidate regions*.
Chromosome Position (Mb) No. of homozygous SNPs
3 8.61 - 14.88 63
6 5.28-23.63 123
9 0.24 - 7.56 44
11 125.62-end 59
18 5.90- 15.07 58
Total 50Mb (-1.7% of genome)
*, Regions that were homozygous in patient but not in siblings.
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D 9S 2169 2 8 3 ,28 7  283 ,287  287,291 283,291 2 8 3 ,2 8 3 4 .8 -6 .2 M b Chr9
D 11S 934
D 11S 1320
30 4 ,30 8  30 4 ,30 8  30 4 ,30 4  30 4 ,30 4  
2 6 1 ,2 6 3  26 1 ,26 3  26 1 ,26 3  261,261
3 0 8 ,3 0 8
2 6 3 ,2 6 3
125.6M b
131.4M b
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ChM 1
D 18S 843
D 18S 542
17 9 ,18 8  188,188 179,188 179,188  
18 2 ,19 0  182,194 182,190 182,194
17 9 ,17 9
1 8 2 ,1 8 2
8.6M b  
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C hr18
Figure 5.12: Microsatellite results confirming the five complex I candidate
regions. The alleles associated with a possible disease haplotype are 
homozygous in the patient and are shown in red. Uninformative alleles are 
shown in blue. Positions of recombination are indicated by an x.
5.4.3.2. Selection of candidate genes for sequencing
NDUFV2 encodes a 24kDa subunit of complex I and is situated in one of the candidate regions 
at 9.1Mb on chromosome 18 (see Figure 5.13). Mutations in this gene have previously been 
associated with complex I defect in patients with cardiomyopathy (Benit et al., 2003). It was 
therefore an obvious candidate gene to sequence. NDUFV2 had not been sequenced initially 
because the patient described here did not have any heart involvement. No NDUFV2 mutations 
were found in genomic DNA. Our Israeli collaborators confirmed that splicing and expression 
levels were normal in cDNA from the patient. No other complex I subunits or CIA30, the one 
known assembly factor (Janssen et al., 2002), were in the candidate regions (see Table 5.8). 
The gene encoding apoptosis inducing factor, a flavoprotein which has been associated with 
complex I function (Vahsen et al., 2004), resides on chromosome Xq25 so can also be excluded 
as the cause of disease in this family.
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♦ P6
-  1423 
1424 
x 1425
* 1427
NDUFV2 AFG3L2
I i ^
S 0.3 
<0 0.2
D18S843 D18S542
20000000
C hro rrp scm e 18
40000000 
chromosome position
60000000
----- 1
80000000
Figure 5.13: Average homozygosity plot along Chromosome 18. The
candidate region is from 5.90-15.07Mb. The region 54.17-76.90Mb is also 
homozygous in the patient, but has been excluded as it is shared with 1424 
and 1427. The locations of the two microsatellites used to confirm 
homozygosity and the two candidate genes NDUFV2 and AFG3L2 are 
shown. GR, inferred position of grandparental recombination. PR, likely 
position of parental recombination in gametogenesis leading to 1424.
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Table 5.8: Nuclear genes encoding complex I subunits.
Gene Protein
Subunit
Ensembl
localisation
Exons Transcript 
length (bp)
Translation 
length (bp)
Physical 
location (Mb)
NDUFV1 51kDa 11 q13.2 10 1540 464 67.1
NDUFV2 24kDa 18p11.22 8 839 231 9.1
NDUFV3 9kDa 21q22.3 6 2023 456 43.2
NDUFA1 MWFE Xq24 3 1771 64 117.8
NDUFA2 B8 5q31.3 3 588 99 140.1
NDUFA3 B9 19q 13.42 4 333 80 59.3
NDUFA4 MLRQ 7p21.3 4 823 81 10.7
NDUFA5 B13 7q31.32 2 711 236 122.7
NDUFA6 B14 22q13.2 3 1044 128 40.7
NDUFA7 B14.5a 19p13.2 4 535 117 8.3
NDUFA8 PGIV, 19kDa 9q33.2 4 841 172 120.3
NDUFA9 39kDa 12p13.32 11 1532 377 4.6
NDUFA10 42kDa 2q37.3 10 1525 355 241.2
NDUFAB1 SDAP, 9.6kDa 16p12.2 5 665 156 23.6
NDUFB1 MNLL 14q32.12 3 417 105 90.6
NDUFB2 AGGG 7q34 4 493 105 139.8
NDUFB3 B12 2q33.1 3 670 98 202.1
NDUFB4 B15 3q13.33 3 525 129 121.6
NDUFB5 SGDH 3q26.33 6 4198 189 180.6
NDUFB6 B17 9p21.1 3 817 113 32.5
NDUFB7 B18 19p13.12 3 541 137 14.5
NDUFB8 ASH I 10q24.31 5 688 186 101.9
NDUFB9 B22 8q24.13 4 711 179 125.5
NDUFB10 PDSW 16p13.3 4 695 172 1.9
NDUFS1 75kDa 2q33.3 19 3417 727 207.2
NDUFS2 49kDa 1q23.3 15 2039 463 158.4
NDUFS3 30kDa 11p11.2 7 895 264 47.6
NDUFS4 AQDQ, 18kDa 5q11.2 5 666 175 52.9
NDUFS5 15kDa 1p34.3 3 510 106 38.9
NDUFS6 13kDa 5p15.33 5 750 124 1.9
NDUFS7 PSST 19p13.3 8 757 213 1.3
NDUFS8 TYKY 11 q13.2 8 782 211 67.6
NDUFC1 KFYI 4q31.1 4 413 76 140.8
NDUFC2 B14.5b 11q14.1 3 2471 119 77.5
NDUFA11 B14.7 19p13.3 4 426 141 5.8
NDUFAF1 CIA30, CGI-65 15q15.1 5 1457 327 39.4
The shading indicates that the gene lies in the candidate region.
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The next candidate gene that was sequenced was AFG3L2. This gene is found at 12.3Mb 
on chromosome 18 (see Figure 5.13). In the inner mitochondrial membrane, AFG3L2 forms 
a complex with paraplegin (a putative metallopeptidase). Mutations in paraplegin result in 
the loss of this complex, causing complex I deficiency and increased sensitivity to oxidant 
stress which ultimately leads to an autosomal recessive form of hereditary spastic paraplegia 
(Atorino et al., 2003). Again, no mutations were found in AFG3L2.
Analysis of six other genes with characteristic N-terminus mitochondrial targeting sequences 
or else with other evidence suggestive of mitochondrial localisation also proved negative 
(see Table 5.9).
Table 5.9: Summary of candidate genes sequenced.
Gene Location Strategy Mutations
NDUFV2 9.1Mb on Chr18 gDNA None
AFG3L2 12.3Mb on Chr18 cDNA None
VHL 10.2Mb on Chr3 gDNA None
OGG1 9.8Mb on Chr3 cDNA None
KIAA0020 2.8Mb on Chr9 cDNA None
LSM3 14.2Mb on Chr3 cDNA None
CAMK1 9.8Mb on Chr3 cDNA None
RCL1 4.8Mb on Chr9 cDNA None
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5.4.4. Results from Cypriot patients
Four regions of extended homozygosity (>30 consecutive SNPs) totalling 72.43Mb were 
found in P7 which hinted at a degree of unreported consanguinity (see Table 5.10).
However, only one region (>30 SNPs) was found in her sister P8, on chromosome 3. This
region did overlap with one of the regions in P7, but this was not shared by P9 (see Table
5.11).
In P9, there was a run of 62 homozygous SNPs on chromosome 9 and a run of 29 SNPs on 
chromosome 6. The chromosome 6 region did not quite reach the threshold level of 
significance, but was within the 66 SNP region found in P7. However, it did not share the 
same ancestral haplotype (see Table 5.12).
Table 5.10: Regions of homozygosity found in Cypriot patients.
P7 Position (Mb) No. of homozygous SNPs
Chr 2 82.42 -1 1 7.35Mb 87
Chr 3 16.23-30.99Mb 65
Chr 6 41.14-53.83Mb 66
Chr 7 21.50 - 31.55Mb 48
P8
Chr3
Chr5
P9
Chr 9 
Chr 6
24.51 - 34.53Mb
81.05 - 92.26Mb
8.26- 15.13Mb 
46.97 - 52.25Mb
40
29 (ns)
62
29 (ns)
ns, not significant.
146
Chapter 5: Homozvaositv mapping of mitochondrial disorders
Table 5.11: SNP calls in chromosome 3 region of interest.
SNP ID Chr Position (bp) P7 P9 P8
rs1394764 3 24,380.015 AA NoCal AB
rs2196427 3 24,508,243 BB AB BB
rs2362772 3 24,893,197 BB BB BB
rs720822 3 25,207,120 AA AA AA
rs2052760 3 25,899,663 BB AB BB
rs 1348979 3 27,002,462 AA AB AA
rs2037472 3 27,045,296 BB AB BB
rs724244 3 27,217,118 BB AB BB
rs2370990 3 27.665,496 BB BB BB
rs2371121 3 27,825,690 BB AB BB
rs 1609729 3 28,278,076 BB AA BB
rs237l341 3 28,724,221 BB AB NoCaR
rs1381392 3 28,724,279 AA AA AA
rs1381391 3 28.724,318 AA BB AA
rs1350867 3 28,724,438 BB AB BB
rs2371342 3 28,724,666 AA AB AA
rs952629 3 28,935,950 AA AA AA
rs1979113 3 29,032,151 BB AB BB
rs28150 3 29,569,051 AA AA AA
rs953663 3 30,092,365 BB AB BB
rs2117233 3 30,146.606 BB AA BB
rs2005210 3 30,221,485 BB AB BB
rs755615 3 30,221,592 AA AB AA
rs755614 3 30,221,712 BB AB BB
rs1433998 3 30,243,482 AA NoCal AA
rs1433997 3 30.243,782 BB BB BB
rs1587126 3 30,344,060 AA AA AA
rs 1994987 3 30,431,493 BB AB BB*
rs728426 3 30.603,136 AA AB AA
rs1019855 3 30,672,626 BB AB BB
rs1962859 3 30,672,874 NoCaH AB BB
rs 1393749 3 30,823,330 BB BB BB
rs1112792 3 30,990,151 AB BB AA
T0P02B
* indicates annotated by eye. Regions of homozygosity 
are shown in bold. The position of the T0P02B  gene is 
indicated by green arrow.
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Table 5.12: SNP calls for chromosome 6 region of interest.
SNP ID Chr Position (bp) P7 P9
rs1028496 6 46,971.821 BB AB
rs1028495 6 46,972.012 BB BB
rs926774 6 47.168.111 AA AA
rs965323 6 47.755.267 AA AA
rs479685 6 47.857,835 BB BB
rs1536818 6 47,925,874 AA AA
rs1576277 6 47.926.190 AA AA
rs722165 6 48.029.849 B B + " *  AA
rs614819 6 48.329,486 BB BB
rs543079 6 48.329,653 BB BB
rs1365720 6 48.656.415 BB BB
rs1938225 6 48,789,473 BB NoCall
rs987105 6 49.213,614 AA AA
rs582561 6 50.061.919 AA AA
rs1417503 6 50,264.549 AA + ■ +  BB
rs1340846 6 50.268.641 A A + h +B B
rs2201199 6 50.337.098 BB AA
rs1830876 6 51.112.593 AA BB
rs2397030 6 51,177.323 BB BB
rs764184 6 51,220.631 AA AA
rs1327277 6 51.274.732 AA AA
rs1327272 6 51.275.735 BB BB
r$1414503 6 51.569.324 BB BB
rs1326588 6 51.720.775 AA « ■ +  BB
rs1321508 6 51.778,609 BB BB
rs746600 6 51.923,007 AA + ■ +  BB
rs1896974 6 51.923.103 B B ^ a tA A
rs1937147 6 52.034.289 AA AA
rs3857604 6 52.162.449 BB AA
rs1413921 6 52.174.363 BB AA
rs1413920 6 52.174.417 BB AA
rs559421 6 52.249.228 AA AB
P7 and P9 are both homozygous for SNPs in this region, 
but the haplotypes are different. The differences are 
indicated by green arrows.
A possible candidate region was identified from 83.67Mb to 85.03Mb on chromosome 2 
consisting of 12 homozygous SNPs shared between P7, P8 P9, although some of these 
included no-calls (see Table 5.13). Interestingly this region contained the SUCLG1 gene (at 
84.6Mb), which is related to SUCLA2, a gene that has in the present study been linked to 
mtDNA depletion (see section 5.5.1 below). However this region was later discounted using 
microsatellites (D2S2964 at 83.8Mb, D2S1790 at 85.0Mb and D2S2333 at 85.4Mb, see 
Table 5.14).
Using the ExcludeAR spreadsheet on siblings P7 and P8 also highlighted three other 
significant regions of interest (see Table 5.15). Two regions were on chromosomes 16 (20 
SNPs at 13.2-21.0Mb and 16 centromeric SNPs at 28.1-51.0Mb) and one was on 
chromosome 5 (20 SNPs at 162.8-167.6Mb). However none of these regions appeared to 
be shared with P9 and did not reach significance when all three sets of results were 
analysed with ExcludeAR (see Table 5.15). The larger of the two chromosome 16 regions 
was also excluded with D16S411 at 48.3Mb (see Table 5.14).
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Table 5.13: SNP calls for overlapping region of
homozygosity on chromosome 2. The position of the 
SUCLG1 is indicated by green arrow. N.B. D2S2333 at 
85.4Mb was run before P8 had been analysed.
SNP ID Chr Position (bp) P7 P9 P8
rs934310 2 82,370,751 AB BB AB
rs1430728 2 82,421,784 AB AB BB
rs1582382 2 83,099,300 AA AA AA
rs4266044 2 83,099,352 AA AA AA
rs1372083 2 83,194,852 BB BB BB
rs967016 2 83,669,471 AA AB AA
rs967015 2 83,669,585 AA NoCall AA
rs993735 2 83,738,396 AA AA AA
rs993736 2 83,738,478 BB BB BB
rs1825740 2 83,895,487 AA AA AA
rs726205 2 83,901,201 BB BB BB
rs725720 2 83,932,848 NoCall AA AA
rs725729 2 84,173,414 BB BB BB
rs763867 2 84,192,522 AA AA AA
rs763866 2 84,192,831 AA AA AA
rs1007901 2 84,222,932 AA AA AA
rs1992845 2 84,279,339 NoCall BB BB
rs2198644 2 84,460,561 BB NoCall BB
rs1192281 2 85,029,133 BB BB AB
rs1561283 2 85,940,309 AA AA AA
rs1401385 2 86,099,706 BB BB AB
rs725046 2 86,302,723 BB BB BB
rs2367204 2 86,378,951 BB BB AB
rs894198 2 88,304,481 BB AB BB
S U C L G 1
Table 5.14: Microsatellite results for regions of interest on chromosomes 2 and 16.
D2S2964 D2S1790 D2S2333 D16S411
D 266 266 296 304 248 256 211 221
M 266 266 296 296 248 250 215 223
Patient 7 266 266 296 296 248 248 211 215
Patient 8 266 266 296 304 248 256 211 215
D 262 266 292 312 252 254 211 219
M 250 258 292 300 250 256 217 219
Sib 250 266 292 312 250 252 211 219
Patient 9 258 262 292 300 254 256 211 217
D 262 266 288 292 254 256 215 219
M 258 270 288 320 248 256 211 215
Patient 10 258 262 292 320 248 256 211 219
D, Dad; M, mum; Sib, unaffected sibling.
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Table 5.15: Output from ExcludeAR spreadsheet (Woods et al., 
2004) using (A) data from Patients 7 and 8 only and (B) all three 
SNP data sets.
cM chrom SNP's
largest 11.77057 16 20 significant
second 9.302101 15 6 not significant
third 9.270730 3 31 significant
fourth 0.503057 5 20 significant
fifth 7.734643 16 16 significant
sixth 7.43902 7 0 not significant
seventh 7.0493 15 6 not significant
eighth 0.323522 19 6 not significant
ninth 0.130448 6 7 not significant
tenth 5.014754 9 7 not significant
cM chrom SNP’s
largest 4.931457 9 4 not significant
second 4.497793 9 4 not significant
third 3.581257 9 4 not significant
fourth 3.290464 1 4 not significant
fifth 3.279045 6 6 not significant
sixth 3.002025 16 6 not significant
seventh 2.874604 1 4 not significant
eighth 2.600759 5 2 not significant
ninth 2.611773 15 6 not significant
tenth 2.007936 15 4 not significant
N.B. ExcludeAR did not pick up the 12 SNP region on
chromosome 2 as the genetic distance was only 0.11cM.
Finally, the individual homozygous regions (see Table 5.10) and raw SNP data from all three 
individuals were compared with the locations of genes that are known to be involved in 
mtDNA maintenance (see Table 5.16 and section 1.2.4.3). No overlapping homozygosity 
was found, which means either that these genes can be excluded as candidates, or that the 
regions of homozygosity were too small to be detectable. A third and more likely explanation 
is that the initial hypothesis of shared ancestral homozygosity was false.
Table 5.16: Nuclear genes involved with maintenance of mtDNA.
POLG 87.7Mb Chromosome 15 15q26.1
POLG2 59.9Mb Chromosome 17 17q24.1
TP 49.3Mb Chromosome 22 22q13.33
ANT1 186.4Mb Chromosome 4 4q35.1
Twinkle 102.7Mb Chromosome 10 10q24.31
SLC25A19 70.8Mb Chromosome 17 17q25.1
LRPPRC 44.0Mb Chromosome 2 2p21
DGUOK 74.1Mb* Chromosome 2 2p13.1
TK2 65.1Mb Chromosome 16 16q22.1
TK1 73.7Mb Chromosome 17 17q25.3
SUCLA2 47.4Mb Chromosome 13 13q14.2
* just misses the homozygous region in P7.
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5.5. Microsatellite results
5.5.1. Results from the Arab-lsraeli mtDNA depletion pedigree
A microsatellite genome-scan had previously identified a ~50Mb region of interest on 
chromosome 13, bordered by D13S175 and D13S156. This large region was homozygous 
for five consecutive markers in the patient. However, because some of these markers were 
non-informative in the parents, additional markers were run in order to determine the 
boundaries of the candidate region more precisely; these microsatellite data narrowed this 
region to 20Mb, bordered by D13S263 and D13S801 (see Figure 5.14).
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Figure 5.14: Microsatellite results in Arab-lsraeli mtDNA depletion pedigree. Candidate 
region is shown in green shading. Alleles that are homozygous in both patients are boxed. 
*, D13S263 was run by Elpeleg and colleagues; a, non-mendelian inheritance; N/A, not 
available.
Mitochondrial localization was predicted (score >60) in only 3 of 113 genes in this region, by 
use of the MitoP2 prediction program (http://ihg.gsf.de/mitop2/start.jsp): S U C LA 2  (encoding 
the (3-chain of the ADP-forming succinyl-CoA ligase), hypothetical protein FLJ25853 and 
ATP7B, encoding a copper-transporting ATPase 2 associated with Wilson disease (Bull et
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al., 1993; Tanzi et al., 1993). Sequencing of SUCLA2 showed a complex rearrangement, 
consisting of a homozygous deletion of 43bp (the last 14bp of exon 6 and the first 29bp of 
IVS6) and insertion of 5bp. This gene encodes a tricarboxylic acid cycle protein and is 
hypothesised to affect mitochondrial nucleotide pools via an interaction with nucleoside 
diphosphate kinase (Elpeleg et al., 2005). Functional studies and screening of controls has 
been carried out by Orly Elpeleg and colleagues (see Appendix II).
5.5.2. Results from P13
Analysis showed that, of the seven microsatellite markers in the region 2p14-16 that had 
previously been linked to a multienzyme mitochondrial disorder (Seyda et al., 2001), only 
A053XF9 was homozygous in patient P13 who, as described in section 5.3.2, also presented 
with a multiple mitochondrial enzyme deficiency (see Figure 5.15). However, this 
microsatellite was uninformative in the mother. Therefore these results effectively excluded 
this locus as the cause of disease in this consanguineous family.
[>4=0
D2S1772 189 193 185 181
A346YB5 97 97 99 112
D2S147 135 123 139 123
D2S337 234 251 236 248
A053XF9 153 158 153 153
D2S1337 175 175 175 171
D2S2739 301 308 308 312
Patient
■
13
■
D2S1772
I
189
1
181 2p14 67 0Mb
A346YB5 97 112 2p14 64.8Mb
D2S147 135 123 2p15 63.6Mb
D2S337 234 248 2p15 61.6Mb
A053XF9 153 153 2p16 1 59.9Mb
D2S1337 175 171 2p16 1 59 3Mb
D2S2739 301 312 2p16 3 49.6Mb
Figure 5.15: Patient 13’s pedigree with the microsatellite 
marker results and chromosomal positions of the markers.
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5.6. Discussion
5.6.1. Israeli complex I family
In this study, a new gene linked to human complex I deficiency has been mapped to one of 
five candidate regions. However, despite sequencing eight candidate genes, the disease- 
causing mutation has not been elucidated. There are currently no plans to sequence any 
more of the >300 genes in the candidate regions, as none have convincing evidence for 
mitochondrial localisation and it would be too expensive and time consuming to sequence 
them all. However, there remain other avenues of research that could be successful.
If any new complex I candidate genes are described in the literature and lie in any of these 
regions, these should be sequenced in this patient.
The asymptomatic parents of the patient are also from consanguineous families and so will 
contain more regions of homozygosity. As these regions will not contain the disease- 
causing gene, they could also be excluded. DNA from the parents should be run on 10K 
GeneChips to help narrow down the complex I candidate region further.
Other less-obvious lines of investigation may also arise. For example, in a recent paper by 
Kirby et al, NDUFS6 mutations are described as a novel cause of lethal neonatal 
mitochondrial complex I deficiency (Kirby et al., 2004). NDUFS6 does not lie in any of the 
postulated candidate regions reported here (see Table 5.7 and Table 5.8). However Kirby et 
al also describe another complex I patient of Polynesian origin with a de novo translocation 
between chromosomes 11 and 18, and hypothesise that this translocation may disrupt a 
disease-causing gene. Since the present study also pointed to regions on these 
chromosomes, we decided to check whether there was any overlap. The breakpoints of this 
translocation were 11 p12 and 18q22.1 (personal communication, Denise Kirby) which 
corresponds to 36.4-43.4Mb and 59.8-64.9Mb respectively. Comparison with our candidate 
regions (see Table 5.7) showed that these did not overlap. Kirby et al also describe the use 
of expression arrays in which reduced levels of NDUFS6 were seen in the two patients. 
There were other genes that were also downregulated in both patients, presumably in 
response to complex I deficiency and thus which may also be candidate genes themselves 
(see Table 5.17). However, none of these genes were located in the present investigation’s 
candidate regions either.
153
Chapter 5: Homozvaositv mapping of mitochondrial disorders
Table 5.17: Genes showing significant
downregulation in patients with NDUFS6 mutations.
Accession Symbol Differential B statistic P value
number expression
(fold change)
AF026942 CIG33 -15.45 11.9 0.0000331
NM_002993 CXCL6 -11.31 8.01 0.00311
AF095844 MDA5 -7.11 11.1 0.0000875
NM_00Q311 PRNP -5.03 10.7 0.000146
NM_0Q2535 OAS2 -4.89 9.57 0.000555
NM 004553 HDUFS6 -3.97 7.33 9.00633
NM„005359 MADH4 -3.01 7.17 0.00746
Data from Kirby et al, 2004. Reproduced with
permission.
It was noticed that one of P7’s sisters (1424) was incorrectly called a male because <7% of 
SNPs on the X chromosome were heterozygous. There are a number of possible 
explanations for this. Firstly there could have been a mix up of the samples. However, Y 
chromosome microsatellite primers (DYS390) did not amplify genomic DNA or post-ligation 
DNA from this sample suggesting that this sample was indeed from a female. One other 
explanation could be that the sibling (1424) has Turner syndrome (XO). However, as this 
family is from Israel, it is not known whether she had any early symptoms characteristic of 
Turner syndrome. It was considered unethical to pursue this possibility further. Another, 
and perhaps more likely explanation is that the sibling had uniparental isodisomy for the X 
chromosome, or else had somehow inherited two identical copies of the same ancestral 
chromosome without them having undergone any observable recombination. In males, 
meiotic recombination between the sex chromosomes is limited to the pseudoautosomal 
region N perhaps these recombinations are not detectable as they are so close to the 
chromosome ends.
It is noticeable that when the GeneChip results are plotted as average SNP homozygosity 
against chromosome position, often the traces are identical for large sections of the 
chromosome. For example, results for P6’s siblings 1423 and 1425 appear identical for the 
first half of chromosome 18, as do results for P6 and 1424 further along the chromosome 
(see Figure 5.13). These regions are where the siblings share the same two parental 
chromosomes and extend until there has been a recombination in parental gametogenesis 
for one or other of the siblings. Recombination events can also be inferred to have occurred 
in the grandparental meiosis where the boundaries of homozygosity are shared by more 
than one sibling, as it is unlikely that the recombination has occurred in the same position 
twice (see Figure 5.13).
One last comment is that if other later-onset diseases present in any of the siblings from this 
family, either individually or in any combination, this same data could be used retrospectively
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to define new candidate regions. For example, if the P6’s siblings 1423, 1424 and 1425 
present later in life with a novel neurodegenerative disorder that is not shared by 1427 or by 
P6, the region around 25Mb on chromosome 18 would be implicated (see Figure 5.13).
5.6.2. Cypriot mtDNA depletion families
Despite the inconclusive results obtained for the Cypriot mtDNA depletion families, the most 
promising candidate at this stage was considered to be a region at around 25Mb on 
chromosome 3, which contains the gene encoding Topoisomerase IIB (see Table 5.11). It is 
postulated that a truncated form of this enzyme is active in the mitochondria (Low et al., 
2003). However, the subsequent analysis of other candidate genes made sequence 
analysis unnecessary (see Chapter 7).
When considering why this strategy proved unsuccessful, it was instructive to look at other 
studies where homozygosity is not as common as expected. For example, the prevalence of 
1 in 18,000 for Bardet-Biedl Syndrome in Newfoundland is considerably higher than in most 
other populations and is partly due to a founder effect in a relatively isolated population. 
Despite this, there are at least nine different BBS mutations in five different genes (Fan et al., 
2005) and so homozygosity is rarely found to flank mutations. Even in a single inbred 
pedigree with a traceable common ancestor only 7-8 generations back, the presence of two 
different mutations has previously confounded attempts to carry out homozygosity mapping 
of a gene causing hyperthyroidism (Pannain et al., 1999). These two examples suggest that 
the hypothesis postulated in the present study, of shared homozygosity in three unrelated 
families from the same island, was too optimistic.
5.6.3. The Arab-lsraeli mtDNA depletion pedigree
Homozygosity mapping has been used in an Arab-lsraeli pedigree to map a novel gene 
involved in mtDNA depletion and encephalomyopathy. A complex rearrangement was found 
in SUCLA2 on chromosome 13. This gene encodes the ADP-forming, beta subunit of 
succinate-CoA ligase, a component of the TCA cycle situated in the mitochondrial matrix and 
whose main role is to catalyze the formation of succinate and ATP from succinyl-CoA and 
ADP. The enzyme is also thought to interact with nucleoside diphosphate kinase (Kadrmas 
et al., 1991; Kavanaugh-Black et al., 1994; Kowluru et al., 2002). This finding that SUCLA2 
mutations can cause mtDNA depletion suggests that this is an important functional 
interaction. Thus SUCLA2 can be added to the growing list of “moonlighting " proteins with 
more than one function (Sriram et al., 2005). Future studies will determine how common 
SUCLA2 mutations are as a cause of mtDNA depletion.
Reprint of paper published in Am J Hum Genet is included in Appendix II.
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5.6.4. Patient with a syndrome affecting multiple mitochondrial functions
A patient has been described with multiple mitochondrial enzyme defects. The clinical 
symptoms were thought to resemble those of four patients described by Seyda et al, in 
which a small region on the short arm of chromosome 2 was implicated (Seyda et al., 2001). 
However, it is very unlikely that homozygosity found at a single marker (A053XF9) within this 
region was due to common ancestry, as this would infer two recombinations within the space 
of the 2.3Mb that separate the flanking markers. Therefore, unless further investigation 
using a denser set of markers between D2S1337 and D2S337 suggests otherwise, this locus 
must be excluded. A different gene is likely to be the cause of multienzyme mitochondrial 
disorder in this patient.
Cell lines from P13 could be analysed for mitochondrial import, as a defect in this pathway 
could be envisaged to cause multifunctional mitochondrial defects. If there is a defect, we 
could look for homozygosity of markers that flank the genes involved with these processes. 
The human deafness dystonia syndrome is caused by mutations in a protein (DDP) which is 
thought to be involved with the mitochondrial import machinery (Koehler et al., 1999). 
However, there are many other proteins involved in this process which could be candidates 
for multiple mitochondrial defects.
It might also be worth assaying complex II and III separately. If complex II is normal, then 
this would be strongly suggestive of a mtDNA maintenance or translation defect, with the 
pyruvate dehydrogenase deficiency and amino acid imbalance being secondary.
If there had been more affected or unaffected siblings in this pedigree, then a whole genome 
screen for homozygosity might have been worthwhile. However this is not the case, and 
unless other candidate genes or loci are described in the literature for multienzyme 
mitochondrial disorder, then the molecular basis of the disease in this patient is likely to 
remain unknown.
The candidate region was initially described as being 2p14-2p13 (Seyda et al., 2001), but 
due to annotations changing in different releases of the human genome, the flanking 
microsatellites have been reallocated to 2p16.1 and 2p14. This again shows that the online 
genome annotations are dynamic.
5.6.5. General discussion
The 10K GeneChip is quick and simple to use and can produce high resolution whole- 
genome homozygosity-scan results in less than a week. However the present work shows 
that with this new technology, it is likely to be the power of the pedigree used that is the 
limiting factor. With the consanguineous family with a complex I deficiency, the candidate
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region could only be refined to one of five large regions, even though this new technology 
employs a very dense set of SNPs. On the other hand, the mtDNA depletion pedigree had 
multiple affected individuals. Even though the less densely spread microsatellites were 
used, a single region of homozygosity was obtained which allowed the identification of the 
disease gene.
Bioinformatic approaches are rapidly increasing in number and utility, and may help with 
mapping of disease genes such as those studied here, especially where the candidate 
regions are large. For example, a web-based tool called “PROSPECTR” has recently been 
developed for sequence based prioritization of candidate genes in any region of interest, see 
www.genetics.med.ed.ac.uk/prospectr (Adie et al., 2005). The algorithm has been trained 
(using known human disease-genes) to use features such as the presence of a signal 
peptide, % homology with mouse homolog, length of 3’ UTR and number of exons to predict 
which genes are likely to cause disease. Although the authors do admit that it gives high 
rates of false-positives and misses some known disease genes, it is useful in some cases. 
For example, retrospective analysis of the chromosome 13 candidate region in the Arab- 
lsraeli complex I pedigree, prioritized SUCLA2 as the number one candidate gene. Other 
useful bioinformatics approaches exist that can help predict whether uncharacterized or 
predicted genes that are in a candidate region are localised to the mitochondria. Programs 
like MitoP2, available online at http://ihg.gsf.de/mitop2/start.jsp (Claros and Vincens, 1996) 
work by analysing the N-terminus sequence to look for the presence of a positively charged 
targeting sequence. This tool helped to find the SUCLA2 gene as described above. Another 
method that has been successful uses functional genomic data sets and determines whether 
global expression of the gene in question resembles that of known mitochondrial proteins 
(Mootha et al., 2003; Tiranti et al., 2004).
A recent bioinformatic comparative-genomics approach similar to that used to identify the 
BBS5 human disease gene (Li et al., 2004) has been used to identify possible complex I 
assembly factors (Ogilvie et al., 2005). The basic idea was to identify orthologous genes 
that are shared by lower eukaryotes that contain complex I (such as Y. lipolytica) but are not 
present in organisms that lack complex I (such as S. cerevisiae). Analysis of the N-terminus 
for a possible mitochondrial targeting sequence was then carried out on this subset of genes 
using MITOPRED. In this way, 16 of the 27 genes known to encode complex I subunits 
were detected. 14 other genes were implicated. In one of these (B17.2L), a stop mutation 
was found in a patient with complex I deficiency and a progressive encephalopathy. 
Immunoblots of native gels showed that B17.2L is part of various complex I subassemblies, 
but not part of the full sized enzyme, further demonstrating that this bioinformatics approach 
has identified a novel complex I assembly factor. B17.2L does not lie in any of the complex I 
candidate regions described here. However, if any of the remaining 13 genes lie in any of 
these 5 regions, they will become very good candidates and should be sequenced.
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If any further homozygosity mapping is carried out, it would be preferable to use the newly 
released 10K mapping array version 2.0, in which the poorly performing SNPs have been 
replaced. Or, if the regions of homozygosity are expected to be much smaller, there is also 
now a 100K mapping array set available (50K on an Xba\ chip and 50K on a /-//ndlll chip) 
which has been designed primarily for whole-genome association studies, but would also 
provide high-resolution homozygosity mapping data (Matsuzaki et al., 2004a).
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Chapter 6: Mutant DNA polymerase gamma associated with 
dominantly inherited premature ovarian failure
6.1. Introduction
Premature menopause, also known as premature ovarian failure (POF) is the cessation of 
menstruation before the age of 40 and occurs in approximately 1% of women. Diagnosis is 
confirmed by measurement of follicle stimulating hormone (FSH) levels on at least two 
occasions. POF is aetiologically heterogeneous and known causes include autoimmunity, 
environmental toxins, infections, galactosaemia and anticancer treatments (Goswami and 
Conway, 2005). Other factors known to influence the age of menopause include smoking 
(Midgette and Baron, 1990), nulliparity (Parazzini et al., 1992) and epilepsy. A recent study has 
shown that women who have more frequent seizures have a significantly earlier menopause 
than women whose seizures are less frequent (Harden et al., 2003).
There is also growing evidence for a major genetic component from familial cases of POF, and 
the trait (age at natural menopause) shows a heritability of around 50% (Murabito et al., 2005). 
Female carriers of a premutation CGG expansion (61-200 copies) in FMR1 appear to have 
increased risk of POF (Allingham-Hawkins et al., 1999), whilst longer expansions (>200) cause 
fragile X mental retardation syndrome in males and some females (Loesch and Hay, 1988). 
POF is associated with Turner syndrome (45, X) and can also be caused by balanced 
X;autosomal translocations most frequently involving two specific regions: POF1 at Xq26-q28 
(Tharapel et al., 1993) and POF2 at Xq13.3-21.1 (Powell et al., 1994).
In a recent study, patients with progressive external ophthalmoplegia (PEO) from seven 
unrelated families were shown to harbour mutations resulting in a defective mitochondrial DNA 
polymerase gamma (Luoma et al., 2004). In three of the families, mutations cosegregated with 
POF (P=0.032, or 0.0044 if extended families were included and PEO was used as a mutation 
marker, because DNA was not available for early generations). In five of these families, 
cosegregation with parkinsonism was observed (P<0.0001).
DNA polymerase gamma is the only polymerase responsible for replication of the 16.6kb 
mitochondrial genome. It comprises a 137kDa catalytic subunit (POLG) and a 52kDa accessory 
subunit (POLG2). Mutations in the gene encoding POLG have previously been associated with 
a variety of clinical features, including PEO, Alpers syndrome, ataxia and epilepsy (Van 
Goethem et al., 2001; Naviaux and Nguyen, 2004; Winterthun et al., 2005). All these conditions 
arise in combination either with large-scale rearrangements or with a quantitative defect of 
mitochondrial DNA (mtDNA). In addition, polymorphisms in the polyglutamine CAG expansion 
in exon 2 of POLG have been associated with male infertility (Rovio et al., 2001). The 
significance of this last finding is unclear as the association has been replicated in some cases 
(Jensen et al., 2004) but not in others (Aknin-Seifer et al., 2005).
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Here, a patient, her mother and grandmother are described, all with dominantly inherited POF 
and PEO. Despite the pedigree being consistent with maternal inheritance, the recent link 
between POLG mutations and premature menopause and parkinsonism (Luoma et al., 2004) 
and the reduced activity of all respiratory chain (RC) enzymes containing mitochondrial- 
encoded subunits, prompted POLG sequence analysis. The well characterized Y955C mutation 
found in these three women represents the second report of mutations in POLG segregating 
with POF. The biochemical consequences of the Y955C were investigated in detail in tissues 
that were available from this family.
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6.2. Patient details
6.2.1. Patient 14
The patient (P14), mother and maternal grandmother all presented with ptosis and PEO with 
onset in their early twenties and had POF at age 28, 35 and 32, respectively (see Figure 6.1). 
At age 57, the mother was noted to have a progressive, parkinsonian-like resting tremor and 
reduced rapid alternating movements affecting her left arm and leg, together with mild 
bradykinesia. This tremor, which responded to levodopa treatment, was not observed in the 
grandmother, however other symptoms of Parkinson's disease (muscle rigidity and postural 
instability) may have been difficult to distinguish from those typically associated with PEO. P14 
has not exhibited any parkinsonian-like symptoms, aged 33, and is of above average 
intelligence with a professional career. Additional symptoms experienced by all 3 women 
include proximal muscle weakness, exertional dyspnoea and sensory ataxia. The proband’s 
mother and grandmother developed dysphagia in later life. P14 suffers episodes of palpitations 
and unusual chest, arm and leg pain thought to be related to peripheral neuropathy. P14’s two 
sisters are asymptomatic and have not presented with POF, aged 36 and 30 respectively.
Gonadotrophins were measured in P14: FSH levels were raised on two successive occasions, 
three months apart (9.0 and 32.4 IU/I aged 28 and 3 months and 28 and 6 months respectively, 
adult female pre-menopausal range 1.0-8.0 IU/I) whilst LH was still normal (4.4 and 7.4 IU/I, 
adult female non-ovulatory peak 2.0-15.0 and higher post-menopause). Resting plasma lactate 
was elevated in P14 (3.5mM, normal range 0.5-2.2mM) whereas the mother’s serum lactate 
was borderline (1.9mM) and CSF lactate was normal (1.1 mM). P14’s blood count, urea and 
electrolytes were normal.
NA
Figure 6.1: Pedigree of Patient 14. Black symbols 
indicate PEO, numbers indicate age at menopause. 
N/A, not applicable (not yet reached menopause).
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Peripheral neuropathy was confirmed by electro-physiological studies in P14. Muscle histology 
in P14’s mother (biopsied at age 52) demonstrated that 4% of muscle fibres were abnormal in 
hematoxylin and eosin-stained sections and corresponded to ragged-red fibres in the modified 
Gomori trichome stain. NADH dehydrogenase and succinate dehydrogenase stained sections 
showed irregularly dense staining and peripherally situated aggregates. Approximately 10% of 
fibres were cytochrome c oxidase negative. Spectrophotometric analysis of muscle 
mitochondrial RC enzymes indicated normal complex II activity, whereas activities of all other 
complexes were reduced (see Table 6.1). The complex III result should be interpreted with 
caution however, as the same day control was also slightly outside the control range.
As complex II is the only RC complex that does not include any mitochondrial-encoded 
subunits, this suggested a defect of mtDNA maintenance or translation of mitochondrial 
mRNAs. However, an initial Southern blot of BamHI-digested DNA from the mother’s muscle 
had not shown any large-scale rearrangements of mtDNA, and testing for the common 
mitochondrial Leu(UUR)/Lys tRNA mutations (3243A>G and 8344A>G) in hair follicles from the 
mother was also negative.
Table 6.1: Mitochondrial RC activities in skeletal muscle from P14’s mother.
Skeletal muscle
A ssay A ffected m other N orm al control O bserved range (n=6-17)
Com plex 1 0.067* 0.192 0.100-0.470
Com plex II 0.223 0.186 0.110-0.330
Com plex l l+ ll l 0.084* 0.155 0.115-0.460
Com plex III 0.097* 0.090* 0.100-0.300
Com plex IV 0.008* 0.014 0.012-0.064
Enzyme activities expressed as ratio to citrate synthase. Asterisks indicate 
where the ratios lie outside the control range. Data from David Thorburn, 
Murdoch Childrens Research Institute, Melbourne, Australia.
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6.3. Methods
6.3.1. mtDNA sequencing
The entire sequence of the mitochondrial genome was determined by Dr. Rob Taylor and co­
workers at the Mitochondrial Research Group (University of Newcastle upon Tyne) using a 
panel of 28 M13-tagged primer pairs generating overlapping fragments of between 600-700bp 
(Taylor et al., 2001a). Amplified samples were purified (ExoSapIT, Amersham Biosciences), 
sequenced using BigDye Terminator cycle sequencing chemistries (v3.1, Applied Biosystems) 
on an ABI3100 Genetic Analyser (Applied Biosystems) and directly compared to the revised 
Cambridge Reference Sequence (Andrews et al., 1999a) using SeqScape software (Applied 
Biosystems).
6.3.2. Sequence analysis of POLG
The entire coding region of POLG, including intron/exon boundaries, was sequenced using 
published primer sequences (Van Goethem et al., 2001). Exon 1 was not sequenced as it 
contains only 5-UTR. Some exons could be sequenced in pairs because of short intronic 
sequences. Thus, the whole coding portion of the gene was amplified in 16 PCR reactions 
(summarized in Table 6.2, with annealing temperatures). Instead of using the EXOSAP method 
as described in chapter 2, primers and unincorporated dNTPs were removed prior to 
sequencing reactions using the QIAquick PCR purification kit (carried out according to 
manufacturer’s instructions, Qiagen). The addition of 1M betaine (an organic compound also 
known as trimethylglycine which helps to prevent secondary structures forming in DNA 
molecules by equalizing the contribution of GC and AT base pairing to the stability of the DNA 
duplex) and an increase in the extension temperature of sequencing reactions was necessary 
for particularly GC rich exons (see Table 6.2). Otherwise, sequencing reactions were carried 
out as described in Chapter 2. Data were analysed using Sequencher™ version 4.2 (Gene 
Codes) and the sequence was compared to the POLG sequence on the Ensembl database 
(ENSG00000140521).
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Table 6.2: POLG sequencing primer sequences (Van Goethem et al., 2001).
Exons Forward Primer (5’-3’) Reverse Primer (5’-3')
PCR
annealing 
temp (°C)
Size
(bp)
Sequencing conditions
1M
betaine
Extension 
temp (°C)
2 CTCCACGTCTTCCAGCCAGTAAAA AGCACGTAACAGGACCTCAGAAAA 60 841 Yes 62
3 ATCTGGCATGTGGCGGTAGGT TTCAGCAAAGGCAACAGAGACACG 58 403 No 60
4 CCACAGTTGCAGCCTCCCTCCTT AGCCCCCTCCAGCACCATACCT 60 498 No 60
5+6 CCGGTGGGCAGGAGCATAGTG GGGCCCGGGTACCAGGAACA 60 532 No 60
7+8 GTGGCTGGGTTGAGGCTTGCTAAA ATCTGCTCCCACCCGCTCATCT 58 653 No 60
9 AGATGAGCGGGTGGGAGCAGAT GAATGGCAGCAGGTCAATAAGTA 55 328 No 60
10 CCCCCAACAACTGCCCTTACCA TTTTCCTGTTTTCCCTTCTTCTGA 58 420 No 60
11+12 GAGTGGGCATCTGGTAATCA AAGAACTAGGTGGGCAAGAGGAAG 55 539 No 60
13 GGAGAAAGCCTGGGTGAGAC T GT GGGCCTT GAGCAGAAT 55 315 No 60
14 GCGCGTGCGTGATACAAT G AAACT GAAGCT AGAGGGGAGACC 55 479 No 60
15+16 ATGGT GGG AT GT GGGATAGATT GAGGAAGAGCAGGGGCCAGAGGTA 55 386 No 60
17+18 CAGGAAT GGGGTAGGAAGAGTC GTAAT GGGCAGGAGAT AGAACAGA 55 645 No 60
19+20 AGCCGTTTCTTCCTCTGA ACTCTGGCCCTACCTACAAACATT 52 670 Yes 62
21 TCGGCTGTCCAGGAAGAGGTA CCAAAGCCCCACATAGGAGCACA 55 463 No 60
22 CTCTAAGGGGTGTGGGGTCATT GCTCT GCT GCCTTCATTTTT G 52 448 No 60
23 AAAAGAAAACAGACCCTCCTAACA CACCCACCCCGATGAAGC 52 292 No 60
PCR reactions and spin-column purifications were carried out by Jan-Willem Taanman, 
University Department of Clinical Neurosciences, Royal Free and University College Medical 
School, London. Sequencing reactions, Sephadex purifications, MegaBACE runs and 
sequence analysis were carried out at the Institute of Child Health.
6.3.3. RFLP analysis of Y955C (2864A>G)
To confirm the mutation and screen additional family members for the mutation, an 
amplification-created restriction site (ACRS) primer was designed (5’-AAT CTT CAA CTA CGG 
CCG CAA C-3’, site of mismatch underlined) and used with the 17+18R sequencing primer. 
Digestion of the wild-type PCR product with HpyCH4III (NEB) gave fragments of 196bp and 
41 bp, whilst the 2864A>G mutation introduced a further recognition site (ACN/GT, site of 
mutation indicated in bold) which resulted in fragments of 173bp, 41 bp and 23bp. Digestions 
were carried out with 8pl of PCR product, 2|J of 10x NEB buffer IV and 10U of enzyme in a total 
reaction volume of 20pl. Incubation was carried out overnight at 37°C. Fragments were 
separated on a 4% agarose gel (1% normal agarose, 3% low melting point agarose).
6.3.4. Biochemical analysis of cultured fibroblasts
A skin biopsy was taken from P14 at age 31. Fibroblasts derived from this were cultured as 
described in Chapter 2, except that the culture media consisted of HAMS F10 (Invitrogen, 
Paisley, UK) supplemented with 12% FBS (Invitrogen) and 50mg/l uridine (Sigma, Poole, UK). 
Analysis of RC enzymes was carried out using standard procedures as described in Chapter 2.
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6.3.5. Southern blotting
Southern blots were carried out by Jan-Willem Taanman at the University Department of Clinical 
Neurosciences (Royal Free and University College Medical School, London). In brief, genomic 
DNA was digested with BamHI, SnaBI or Pvull, resolved on a 0.6% agarose gel, transferred to 
a Hybond membrane (Amersham Biosciences) using standard procedures and then probed with 
heat-denatured 32P-labelled mtDNA. A probe for the multi-copy nuclear 18S rRNA gene was 
used to determine the ratio of mtDNA to nuclear DNA (nDNA), essentially as described (Blake 
et al., 1999). In addition to the experimental variability, 18S rRNA copy number is polymorphic 
in mammals (Rowe et al., 1996). Therefore, multiple control samples were run on quantitative 
blots; depletion was indicated by a mtDNA/nDNA ratio outside the age matched control range. 
Pvt/I l-digested DNA was used for quantitative Southerns as the BamHI and SnaBI-digested 
fragments containing the 18S rRNA are not suitably sized (2,159/5,102bp and 14,586bp 
respectively).
6.3.6. RFLP analysis of Q1236H (3708G>T)
To confirm whether the 3708G>T allele found in P14 was in c/s with 2864A>G, the 292bp wild- 
type exon 23 amplicon was digested with BstF5\ (SibEnzyme). The wild-type allele resulted in 
158bp and 134bp fragments, whilst the 3708G>T allele introduced a further site (GGATGNNI) 
which cut the 158bp fragment into 91 bp and 67bp fragments. Digestions were carried out with 
6pl of PCR product, 1.5pl of 10x SE buffer Y and 20U of enzyme in a total reaction volume of 
15|il. Incubation was carried out for 3h at 65°C. Fragments were separated on a 2.5% agarose 
gel.
6.3.7. Quantitative PCR methods
Quantitative PCRs studies were carried out by David Thorburn and Adrienne Laskowski, at the 
Murdoch Childrens Research Institute (Royal Children’s Hospital, Melbourne, Australia). In 
brief, the percentage of deleted mtDNA was calculated by real-time amplification of fragments 
within the ND1 and ND4 genes, as described (He et al., 2002). These regions were chosen 
because ND1 is rarely deleted, whereas ND4 is in the middle of the major arc where mtDNA 
deletions predominate (see Figure 1.3 in Introduction). ND4 has found to be deleted in 96% of 
cases with multiple deletions. Levels of mtDNA depletion were determined by comparison of 
ND1 levels to a non-polymorphic region of CFTR, a single-copy nuclear gene. To aid 
reproducibility, DNA was prepared in a similar way for all samples. Six adult muscle samples 
(from needle biopsies, obtained with informed consent) were used as controls and results are 
the means of two independent runs, with samples assayed in triplicate in each run.
166
Chapter 6: Mutant DNA polymerase gamma associated with dominantly inherited premature ovarian failure
6.3.8. Blue Native gel analysis of ONA polymerase gamma stability
For immunoblot analysis of one-dimensional native gels, mitochondrial fractions were prepared 
from fibroblasts using differential centrifugation. Proteins were solubilised with n-dodecyl-beta- 
D-maltoside and resolved on blue native 8-18% polyacrylamide gels as devised by Schagger 
(Schagger, 1995; Williams et al., 2004). Proteins were transferred to a 0.45pm Hybond-P 
transfer membrane (Amersham Biosciences) and probed with a 1/400 dilution of POLG Ab3 N- 
terminal antibodies, a 1/400 dilution of POLG Ab4 cocktail (NeoMarkers, Lab Vision 
corporation), or a 1/7,500 dilution of MTC02 antibodies to ensure equal loading conditions 
(Molecular Probes™, Invitrogen). The Ab4 cocktail consisted of Ab-1, Ab-2 (both C-terminal 
antibodies), and Ab-3. The manufacturers recommend the use of Ab-4 in experiments requiring 
sensitive detection of DNA polymerase gamma.
Differential centrifugation, Blue Native gel electrophoresis and immunoblotting protocols are all 
described in detail in Chapter 2.
6.3.9. Determination of DNA polymerase gamma activity
DNA polymerase gamma activity assays were carried out on mitochondrial preparations from 
patient fibroblasts by Jan-Willem Taanman (University Department of Clinical Neurosciences, 
Royal Free and University College Medical School) using a reverse transcriptase primer- 
extension assay in the presence of the nuclear DNA polymerase inhibitor aphidicolin, as 
described (Longley etal., 1998; Spelbrink et al., 2000).
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6.4. Results
6.4.1. mtDNA sequencing
The apparent maternal transmission of disease in this pedigree initially led to the sequencing of 
mtDNA from maternal skeletal muscle. The sequence differed from the revised Cambridge 
Reference Sequence (Andrews et al., 1999a) at 35 positions. Of these, only a single base- 
change (4561 T>C in MTND2) was absent from the MITOMAP database of neutral mtDNA 
polymorphisms (www.mitomap.org). 4561 T>C appeared to be homoplasmic on the sequence 
electropherogram and predicted a V31A amino-acid change in the ND2 subunit of RC complex 
I. However, it was unlikely that a mutation in a complex I subunit could be responsible for 
multiple RC defects and cytochrome c oxidase negative fibres. 4561T>C was also represented 
in approximately 1% of sequences in the large Uppsala database of mtDNA sequence variants 
found in healthy individuals (www.genpat.uu.se/mtDB) and was therefore deemed non- 
pathogenic.
6.4.2. POLG sequence analysis results
Sequence analysis of POLG in P14 revealed a heterozygous A to G transition mutation at 
nucleotide position 2864 in exon 18 (see Figure 6.2). This predicted a tyrosine to cysteine 
change at residue 955 (Y955C) in the highly conserved polymerase motif B (see Figure 6.3). 
Because of a common heterozygous GTAG insertion (rs2307433) in the intron 17-18 (see 
Figure 6.4), the fact that exons 17 and 18 were sequenced together meant that the Y955C 
mutation could not be confirmed in the forward sequencing reaction. (rs2307433 is 39bp from 
the exon 17 splice donor site, has an allele frequency of 56.5% in the NIH Polymorphism 
Discovery Resource which contains DNA from 450 anonymous, unrelated individuals with equal 
numbers of females and males, so is likely to be of no functional relevance.)
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Phe Asn Tyr Gly Arg lie Gly Ala Gly Gin Pro Phe
Phe Asn Tyr Gly Arg lie Tyr Gly Ala Gly Gin Pro Phe
Figure 6.2: Sequencing electropherogram from 17+18R
primer with amino-acid translation. A, P14 harbours a 
heterozygous Y955C mutation, indicated with an arrow. B, 
wild-type sequence.
Homo
Pan
Canis
Rattus
Mus
Gallus
Xenopus
Fugu
Tetraodon
Danio
Drosophila
Anopheles
Apis
Saccharomyces 
Caenorhabditis 
T7 Polymerase
ATTVGISREH
ATTVGISREH
AATVGISREH
AATVGISREH
AATVRIHREH
AATVGISREH
ASTVGISREH
ADAVGISREH
ADAVGISREH
ADAVGISREH
AKAVGISRDH
AQAVGISRDH
AKAIGISRNQ
AQILGCSRNE
ASQLKISRNH
IAAELPTRDN
AKIFNYGRI Y GAG QPFAERLLMQFNHRLT 974
AKIFNYGRI Y GAG QPFAERLLMQFNHRLT 284
AKIFNYGRI Y GAG QPFAERLLMQFNHRLT 732
AKVFNYGRI Y GAG QSFAERLLMQFNHRLS 951
AKIFNYGRI Y GAG QSFAERLLMQFNHRLT 952
AKVFNYGRI Y GAG QPFAERLLMQFNHRLT 358
AKVFNYGRI Y GAG QAFAERLLMQFNHRLT 941
AKVFNYGRI Y GAG QPFAERLLMQFNHRLS 905
AKVFNYGRI Y GAG QAFAERLLMQFNHRLS 994
AKVFNYGRI Y GAG QPFAERLLMQFNHRLS 822
AKVINYARI Y GAG QLFAETLLRQFNPTFS 892
AKVLNYARI Y GAG QQFAERLLKQFNPTLT 823
AKIINYARI Y GAG QKFAETLLKQFNPSMT 724
AKIFNYGRI Y GAG AKFASQLLKRFNPSLT 802
AKVLNYARL Y GSG ETHAGKHLMRVGG-LK 780
AKTFIYGFL Y GAG D----------------------- 534
Figure 6.3: Alignment of POLG proteins from different species using
ClustalW (www.ebi.ac.uk/clustalw). Y955 is in the highly conserved POLG B 
motif (boxed) and conserved across all species.
169
Chapter 6: Mutant DNA polymerase gamma associated with dominantly inherited premature ovarian failure
AGCCCAGCCCCTCAGCATATTGACAGTTC
Normal sequence GTAGCATATTGACA
insGTAG
Figure 6.4: Electropherogram showing heterozygous GTAG
insertion in P14 (rs2307433) which meant that the Y955C mutation in 
exon 18 could not be confirmed in the forward direction.
6.4.3. RFLP analysis of Y955C
To confirm the Y955C mutation (in the absence of a readable forward sequence), and to check 
for segregation in other family members, an ACRS-PCR primer was designed and used with 
primer 17+18R (see section 6.3.3). P14’s mother was also heterozygous for the mutation, 
whereas her two unaffected sisters, father and maternal uncle were all wild-type, thus showing 
that the mutation segregates with the disease in this pedigree (see Figure 6.5).
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Figure 6.5: The inheritance of the Y955C allele in the pedigree was determined 
by PCR-RFLP. /-/pyCH4lll digestion of the ACRS PCR products resulted in 
196bp and 173bp fragments which were separated on a 4% agarose gel, and 
correspond to the wild-type and Y955C alleles, respectively. Thus Y955C 
segregates with the disease. Gel lanes are aligned with the pedigree except for 
the grandparents from whom DNA was not available. Black symbols indicate 
progressive external ophthalmoplegia, numbers indicate age of menopause. UC, 
uncut; N/A, not applicable (not yet reached menopause).
6.4.4. Biochemical and molecular studies of P14’s fibroblasts
Biochemical analysis of a fibroblast culture derived from P14 at age 31 indicated that, in 
contrast to the clinical results obtained for skeletal muscle from P14’s mother, the RC defect 
was not expressed (see Table 6.3).
Table 6.3: Mitochondrial RC activities in P14’s cultured fibroblasts.
Fibroblasts
Assay P14 Normal control Observed range (n=12)
Complex II 0.105 0.112 0.095-0.205
Complex ll+ lll 0.129 0.104 0.070-0.243
Complex IV 0.011 0.010 0.007-0.036
Enzyme activities expressed as ratio to citrate synthase.
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6.4.5. Southern blot results
In some patients with mtDNA depletion syndrome, mtDNA progressively depletes in cultured 
fibroblast and myoblasts (Taanman et al., 1997). Therefore mtDNA levels were investigated in 
six alternate cell passages (from 11 to 21). The Southern blot indicated that the levels of 
mtDNA in P14’s fibroblasts were depleted, but remained stable at around 43% of three controls 
(see Figure 6.6). The mtDNA/nDNA ratios were 2.13+/-0.57 and 4.94+/-0.65 (expressed as 
mean+/-SD) for P14 and controls, respectively. This difference was statistically significant 
(p<1x10‘11, unpaired one-tailed T test).
A P14 Control 2
11 13 15 17 19 21 11 13 15 17 19 21
«■* 4 #  w  mm w  w  W  W  «■» « mtDNA
' ' 418S rRNA
6
O  K  1 .
S if
3 4 -
Control 1 
Control 2 
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2
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Cell passage number
Figure 6.6: Data from fibroblast DNA Southern blotting experiments. A.
Southern blot probed for mtDNA and the 18S rRNA gene from alternate 
passage numbers of P14’s fibroblasts and a control culture. B. The 
mtDNA/nDNA ratios, quantified by phosphorimaging, were 2.13 (+/-0.57,
1.3-2.8) and 4.94 (+/-0.65, 3.9-5.9) for P14 and controls, respectively.
Expressed as mean (+/-SD, observed range). Figure supplied by Jan- 
Willem Taanman.
6.4.6. RFLP analysis of Q1236H and repeat Southern analysis on muscle DNA.
Besides the Y955C and rs2307433 changes already mentioned, five additional heterozygous 
PO LG  polymorphisms were found in P14. Four of these were intronic: two SNPs (rs2302084 
and rs2246900) were found on the same allele in intron 19-20, whilst two more (rs2072267 and 
rs2307438) were found in introns 11-12 and 21-22 respectively. The fifth change, 3708G>T 
(rs3087374) predicted a Q1236H substitution three amino acids away from the C-terminus (see 
Figure 6.7A). The Q1236H allele has previously been found to have a frequency of 4.0% in the 
NIH Polymorphism Discovery Resource and so is likely to be a neutral polymorphism.
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However, recent evidence indicates that Q1236H can modify the function of a pathogenic 
mutation (R627Q) when found in cis (Luoma et al., 2005). Therefore it was conceivable that 
Q1236H might also modulate the effect of Y955C, resulting in mtDNA depletion rather than the 
multiple deletions usually observed with this mutation. However, digestion of exon 23 
amplicons with BstF5\ indicated that Q1236H was inherited from the asymptomatic father, who 
was homozygous for Q1236H (see Figure 6.7B), providing further evidence that Q1236H is non- 
pathogenic, and more importantly demonstrating that it was in trans with Y955C in P14.
H isSer Leu Glu Lys Arg Ser Pro Gly Pro Stop
Gin
T C C  T T C  0  A A A a A C G A  A G C C A C C T G G  A C C  A T A G
A
292bp>
«158bp
*134bp
«91bp
«67bp
Figure 6.7: Q1236H was detected by sequence analysis and confirmed with PCR- 
RFLP. A. Sequencing electropherogram from 23F showing the heterozygous 
Q1236H mutation in P14, indicated by arrow. B. Inheritance of Q1236H in this 
pedigree was determined by BsfF5l digestion of the exon 23 amplicon. The 
fragments were separated on a 2.5% agarose gel. The wild-type 158bp fragment is 
cut into 91 bp and 67bp fragments in the Q1236H allele. This shows that Q1236H 
has been paternally inherited. Lanes run in same order as in Figure 6.5. UC, uncut; 
S, sister; F, father; M, mother; U, uncle.
Repeat Southern analysis of some of the remaining skeletal muscle DNA from P14’s mother 
(performed in light of all the molecular findings described above) demonstrated multiple 
deletions with BamHI, SnaBI and Pwvll-digested DNA (see Figure 6.8). The relatively low levels 
present explain why these were missed in the initial screen for rearrangements in muscle 
mtDNA.
173
Chapter 6: Mutant DNA polymerase gamma associated with dominantly inherited premature ovarian failure
BamH\ SnaB\ PvuW PvuW
Figure 6.8: Southern blots of muscle DNA from P14’s mother reveals rearrangements 
of mtDNA, present at low levels. UC, uncut; +, DNA from a patient with a single large- 
scale mtDNA deletion; control DNA. Rearrangements are indicated with an 
arrowhead. Figures supplied by Rosetta Marotta and Jan-Willem Taanman.
6.4.7. Quantitative PCR results
Quantitative PCR was used to confirm the levels of deleted mtDNA present in the muscle 
sample. The ratio of ND4.ND1 in the muscle sample from P14’s mother (0.73 in both runs) was 
reduced in comparison to six controls (1.007+/-0.085, 0.911-1.137; expressed as mean+/-SD, 
observed range). This suggested that approximately 27% of mtDNA molecules harboured 
deletions that span ND4. The presence of these shorter mtDNA species and some degradation 
of DNA (see Figure 6.8), caused difficulties in the quantification of the signal from the 18S rRNA 
gene (which runs at 12,035bp) on the Pvt/ll digested Southern blot. Therefore qPCR was again 
used to determine the amount of mtDNA in relation to nDNA using a nuclear probe for CFTR. 
The ratio of ND1.CFTR  in the muscle sample from P14’s mother (1.67 and 1.74 in two separate 
analyses) was higher than the mean value of six controls (1.17+/-0.67, 0.498-2.077; expressed 
as mean+/-SD, observed range). Thus there was no evidence of mtDNA depletion in skeletal 
muscle from P14’s mother.
23,130bp
9,416bp 
6,557bp
4,361 bp
2,322bp
2,027bp
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6.4.8. Blue Native gel analysis of DNA polymerase gamma stability
Immunoblotting of Blue-Native gels with antibodies against POLG showed a double band 
migrating between complex IV (~200kDa) and complex II (~130kDa, see Figure 6.9). In 
subsequent experiments, the upper band recognised by anti-POLG was found to co-migrate 
with the band recognised by POLG2 antibodies (personal communication, Jan-Willem 
Taanman; antibodies as described, Magnusson et al., 2003). These results suggest that the 
upper band represents the 189kDa POLG-POLG2 complex, whereas the lower band represents 
the 137kDa POLG protein on its own. The intensity of the bands in P14 was similar to that in 
the control, indicating that the stability of holo-DNA polymerase gamma was not affected by 
Y955C. These data contradict recent studies that suggest the enzyme acts as a heterotrimer 
(Yakubovskaya et al., 2006).
POLG: cocktail of antibodies
200kDa^ <<POLG and POLG2 -  189kDa 
«*POLG -  137kDa
130kDa*
POLG: N-terminal antibody W M M l
-4P0LG and POLG2 -  189kDa 
-4P0LG -  137kDa
Complex IV: MTC02 antibody
•*COX-2O0kDa
Figure 6.9: Immunoblots of Blue Native gels showing DNA polymerase gamma 
and complex IV. Complex IV was probed to control for loading amounts. C, 
control sample. The migration of complex II (130kDa) and complex IV (200kDa) 
are indicated in the top panel. The sizes of POLG and POLG2 refer to the 
mature proteins after cleavage of N-terminal targeting sequences.
6.4.9. Determination of DNA polymerase gamma activity
To assess the activity of the enzyme, the reverse transcription activity was determined in 
mitochondrial fractions of cultured fibroblasts in the presence of the nuclear DNA polymerase 
inhibitor aphidicolin, by measuring the dTTP incorporation using poly(rA) as template. The 
activity in the P14 sample was 9.38pmol incorporated dTTP/mg of protein/min, whereas the 
mean activity (+/-SD, range) of the 12 control samples was 14.03 (+/-3.92, 7.30-19.92) pmol 
incorporated dTTP/mg of protein/min. Thus in its heterozygous state, Y955C appears to result 
in a trend toward a decrease in activity of the enzyme (67% of controls); however the decrease 
was not significant.
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6.5. Discussion
A three-generation pedigree has been described with familial premature menopause associated 
with PEO, proximal myopathy, sensory ataxia and parkinsonism. In this family the disease 
segregates with an autosomal dominant Y955C mutation in the highly conserved catalytic 
polymerase domain (POLG B motif) of DNA polymerase gamma. Although DNA from the 
maternal grandmother was not available, she is likely to have harboured Y955C since she also 
presented with PEO. To our knowledge, these three women constitute only the second 
reported family in whom mutations in POLG segregate with POF in multiple generations. 
Luoma et al (2004) reported POLG mutations in seven PEO families. Five women from three of 
these families exhibited premature menopause (<40 years) or primary amenorrhoea. Two of 
these families harboured the dominant Y955C mutation found here, whilst a woman from the 
third family was a compound heterozygote for the N468D and A1105T mutations. In one of the 
Y955C families described by Luoma et al (family S), POF was also documented in the extended 
family (Melberg et al, 1996), whereas the other two pedigrees each contained only a single case 
of POF. The data described here support the causal link between mutant POLG and POF, and 
suggest that POF may be a relatively common feature in women with PEO caused by mutations 
in POLG, and by Y955C in particular. Women with Y955C and other POLG mutations should 
be counselled about their reproductive options.
Nulliparity has been associated with a slightly earlier menopause (Parazzini et al., 1992). This 
is because women who have borne children have experienced a temporary pause of their 
menstrual cycle (and therefore ovulation) during pregnancy. For example, P14’s mother gave 
birth to 3 children (at age 23, 26 and 30). This means she had about 27 months in total, without 
ovulation. In contrast, P14 had no children by the age of 28 when she experienced POF. The 
same pattern can be observed in family S described by Luoma et al (2004); the woman 
designated “1-1” gave birth to 8 children and had menopause at 44, whereas other affected 
women in this family had a much earlier onset of menopause.
In family S described by Luoma et al, affected men had testicular atrophy (Lundberg, 1962). 
However, in the family described here, it has not been possible to confirm an effect of Y955C on 
male fertility, since all affected family members were female in this pedigree.
In 25% of three-generation pedigrees such as the one described here, the autosomal-dominant 
mutation will have been inherited from the maternal grandmother. In such cases of apparent 
maternal inheritance, when the unknown disease-gene relates to energy metabolism, it is 
tempting to assume a maternal mode of inheritance and proceed immediately to mtDNA 
sequencing. This study highlights that nuclear genes must also be considered.
In this family, there was additional evidence that the maternal great-grandmother was also 
affected with a neuromuscular disorder, since myasthenia gravis was recorded on her death
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certificate. Nowadays, the main diagnostic method for myasthenia gravis is by detection of 
AChR antibodies (>0.5nM in the serum) and by the improvement of symptoms upon treatment 
by edrophonium hydrochloride (a cholinesterase inhibitor). However, the autoimmune nature of 
this disease was only discovered in the 1960-70s when it was demonstrated that myasthenic 
syndrome could be induced in mice with purified acetylcholine receptor proteins (Patrick and 
Lindstrom, 1973) and by injection of antibodies derived from the serum of patients with the 
disease (Toyka et al., 1977). Therefore, these two methods for confirmation of the diagnosis 
would not have been possible in the 1940-50s when the great-grandmother was likely to have 
presented with the disease. In view of the dominant nature of the POLG mutation in this 
pedigree, and the similarity between PEO and myasthenia gravis, it is highly likely that the 
great-grandmother actually presented with PEO caused by the Y955C mutation. It is not known 
whether this woman experienced POF or parkinsonism.
mtDNA levels in six alternating passages of P14’s fibroblasts were consistently lower than in 
three control cell lines. This shows for the first time that the Y955C mutation can result in 
mtDNA depletion in cultured fibroblasts. The levels of mtDNA depletion did not increase with 
passage number, and were not severe enough to affect the RC enzymes (see Table 6.3). With 
the exception of a single case report of mtDNA depletion in which the inheritance pattern was 
suggestive of dominance (the patient’s two paternal half-siblings had died in infancy of an 
undiagnosed myopathy, Mazziotta et al., 1992), this is the first description of mtDNA depletion 
caused by a dominant mutation. In contrast, multiple mtDNA rearrangements were seen in 
muscle, consistent with the relative sparing of nuclear-encoded complex II activity compared 
with other RC enzymes (see Table 6.1). Unfortunately, fibroblasts from the mother and muscle 
tissue from P14 were not available to further investigate this apparent tissue specificity.
Although the initial Southern blot of skeletal muscle DNA did not show any evidence of mtDNA 
rearrangements, repeat blots using three different restriction enzymes indicated that low levels 
of deleted molecules were present. These results demonstrate the experimental variability 
between different Southern blots and the care needed with their interpretation. As shown here, 
qPCR-based methods are now able to quantify mtDNA deletions and depletion, and can be 
used to confirm Southern blot data. In cases where mtDNA deletions are present at even lower 
levels, more sensitive long-range PCR methods have previously been used (Van Goethem et 
al., 2004; Luoma et al., 2005). However, due to preferential amplification of shorter mtDNA 
fragments, these studies are not quantitative and in some case have been shown to produce 
artefactual results (Lightowlers et al., 1999). These PCR-based methods are especially 
important when, as is often the case with paediatric patients, limited amounts of tissue are 
available for study. (See also Chapter 4 where P4 required a repeat biopsy.) A single Southern 
blot requires approximately 3 micrograms of DNA, whilst PCR methods can be used on lysates 
from single muscle fibres (He et al., 2002). In this case, qPCR confirmed that 27% of mtDNA 
from skeletal muscle harboured deletions containing ND4. Further studies on individual muscle 
fibres could determine the relative levels of multiple mtDNA deletions in cytochrome c oxidase 
positive versus negative fibres.
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Y955C, the first mutation described in POLG , was initially found in a Belgian pedigree 
presenting with PEO associated with the accumulation of large-scale mtDNA deletions (Van 
Goethem et al., 2001). More recent microsatellite studies have failed to detect a common 
haplotype around Y955C, suggesting that this site might be a hotspot for mutations rather than 
an ancestral mutation (Lamantea et al., 2002).
The human POLG structure is not yet available. However the crystal structure of the closely 
related T7 DNA polymerase has been resolved to 2.20A. The Y530 that is analogous to the 
highly conserved Y955 (see Figure 6.3) is positioned in the active site (see Figure 6.10). A 
recent structural model of mitochondrial DNA polymerase gamma, based on the T7 and three 
other DNA polymerases, provides further evidence that this tyrosine residue is likely to 
participate in the recognition of the incoming dNTP (Graziewicz et al., 2004). The functional 
results described here are consistent with this hypothesis, since polymerase activity fell towards 
the lower end of the control range (67% of mean), despite native gels demonstrating normal 
stability of the enzyme.
• I^ncon i^ng dNTP
Figure 6.10: Structure of T7 DNA polymerase at 2.20A resolution (PDB entry 
1T7P). Viewed with DeepView / Swiss-PdbViewer (www.expasy.org/spdbv) 
with subunit A in orange shading, subunit B in red, and the template and 
replicating strands of DNA in blue and green respectively. The positions of
tyrosine 530 and the incoming dNTP are indicated.
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Parkinson’s disease is the second most prevalent neurodegenerative disorder, with a lifetime 
incidence of approximately 2% (Polymeropoulos et al., 1997). In most cases, the aetiology is 
unknown. However, recent studies have linked the disorder to mutations in a-synuclein 
(Polymeropoulos et al., 1997), parkin  (Kitada et al., 1998), PINK1 (Valente et al., 2004), DJ-1 
(Bonifati et al., 2003), ubiquitin C-terminal hydrolase L1 (Leroy et al., 1998), LRRK2 (Zimprich et 
al., 2004; Paisan-Ruiz et al., 2004) and PO LG  (Luoma et al., 2004). Mitochondrial involvement 
in Parkinson’s disease was first suggested in 1990 when a specific defect of Complex I activity 
was detected in the substantia nigra of nine post-mortem samples (Schapira et al., 1990). More 
recently, studies have shown that individuals in the European mtDNA haplogroup J have a 
significantly decreased risk compared to those from common haplogroup H (van der Walt et al.,
2003). It appears to be a specific SNP, 10398A>G that causes a non-conservative amino-acid 
change from threonine to alanine at position 114 within the ND3 subunit of RC complex I, that is 
crucial for this protective effect. PINK1 encodes a kinase that is located in the mitochondria 
(Valente et al., 2004). Previous studies have linked DJ-1 to mitochondrial function; as in 
conditions of oxidative stress, DJ-1 translocates to the outer mitochondrial membrane and is 
associated with neuroprotection (Canet-Aviles et al., 2004). Mitochondrial dysfunction has also 
been described in mouse parkin knockouts; a 2D gel electrophoresis proteomic analysis 
indicated that several mitochondrial proteins involved in RC function were decreased, explaining 
the low enzyme activities of complexes I and IV (Palacino et al., 2004).
As P14 is only 33 years of age and clinical details from the grandmother and great grandmother 
are incomplete, it is not possible to comment on the penetrance with which Y955C causes 
parkinsonism in this family. However the levodopa-responsive parkinsonian tremor described in 
P14’s mother provides further evidence that mutations POLG  can be implicated in Parkinson’s 
disease (Luoma et al., 2004) and supports the hypothesis that mitochondrial dysfunction is 
involved in the mechanisms underlying this disorder.
These results also led to the sequencing of PO LG  in two other patients with parkinsons-like 
features. The onset of disease in these patients was age 65 and 71 years. The interesting 
aspect of their disease was an association with OXPHOS abnormalities. Firstly, a complex I 
enzyme activity defect had previously been demonstrated in platelets and cybrids carrying 
patient platelet mtDNA. Secondly, mosaic COX I immunocytochemical staining was 
demonstrated in fibroblasts. Unlike P14 however, these two patients did not have PEO, so it 
was not altogether surprising that no POLG  mutations were found.
According to a recent review (Jansen and Burton, 2004), the number of mitochondria increases 
exponentially from approximately 10 in the pre-migratory primordial germ cell, to about 500,000 
found in secondary oocytes. It is important that mtDNA replication can keep pace with this huge 
increase in mitochondria. The mature oocyte has the highest mtDNA copy number of all cells 
(Steuerwald et al., 2000), so is likely to be more sensitive to reduced DNA polymerase gamma 
activity than other tissues. Indeed, a recent study demonstrated a significantly higher mtDNA 
copy number in human oocytes that were successfully fertilised and developed into embryos
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than in those that did not survive (Almeida Santos, in press). This was consistent with an earlier 
study that had shown that ATP content of the oocyte correlated with the developmental potential 
of the embryo after fertilisation in vitro (Van Blerkom et al., 1995). A recent report also 
highlighted the importance of oxidative phosphorylation (and therefore mtDNA) in the normal 
development of mouse ovarian follicles (Wycherley et al., 2005). Reduced fertility and 
premature ageing has also been observed in a mouse model with a proof-reading deficient 
version of POLG associated with accumulation of mtDNA point mutations, as well as increased 
amounts of deleted mtDNA molecules (Trifunovic et al., 2004). In light of these results, it may 
be worth screening PO LG  (including CAG repeat length) in women with POF and with other 
forms of reduced fertility, even in the absence of PEO. This would help to determine the extent 
and variability of the PO LG  mutant phenotype. In family S described by Luoma et al (2004), 
four out of five patients for whom information is available showed hypogonadism prior to 
presenting with PEO (Melberg et al., 1996), therefore it is conceivable that POLG  mutations that 
are milder than Y955C might cause POF in the absence of PEO.
If dominantly acting variations in POLG  can influence age of menopause in the absence of 
PEO, this will raise important reproductive counselling issues for affected women (e.g. timing of 
families, possibility of cryopreservation of ovarian tissue), especially if the current trend towards 
having children later in life continues.
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Chapter 7: Screening the gene encoding mitochondrial DNA 
polymerase gamma in paediatric patients with mtDNA depletion
7.1. Introduction
Depletion of mitochondrial DNA has traditionally been detected by running DNA from skeletal 
muscle and liver (or in some cases from fibroblasts derived from the patient) on Southern blots 
and using a probe for mtDNA and another for nuclear DNA (usually the 18S rRNA gene). The 
relative intensities of these two signals determines the mtDNA/nDNA ratio. Where the value 
obtained for a patient lies outside the normal age-matched control range, the patient is said to 
have mtDNA depletion.
mtDNA depletion is a genetically heterogeneous condition. It can be caused by recessive 
mutations in two genes associated with maintenance of nucleotide pools within the 
mitochondria: mutations in thymidine kinase 2 result in a predominantly myopathic phenotype 
and are found in around 11% of such cases (Mancuso et al., 2002), whereas mutations in 
deoxyguanosine kinase account for about 14% of all hepatocerebral presentations (Salviati et 
al., 2002). Recently, mutations in the gene encoding the catalytic subunit of the mitochondrial 
DNA polymerase gamma (POLG) have also been recognised as a third factor involved in 
mtDNA depletion, causing Alpers syndrome (Naviaux and Nguyen, 2004). Alpers syndrome 
was first described in 1931 in a girl who presented at 6 months with intractable generalized 
seizures and in whom progressive degeneration of the gray matter of the cerebrum was 
observed (Alpers, 1931). The disease is characterized by a clinical triad of symptoms including 
liver failure, psychomotor retardation and intractable epilepsy, and has a typical age of onset of 
1-2 years. Diagnosis is confirmed by postmortem examination of liver and brain tissues, which 
show characteristic neuropathological lesions accompanied by spongiform or microcystic 
cerebral degeneration (Harding et al., 1995).
Mitochondrial DNA polymerase gamma is composed of a catalytic subunit (POLG, 139.6kDa) 
and an accessory subunit (POLG2, 54.9kDa). The genes that encode these proteins consist of 
23 and 8 exons and are located at 87.7Mb and 59.9Mb on chromosomes 15q and 17q, 
respectively. Once the 25 amino-acid N-terminal mitochondrial targeting sequences have been 
cleaved, the subunits are slightly smaller (136.9kDa and 52.2kDa). The catalytic activity of the 
enzyme is to synthesise DNA using deoxynucleoside triphosphate molecules. The enzyme also 
has a 3’ exonuclease activity, allowing it to remove bases that have been inserted incorrectly.
Although DNA polymerase gamma is thought to function primarily as a DNA-directed DNA 
polymerase in vivo, in vitro experiments have demonstrated that it also possesses a potent 
RNA-directed DNA polymerase (reverse transcriptase) activity (Murakami et al., 2003). Cloning 
and characterisation of human PO LG  has indicated that there are three highly conserved motifs 
within the exonuclease domain (EXO I at amino-acid positions 195-201, EXO II at 265-272 and
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EXO III at 395-404) and three highly conserved motifs within the polymerase domain (POL A at 
886-893, POL B at 946-958 and POL C at 1132-1141) separated by a linker region within this 
large protein (Ropp and Copeland, 1996). Although the linker region is not conserved through 
evolution, it is thought to be of structural importance. The relatively common A467T linker 
region mutation, found in 0.6% of the Belgian population (Van Goethem et al., 2003a), results in 
a defective association with the POLG2 accessory subunit and compromises the enzyme’s 
processivity (Chan et al., 2005).
The first mutations to be described in P O LG  were associated with autosomal dominant PEO 
and multiple mtDNA deletions (Van Goethem et al., 2001). However, because of the recent 
work linking PO LG  to mtDNA depletion and Alpers syndrome (Naviaux and Nguyen, 2004), this 
23 exon gene was sequenced in the cohort of patients with Alpers syndrome or a 
hepatocerebral presentation of mitochondrial disease described here. In the majority of these 
patients, Southern blot analysis had already indicated mtDNA depletion.
A schematic diagram of the POLG protein with its three functional domains is shown in Figure
7.1. The 49 mutations in POLG that are currently known to cause human disease (as of 3rd 
November, 2005) are also presented.
Mutations in DNA polymerase y, POLG
Exonuclease domain Linker region Polymerase domain
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Figure 7.1: Mutations in DNA polymerase gamma, as of 3rd November 2005, from 
http://dir-apps.niehs.nih.gov/polg. Reproduced with permission from William C. Copeland.
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7.2. Patient Details
The clinical details of the Cypriot patients (P7-10) have already been described in Chapter 5. 
Because patients 7 and 8 are sisters, the elder sister (P7) was assigned as the index case for 
the purposes of this chapter. The clinical details of this cohort of patients are summarised in 
Table 7.1.
Table 7.1: Summary of patient cohort.
Patient Diagnosis
Age of 
onset/death
mtDNA defect 
(residual levels)
Analysis of 
DGUOK
RC defect
7 Infantile hepatocerebral mtDNA 
depletion syndrome with cataracts
Neonate/9m 10.4% in skeletal 
muscle
Normal I, IV
9 Infantile hepatocerebral mtDNA 
depletion syndrome with cataracts
2wk/5m 0.3% in skeletal 
muscle
Normal I, III, IV
10 Infantile hepatocerebral 
depletion syndrome
mtDNA 5m/- 10.0% in skeletal 
muscle
Normal I, III, IV
15 Infantile hepatocerebral 
depletion syndrome
mtDNA 3m/6m 16.2% in fibroblasts Normal I, ll+lll, IV in 
fibroblasts
16 Infantile hepatocerebral 
depletion syndrome
mtDNA 4wk/7.5m 9.6% in skeletal 
muscle, 11.3% in liver
Normal Normal
17 Infantile hepatocerebral 
depletion syndrome
mtDNA 6m/23m 6.4% in skeletal 
muscle, 11.5% in liver
Normal I, III, IV
18 Alpers 3y/5.5y 33% in skeletal 
muscle, 55% in heart, 
25% in liver
N/A N/A
19 Alpers 6m/6m Normal in brain and 
skeletal muscle
N/A N/A
20 Infantile hepatocerebral 
depletion syndrome
mtDNA Neonate/6m 18% in skeletal 
muscle, 7% in liver
Normal IV in liver
21 Alpers 11.5m/14.5m 14% in skeletal 
muscle
N/A I, IV
22 Alpers 9m/11 m 8% in skeletal muscle, 
8% in liver
N/A N/A
23 Alpers 17m/26m 24% in skeletal 
muscle
N/A IV
24 Alpers N/A 11% in liver, 60% in 
fibroblasts
N/A N/A
25 Alpers 6.5y/7y9m 50% in fibroblasts N/A I, IV in liver
26 Alpers and gastrointestinal problems 18y/18.5y Normal in brain and 
skeletal muscle
N/A N/A
27 MNGIE-like 2m/- Multiple deletions in 
muscle
N/A I, III, IV
28 Leigh syndrome 6m/1y 50% in fibroblasts N/A IV in 
fibroblasts
RC activity results are from muscle biopsies, unless otherwise stated. N/A, not available. -, still alive.
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7.2.1. Patient 7
The clinical details of P7 are described in Chapter 5.
7.2.2. Patient 9
The clinical details of P9 are described in Chapter 5.
7.2.3. Patient 10
The clinical details of P10 are described in Chapter 5.
7.2.4. Patient 15
Patient details for P15 have been published previously (Clayton et al., 1986). The patient was 
the third child of healthy unrelated Caucasian parents. She was born at 38 weeks gestation 
weighing 2.95kg. At three months, poor feeding and vomiting was reported and her weight had 
fallen from the 50th centile to the 10th. At 16 weeks of age she collapsed with profound 
hypoglycaemia. Examination revealed hepatomegaly and peripheral oedema. Biochemical 
investigations indicated impaired liver function and a biopsy showed giant cell transformation of 
hepatocytes. A 7h fast triggered hypoglycaemia and raised lactate in blood (5.4mM). EEG 
showed excessive rhythmic slow activity. At 6 months, she developed gastrointestinal bleeding 
and deterioration in liver function, hyperammonaemia and metabolic acidosis and soon 
afterwards developed septicaemia and died. The eldest sibling was healthy, however the 
second-born brother presented with a similar symptoms to P15, but died aged 4 weeks of 
sudden infant death syndrome. Initial biochemistry studies on a fibroblast culture derived from 
P15 suggested that deficiency of phosphoenolpyruvate carboxykinase was the cause of disease 
(Clayton et al., 1986). A younger brother was born subsequently, with the same clinical 
symptoms and liver failure, yet phosphoenolpyruvate carboxykinase activity was normal 
demonstrating that this was not the primary defect in this family (Leonard et al., 1991). Further 
studies on fibroblasts from P15 indicated that levels of mtDNA were 16.2% of controls, whilst 
the activities of complexes I, ll+lll and IV were reduced to 32%, 18% and 23% of controls 
(Bodnar et al., 1995). Nuclei from A549 cells could complement the defect, suggesting that the 
depletion was under the control of the nuclear genome (Bodnar et al., 1993).
7.2.5. Patient 16
Patient details for P16 have been published previously (Taanman et al., 1997; Morris et al., 
1998; Hargreaves et al., 2002). This boy was the third child of healthy, non-consanguineous, 
English parents. He was born at term weighing 3.5kg but fed poorly and at 24h was mildly 
hypoglycaemic (2.3mM). Blood lactate concentrations were normal or borderline (1.3 to 
2.6mM), but the CSF lactate concentration was raised at 3.2mM. Roving eye movements were
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noticed at 4 weeks of age, with normal optic fundi. He fed poorly with frequent vomiting. At 8 
weeks he was markedly hypotonic, subsequently becoming areflexic. Nystagmus and papillary 
abnormalities were present from 4 months of age, the right pupil first constricting with a sluggish 
response to light and subsequently becoming fixed and dilated. Cranial MRI was normal but the 
CSF protein was raised (1.25g/l). From the age of 5.5 months, he was stuporous but irritable on 
handling, with hepatomegaly and abnormal liver function. At 7.5 months he developed 
jaundice, ascites and intractable seizures requiring thiopentone. When this was stopped, he 
remained deeply unconscious with no oculocephalic, corneal or gag reflexes; 
electroencephalography showed severely impaired cortical function and, after discussion with 
the family, ventilation was discontinued. Muscle and liver biopsies were obtained at the age of 
2 months and immediately on postmortem. Muscle histology initially revealed only mild lipid 
accumulation, with normal COX staining. Liver histology showed only minor changes. The 
postmortem biopsies showed no change in muscle histological appearance. Liver histology 
revealed micronodular cirrhosis, with collapse and fibrosis. COX staining in liver was now 
patchy, with weak activity in a proportion of hepatocytes. Residual levels of mtDNA were 11.3% 
in liver (Morris et al., 1998). In skeletal muscle, residual levels of mtDNA were 9.6%, whilst RC 
enzyme activities remained normal (Hargreaves et al., 2002). mtDNA was also depleted in 
fibroblasts and myoblasts derived from P16. This patient had two affected sisters who died at 5 
and 3 months of age after having had hypotonia, poor visual fixation and progressive liver 
failure. The eldest sister is unaffected.
7.2.6. Patient 17
P17’s clinical details have been published previously (Hargreaves et al., 2002). The patient was 
born at full term, weighing 3.3kg to healthy, non-consanguineous, English parents. He 
remained well until 6 months of age, when his weight gain became poor despite a good 
appetite. Mild floppiness was also noted at 6 months. At 15 months he developed an episode 
of hypoglycaemic encephalopathy following a diagnostic fast. On examination at 18 months he 
was markedly hypotonic and hyporeflexic, and a 4cm liver edge was palpable. Investigations 
revealed elevated lactate in blood (6.2mM, reference range <1.8mM) and CSF (7.2mM, 
reference range <2mM). Brain MRI was normal. Muscle biopsy showed many fibres with 
excess red granular staining in the trichrome preparation. These fibres also contained excess 
lipid droplets and were strongly positive for succinate dehydrogenase (SDH) activity. 
Cytochrome oxidase (COX) activity was normal in type 1 fibres but absent in type 2 fibres. 
Electron microscopy demonstrated occasional abnormal mitochondria with concentric cristae. 
He continued to deteriorate and died at 23 months of age. Residual levels of mtDNA were 
11.5% in liver (Morris et al., 1998). In skeletal muscle, residual levels of mtDNA were 6.4% and 
analysis of RC enzymes indicated that the activities of complexes I, III and IV were reduced, 
whilst the activity of complex II was normal (Hargreaves et al., 2002). mtDNA was also depleted 
in fibroblasts and myoblasts derived from P17. His elder brother had also been affected and 
had died at a similar age. The clinical details of this brother have also been published 
previously (Morris et al., 1998).
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7.2.7. Patient 18
P18 presented with seizures at 3 years of age and died aged 5.5 years. A diagnosis of Alpers’ 
syndrome was made and reduced levels of mtDNA were demonstrated in skeletal muscle 
(residual levels were 33% of controls), heart (55%), liver (25%), but not in kidney.
7.2.8. Patient 19
Presented with status epilepticus, hepatopathy and cardiac failure aged 6 months and died 
shortly afterwards. Plasma and CSF lactate were 2.8 and 1.9mM respectively. A diagnosis of 
Alpers’ syndrome was made. Levels of mtDNA appeared normal in brain and muscle. Other 
tissues were not investigated.
7.2.9. Patient 20
Patient details for P20 have been published previously (Blake et al., 1999). P20 was born at 
term, the second child of healthy Caucasian parents. Although well at birth, she quickly 
developed hypoglycaemia, and later lactic acidosis (blood lactate 5.8mM). There was 
progressive liver disease which led to liver failure resulting in death at 6 months. A liver biopsy 
showed micronodular cirrhosis with proliferation of bile ducts and abundant neutral fat and bile 
pigment in hepatocytes. Complex IV activity and histochemical staining were severely depleted 
in liver, but not in muscle. Southern blots showed that mtDNA in liver was severely depleted to 
7% residual compared to controls in liver and 18% of controls in muscle (Blake et al., 1999). 
mtDNA was also depleted in fibroblasts and myoblasts derived from P20. These findings led to 
a diagnosis of hepatocerebral mtDNA depletion syndrome. The patient’s elder brother had also 
presented with a very similar progressive liver disease and had died at 7 weeks.
7.2.10. Patient 21
P21 presented with focal seizures aged 11.5 months. CT was normal but an EEG showed 
widespread irregular activity. Her motor development regressed following seizures and she 
became jaundiced due to acute liver failure. A second CT scan showed mild cerebral atrophy. 
She died at 14.5 months. Complex I and IV activities were both reduced in skeletal muscle 
(32% and 56% of controls, respectively) and muscle histochemistry confirmed that ~20% of 
fibres were COX negative. There was also reduced levels of mtDNA in skeletal muscle (14% of 
controls).
7.2.11. Patient 22
P22 presented with status epilepticus aged 9 months. She became unresponsive, yet an MRI 
scan was normal. Initial liver function tests were unremarkable. EEG studies showed 
continuous high voltage spikes and sharp wave complexes. Seizures were controlled with
187
Chapter 7: Screening the gene encoding mitochondrial DNA polymerase gamma
phenytoin and other anti-epilepsy drugs, although with limited success. The patient then 
became jaundiced, deteriorated rapidly and died aged 11 months. CSF lactate was elevated at 
3.2mM, whereas plasma lactate and amino-acids were normal. Karyotype was normal and 
mitochondrial mutations at positions 3243 and 8344 were excluded. A diagnosis of Alpers 
syndrome was made and reduced levels of mtDNA were demonstrated in muscle and liver (8% 
of controls in both tissues), but not in fibroblasts.
7.2.12. Patient 23
P23 presented aged 17 months with seizures with a left temporal focus on EEG, resulting in 
right hemianopia. Two months later he had more prolonged left-sided seizures, and at 22 
months he had further focal seizures and persistent muscle spasms in the left leg followed by 
hemiplegia and cortical blindness. CT showed atrophy of both cerebral hemispheres and the 
thalami. Plasma lactate varied from 1.9-11.7mM whilst CSF lactate was 3.9mM. A diagnosis of 
Alpers syndrome was made. Liver failure ultimately led to the patient’s death aged 26 months. 
Reduced levels of mtDNA were found in skeletal muscle (24% of controls), and a partial 
deficiency of complex IV was detected in muscle (30% of controls, expressed as a ratio to 
complex II). Complex I activity was normal. A younger sibling was unaffected.
7.2.13. Patient 24
Patient 24 was suspected to have Alpers syndrome. Reduced levels of mtDNA were found in 
liver (11% of controls) and in fibroblasts (60% of controls and stable during culturing).
7.2.14. Patient 25
P25 presented with a prolonged status epilepticus at age 6.5 years. He went on to have liver 
failure, and despite a liver transplant, he went on to deteriorate neurologically. CSF showed 
raised lactate and protein. In liver there was a complex I and IV deficiency. A diagnosis of 
Alpers syndrome was made. Screening for mtDNA mutations was negative, however there was 
reduced levels of mtDNA in fibroblasts from P25 (50% of controls and stable during culturing). 
An older sister has also developed symptoms of Alpers disease at a later age; her liver still was 
not affected aged 10.
7.2.15. Patient 26
P26 presented with vomiting and epigastric pain (both experienced since age 5), anorexia and 
weight-loss aged 18 years. Following a barium meal, an obstruction was noticed in the 
duodenum. The patient also had numerous tonic-clonic seizures, yet a CT scan and initial MRI 
were both normal. A later MRI showed a high signal in the right occipital and parietal cortex. 
EEG indicated a slow wave focus in the right posterior quadrant and an almost continuous right 
occipital epileptiform discharge. Nerve conduction studies were consistent with a peripheral
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axonal neuropathy. ECG was normal. Other symptoms included generalized muscle wasting, 
left hemiparesis, left hemianopia and nystagmus. Blood lactate was 1.9mM. The 3243, 8344 
and 8993 mitochondrial mutations were excluded. He had increasing respiratory problems and 
died 5 months after the initial presentation. There was no family history of neurological or 
gastrointestinal disease. Southern blot indicated that levels of mtDNA in brain and skeletal 
muscle were normal. The clinical details of this patient have recently been published (Murray et 
al., 2006).
7.2.16. Patient 27
P27 presented at 2 months of age with gut, liver and brain involvement due to metabolic 
collapse and lactic acidosis. A muscle biopsy was taken aged 22 months. Spectrophotometric 
assay of the RC enzymes indicated decreased activity of complex I, III and IV, whereas 
complex II was normal. Southern blotting indicated no quantitative abnormalities of mtDNA, 
however low levels of multiple deletions were observed in mtDNA extracted from muscle. 
mtDNA extracted from a myoblast culture was normal.
7.2.17. Patient 28
P28 was born to unrelated parents with no family history suggestive of mitochondrial disease. 
He was referred at age 6 months with stridor and a mild respiratory infection which was followed 
by a progressive neurological deterioration and increasing levels of hypotonia. At 1 year of age 
he deteriorated rapidly with metabolic collapse with a lactate of 11.7mM but no amino-acid 
abnormality. An MRI scan indicated a high signal in the basal ganglia and other features 
characteristic of Leigh syndrome. He was transferred to intensive care, requiring oxygen and 
died shortly afterwards. Complex IV activity was low in fibroblasts, whereas in liver the activity 
of complex I and of complexes ll+lll were raised. The 8344, 3243 and 8993 mitochondrial point 
mutations were excluded and there was no evidence of mtDNA rearrangements, however a 
Southern blot later demonstrated depletion of mtDNA in fibroblasts. The residual levels of 
mtDNA were 50% and stable during culturing. P28 had a normal male karyotype (46XY). An 
older sibling is asymptomatic.
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7.3. Methods
7.3.1. Sequencing
Methods for sequence analysis of PO LG  are described in Chapter 6. For novel mutations, 
sequence alignment was carried out using the CLUSTALW tool on the EBI website 
(www.ebi.ac.uk/clustalw) using POLG amino-acid sequences obtained from the NCBI protein 
database (www.ncbi.nlm.nih.gov).
7.3.2. Restriction Digests
7.3.2.1. R FLP analysis o f G848S (2542G>A)
Nae\ cuts the wild-type 386bp exon 15+16 amplicon into 291 bp and 95bp fragments. The 
recognition site (GCC/GGC, site of mutation shown in bold) is disrupted by the G848S mutation. 
Digestions were carried out with 6pl of PCR product, 1.5pl of 10x NEB buffer I and 20U of 
enzyme in a total reaction volume of 15^ 1. Incubation was carried out overnight at 37°C. This 
method was used to confirm segregation of PO LG  mutations in P17’s parents.
7.3.2.2. R FLP analysis o fE 1 1 3 6 K  (3406G>A)
In order to screen Cypriot controls, an ACRS forward primer was designed (5-GCT TCT GCA 
TCA GCA TCC ATG IC-3’, mismatch underlined) for use with 21R (see Table 6.2 in the 
previous chapter). In the wild-type, the 155bp PCR product is cut into 22bp and 133bp 
fragments by Taq\. The recognition site (T/CGA) is disrupted by the E1136K mutation. 
Digestions were carried out with 6pl of PCR product, 1.5pl of 10x NEB buffer III, 100ng/ml of 
BSA and 40U of enzyme in a total reaction volume of 15pl. Incubation was carried out 
overnight at 65°C. This method was also used for a pre-natal test (carried out by Jan-Willem 
Taanman).
7.3.2.3. R FLP analysis o f P524A (1570C>G )
In order to screen Cypriot controls, an ACRS forward primer was designed (5’-GAG GGG GCT 
GGG GCC CCT GGG GA-3’) for use with 7+8R (see Table 6.2). BamHI cuts the wild-type 
161 bp PCR product into 21 bp and 140bp fragments. The P524A mutation disrupts the 
recognition site (G/GATCC). Digestions were carried out with 10pil of PCR product, 1.5pl of 10x 
NEB buffer II, 10Ojixg/ml of BSA and 40U of enzyme in a total reaction volume of 15}al. 
Incubation was carried out overnight at 37°C.
190
Chapter 7: Screening the gene encoding mitochondrial DNA polymerase gamma
7.3.2.4. RFLP analysis ofP587L (1760C>T)
Sma\ cuts the wild-type 420bp exon 10 amplicon into 104bp and 316bp fragments. The P587L 
mutation disrupts the recognition site (CCC/GGG). Digestions were carried out with 6pl of PCR 
product, 1.5pl of 10x NEB buffer IV, and 40U of enzyme in a total reaction volume of 15pl. 
Incubation was carried out overnight at 25°C. This method was used to confirm segregation of 
the mutation in the pedigrees of P7 and P9, and for a pre-natal for P7’s mother (carried out by 
Jan-Willem Taanman at the University Department of Clinical Neurosciences, Royal Free and 
University College Medical School, London).
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7.4. Sequencing results
7.4.1. P7
Three heterozygous changes were observed in P7. A 752C>T transition was found in exon 3 
which predicted a T251I amino-acid substitution near the EXO II motif of POLG (see Figure 
7.2A). There was also a 1760C>T transition in exon 10 which predicted a P587L change in the 
linker region (see Figure 7.2B) and a novel 3406G>A transition in exon 21 which predicted a 
E1136K change in the POL C motif (see Figure 7.2C). The affected sister (P8 described in 
Chapter 5) also harboured all three changes. Sequencing of parental DNA indicated that the 
exon 3 and exon 10 changes were both inherited from the father and thus were in cis, whilst the 
exon 21 change was inherited from the mother. A pre-natal was later carried out for this family 
which indicated that the pregnancy carried the paternal disease allele, but not the maternal 
E1136K mutation (see Appendix III).
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G A C G A C C C T G C A T G G A C C C C  
As p  As p  P r o  A l a  T r p  T h r  P r o
E1136K in exon 21 |
//wwyWiM/wviA/v!^
G G G  C C C C A G C C T C C T C A G C  
G l y  P r o  Se r  L e u  L e u  Se r
T G C A T C A G C A T C C A T G A C ^ A  
Cy s  l i e  Se r  X l e  H i s  As p
G G T T C G  C T A C C T G G T G C G G  
*  V a l  Az g  T y r  L e u  V a l  A z g
T G C A T C A G C A T C C A T G A C G A G G T T C G C T A C C T G G T G C G G  
Cys l i e  s*z X I *  H i s  As p  G l u  V a l  A r g  T y r  L e u  V a l  A z g
Figure 7.2: Electropherograms showing T251I, P587L and E1136K 
mutations in P7. Amino acid translation is shown. WT, wild-type.
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7.4.2. P9
The mutations in P9 were identical to those found in PI. The T251I and P587L mutations (see 
Figure 7.3A and B) were again in cis and inherited paternally, whilst the E1136K mutation (see 
Figure 7.3C) was inherited from the mother. None of these three mutations were found in a 
healthy sibling.
A -  T251I in exon 3
»  ; / y w w y
i
WT
A T C C C C C T G G A G G T C C C T A C T G G T G C C A G C A G C C C C A C C  
l i e  F r o  L e u  G l u  T e l  F r o  P i t  G l y  A l a  Se r  Se r  F r o  H i t
B -  P587L in exon 10
P9
G A C G A C C C T G C A T G G  A C C C  ^ G G G C C C C A G C C T C C T C A G C  
As p  As p  F r o  A l a  T r p  t t i r  L e u  G l y  F r o  Se r  L e u  L e u  Se r
WT \ \l \/vv V
G A C G A C C C T G C A T G G A C C C C G G G C C C C A G C C T C C T C A G C  
As p  As p  F r o  A l a  T r p  T h r  F r o  G l y  F r o  Se r  L e u  L e u  S e r
C -  E1136K in exon 21
1
m  m r n m i r j  m m  :a: i m u m u  ,
T G C A T C A G C A T C C A T G A C ^ A G G T T G G C T A C C T G G T G C G G
Cy s  H e  S e r  l i e  H i s  Asp L y s V a l  A r g  T y r  L e u  V a l  A r g
WT
T G C A T C A G C A T C C A T G A C G A G G T T C G C T A C C T G G T G C G G  
Cys l i e  S e r  l i e  H is  A sp  G lu  V a l  A rg  T y r  L e u  V a l  A r g
Figure 7.3: Electropherograms showing T251I, P587L and E1136K
mutations in P9. Amino acid translation is shown. WT, wild-type.
7.4.3. P10
Only one maternally inherited heterozygous mutation was found in P10 (see Figure 7.4). This 
was a novel 1570OG transversion in exon 8 which predicted a P524A substitution in the linker 
region.
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P524A at the end of exon 8
P 10
G C T  G G G G C C C C T G G T G A T  ® C C A T G G A T C A G G A A  G / g  t  g g g 
Al a  G l y  A l a  F r o  G l y  Asp M et Asp Gi n  Gl u  A s p / in t r o n
W T
G C T G G G G C C C C T G G T G A T C C C A T G G A T C A G G A A  G / g  t  g g g 
Al a  G l y  Al a  Pr o  G l y  Asp Pr o  Me t  Asp Gi n  Gl u  A s p / in t r o n  8 - 9
Figure 7.4: Electropherogram showing P524A mutation in P10. Amino 
acid translation is shown. WT, wild-type.
7.4.4. P15
Two heterozygous mutations were found in P15. Exon 16 contained a 2492A>G transition (see 
(see Figure 7.5A) which predicted a Y831C change to the amino-acid sequence at the start of 
the polymerase domain, and was inherited from the mother. Exon 21 contained a novel 
3401 A>G transition (see Figure 7.5B) which predicted a H1134R substitution in the POL C motif 
that was inherited from the father. Both mutations were also found in P15’s affected brother.
P I 5
A -  Y831C near the beginning of exon 16
C C C S C C « g / a  C A C  C C C G A C T  g  T G A T  G A G G A A 6  9  C C T  C T  A T  
in t r o n /A r g  H is  P ro  Asp Asp G lu  G lu  G ly  Leu T y r
WT
c c  c  a  c  c  a g /G  c a c c c c g a c t a t g a t o a g g a a g g c c t c t a t  
in t r o n /A r g  H is  P ro  Asp T y r  Asp G lu  G lu  G ly  Leu T y r
B -  H1134R in exon 21
P I 5
I u S M l
C G C T T  C T G C A T C A G C A T C C ^ T G A C G A G G T T C G C T A C C T G
Ar g  Phe Cys H e  Se r  l i e  Hi s  Asp Gl u  Va l  Ar g  T y r  Leu
Ar g
W W W m / ^ M V W M W V l ^
C G C T T  C T G C A T C A G C A T C C A T G A C G A G G T T C G C T A C C T G  
Ar g Phe Cys l i e  Se r  l i e  Hi s  Asp Gl u  Va l  Ar g  T y r  Leu
Figure 7.5: Electropherograms showing Y831C and H1134R
mutations in P15. Amino acid translation is shown. WT, wild-type.
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7.4.5. P16
Four heterozygous changes were found in P16. Exon 13 contained a 2243G>C transversion 
(see Figure 7.6A) which predicted a W748S substitution in the linker region. A novel 3328C>T 
transition in exon 21 (see Figure 7.6B) predicted a H1110Y substitution close to the POL C 
motif. Exon 21 also contained a 3428A>G transition (see Figure 7.6C) which predicted an 
E1143G substitution close to the POL C motif. Exon 23 contained a 3708G>T transversion (see 
Figure 7.6D) which predicted a Q1236H substitution, as described in Chapter 6. The W748S 
and E1143G changes were both inherited from the mother and thus were in c/s, whilst the 
H1110Y and Q1236H changes were inherited from the father. An affected sister was also 
shown to harbour both disease alleles.
A -  W748S in exon 13
« .  A*  A * . A  .  . A . \A
y m  v
WT
0 T 8 0 A C A T C C C T 8 8 C T 8 C T c 0 T T T T T C A A a C T a C C T C A C  
V a l A sp  l i e  P ro  s l y  C ys Phe Phe L y s  L e u  P ro  H is
a
\  A /  
1 1
>A A A / \ A a a  a / u  V v V V XV
G T G 8 A C A T C C C T 8 0 C T S C T G G T T T T T C A A G C T G C C T C A C  
V a l A sp  l i e  P ro  S ly  Cys T r p  Phe Phe L y s  L e u  P ro  H is
B -  H1110Y in exon 21
PI 6 A A a A(A A A A i
T C T 8 C T 8 T T 8 A C T A C T T a £ a C C T C A T G C T T 8 T G 8 C C A T G  
S e r A la  V a l A sp  T y r  L e u  H is  L e u  n e t  L e u  V a l A la  M e t
" r
T C T S C T 0 T T 8 A C T A C T T A C A C C T C A T 8 C T T 8 T 8 8 C C A T 8  
S e r A la  V a l A sp  T y r  L eu  H is  L e u  M e t L e u  V a l A la  H e t
C -E 1143G  in exon 21
PI 6
WT
0 T T C 8 C T A C C T B S T 8 C S S G „ S G A G G A C C S C T A C C S C 0 C T
V a l A rg  T y r  L eu  V a l A rg 81 u  A sp  A rg  T y r  A rg  A la
0 T T C 8 C T A C C T G 8 T 8 C G 8 8 A 0 0 A G 0 A C C 0 C T A C  
V a l A rg  T y r  L e u  01 u A rg  81 u  01 u  A sp  A rg  T y r
D-Q 1236H in exon 23
P I 6
T C C T T 8 8 A A A A A C 8 A A 8 C C A - C C T G 8 A C C A T A 8 C A C T 3 C
S e r L e u  8 1 u  L y s  A rg  S e r H isGi n P ro  G ly  P ro  S to p
WT
T C C T T G G A A A A A C S A A 0 C C A 6 C C T G G A C C A T A G  
S e r L eu  81 u L y s  A rg  S e r  G in  P ro  S ly  P ro  S to p
C A C T G C
Figure 7.6: Electropherograms showing W748S, H1110Y,
E1143G and Q1236H mutations in P16. Amino acid translation is 
shown. WT, wild-type.
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7.4.6. P17
P17 was also a compound heterozygote. There was a novel 695G>A mutation in exon 3 (see 
Figure 7.7A) which corresponded to a R232H substitution at the amino-acid level in between the 
EXO I and II motifs and a 2542G>A mutation in exon 16 (see Figure 7.7B) which predicted a 
G848S substitution near the POL A motif. An affected brother also contained both these 
changes. Sequence analysis indicated that the R232H mutation was maternally inherited. 
Because the G848S mutation in P17 knocks out a naturally occurring A/ael site in the exon 
15+16 amplicon, a restriction digest was used to confirm that the G848S mutation was inherited 
paternally (see Figure 7.8).
A -  R232H in exon 3
P I  7
W T
I A/
P I 7
WT
C A 0  C 6  G 
9 1 n Ar g
Y- \  J  \ — —A M------ ^____ tk-- h. A ---1 '
I C T 0 G T G G A A 0 A 9 C  g  T T A C
Leu V a l  Gl u  Gl u  T y r  
Ar g
T C T T G G A C C A G C C A G  
Ser  T r p  T h r  Se r  Gi n
\  a aM A aM a a M AV m  V r A y v  AV'
C A 0 C 0 S C T 9 9 T 8 G A A 8 A 9 C C  
Gi n Ar g  Leu V a l  Gl u  Gl u  Ai
-  G848S in exon 16
M f V V y W v ^
I T T A C T C T T G G A C C A 9 C C A G  
rg T y r  Se r  T r p  T hr  Se r  Gi n
/ W # M # V A / w \
c c c c
Pr o
/W J
: a  j
Gi n
f
. G T G G T G A C T G C C g G C A C C  
V a l  V a l  T h r  A l a  T h r
A T  C A 
H e  1
M '
C T C O C C G G G C T  
r hr  Ar g  A r g  A l a
C C C C A A 0 T 0 0 T 0 A C T 0 C C 0 0 C A C C A T C A C T C 0 C C 9 G 0 C T  
p r o  01 n v a l  v a l  T h r  A l a  31 y  T h r  l i e  T h r  A r g  A r g  A l a
Figure 7.7: Electropherograms showing R232H and G848S mutations 
in P17. Amino acid translation is shown. WT, wild-type.
400bp^
300bp^
200bp^
100bp^
Figure 7.8: PCR-RFLP confirmed that the G848S was
inherited paternally. A/ael cuts the wild-type 386bp exon 
15+16 PCR product into 291 bp and 95bp fragments. The 
G848S mutation disrupts the A/ael consensus cut sequence 
resulting in an uncut 386bp fragment. F, father; M, mother.
-4386bp 
<4291 bp
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7.4.7. P18
P18 was homozygous for the relatively common 1399G>A transition mutation in exon 7 (see 
Figure 7.9) which predicted an A467T change in the linker region. Unfortunately no DNA was 
available from the parents to confirm segregation.
A467T in exon 7
P I  8
A A G T C G T T G A T G G A T C T G A C C A A T G A T G C C T G C C A G C T G
Lys Ser Leu Met Asp Leu Thr Asn Asp Ala Cys Gin Leu
W T
A A G T C G T T G A T G G A T C T G G C C A A T G A T G C C T G C C A G C T G  
Lys Ser Leu Het Asp Leu Ala Asn Asp Ala Cys Gin Leu
Figure 7.9: Electropherogram showing A467T mutation in P18. Amino 
acid translation is shown. WT, wild-type.
7.4.8. P19
No POLG mutations were found in P19.
7.4.9. P20
No POLG mutations were found in P20.
7.4.10. P21
Two heterozygous mutations were found in P21. The first was the common 1399G>A transition 
mutation in exon 7 (see Figure 7.10A) which predicted an A467T substitution, also found in P18. 
The other change was a 2542G>A transition in exon 16 (see Figure 7.1 OB) which predicted a 
G848S mutation as described in P17. No DNA was available from the parents to confirm 
segregation.
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A -  A467T in exon 7
P21 c L w imL J & L :
A A Q T C G T T Q A T G G A T C T G g C C A A T G A T Q C C T G C C A G C T G  
Lys S e r  L e u  M e t  Asp L e u  As n  As p A l a  Cys S i n  L e u
WT
m m m w r n w ! '
A A G T C G T T G A T G G A T C T G G C C A A T G A T G C C T G C C A G C T G  
Lys S e r  L e u  M e t  Asp L e u  A l a  As n  As p A l a  Cys  S i n  L e u
B -  G848S in exon 16
P21
C C C C A A G T G G T G A C T G C C g S C A C C A T C A C T C G C C G G G C T
Car
Pr o  G i n  V a l  V a l  T h r  A l a  T h r  l i e  T h r  A r g  A r g  A l a
WT
' X V m w y y v w \
C C C C A A G T G G T G A C T G C C G G C A C C A T C A C T C G C C G G G C T  
P r o  G i n  V a l  V a l  T h r  A l a  Gly T h r  H e  T h r  A r g  A r g  A l a
Figure 7.10: Electropherograms showing A467T and G848S mutations 
in P21. Amino acid translation is shown. WT, wild-type.
7.4.11. P22
Two heterozygous mutations were found in P22. The first was the common 1399G>A transition 
mutation in exon 7 (see Figure 7.11 A) which predicted the A467T mutation, also found in P18 
and P21. The other change was a novel 2740A>C transition in exon 18 (see Figure 7.11B) 
which predicted a T914P substitution in between the POL A and B motifs. P22 inherited A467T 
from her father and T914P from her mother.
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A -  A467T in exon 7
P22
M e t A s p  L e u A s p  A la  C y s  S i n  L e uL y s  S e r L e u
WT
P22
L m m M i m m r x Y j o u
A A 8 T C S T T O A T S O A T C T S S C C A A T Q A T 8 C C T 8 C C A O C T 8  
L y s  S e c  L e u  M e t  A s p  L e u  A l a  A s n  A s p  A l a  C y s  S i n  L e u
B-T914P in exon 18
WT
i n t r o n / S l y  C y s  T h r  A la  P h e  S l y  T r p  M e t  T h r  
P ro
g c t t g t c t t c c a  g / s  C T 8 C A C A S C C T T T S S 3 T S S A T S A C A  
i n t r o n / S l y  C y s  T h r  A la  P h e  S l y  T r p  M e t  T h r
Figure 7.11: Eiectropherograms showing A467T and T914P
mutations in P22. Amino acid translation is shown. WT, wild-type.
7.4.12. P23
In P23, identical mutations were found as described for P22. No DNA was available from the 
parents to confirm the inheritance of the A467T (see Figure 7.12A) and T914P (see Figure 
7.12B) mutations.
A -  A467T in exon 7
P23
WT
1
.w  M m m m m
A A O T C O T T S A T S S A T C T S ' C C A A T S A T S C C T S C C A S C T S
L y s  S e r  L e u  M e t A s p  L e u  A s n  A s p  A la  C y s  S in  L e u
WIWmiM mr. Wx_m IfJi
A A S T C 8 T T 8 A T S 6 A T C T S S C C A A T S A T S C C T S C C A S C T S  
L y s  S e r  L e u  Me t  As p  L e u  A l a  A s n  A s p  A l a  Cy s  S i n  L e u
B -  T914P in exon 18
P23
g c t t g t c t t c c a  g / S  C T S C g C A S C C T T T S S S T S S A T S A C A
i n t r o n / S l y  C y s  ThE  A la  P he  G ly  T r p  M e t T h r  
P ro
WT
g c t t g t c t t c c a  g / S  C T S C A C A S C C T T T S S S T S S A T S A C A  
i n t r o n / S l y  C y s  T h r  A la  P he  S l y  T r p  M e t T h r
Figure 7.12: Eiectropherograms showing A467T and T914P
mutations in P23. Amino acid translation is shown. WT, wild-type.
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7.4.13. P24
P24 harboured identical mutations as found in P22 and P23. A467T (see Figure 7.13A) was 
inherited from the father and T914P (see Figure 7.13B) from the mother.
A -  A467T in exon 7 1
P24
A A 8 T C 8 T T 8 A T S 0 A T C T 3 ' ‘ C C A A T S A T 8 C C T S C C A S C T S
WT
  S T  Q 9  '
L e u  H e t  A sp
A / W W W V V A M W W M
A A S T C  S T T  O A T  S 9 A T C T S 8 C C A A T 9 A T 9 C  C T S C C A S C T  9 
L y s  S e r  L e u  H e t A s p  L e u  A la  A s n  A sp  A la  C ys  S in  L e u
B -  T914P in exon 18
P24 i \ A a M a A a A / W \  / W W W  11 YJYx L iJ L rJ m X .
g c t t g t c t t c c a  g / s  C T S C g C A S C C T T T S S S T S S A T S A C A
I n t r o n / S l y  Cys T h r  A la  P he  S ly  T r p  M e t T h r  
P ro
WT
g c t t g t c t t c c a  g / s  C T S C A C A S C C T T T S S G T S S A T S A C A  
i n t r o n / S l y  C ys T h r  A la  Phe S ly  T r p  H e t T h r
Figure 7.13: Eiectropherograms showing A467T and T914P
mutations in P24. Amino acid translation is shown. WT, wild-type.
7.4.14. P25
Three heterozygous changes were found in P25. The W748S and E1143G mutations (see 
Figure 7.14A and C) that were found in P16 were again in cis. This allele was inherited from the 
father. The E1143G substitution was homozygous in the unaffected father (see Figure 7.14C), 
demonstrating that this change by itself is not pathogenic. The maternal allele harboured the 
2542G>A transition which predicted a G848S substitution, as described in P17 and P21 (see 
Figure 7.14B). The patient’s affected sister was also shown to have inherited both disease 
alleles.
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A -  W748S in exon 13
WT
S T 8 0 A C A T C C C T S S C T G C T G G T T T T T C A A S C T S C C T C A C  
V a l  A s p  l i e  P r o  S l y  Cy s  T r p  Ph e  Ph e  L y s  L e u  P r o  H i s
B -  G848S in exon 16 I
P25 A A 1 A ' AA XA>
C C C C A A  S T S S T S A C T S  C C g S C A C C A T C A C T C G C C G S G C T
P r o  S i n  V a l  V a l  T h r  A l a  T h r  H e  T h r  A r g  A r g  A l a
WT
/ M f v W w / y W v / ) m
C C C C A A  S T S S T S A C T S C C G G C A C C A T C A C T C G C C G S G C T  
P r o  S i n  V a l  V a l  T h r  A l a  S l y  T h r  l i e  T h r  A r g  A r g  A l a
C -  E1143G in exon 21
P25 a A A a  A / v \ A a A / \ a a A A a A a A a / V  \a / V  v v
X  M  l l i i A i  u ^Y W lrA h -
S T T C S C T A C C T S S T S C S S S g S S A S S A C C S C T A C C S C S C T
V a l  A r g  T y r  L e u  V a l  A r g  S l u  A s p  A r g  T y r  A r g  A l a
S l yP25-father
WT
S T T C S C T A C C T S S T 8 C 8 0 S 8 S S A S S A C C S C T A C C 8 C S C T  
V a l  A r g  T y r  L e u  S l u  A r g  S l y  S l u  As p  A r g  T y r  A r g  A l a
S T T C S C T A C C T S S T 0 C S S S A S 8 A S 8 A C C S C T A C C 8 C 8 C T  
V a l  A r g  T y r  L e u  s l u  A r g  S l u  S l u  A s p  A r g  T y r  A r g  A l a
Figure 7.14: Eiectropherograms showing W748S, G848S and 
E1143G mutations in P25 and E1143G in P25’s father. Amino 
acid translation is shown. WT, wild-type.
7.4.15. P26
Two heterozygous changes were found in P26. Exon 16 contained both the 2492A>G transition 
(see Figure 7.15A) that predicted a Y831C substitution as described in P15, and a novel 
2551 A>G transition mutation (see Figure 7.15B) which predicted a T851A substitution near the 
start of the polymerase domain. The Y831C mutation was inherited from the father, whilst the 
novel T851A mutation was from the mother.
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A -  Y831C in exon 16
P26
I
C  C C a C C a g/ S C A C C C C 0 A C T a T S A T S A S 0 A A S S C C T C T A Ta
l n t r o n / A r g  B is  P ro  A s p  A s p  S lu  S lu  S l y  l ie u  T y r
m  A n  A a  a A A „  n  n n  A n  A AA„AAA
W  V
C C C a C C a g / s  C A C C C C S A C T A T S A T S A S S A A S S C C T C T A T  
i n t r o n / A r g  B is  P ro  A s p  T y r  A s p  Sl u  S l u  S l y  Leu T y r
B-T851A in exon 16
P26
W u m i m H I I
S T S A C T S C C S G C A C C A T C g C T C S C C S S S C T S T S S A S C C C  
V a l  T h r  A l a  S l y  T h r  l i e  A r g  A r g  A l a  V a l  S l u  P r o
WT
S T S A C T S C C S S C A C C A T C A C T C S C C S S S C T S T S S A S C C C  
V a l  T h r  A l a  S l y  T h r  H e  T h r  A r g  A r g  A l a  V a l  S l u  P r o
Figure 7.15: Eiectropherograms showing T831C and T851A
mutations in P26. Amino acid translation is shown. WT, wild-type.
7.4.16. P27
No POLG mutations were found in P27.
7.4.17. P28
There were no POLG mutations in P28, although interestingly it was noticed that all 6 intronic 
SNPs found (rs3176183, rs2072267, rs2307433, rs2246900, rs2302084 and rs2307438) 
appeared to be homozygous.
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7.5. Analysis of novel mutations
7.5.1. Phylogenetic analysis of POLG protein sequence
Seven of the POLG mutations described here are novel. Therefore, to assess the likely impact 
of these mutations and thus provide evidence for pathogenicity, the phylogenetic conservation 
of the mutated residue was assessed using POLG protein sequences from a variety of 
organisms ranging from Homo sapiens to Caenorhabditis elegans.
The P524 residue that is mutated in P10 is situated in the linker region, and thus is not 
conserved. However, the substitution of a proline (which tends to introduce a kink into the 
amino-acid chain) for an alanine residue would be expected to distort the structure of the 
protein.
H1134 and E1136 lie within the POL C motif and are both highly conserved throughout 
evolution (see Figure 7.16A). T851, T914 and H1110 are also highly conserved residues (see 
Figure 7.16A and B). R232 is only moderately well conserved (see Figure 7.16C), however a 
previous study has described a patient with a pathogenic mutation in which R232 is substituted 
for glycine (Ferrari et al., 2005), and not histidine as described here, emphasizing that this is 
likely to be an important residue.
Meanwhile, the E1143G substitution lies just outside the POL C motif (see Figure 7.16A), is 
listed in Ensembl as a neutral polymorphism and was found homozygous in the asymptomatic 
father of P25, and thus is non-pathogenic. This helps to explain why residue E1143 is only 
conserved in mammals.
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A. H1110, H1134 and E1136 are all highly conserved. E1143 is not so well conserved
Homo VVQSSAVDYL H LMLVAMKWLFEEFAIDGRFCI SI H D E VRYLV R E EDRYRAALAL 1153
Pan WQSSAVDYL H LMLVAMKWLFEEFAIDGRFCI SI H D E VRYLV R E EDRYRAALAL 463
Canis VVQSSAVDYL H LMLVAMKWLFEEFAIDGRFCI SI H D E VRYLV R E EDRYRAALAL 870
Rattus VVQSSAVDYL H LMLVAMKWLFEEFAIDGRFCI SI H D E VRYLV R E EDRYRAALAL 1130
Mus VVQSSAVDYL H LMLVAMKWLFEEFAIDGRFCI SI H D E VRYLV R E EDRYRAALAL 1131
Gallus VVQSSAVDYL H LMLVSMKWLFEEYDINGRFCI SI H D E VRYLV Q E QDRYRAALAL 538
Xenopus VVQSSAVDYL H LMLVAMKWL FEAY DIDGRFCI SI H D E VRYLV Q S KDRYRAALAL 1119
Fugu AVQSSAVDYL H LMLVAMKWLCEEHDIDARFCI SI H D E VRYLV S S EDRYRAALAL 1084
Tetraodon AVQSSAVDYL H LILVAMKWLCQEHDIDGRFCI SI H D E VRYLV S s EDRYRACAG- 1172
Danio VVQSSAVDYL H LMLVSMRWLFEEHDIDGRFCI SI H D E VRYLV T s EDRYRAALAL 1001
Drosophila VVQSGAVDFL H LMLVSMRWLMG---SHVRFCL SF H D E LRYLV K E ELSPKAALAM 1057
Apis WQSGAVDFL H LMLV SMKWLMK---DHARFCL SF H D E VRYLV P s KYKYNAALAM 888
Saccharomyces AIQSSGVDYL H LLCCSMEYIIKKYNLEARLCI SI H D E IRFLV S E KDKYRAAMAL 936
Caenorhabditis IVQSSAVDFL H LLLVSMQWLCDTYKIDARFVI SI H D E VRYMC K E PDAPRLALAL 1000
B. T851 and T914 are both highly conserved
Homo WTAGTI T RRAVEPTWLTA 862 HFAGMHGC T AFGWMTLQGRKS RGT DLHSK 934
Pan WTAGTI T RRAVEPTWLTA 172 HFAGMHGC T AFGWMTLQGRKSRGTDLHSK 244
Canis WTAGTI T RRAVEPTWLTA 620 HFAGMHGC T AFGWMTLQGRKSRGTDLHSK 692
Rattus WTAGTI T RRAVEPTWLTA 839 HFAGMHGC T AFGWMTLQGRKSRGTDLHSK 911
Mus WTAGTI T RRAVEPTWLTA 840 HLAGMHGC T AFGWMTLQGRKSRGTDLHSK 912
Gallus WTAGTI T RRAVEPTWLTA 275 HFAGMHGC T AFGWMTPQGKKSDGTDLHSK 318
Xenopus W SAGTI T RRAVEPTWLTA 829 HFAGIHGC T AFGWMTLQGKKSTGTDLHSK 901
Fugu VITAGTV T RRAVEPTWLTA 793 HFASMHGC T AFGWMTLQGKKSQGTDLHSR 865
Tetraodon VITAGTV T RRAVEPTWLTA 882 HFAGMHGC T AFGWMTLQGKKSQGTDLHSR 954
Drosophila WA CGTL T RRAMEPTWMTA 780 YACGEHGA T PLGWMTLSGSKSNGSDMHSI 852
Apis VAVCGTL T RRAVEPTWMTA 612 YYKKIHGA T PFGWMTLIGTKANETDMHSV 684
Saccharomyces IVPMGTI T RRAVENAWLTA 691 -IFNVHGG T AIGWMCLEGTKNEGTDLHTK 762
Caenorhabditis WPAGTI S RRSVHKLWVTL 661 LEKRVAGK T AFSNMMLAGSKS DNTDLHSV 741
C. R232 is moderately well conserved
Homo AWY SWCSQRLVEE R Y SWT SQLS PADLIPLEVP 250
Bos AWYSWCSRRLVEE R YSWTSQLSPADLIPLEVP 234
Canis AWYSWCSRRLVEE R YSWTSQLSPADLIPLEVP 188
Rattus AWYSWCSRRLVEE R YSWTSQLSPADLIPLGVS 233
Mus AWYSWCSRRLVEE R YSWTSQLSPADLTPLGGS 233
Xenopus YWYSWCSRRLIED R YTWSKELSLSDLIPLETS 224
Fugu NWYSWCSKRLIED R YTWSKDLSLADLIPLETP 197
Tetraodon NWYSWCSKRLIEE R YTWSKELTLADLIPLETP 202
Danio AWYSWCSHRLVED R YAWSSDLSLADLIPLETL 203
Drosophila RWYSWVSSKLTKH R LSVEKLEPLDVDTDSERP 237
Anopheles CWYSWTSPLLSSG E AAPTDQTAADYRLSQLIP 185
Apis AWYGWVSKSLIDG - -VSRNFEGKQYTMDELIP 85
Saccharomyces
Caenorhabditis
AWYLWCSP-----
AWYGWCSDRLIYE _S_
----- FICGGDDPAALIP
EIPEIPTKADLIPIGEIG
238
194
Figure 7.16: The likely impact of the 7 novel mutations was assessed by
phylogenetic alignment of POLG sequences from a variety of species using the 
ClustalW tool (www.ebi.ac.uk/clustalw). A. H1110, H1134 and E1136 are all 
highly conserved and therefore likely to be important residues, whilst E1143 is not 
so well conserved. The mutated residues and the POL C motif are boxed. B. T851 
and T914 are both highly conserved. C. R232 is moderately well conserved.
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7.5.2. Screening of Cypriot controls
To further ensure that the seven novel POLG  mutations found in the present investigation were 
not simply neutral polymorphisms found in healthy individuals, it was necessary to screen 
panels of healthy controls from a similar ethnic background. Access to a suitable panel of 
Cypriot control DNA samples persuaded us to start with the two novel mutations found in the 
Cypriot patients, E1136K found in P7 and P9 and P524A found in P10.
In order to screen for the E1136K mutation, an ACRS forward primer was designed for use with 
21R (see section 7.3.2.2). The assay was tested on the DNA available from the families of P7 
and P9. Taq\ digestion of the wild-type PCR product resulted in 133bp and 22bp fragments as 
expected, whereas the E1136K allele resulted in an uncut 155bp fragment. This PCR-RFLP 
assay thus confirmed the sequence data by showing that P7, P8 and P9 were heterozygotes for 
E1136K whilst P9’s unaffected sibling did not carry the mutation, and that in both pedigrees this 
mutation had been inherited from the mother (see Figure 7.17). PCR products from 49 Cypriot 
controls and one other anonymous DNA sample (that was being used as a PCR control) all 
digested fully into 133bp and 22bp fragments and so a total 100 chromosomes were negative 
for the E1136K mutation.
hO O rO
<*300bp
«200bp
155bp^
133bp>-
-*100bp
Figure 7.17: Segregation of the E1136K mutation in the pedigrees of P7 and P9. 
Taqrl digestion of the wild-type ACRS PCR product resulted in a 133bp fragment. 
The E1136K mutation disrupts the single cut site resulting in a second 155bp 
fragment indicating that P7 and P9 both inherited E1136K from their mother. Black 
symbols indicate affected, half shading indicates carrier status.
A second ACRS primer was designed in order to screen for the P524A mutation (see section 
7.3.2.3). The assay was tested on the DNA from the P10 pedigree. Ba/nHI digestion of the 
wild-type PCR product resulted in 140bp and 21 bp fragments as expected, whereas the P524A 
allele resulted in an uncut 161 bp fragment. This PCR-RFLP assay thus confirmed the 
sequence data by showing that P10 was a heterozygote for P524A and had inherited this 
mutation from his mother (see Figure 7.18). This second PCR-RFLP was more sensitive to
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quality of template and not all amplifications worked. However, 41 Cypriot controls and the 
anonymous PCR control DNA were successfully amplified and digested fully into 140bp and 
21 bp fragments, so in total 84 chromosomes were shown to be negative for the P524A change.
P10i
200bp
161 bp^
140bp^
100bp
Figure 7.18: Segregation of the P524A mutation in P10’s 
family. BamHI digestion of the wild-type ACRS PCR 
product resulted in a 140bp fragment. The P524A 
mutation disrupts the single cut site resulting in 161 bp 
fragments which indicate that P10 inherited P524 from his 
mother. Black symbols indicate affected, half shading 
indicates carrier status.
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7.6. Discussion
7.6.1. Summary of sequencing results
POLG mutations were found in 13 of the 17 paediatric index cases (summarized in Table 7.2), 
including all the Cypriot patients described in Chapter 5. Seven of the POLG mutations 
(R232H, P524A, T851A, T914P, H1110Y, H1134R and E1136K) are novel, whilst the other 
eight substitutions seen (T251I, A467T, P587L, W748S, Y831C, G848S, E1143G and Q1236H) 
have previously been described. All of the novel mutations showed a good degree of 
phylogenetic conservation, except P524A which was in the linker region. Screening for the two 
novel Cypriot mutations (E1136K and P524A) in a panel of suitable controls indicated that both 
were unlikely to be common population-specific polymorphisms. The five other novel POLG 
mutations (R232H, T851A, T914P, H1110Y and H1134R) were found in Caucasian patients. A 
panel of 100 Caucasian control DNA samples should be screened for these mutations using 
PCR-RFLP, to confirm that these are also not polymorphic variants.
Table 7.2: Summary of sequencing results.
Patient ref Allele 1 Allele 2
P7 T251I & P587L (p) E1136K (m)
P9 T251I & P587L (p) E1136K (m)
P10 P524A (m) WT
P15 Y831C (m) H1134R (p)
P16 H1110Y & Q1236H (p) W748S & E1143G (m)
P17 R232H (m) G848S (p)
P18 A467T A467T
P19 WT WT
P20 WT WT
P21 A467T G848S
P22 A467T (p) T914P (m)
P23 A467T T914P
P24 A467T (p) T914P (m)
P25 W748S & E1143G (p) G848S (m)
P26 Y831C (p) T851A (m)
P27 WT WT
P28 WT WT
m, maternal; p, paternal. Red indicates novel mutations. Blue
indicates non-synonymous polymorphic SNPs listed in Ensembl.
Mutations resulting in premature stop codons and splicing errors have previously been 
described in POLG; for example R709X (Di Fonzo et al., 2003), E873X (Naviaux and Nguyen,
2004), W1020X (Nguyen et al., 2005), 3482+2T>C (Ferrari et al., 2005) and Y1210fs1216stop
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(Ferrari et al., 2005). However, the vast majority of PO LG  mutations described to date (see 
Figure 7.19) are missense. All the changes described here (plus the Y955C mutation in the 
previous chapter) are also missense. The reason why missense mutations in POLG  
predominate is not known.
For ten pedigrees where parental DNA was available, segregation of the mutations was 
confirmed, except for P10 in whom only one maternal mutation was found. DNA was also 
available from 5 affected siblings (of P7, P15, P16, P17 and P25) and one unaffected sibling (of 
P9), and in all cases mutations appeared to segregate with disease in a fashion consistent with 
a recessive mode of inheritance.
7.6.2. Is P524A a pathogenic mutation?
A single maternal P524A mutation was found in P10. The mother was asymptomatic, 
suggesting that a dominant mode of inheritance was unlikely, unless there is reduced 
penetrance. A paternally inherited POLG  promoter mutation or a cryptic splice site introduced 
into an intron (resulting in a premature termination codon and nonsense-mediated-decay) could 
result in mono-allelic expression of the P524A allele in P10. Such mutations would have been 
missed by the sequencing strategy used in the present study. Sequencing exon 8 from cDNA 
would therefore confirm whether or not the wild-type allele is expressed. Alternatively, a 
paternally inherited mutation at a second locus (e.g. POLG2), could be involved. Digenic 
inheritance has been described previously in a pedigree with PO LG  and twinkle mutations (Van 
Goethem et al., 2003c). A recent study has also hypothesized that mtDNA deletions caused by 
a POLG  mutation can also hasten age of onset of APOE4/4 associated Alzheimer’s disease 
(Melberg et al., 2005).
Functional studies of DNA polymerase gamma in fibroblasts derived from P10 would confirm 
whether the enzyme function is indeed defective. It may turn out that P524A is just a neutral, 
but rare or even private sequence variant. The fact that P524A does not lie in an important 
functional part of the protein, and is the only one of our seven novel mutations not to show 
some degree of phylogenetic conservation, is evidence against pathogenicity. However, many 
other spacer region mutations (see Figure 7.19) have been proven to be pathogenic, and a 
proline to an alanine change might be expected to cause a major structural change in the 
protein as proline residues tend to be found in the bends of folded protein chains.
7.6.3. Amino acid substitutions found in cis
In three index patients (P7, P9 and P25) there were three non-synonymous amino-acid changes 
and in one patient (P16) there were four changes. E1143G was found in cis with W748S in P16 
and P25. The E1143G change was homozygous in P25’s asymptomatic father so must be non- 
pathogenic, despite its close proximity to the POL C motif. It is also listed in the Ensemble 
database of POLG  neutral polymorphisms with an allele frequency of 3.7% (NIH Polymorphism
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Discovery Resource). E1143G and W748S have previously been detected in cis in four 
patients (Davidzon et al., 2005). The W748S mutation may have arisen in a very distant 
common ancestor of these 6 patients on a genetic background that included E1143G, and due 
to their close proximity, linkage disequilibrium has been since maintained. As W748S has not 
been detected in isolation, it is not known whether it would be pathogenic by itself, or only in 
combination with E1143G.
In P16, the neutral C-terminal Q1236H polymorphism discussed in the previous chapter was 
found in cis with a novel H1110Y mutation. As this histidine residue at position 1110 is highly 
conserved, H1110Y is likely to be pathogenic even without Q1236H, however a previous study 
has shown that in some cases Q1236H can modify the effect of a pathogenic mutation (Luoma 
et al., 2005). Q1236H was found in cis with R627Q and seemed to partially compensate the 
biochemical defect, as both processivity and DNA binding were closer to the wild-type values in 
the double mutant than in R627Q alone. In the future, structural modelling could be used to 
determine whether H1110 and Q1236 residues are found in close proximity in the three 
dimensional structure of the protein. However at present, only the X-ray crystal structures of T7 
DNA polymerase, T. aquaticus DNA polymerase I and other closely related polymerases from 
lower organisms are available. This limits the modelling of amino-acids to those that show a 
high degree of conservation such as Y955 (see Figures 6.3 and 6.10 in previous chapter). Only 
once the human POLG has been successfully crystallised and its structure solved, will it be 
possible to determine the relative positions of these less well conserved amino-acid residues 
with any certainty.
The combination of three POLG  mutations found in Cypriot patients P7 and P9 was identical. 
T251I and P587L were found in cis on the paternally inherited allele in both cases, whilst the 
maternal mutation was a novel E1136K. The likelihood of these patients sharing common 
ancestry is discussed in Chapter 5 (see also Table 8.1). The T251I and P587L mutations are 
not listed by Ensembl as polymorphisms and have previously been found in cis on five 
occasions (Van Goethem et al., 2003b; Di Fonzo et al., 2003; Lamantea and Zeviani, 2004; 
Ferrari et al., 2005; Gonzalez-Vioque et al., 2006). P587L has been found on one occasion in 
the absence of T251I (Gonzalez-Vioque et al., 2006), so must be considered pathogenic. 
However, it is not known whether T251I would constitute a pathogenic allele without P587L.
7.6.4. Location of mutations within POLG
Mutations in the polymerase domain predominated in the cohort of patients described here: 
seven mutations were found in this C-terminal region (Y831C, G848S, T851A, T914P, H1110Y, 
H1134R and E1136K). Only two POLG  mutations were found in the N-terminal exonuclease 
domain (R232H and T251I), whilst four mutations were found in the linker region (A467T, 
P524A, P587L and W748S). The locations of all mutations are summarized in Figure 7.19.
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Figure 7.19: The updated human mitochondrial DNA polymerase gamma
mutation database as of 3rd November 2005. The seven new mutations described 
here have been added in red. Adapted from http://dir-apps.niehs.nih.gov/polg/.
7.6.5. Genotype-phenotype correlations
Three of the four Cypriot patients (P7, P8 and P9) harboured identical T251I, P587L and 
E1136K mutations. These three patients all had very similar clinical presentations of disease, 
including cataracts as discussed in Chapter 5. Three of the unrelated Caucasian patients (P22, 
P23 and P24) also harboured the same combination of A467T and T914P alleles and showed a 
very similar clinical presentation and age of onset. These cases alone would indicate a good 
genotype-phenotype correlation and suggest that P O LG  mutations cause disease without much 
influence from the environment and from other genetic modifiers.
However, other patients did not show such good correlation. For example, P25 presented aged 
6.5 years in status epilepticus, quickly followed by liver failure, and deteriorated rapidly. In 
contrast, P25’s sister harboured the same PO LG  mutations as her brother and yet her liver had 
functioned normally until after 10 years of age. P18 harboured homozygous A467T alleles and 
presented at age 3 years with Alpers syndrome associated with mtDNA depletion. A recent 
Spanish study described a patient with the same A467T mutation in a homozygote state but 
who presented with PEO aged 33 years, with multiple mtDNA deletions (Gonzalez-Vioque et al., 
2006). Another patient described with an identical combination of mutations presented aged 17 
years with features characteristic of MERRF (Van Goethem et al., 2003d). A third patient 
described in the literature homozygous for the A467T mutation presented with a less severe
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form of Alpers and survived until age 19 (Ferrari et al., 2005). The fact that these patients share 
the same combination of mutations as P18 and yet have such a contrasting phenotypes, 
severity of disease and mtDNA pathology, indicates that genetic background and environmental 
factors are likely to influence the expressivity of POLG  mutations in some cases.
7.6.6. SNP results from P28 raise questions about de novo deletions or 
uniparental isodisomy
In P28, all 6 SNPs identified (rs3176183 in intron 9-10, rs2072267 in intron 11-12, rs2307433 in 
intron 17-18, rs2246900 and rs2302084 in intron 19-20 and rs2307438 in intron 21-22) were 
homozygous. Even though all these polymorphisms have a relatively high allele frequency, it is 
unlikely that this pattern has arisen by chance. As the parents were not consanguineous, it is 
unlikely that both POLG  alleles are “Identical by Descent”, although perhaps all these SNPs fall 
within a small ancient haplotype-block and show conserved linkage disequilibrium (Altshuler et 
al., 2005). However, it was considered that these SNPs results, together with this patient’s 
Leigh-like syndrome with mtDNA depletion observed in fibroblasts, could have been more than 
a coincidence. Therefore other possible explanations could include either a de novo deletion of 
one of the alleles or alternatively uniparental isodisomy. Sequencing the SNP-containing 
regions in DNA from parents would be necessary to find out from which parent this combination 
of six SNPs was inherited from, or whether it is present in both parents. If non-Mendelian 
inheritance were to be observed, the next step would be to check for uniparental isodisomy by 
analysing chromosome 15 microsatellites. This approach has been used in a recent paper 
where heterozygosity of 16/18 markers on chromosome 5 suggested that the apparent 
homozygous nature of a B17.2L mutation (found in a patient with a complex I assembly defect), 
was likely to be due to hemizygosity caused by a microdeletion rather than by uniparental 
isodisomy (Ogilvie et al., 2005). If similar results were to be observed for P28, fluorescent in 
situ hybridisation using the patient’s fibroblasts, or array-CGH could be done at a later stage to 
confirm and map deletion break-points. Functional studies of DNA polymerase gamma activity 
and stability (as described in Chapter 6) would also help determine whether or not this enzyme 
is involved in the pathogenesis of disease in P28.
7.6.7. POLG negative patients
In the present study, there were 4 patients in whom no POLG  mutations were identified. 
Although mtDNA depletion had been demonstrated in a fibroblast culture, P28 was slightly 
different clinically from the rest of the cohort. An MRI scan had indicated a high signal in the 
basal ganglia and other features characteristic of Leigh syndrome. No mutations were found in 
POLG, although further work is required to confirm that the homozygous nature of the SNPs is 
consistent with Mendelian inheritance rather than a de novo deletion or uniparental isodisomy 
(see discussion above).
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Although P19 was diagnosed with Alpers, mtDNA was normal in skeletal muscle and brain 
samples. P27 also shared some clinical features to other patients in this cohort, with liver, brain 
and gut involvement due to metabolic collapse and lactic acidosis. However, mtDNA 
rearrangements were observed in muscle tissue rather than the quantitative mtDNA defect that 
had been found in the majority of the other paediatric patients described. Therefore, it was not 
altogether surprising that no PO LG  mutations were found in P19 or P27.
Of the remaining patients with Alpers or hepatocerebral mtDNA depletion syndrome, the 
present finding that 13/14 paediatric patients have PO LG  mutations highlights this as a common 
cause. P20 was the only patient with a clinical presentation consistent with POLG  involvement, 
and in whom mtDNA depletion had been demonstrated, who did not harbour a POLG  mutation. 
Therefore although PO LG  is a relatively common cause of mtDNA depletion and Alpers-like 
syndromes, it is not the only cause. Alpers syndrome is therefore genetically heterogeneous.
The deoxyguanosine kinase gene has already been sequenced in many, although not all of the 
patients from this cohort. Other genes that would be worth sequencing in these POLG  negative 
patients include thymidine kinase 2, thymidine phosphorylase (especially in P27 who presented 
with a MNGIE-like condition), the adenine nucleotide translocator (ANT1) and twinkle 
(C10ORF2). Alternatively, it is highly plausible that these patients may harbour mutations in 
genes that are not yet known to be involved with mtDNA maintenance.
7.6.8. Suggestions for future studies
Blue Native gel analysis and immunoblotting can be used to assess the stability of DNA 
polymerase gamma, whilst the activity of this enzyme can be determined using a reverse 
transcriptase primer-extension assay in the presence of aphidicolin, a nuclear polymerase 
inhibitor (see Chapter 6). These two methods will be used to analyse mitochondrial fractions 
from patient fibroblasts (where available), and should help confirm the deleterious nature of 
these novel mutations. It will be interesting to find out whether the linker region mutations 
(especially A467T, found in P18 and P21-24) result in defective association of POLG with its 
accessory subunit, as described previously (Chan et al., 2005). If so, running the radioactive 
primer-extension products on acrylamide gels would determine whether there is an effect on the 
processivity of the enzyme that is not detectable by just measuring total amount of radioactivity 
incorporated. Unfortunately, as the majority of patients were compound heterozygotes, in most 
cases it will only be possible to determine the effect of a novel mutation either in combination 
with another mutation, or where fibroblasts are available from the patient’s parents, in tandem 
with a wild-type allele. The only mutation found in its homozygous state was the relatively 
common A467T, however fibroblasts from P18 were not available for study. Another, more 
accurate way to determine the functional effect of the seven novel mutations in isolation would 
be to use site directed mutagenesis to artificially express and purify the mutant proteins for each 
novel change.
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Recent studies of a POLG mouse model have shown that a mutation in the exonuclease 
domain can lead to a higher increase of mtDNA point mutations and premature aging 
(Trifunovic et al., 2004). It would be interesting to determine whether the two exonuclease 
domain mutations described in the present study (R232H in P17 and T251I in P7 and P9), have 
any affect on the proofreading ability of the enzyme and hence on the accumulation of mtDNA 
point mutations.
7.6.9. Genetic counselling
The underlying genetic cause of disease has been identified in 13 families from this cohort of 
patients with mtDNA depletion. In 12 of the families where two pathogenic POLG alleles have 
been identified, the inheritance pattern is recessive and the recurrent risk of disease for each 
future pregnancy will be 25%. These families may request counselling about their future 
reproductive options as well as the possibility of pre-natal testing. In fact, one mother, being 
already pregnant, did request for a pre-natal test to be carried out on a research basis (see 
Appendix III). However, many of these patients are historical cases (for example, studies on 
P15 have been going on for over 20 years, see Clayton et al., 1986) and their families are no 
longer in touch with the referring paediatrician. In these cases, the mothers are also likely to be 
past child-bearing age and so counselling would be of limited use.
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The aim of this thesis was to identify novel mutations and new genes involved with mitochondrial 
disorders. Due to the genetic heterogeneity observed in patients with mitochondrial disorders, three 
main experimental approaches were taken. The first approach taken in Chapter 3 was to sequence 
mitochondrial DNA in patients for whom a mtDNA mutation was considered a likely cause of 
disease.
In patients where biochemical data had indicated a specific enzyme complex defect, or where 
Southern blotting had shown impaired mtDNA maintenance, specific nuclear candidate genes were 
sequenced. Thus in Chapter 4, SDHA was sequenced in a patient with an isolated succinate 
dehydrogenase deficiency. In Chapters 6 and 7, POLG sequence analysis was carried out in a 
cohort of patients in the majority of whom mtDNA instability had been described.
In four cases where all good candidate genes had been excluded, a homozygosity mapping 
approach was taken. In two cases the novel Affymetrix GeneChip system was used, and in another 
two cases a conventional microsatellite approach was taken.
8.1. mtDNA sequencing
It is important to exclude mtDNA mutations prior to searching for novel nuclear disease genes. Due 
to the relatively small size of the mitochondrial genome in relation to its 3x109bp nuclear 
counterpart, and the automated sequencing technologies available today, this is a relatively quick 
process. Therefore, although the ultimate goal of this project was to identify nuclear genes, the first 
approach taken was to sequence the 16.6kb mitochondrial genome in selected patients.
As mitochondrial mutations account for approximately only 1 in 5 OXPHOS diseases (Smeitink et 
al., 2001), it was decided to focus on three patients in whom there was already some evidence 
suggesting the possible involvement of mtDNA.
8.1.1. P1
P1 and her maternal half-sister presented with infantile retinal dystrophy. This inheritance pattern 
would be consistent with a mitochondrial mutation, with reduced levels of heteroplasmy in the 
asymptomatic mother. Two mitochondrial tRNA sequence variants (5774T>A and 15942T>C) were 
detected which both appeared homoplasmic upon PCR-RFLP analysis. However, the mother was 
asymptomatic and yet carried the same homoplasmic tRNA variants. In addition, 15942T>C was 
found in 6 normal control mtDNA sequences in an online database.
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The importance of a specific amino acid can be demonstrated by its phylogenetic conservation. In 
a similar way, conservation of specific bases in tRNA molecules in different species indicates that 
the base might have a specific role, either in promoting structural stability of the molecule, or in 
determining the anti-codon / amino-acyl synthetase specificity of the molecule. An online resource 
that proved very useful in the analysis of PTs mtDNA tRNA sequence variants was the tRNA 
database (http://mamit-trna.u-strasbg.fr/Sequences.html). This data indicated that both mutations 
found in P1 were at tRNA positions that had not been conserved through evolution, and thus 
provided further evidence against pathogenicity. Autosomal dominant inheritance with reduced 
penetrance, or germ line mosaicism must therefore be considered.
A new bioinformatics program has recently been developed for the prediction of tRNA 
pathogenicity. The method uses an algorithm which looks not only at phylogenetic sequence 
conservation, but also at whether any compensatory mutations have occurred that maintain 
Watson-Crick base pairing in the stem (Kondrashov, 2005). Using this method, both tRNA changes 
found in P1 were predicted to be benign. However, like other bioinformatics programs this tool 
does not have a 100% success rate for all mutations, especially for milder tRNA mutations. For 
example, there is a pathogenic 14709T>C mutation in tRNA for glutamic acid (McFarland et al., 
2004b) which is misclassified as benign. The fact that this mutation has been found to be 
homoplasmic in an asymptomatic individual indicates that this mutation is not severe enough to 
cause disease in all nuclear genetic environments. Another pathogenic mutation, 10044A>G in the 
tRNA for glycine, has been detected at 91-99% in blood from affected siblings and 88% in the 
asymptomatic mother (Santorelli et al., 1996). The high threshold needed for pathogenicity 
indicates that this mutation is also milder than most tRNA mutations. This mutation was also 
misclassified as benign by this algorithm. If mutations that are homoplasmic in unaffected 
individuals and are not conserved in evolution can in some cases still be pathogenic, then perhaps 
5774T>A could be pathogenic. PTs mother might have a compensatory nuclear background 
resulting in an increased glycolytic capacity. In light of the two reports discussed above, cybrid 
studies should be undertaken to confirm whether the functional studies on these two tRNA variants 
should be carried out, as discussed in section 3.5.1.
8.1.2. P2
The second patient had an isolated complex III defect and so sequencing cytochrome b, the only 
mitochondrial encoded subunit, was an obvious place to start. Sequence analysis identified a 
single homoplasmic variant (15431G>A) which predicted a relatively conservative amino acid 
substitution (alanine to threonine). The lack of phylogenetic conservation, the presence of this 
mutation in normal control mtDNA sequences and the fact that the mutation was homoplasmic led 
to the conclusion that the cytochrome b mutation was not the cause of disease in this patient. 
Functional studies in yeast further confirmed this interpretation. Exclusion of cytochrome b thus
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allowed us to consider possible nuclear candidate genes. The nuclear-encoded complex III 
assembly factor BCS1L was therefore sequenced and is also now excluded as the cause of the 
isolated complex III deficiency in P2. Recent studies have shown that mutations in UQCRB, a 
structural subunit of complex III, can cause hypoglycaemia and lactic acidosis in humans by 
impairing complex III function (Haut et al., 2003) and so should be sequenced in P2. Alternatively, 
one of the 9 other nuclear encoded subunits that make up complex III might be involved.
8.1.3. P3
Transmitochondrial cybrid studies had previously indicated that a mtDNA mutation was the likely 
cause of cardiomyopathy in P3. A cybrid clone was chosen for sequence analysis on account of its 
low COX activity and presumed high mutant load, and a 10306A>G mutation was detected in ND3. 
The level of heteroplasmy in blood, fibroblast and muscle DNA samples from P3 (as determined by 
last cycle fluorescence PCR-RFLP) was 70%, 71% and 49% respectively. This pattern was 
considered unusual as there is often higher mutant load in muscle and other post-mitotic tissues 
than in blood or fibroblasts (Ciafaloni et al., 1992). A more recent meta-analysis has indicated that 
in 90% of individuals with the 3243A>G MELAS mutation and 91% of individuals with the 8344A>G 
MERRF mutation, there was a lower mutant load in blood than in muscle (Chinnery et al., 1999).
Although the functional data failed to confirm pathogenicity (the possible reasons for which are 
discussed in Chapter 3), various other lines of evidence suggest that this mutation is pathogenic. 
The mutant load in a blood sample from P3 was 70% in comparison to 40% in the unaffected 
mother, thus showing that the mutation segregated with disease. The mutation predicted an 
asparagine to serine substitution at a moderately well conserved position in ND3. In addition, 
10306A>G was not present in an online database of over 2000 normal control mtDNA sequences, 
and was the only difference detected between a cybrid cell line with a high residual complex IV 
activity and another cell line with a low activity.
How could a mutation in ND3, a complex I subunit, cause a complex IV deficiency? Such a 
combined enzyme defect would not be without precedence, as mutations in a complex I subunit 
have been associated with complex III deficiency (Budde et al., 2000) and cytb mutations can affect 
complex I as well as complex III (Blakely et al., 2005). These findings may be explained by the fact 
that respiratory chain complexes are fragments of larger structural and functional units or 
“supercomplexes” (Schagger, 2002). Perhaps 10306A>G disrupts some sort of interaction between 
complexes I and IV. An alternative explanation worth investigation could be that the complex I 
defect caused by 10306A>G results in the generation of reactive oxygen species (ROS) and that 
the complex IV deficiency is secondary.
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8.1.4. General discussion on mtDNA sequencing
Although mtDNA mutations appear to have been excluded in P1 and P2, a remote possibility still 
exists that the pathogenic mutation was missed. In P1, mtDNA was sequenced from blood and as 
discussed in Chapter 3 this is not always the best tissue to sequence from. A blind inter-laboratory 
study has recently been conducted in which 12 groups using various mutation detection methods 
were asked to screen for a mitochondrial mutation. The test samples used consisted of 
heteroplasmic mixes ranging from 1% to 50%. The majority of methods were unable to detect 
mutations present at levels below 20% (Hancock et al., 2005). More sensitive techniques such as 
pyrosequencing (White et al., 2005) or denaturing high performance liquid chromatography (van 
Den Bosch et al., 2000; Meierhofer et al., 2005) should be used to complement standard mtDNA 
sequencing. The studies described in Chapter 3 also demonstrate the difficulties that can be 
associated with proving pathogenicity of mtDNA mutations.
8.2. Complex II patient and biochemical candidate gene approaches
In Chapter 4, the first paediatric complex II deficient patient from the UK was described. Complex II 
is the smallest of the RC enzyme complexes, with only four subunits. Mutations that cause Leigh 
syndrome have only previously been described in the flavoprotein subunit (SDHA) and so this was 
the obvious candidate gene to examine. Sequence analysis identified a mutation that predicted a 
G555E substitution in SDHA, at a residue that is highly conserved through evolution. The only 
other report of the G555E mutation has been in a patient with a lethal-infantile presentation (Van 
Coster et al., 2003). Biochemical investigation of fibroblasts derived from both patients confirmed 
that the mutation acts by disrupting the stability of the holo-enzyme, however could not explain the 
noticeable difference of clinical severity in both patients. A number of possible reasons for the 
relatively mild clinical presentation of Leigh syndrome observed in P4 are discussed in Chapter 4.
In many diseases which were originally thought to be monogenic, modifier genes have been 
identified. For example, in cystic fibrosis (CF), the primary mutation in the CFTR gene does not 
always correlate with expressivity of the disease. Studies of affected CF twins and siblings indicate 
that genetic factors must play a substantial role in intestinal manifestations. A murine CF model 
demonstrated that a locus on the mouse chromosome 7 was linked to intestinal disease severity 
(Rozmahel et al., 1996). This region is syntenic to human chromosome 19q13 and a study of 
human CF patients later confirmed that there was a high degree of allele sharing around this locus 
in CF siblings concordant for meconium ileus that was not seen in discordant CF siblings (Zielenski 
et al., 1999). Although this was the first example of a modifier gene discovered in mice and 
subsequently replicated in humans, the modifier gene has still not been identified yet. Perhaps
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there is also a modifier locus which protects P4 against the more severe form of the disease that 
was previously associated with G555E.
Magnetic resonance spectroscopy (MRS) is a non-invasive method of investigating defective 
energy metabolism in vivo. It has previously been used to detect elevated brain lactate in skeletal 
muscle and brain (Gadian and Leonard, 1996). In another more recent study, MRS demonstrated 
the presence of an abnormal MRS peak, corresponding to the accumulation of succinate, in 
patients who were later shown to have succinate dehydrogenase deficiency (Brockmann et al., 
2002). It may be possible to use this technique to monitor the progress of disease in P4. Future 
applications might also be to screen for other patients with complex II defects and to assess the 
effectiveness of any possible treatments.
8.3. Homozygosity mapping work
Due to their severity, many mitochondrial disorders tend not to appear in large pedigrees needed 
for conventional linkage analysis. In addition, the rarity and genetic heterogeneity of these 
disorders make combining pedigrees risky. As a result, homozygosity mapping has become an 
attractive alternative approach. However, the main limitation on this method is that consanguineous 
families are relatively rare in the UK. In Chapter 5, two consanguineous Israeli pedigrees were 
used to try and map novel genes involved in complex I function and in maintenance of mtDNA. In 
the other two studies, a degree of consanguinity was suspected but had not been confirmed.
8.3.1. Israeli complex I family
Complementation approaches such as microcell mediated chromosome-transfer, or transfection of 
candidate cDNAs were of no use in this case as P6’s complex I defect was not expressed in 
fibroblasts. Therefore, as his parents were first cousins, a homozygosity mapping approach was 
used. Due to the limited power of this pedigree, the Affymetrix 10K GeneChip platform could only 
narrow down the candidate region to one of five loci. Despite sequencing eight candidate genes, 
the disease-causing mutation has not been found.
The consanguinity of P6’s family made autosomal recessive by far the most likely mode of 
inheritance. This was the premise on which the homozygosity mapping approach described in 
Chapter 5 was based. However, as there was only 1 affected child, there existed a remote 
possibility that this was not a recessive condition, but a sporadic, dominantly acting genetic event. 
In addition to looking at the relative signals obtained to genotype SNPs, it is also possible to use the 
Affymetrix Chromosome Copy Number Analysis tool (which calculates the total signal from all 40 
oligonucleotides for each SNP present on the GeneChip microarrays) to enable the identification of
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genome-wide chromosomal gains and losses (Huang et al., 2004). Regions where the signal is 
consistently lower than average may help to identify any submicroscopic deletions present in the 
sample. There were no obvious signs of any copy number changes in P6, except for the X 
chromosome which (as this patient was male) was present as a single copy (see Figure 8.1 A). This 
data also excluded Turner syndrome as an explanation of why <7% heterozygosity was seen on the 
X chromosome of P6’s sister (1424), because in contrast to P6, there were clearly two copies of this 
chromosome present (see Figure 8.1B).
A recent study has shown that segmental uniparental disomy (UPD) caused by mitotic 
recombination followed by positive selection can be an important mechanism in the tumorigenesis 
of acute myeloid leukaemias (Fitzgibbon et al., 2005). In contrast to array-CGH, which is only 
concerned with changes in copy number, GeneChip arrays can analyse both homozygosity and 
copy number and so can distinguish between UPD and genomic deletions. This method will 
therefore be very useful in future cancer genetics research.
P6 -  CPA_pV«l
A
1424 - CPA-pVal
B
Figure 8.1: Copy number analysis of GeneChip data for A. P6 and B. 1424. 
The X chromosomes, present as a single copy in P6, and two copies in 1424, are 
indicated with arrows. The X-axis corresponds to the SNP ID number (from 
chromosome 1 on the left hand side to the X chromosome on the right hand 
side). The continuous point analysis (CPA) p-value score is given on the Y axis.
Although the complex I defect was not detectable in P6’s fibroblasts using spectrophotometric 
enzyme assays, there could still be a mild assembly defect that does not affect NADH 
dehydrogenase activity of the enzyme. If such a complex I sub-assembly is present and can be 
detected using Blue-Native gels, it could be possible to use a complementation approach after all.
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Another avenue for future work is to use proteomic tools such as the surface enhanced laser 
desorption ionization (SELDI) mass spectrometer to see if any supernumerary proteins (i.e. 
cofactors, chaperones or assembly factors) are associated with complex I in muscle, but not in 
fibroblasts. As this pattern would match the expression of the RC defect in P6, any such proteins 
would be good candidates. The technology is now available for these type of studies and a recent 
shot-gun proteomic study has detected 30 factors which co-purify with complex I (Pocsfalvi et al.,
2005).
8.3.2. Cypriot mtDNA depletion families
Three Cypriot families have been described, in which patients presented with an early onset, 
hepatocerebral mtDNA depletion syndrome. The clinical course was rapid, with all four patients 
presenting within the first 6 months of life with hypotonia, soon followed by liver failure. It was 
considered that for children from three unrelated families to present with such a rare clinical 
condition, including cataracts in two of the families (P9 being the first ever reported case of mtDNA 
depletion associated with cataracts, see case 3 in Morris et al., 1998), and to all come from a similar 
region in a relatively isolated population such as Cyprus, was unlikely. Therefore, although these 
families were not known to be consanguineous, a shared ancestral mutation was hypothesized. 
However, no significant regions of homozygosity were detected that were shared between all three 
of the patients analysed.
Soon after the homozygosity mapping experiments had been carried out, a study describing the link 
between DNA polymerase gamma and mtDNA depletion in Alpers patients (Naviaux and Nguyen, 
2004) led to the sequencing of this 23 exon gene in these four patients. Mutations were found in all 
affected individuals, indicating that the underlying cause of disease in all three families was due to 
the same gene, as predicted. However, the compound heterozygote nature of the mutations found 
in P7-P9, and a different heterozygous mutation in P10 indicated that our initial hypothesis of a 
single, homozygous ancestral mutation was false.
Once these mutations had been found, a retrospective inspection was made of the SNP data 
around the POLG locus on chromosome 15. The lack of any homozygosity was consistent with the 
compound heterozygote nature of the POLG mutations. However, although the initial hypothesis of 
a single homozygous ancestral mutation was incorrect, the two families in which patients had 
cataracts did share the same combination of POLG mutations: T251I and P587L found in c/'s, and a 
novel E1136K in exon 21. Genotypes for 11 consecutive SNPs flanking POLG were also identical 
over a 0.7cM region extending from rs2351254 to rs1371386 (87.38-87.82Mb, see Table 8.1). 
Therefore, although SNP haplotypes were not determined, it is highly likely that that the same two 
ancestral haplotypes are involved.
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Table 8.1: SNPs in and around the POLG locus on chromosome 15.
SNPs / mutations bp P7 P9 P8
rs698621 87,203,600 G/T G/T G/T
rs953066 87,203,900 A/G A/G N/A
rs953065 87,203,929 T/T C/T T/T
rs2351254 87,381,303 GIG GIG GIG
rs875390 87,536,252 A/A A/A A/A
rs2307438 (intron 21-22)* 87,661,790 T/G T/G N/A
E1136K (exon 21)* 87,662,852 +/- +/- +/-
rs2302084 (intron 19-20)* 87,663,345 A/G A/G N/A
rs2246900 (intron 19-20)* 87,663,370 T/C T/C N/A
rs2307433 (intron 17-18)* 87,665,320-1 -/GTAG -/GTAG N/A
rs2072267 (intron 11-12)* 87,668,158 C/T C/T N/A
P587L (exon 10)* 87,669,874 +/- +/- +/-
rs2351002 (intron 9-10) 87,670,333 C/G C/G C/G
rs2074885 (intron 9-10) 87,670,670 C/T C/T C/T
rs2351000 (intron 9-10) 87,670,737 T/T T/T T/T
T251I (exon 3)* 87,674,419 +/- +/- +/-
rs1371386 87,824,056 C/T C/T C/T
rs968136 87,870,512 C/T C/C C/T
rs968137 87,870,626 GIG A/G GIG
rs751218 88,128,672 C/C C/C C/C
POLG is situated at 87,660 563-87,679,0303bp. Ens smble gene and SN
annotations as of 24.8.05 were used. * Determined by direct sequencing, all 
other SNPs analysed on the 10K GeneChip. N/A, not determined. Presumed 
sharing of two ancestral haplotypes is boxed. Region of shared SNP alleles 
extend 39.1cM or 25.7Mb (67,788-93,526kb) in siblings P7 and P8.
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8.3.3. Arab-lsraeli mtDNA depletion pedigree
A novel gene involved in mtDNA depletion was mapped to a 20Mb region on chromosome 13 and a 
complex rearrangement was subsequently found in SUCLA2. This gene encodes the beta subunit 
of the ADP-forming succinyl-CoA synthetase (SCS-A, EC 6.2.1.5). This enzyme catalyzes the 
reversible ATP-specific synthesis of succinyl-CoA from succinate and CoA. The reverse reaction 
occurs in the citric acid cycle. SCS-A is a heterodimer that shares its alpha subunit with another 
succinyl-CoA synthetase which uses GDP (SCS-G, EC 6.2.1.4). Thus SCS-G and SCS-A catalyze 
a similar reaction by using different phosphate donors, with their beta subunits determining the 
nucleotide specificity.
SCS-A is thought to interact with nucleoside diphosphate kinase (Kadrmas et al., 1991; Kavanaugh- 
Black et al., 1994; Kowluru et al., 2002). The present study showing that mutations in SUCLA2 can 
cause mtDNA depletion suggests that this interaction is of functional relevance. Thus, in contrast 
with POLG, which is directly involved with mtDNA replication, SUCLA2 appears to be indirectly 
involved with the maintenance of mtDNA by impairing the final step of the mitochondrial salvage 
pathway and resulting in imbalanced pools of dNTP (see Figure 8.2). Functional studies on mutant 
SUCLA2 should be carried out in the future, to confirm that nucleoside diphosphate kinase activity 
is reduced. In light of these results, the mitochondrial nucleoside diphosphate kinases themselves: 
nm23-H4 (Milon et al., 2000) and nm23-H6 (Tsuiki et al., 1999), must now be considered to be 
candidates for mtDNA depletion also.
Previous studies have demonstrated that whilst SCS-G and SCS-A are both expressed at high 
levels in mitochondria from rat liver, kidney and heart, SCS-A appears to predominate in the brain 
(Lambeth et al., 2004). This tissue specific expression pattern might help explain the vulnerability of 
brain tissue observed in the consanguineous Israeli family described here.
A recent report demonstrated that aconitase (another mitochondrial matrix enzyme that acts a 
couple of steps earlier in the citric acid cycle) also couples metabolic regulation to mitochondrial 
DNA maintenance in yeast (Chen et al., 2005). Perhaps it should also be considered a candidate 
gene for quantitative defects of mtDNA in humans.
Further studies will determine how common SUCLA2 mutations are as a cause of mtDNA depletion. 
The SUCLA2 gene should also be screened in the three patients with impaired mtDNA 
maintenance described in chapter 7 (P20, P27 and P28) for whom POLG was excluded.
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Figure 8.2: Mitochondrial nucleotide metabolism, mtDNA replication and the salvage
pathway. Enzymes are shown in red. dGK, deoxyguanosine kinase; TK2, thymidine 
kinase 2; mdN, mitochondrial deoxynucleotidase; cdN, mitochondrial deoxynucleotidase; 
TK1, thymidine kinase 1; dCK, deoxycytidine kinase; TP, thymidine phosphorylase; mtSSB, 
mitochondrial single-strand DNA binding protein; TFAM, mitochondrial transcription factor 
A; DNC, mitochondrial deoxynucleotide carrier; ANT, adenine nucleotide transporter 1; RR, 
ribonucleotide reductase. Blocks to these biochemical pathways that cause disease and 
impaired mtDNA maintenance in humans are shown in blue.
8.3.4. A patient with a syndrome affecting multiple mitochondrial enzymes
In Chapter 5, a patient was described with multiple mitochondrial enzyme defects. The clinical 
symptoms were thought to resemble those of four patients in which a small region on chromosome 
2p had been implicated (Seyda et al., 2001). However, analysis of microsatellites in the 
consanguineous family described here has now excluded this locus, suggesting that a novel gene 
might be the cause of disease in this patient. If there had been more affected (or unaffected) 
siblings in this pedigree, then a whole genome screen for homozygosity might have been 
worthwhile. As the complex IV and pyruvate dehydrogenase deficiencies were expressed in 
fibroblasts, a biochemical complementation approach such as MMCT could be used to map the 
disease gene.
A defect in the mitochondrial import pathway could be envisaged to cause multiple RC defects as 
well as pyruvate dehydrogenase deficiency and an imbalance of amino acids. If such a defect was 
observed in the cell line derived from this patient, markers that flank the genes involved with these
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processes (e.g. the subunits of the TIM and TOM complexes) could be analysed for the presence of 
homozygosity. This homozygosity mapping approach to prioritise candidate genes was recently 
used successfully to map a disease gene involved in the assembly of ubiquinone (Quinzii et al., 
2006). In this study, levels of ubiquinone (CoQ10) were reduced in the skeletal muscle of patients 
from a consanguineous family with complex ll+lll and l+lll deficiency. This implicated the enzymes 
responsible for the CoQ10 biosynthetic pathway as a possible cause of disease. Microsatellites 
flanking the eight known chromosomal loci for genes encoding human CoQ10 biosynthetic proteins 
were run. The presence of heterozygosity at five loci helped to exclude these genes before 
embarking on sequence analysis of the remaining three candidate genes. A transition mutation 
was found in COQ2 (para-hydroxybenzoate-polyprenyl transferase) which segregated with disease, 
was absent from a panel of 100 controls and predicted the substitution of a well conserved tyrosine 
residue for a cysteine. Radioisotype assays confirmed a significantly decreased rate of CoQ10 
synthesis in patient fibroblasts. Thus COQ2 is also now a good candidate gene if defective 
complex l-lll and complex ll-lll RC results are obtained.
Due to the number of proteins involved in mitochondrial ribosome function (54 were described and 
mapped in a paper by Kenmochi et al., 2001), a similar approach might also be useful for 
mitochondrial translation defects in consanguineous families, where known candidates (e.g. PUS1, 
EGF1, MRPS16 and mitochondrial tRNA/rRNAs) have been excluded.
8.4. Analysis of DNA polymerase gamma
8.4.1. Pleotropic nature of POLG
Mutations in POLG can be either dominant (see Chapter 6) or recessive (see Chapter 7). They can 
cause either mtDNA depletion or multiple mtDNA rearrangements, or both, depending on the tissue 
in question (see Chapter 6). Another interesting facet of this gene is the wide phenotypic range that 
can result from POLG mutations. Work described in Chapter 6 has provided confirmation that 
mutations in POLG can cause autosomal dominant PEO associated with premature menopause 
and parkinsonism. In Chapter 7, we have shown that defective POLG is a relatively common cause 
of paediatric Alpers syndrome and hepatocerebral mtDNA depletion syndrome, with mutations 
being identified in 13 of the 17 index cases presented. However there are other associations 
between POLG and old age (Trifunovic et al., 2004), male infertility (Rovio et al., 2001), spino­
cerebellar ataxia-epilepsy (Winterthun et al., 2005) and sensory and ataxic neuropathy (Van 
Goethem et al., 2003a) also described in the literature. Future studies will aim to explain the 
underlying mechanisms behind these differences in phenotype.
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As well as being used to confirm depletion of mtDNA and the presence of multiple rearrangements 
(as described in Chapter 6), qPCR can be used to assess ROS induced damage to DNA (Ayala- 
Torres et al., 2000). The polymerase cannot traverse a lesion and therefore DNA damage means 
that replication will be inhibited in the first round of amplification. After ~20 PCR cycles, the amount 
of amplified DNA will be inversely proportional to the number of lesions. A recent study modelling 
human POLG mutations in yeast used this method to show that a linker region mutation analogous 
to human A467T can result in elevated DNA damage in the nucleus as well in the mitochondria 
(Stuart et al., 2006). If confirmed, this finding might help to explain the pathogenic mechanisms 
behind the linker region mutations and also perhaps some of the phenotypic variability observed.
In one of the Cypriot patients described here (P10), only one disease allele (P524A) was identified. 
The mother also carried this mutation and yet was asymptomatic, suggesting that this mutation was 
recessive. Other recent mutation reports have also found patients with characteristic mtDNA 
maintenance defects and only one POLG mutation (Kollberg et al., 2005; Gonzalez-Vioque et al.,
2006). It seems possible that these patients might also have a digenic inheritance pattern similar to 
that described previously in a pedigree with POLG and twinkle mutations (Van Goethem et al., 
2003c). A mutation report on the BBS2 and BBS6 genes involved in Bardet-Biedl syndrome 
observed that in four pedigrees, all affected patients harboured three mutant alleles, whereas an 
individual with two recessive BBS2 mutations was unaffected (Katsanis et al., 2001). A “triallelic” 
model of disease transmission was hypothesized, in which the two genes act in tandem and can 
partially compensate for one another. Perhaps a similar mechanism, involving POLG and other 
mtDNA maintenance factors, might help explain these interesting cases.
To date, over 50 different POLG mutations have been described which can cause mitochondrial 
disease (see Figure 7.19 in the previous chapter). Overall, there is a slight bias towards mutations 
in the polymerase domain. Autosomal dominant PEO mutations (such as Y955C as described in 
Chapter 6) certainly seem to cluster in the polymerase domain. However, other than this, the 
mutations seem to be spread randomly throughout the gene.
8.4.2. Premature ovarian failure and POLG
In Chapter 6, a three-generation pedigree was described with familial premature menopause 
associated with PEO, proximal myopathy and sensory ataxia. In this family the disease segregated 
with an autosomal dominant Y955C mutation in the highly conserved catalytic polymerase domain 
of DNA polymerase gamma. The mutation resulted in mtDNA depletion in fibroblasts in contrast to 
multiple mtDNA deletions in muscle. Further studies are needed to elucidate the pathogenic 
mechanism of ovarian failure associated with POLG mutations. For example, qPCR could be used 
to determine the presence of mtDNA depletion and/or multiple rearrangements in single oocytes, 
and levels of ROS could also be measured. However, due to the obvious ethical difficulties
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associated with obtaining ovarian tissues, it is unlikely that these experiments will be carried out in 
the near future. However, it may be that this issue could be addressed in the POLG mutant mouse 
model, which also showed reduced fertility (Trifunovic et al., 2004).
The recent public interest and resulting media attention on reproductive health is exemplified by a 
recent report about the availability of a new hormonal method to assess the number of eggs left in a 
woman’s ovaries (Lister, 2006). It will therefore be important for future studies to determine whether 
dominantly acting variations in POLG can influence age of menopause in the absence of PEO, as 
this would raise important reproductive counselling issues for affected women, especially if the 
current trend towards having children later in life continues.
There are two experimental approaches to address this question. The first is to study a cohort of 
women with POF and screen for the Y955C mutation. Perhaps in some individuals this mutation 
can result in POF at a much earlier age of onset than it does PEO. Further studies could then 
include screening for the common A467T mutation (described in 0.6% of the Belgian population, 
Van Goethem et al., 2003a) or the polyglutamine tract expansion in exon 2 that has previously been 
linked to male infertility (Rovio et al., 2001). If resources are available then sequencing the whole of 
the POLG gene could be undertaken to look for other recessive PEO, Alpers or novel mutations 
that might act dominantly with respect to ovarian function. It might also be interesting to determine 
whether there is an increased frequency of any of the common non-synonymous POLG SNPs (see 
Table 8.2) in women with POF.
Table 8.2: Non-synonymous coding region SNPs found in POLG.
AA AA co- Minor allele
ID alleles Ambiguity Chr 15 pos SNP type change ordinate freq.
1. rs3087373 e r r Y 87677938 NON_.SYNONYMOUS..CODING P/S 18 0.6%
2. rs3176162 G/A R 87677412 NON..SYNONYMOUS..CODING R/Q 193 0.6%*
3. rs2307437 C/T Y 87673231 NON..SYNONYMOUS..CODING P/S 324 0.6%
4. rs2307447 CAT Y 87670923 NON..SYNONYMOUS..CODING R/C 546 1.1%
5. rs2307450 G/A R 87668428 NON..SYNONYMOUS..CODING E/K 662 2.8%
6. rs2307442 C/T Y 87662834 NON..SYNONYMOUS..CODING R/W 1142 0.6%
7. rs2307441 A/G R 87662830 NON..SYNONYMOUS..CODING E/G 1143 3.7%
8. rs2307440 C/T Y 87662822 NON..SYNONYMOUS..CODING R/C 1146 0.6%
9. rs3087374 G/T K 87660998 NON..SYNONYMOUS..CODING Q/H 1236 4.0%
Allele frequencies are from the NIH Polymorphism Discovery Resource (NIHPDR) which contains cell lines and 
DNA from 450 anonymous unrelated individuals with equal numbers of females and males. No medical, 
phenotypic, or ethnicity is included. * 90 individual subset. Data from Ensembl (10.1.06).
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Even if mutations in POLG can reduce age of menopause, it might do so only in a small proportion 
of women from any POF cohort. Therefore the cohort may have to be very large before any 
significance could be reached. A much more direct way to address this question would be to 
approach the problem in reverse. One could take a group of women known to harbour pathogenic 
POLG mutations, such as the mothers of the Alpers patients described in Chapter 7. Comparing 
the average age of menopause in this group to the 51 years observed in western populations could 
indicate whether there is a link between reproductive health and POLG function. However, there 
are a number of flaws with this approach. Firstly, some of these women may not have reached 
menopause yet, so there would be an ascertainment bias towards a lower average menopausal 
age. Secondly, in contrast to the general population, all of these women have by definition had at 
least one child. As nulliparity is known to influence menopausal age (Parazzini et al., 1992), this 
might be another confounding factor. A third possible confounding factor is that these women have 
all had the major trauma of having had severely affected children. Dysregulation of the body’s 
stress responses (particularly the hypothalamic-pituitary-adrenal axis function) is known to influence 
human health. Previous studies have shown that stressful life events can affect the menstrual cycle 
and may be a factor in determining age of menopause (Matteo, 1987; Allsworth et al., 2001).
To circumvent these issues, a slight modification to this approach is proposed in which both the 
maternal and paternal grandmothers of the Alpers patients are questioned about their reproductive 
health. To our knowledge, sporadic POLG mutations appear to be uncommon as there are none 
described in the literature, therefore there is a 50% chance that each of these grandmothers will 
harbour the pathogenic POLG mutation that has been transmitted to their grandchild (see Figure 
8.3A). These women could thus be divided into two groups on the basis of their POLG status and 
the mean ages of menopause could be compared. The grandmothers who do not harbour the 
known POLG mutation would constitute an ideal control group. The more Alpers patients that could 
be collected to carry out this study, the greater the probability that these two groups would be of 
approximately equal size. Blood would be taken from the grandmothers at the same time as filling 
in the questionnaire. However, to ensure a double-blind experimental design, screening for the 
POLG mutations would not be carried out until all the questionnaire data has been analysed. To 
split the women into two groups would then be very simple experimentally, as it is already known 
which mutations to look for. For example, the paternal grandmother of P15 would be screened for 
the H1134R mutation in exon 21 whilst the maternal grandmother would be screened for the Y831C 
mutation in exon 16 (see Figure 8.3A).
In studies with this type of experimental design, power calculations should be carried out to 
determine the numbers needed to have a reasonable chance of reaching statistical significance. In 
previous studies on factors influencing age of menopause, the standard deviation has been around 
4-5 years (see references in the Introduction to Chapter 6). To do these calculations, it has been 
assumed that the standard deviation in this study would be 4.75 years and that harbouring a
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recessive POLG mutation can decrease the age of menopause by 4 years. For an 80% chance of 
detecting this difference (to a 5% significance level), 23 grandmothers would be needed in each 
group, whilst for a 90% chance of picking up the difference, 30 women would be needed in each 
group (see Figure 8.3B). However, many of these grandmothers are likely to be either 
uncontactable, or no longer alive. Assuming a questionnaire return rate of 50%, 46 Alpers families 
would be needed before such a study could be carried out with 80% power. We currently only have 
13 families (see Chapter 7). These calculations were done assuming these POLG mutations make 
a difference of 4 years. However, the greater the effect of POLG mutations on the age of 
menopause, the fewer women in each group would be needed to reach statistical significance (see 
Figure 8.3C).
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Figure 8.3: A. Pedigree of P15. Shading indicates affected, 
half shading indicates carrier status. B and C. Power 
calculations for suggested study (at P=0.05).
Major ethical implications would have to be addressed before such a study could be carried out. 
For example, would the POLG results be fed back to the family? Upon finding out that she 
harboured a recessive POLG mutation, the grandmother might blame herself for the disease of her 
grandchild. In addition, would she want to find out that she carried a mutation in a gene that has 
been associated with Parkinsons disease, for which there is no cure? The fact that these women 
will mostly be past child-bearing years, means that this information might be of limited medical 
benefit.
In view of the recent POLG mutant mouse model (Trifunovic et al., 2004), a similar study design as 
that suggested above could be used to determine whether harbouring a single recessive POLG
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mutation can influence other aging-related defects such as weight loss, alopecia, kyphosis and 
osteoporosis. As a final point, it would also be interesting to determine whether other proteins 
involved with maintenance of mtDNA can also influence age of ovarian failure, or whether this 
phenotype is unique to POLG deficiency.
8.5. Conclusions
This thesis has shown that a multidisciplinary approach combining sequence analysis of mtDNA, 
nuclear candidate gene analysis and functional studies can be used to investigate the molecular 
basis of mitochondrial disorders. Mutations in ND3, SDHA and POLG have been identified in a 
number of patients with mitochondrial disease. Blue Native polyacrylamide gel electrophoresis and 
immunoblotting indicated that whilst the Y955C mutation in POLG did not affect assembly of the 
DNA polymerase gamma enzyme, the G555E mutation in SDHA did disrupt the stability of 
succinate dehydrogenase. Due to the effort required in designing sequencing primers and 
optimising PCR reactions, it is preferable to assemble larger cohorts of patients, such as the 
Alpers/hepatocerebral mtDNA depletion patients (described in Chapter 7), before commencing 
work.
POLG mutations were found in 13/14 patients with hepatocerebral mtDNA depletion syndrome or 
Alpers syndrome. It is rare to have such a high rate of positives when sequencing candidate genes 
in mitochondrial disease cohorts. The only comparable nuclear disease gene that is also largely 
responsible for a major category of respiratory chain disorders is SURF1. This gene is associated 
with approximately 26-75% of Leigh syndrome cases with complex IV deficiency (Sue et al., 2000; 
Tiranti et al., 1999). The reasons for this high rate of mutations found in chapter 7 include, i) over 
the 10 years during which this cohort had been collected, clinical features, liver function, MRI scans, 
histological, Southern blot and enzyme studies had all suggested that these patients were clinically 
and biochemically homogeneous, ii) the clinical presentations and biochemical data resembled 
other patients with mtDNA depletion in whom POLG mutations had recently been identified 
(Naviaux and Nguyen, 2004; Ferrari et al., 2005), and iii) that patients harbouring a defective 
version of deoxyguanosine kinase had already been excluded from this cohort (Taanman et al., 
2002). This chapter therefore shows the value of having a clinically and biochemically well defined 
cohort prior to commencing sequencing projects.
In contrast, mtDNA sequencing in three patients with heterogeneous mitochondrial disease 
detected only one mutation (with pathogenicity still unproven). Although some diseases fall into 
well characterised mitochondrial syndromes (e.g. MELAS and MERRF, in which specific mtDNA 
mutations are responsible for the majority of cases and can be screened), for less common 
respiratory chain disorders, other evidence such as a maternal inheritance pattern, or cybrid cell
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studies can lead to the sequencing of mtDNA. However, apparent maternal inheritance does not 
always indicate a mitochondrial mode of inheritance (see Chapter 6) and will not be observed for 
sporadic mtDNA mutations. Moreover, data from cybrid cell studies should be interpreted with 
caution; cancer cell lines such as A549 are commonly used as the nuclear donor cell line, but these 
nuclei by their nature are not truly wild-type. Respiratory chain enzymology should also be viewed 
with caution, because citrate synthase (commonly used to normalise for mitochondrial enrichment) 
can show variable expression. In these cases, activity ratios of individual respiratory chain 
complexes may help to pinpoint the precise defect. In view of the points above in addition to the 
modern high throughput technology with which mtDNA can be analysed, it may be worthwhile 
sequencing all unusual cases to pick out the approximately 20% of mitochondrial disorders that are 
caused by mtDNA mutations, before consideration of nuclear disease genes.
Analysis of homozygosity in an Arab-lsraeli family was used to map a novel gene involved in 
mtDNA maintenance. The SUCLA2 gene was subsequently identified as the cause of disease, 
therefore fulfilling the primary aim of this project to identify a novel nuclear gene involved with 
paediatric RC disorders. Future work will hopefully pinpoint the complex I disease gene from the 5 
candidate regions identified in the other Israeli family. A novel online “integrative genomics” tool 
may be of use in this regard (Calvo et al., 2006). The fundamental lesson that should be learnt 
from the work on the Cypriot families is that, however persuasive a hypothesis might sound, there 
should be definitive evidence of consanguinity before any homozygosity mapping project is 
embarked upon.
Considerable phenotypic variability was observed in the two patients described with identical 
mutations in SDHA and similar residual levels of complex II activity. This suggested that other 
genetic factors might be acting as modifiers. The A467T mutation in POLG also showed phenotypic 
variability in that P18 described here harboured two copies of this mutation and presented at age 3 
years with Alpers syndrome associated with mtDNA depletion in multiple tissues, whereas a recent 
Spanish study described a patient with identical homozygous A467T mutations, but who presented 
with PEO aged 33 with multiple mtDNA deletions (Gonzalez-Vioque et al., 2006). Premature 
menopause is seen in some POLG pedigrees (see Luoma et al., 2004 and family described in 
Chapter 6), but not in others (Gonzalez-Vioque et al., 2006). Finally, the Y955C mutation in POLG 
can result in parkinsonism in some PEO patients, but not in others. All this evidence adds weight to 
the prevailing hypothesis that very few human genetic disorders are, in reality, entirely monogenic.
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Appendix I: Research Images as art 2003/2004
UCL - Research Images as Art 2003/2004
Genetic Blueprint
Homozygosity mapping is an efficient strategy for mapping human genes that cause disease in 
consanguineous families. The method works by virtue of the fact that the DNA surrounding the 
gene in question will be homozygous by decent in all affected children, but not in their unaffected 
siblings. The new Affymetrix GeneChip 10K SNP platform was used to try and locate a gene for 
NADH:CoQ oxidoreductase deficiency in an Israeli family in which the parents were first-cousins. 
This picture shows raw data produced by the scanner for DNA from an affected child. This is 
interpreted as SNP (single-nucleotide polymorphism) calls by dedicated software, which in turn 
allows us to look for regions of homozygosity. There are 40 probes per SNP and thus over 40,000
spots on each array.
Entry #10
(see www.grad.ucl.ac.uk/events/2004/research)
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Appendix III: Analysis of P O L G  as a pre-natal test
T251I mutation in exon 3 of POLG E1136K mutation in exon 21 of POLG
Control
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Mother
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P587L mutation in exon 10 of POLG
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^ _ Work carried out on a research basis by Jan-
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